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Abstract 
 
HOX11 is a homeodomain transcription factor that has been implicated in leukaemic 
transformation associated with T-cell acute lymphoblastic leukaemia (T-ALL). Its role in 
leukaemogenesis remains enigmatic, nevertheless, in vitro and in  vivo studies have provided 
additional evidence supporting the role of HOX11 as an oncogene. The mechanism by which 
HOX11 transforms cells is yet to be elucidated, however, HOX11 has been postulated to function 
by binding regulatory elements within the promoter regions of specific target genes in order to 
control gene transcription. The identification of transcriptional targets is thus thought to be critical 
to our understanding of the pathways controlled by this master gene regulator. To date, only three 
candidate HOX11 target genes have been reported and given that HOX11 overexpression can 
have a profound impact on cell behaviour, it is likely that many more exist. In this study, we 
sought to further understand the role of HOX11 in tumorigenesis by: 1) The identification of novel 
putative HOX11 target genes by profiling gene expression in response to HOX11 in a number of 
cell lines using a combination of RDA, cDNA microarray and GeneChip approaches and 2) 
confirming target gene status by assessing whether the proximal promoters of the leading 
candidates identified are transcriptionally regulated by HOX11. 
 
To identify genes whose expression was altered by HOX11, three techniques were employed, 
namely representational difference analysis, cDNA microarray and Affymetrix GeneChip array. 
Because of the relative novelty of these technologies, all three methods were employed in a 
complementary manner. While representational difference analysis did not require dedicated 
equipment and enabled the identification of novel genes, the technique was labour-intensive and 
also exhibited a number of problems including high levels of background. Emphasis was 
therefore placed on the more systematic microarray approaches that enabled a global 
investigation of expression patterns and thus the identification of a range of candidate target 
genes. Initially, this involved cDNA microarray experiments, however, during the course of this 
work Affymetrix GeneChip technology became available. The latter was identified as the most 
appropriate technology for the identification of candidate target genes because of its relative ease 
of use, as well as its employment of multiple independent probe pairs which greatly improved 
background noise, increased the range and accuracy of detection, minimized the effects of cross 
hybridization and drastically reduced the rate of false positives and miscalls. 
 
Using these combined approaches, several genes of interest were identified which were 
differentially regulated in the presence of HOX11 and thus may represent oncogenically or 
physiologically relevant target genes. These included OSTEOPONTIN,  PAG,  GUANOSINE 
DIPHOSPHATE DISSOCIATION INHIBITOR 3,  SUR8,  GAS3,  C-KIT,  VEGFC,  NOR1  and  
  iv
SMARCD3. In order to confirm their role as target genes, four candidates (C-KIT, VEGFC, NOR1 
and  SMARCD3) were characterized in terms of the ability of their proximal promoters to be 
transcriptionally regulated by HOX11 using luciferase reporter assays. Significant repression of 
the proximal promoters of C-KIT and VEGFC by HOX11 was observed, which provided further 
evidence for their status as target genes. This repression was, however, in stark contrast to the 
transcriptional activation seen when the C-KIT and VEGFC proximal promoters were co-
transfected with a HOX11 mutant lacking the third helix of the DNA-binding homeodomain. This 
unexpected finding suggested that the transcriptional activity of HOX11 is complex and highly 
context-dependent, and in particular, highlighted the importance of an intact homeodomain for 
HOX11 function. 
 
C-KIT and VEGFC are both involved in tyrosine kinase signal transduction pathways, as a 
receptor tyrosine kinase and tyrosine kinase ligand, respectively. C-KIT plays an important role in 
the survival and self-renewal of haematopoietic cells. It is a previously identified and relatively 
well characterized oncogene known to be regulated by other transcription factors (SCL/TAL1 and 
LMO) implicated in the pathogenesis of T-ALL. VEGFC is a member of the vascular endothelial 
growth factor family that functions in angiogenesis and lymphangiogenesis. A paracrine loop 
involving VEGFC and its receptor VEGFR-3 has previously been implicated in leukaemic cell 
survival. While further work is required in order to confirm the status of VEGFC and C-KIT as 
oncogenically-relevant HOX11 target genes and to characterize their exact mode of regulation, 
these findings implicate receptor tyrosine kinases in HOX11-mediated tumorigenesis and 
underscore their  potential importance as therapeutic targets in haematological malignancies.  
  v
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1.1  The Molecular Biology of Cancer 
The process by which normal cells become progressively transformed to malignancy requires 
the sequential acquisition of mutations which arise as a consequence of damage to the 
genome from the action of one or a combination of chemical, physical, biologic or genetic 
insults. Although normal cells have a means to repair such genomic damage, for various 
reasons errors occur introducing permanent changes in the genome or mutations. The 
evolution of a normal cell to a malignant one involves processes where genes involved in 
normal homeostatic mechanisms that control proliferation and cell death suffer mutational 
damage. This damage results in the activation of genes stimulating proliferation, `oncogenes’ 
or the inactivation of genes which would normally inhibit proliferation, `tumour suppressor 
genes’ (Bertram et al., 2001; Pitot et al., 1993).  
The genetic alterations associated with human malignancies largely take the form of point 
mutations, gene amplifications, gene deletions or chromosomal translocations. Point 
mutations result from a single base pair change; this change can lead to either a missense 
mutation (replacement of one amino acid for another in the protein product) or if the change 
produces a termination codon a nonsense mutation (premature truncation of a protein 
product). Gene amplification results from a region of the genome being replicated numerous 
times, leading to over expression of genes located within the amplified region or amplicon. 
Gene amplification may result in cells having hundreds of copies of the genes located within 
the amplicon. Gene deletions result from a loss of genetic material from the cell; because a 
normal cell has two copies of all autosomal chromosomes, the deleted gene’s function can 
sometimes be accomplished by the remaining normal copy of the gene. The remaining copy 
can be inactivated by point mutation, hypermethylation or deletion. Finally, chromosomal 
translocation results in the fusion of a gene with another gene as a result of chromosomal 
breakage and rearrangement. This most commonly results in the production of a chimeric 
protein with altered function, but can also result in the aberrant regulation of a structurally 
normal protein (Thandla et al., 1997). 
Damage to DNA itself is not a mutagenic event, but if unrepaired can be converted to a 
mutagenic event during the process of DNA replication. DNA synthesis itself is a tightly 
controlled, highly coordinated process. Thus, delays in progression through to S phase of the 
cell cycle as a consequence of DNA damage, insufficient availability of protein or DNA 
precursors, frequently result in cell death, chromosomal abnormalities or mutations. Since the 
latter two events are intimately associated with carcinogenesis, it is not surprising that many 
of the genes found to be damaged in cancer cells have actions related to G1/S cell cycle 
checkpoint control. Four major events occur in the genesis of a cancer cell: 1) The Introduction  3
development of independence in growth signals 2) Development of a refractory state to 
growth inhibitory signals 3) Development of resistance to programmed cell death and 4) 
Development of an infinite proliferative capacity (Bertram et al., 2001). 
By the direct targeting of the genetic defects that are responsible for malignancy it is a 
realistic expectation that increasing numbers of tumour specific drugs will become available 
which will spare the patient from the devastating effects exerted by conventional cytotoxic 
therapeutic agents on normal cells (Bertram et al., 2001). To be effective, conventional 
agents must be used at dosages which are acutely life threatening to the patient. 
Furthermore, many currently available drugs also induce genetic damage which can itself be 
carcinogenic. Fortunately, targeted anti-cancer therapies are starting to become available, 
the most notable to date being Imatinib mesylate  (Gleevec) which directly targets the 
tyrosine kinase involved in chronic myeloid leukaemias possessing the BCR-ABL 
translocation (Weisberg et al., 2003). Ultimately, the development of other targeted therapies 
will greatly improve cancer treatment. 
1.2   Leukaemia 
In haematopoiesis, pluripotent stem cells develop into at least eight phenotypically distinct 
mature blood cell lineages. In order to ensure that each resulting cell type expresses the 
genes necessary for its function, transcription factors must be able to be employed in both 
general and restricted expression patterns. In this way, they enable haematopoietic cells to 
attain functionally distinct phenotypes through the activation of specific genes and thus, 
control much of haematopoiesis (Crans et al., 2001; Ravid et al., 2001). 
Leukaemia is the abnormal, uncontrolled proliferation of one or more cells of the 
haematopoietic lineage that fail to differentiate. Leukaemias result from the accumulation of 
mutations in genes, such as oncogenes and or tumor suppressor genes and the loss of 
coordination between proliferation and differentiation in the haematopoietic progentior cell 
pool. Processes such as stem cell self renewal or commitment to differentiation and 
progenitor cell expansion or terminal differentiation are controlled by the activity of growth 
factors and nuclear regulators. Alterations in any part of the signaling pathways have the 
potential to induce transformation (Crans et al., 2001). 
The different types of leukaemia are classified according to duration of the disease and the 
type of white blood cell involved. Leukaemias can be separated in two major classes based 
on the lineage from which each is derived; namely myeloid and lymphoid.  Lymphoid 
leukaemias involve one of two cell types, T-cells or B-cells or their precursors. These can be 
further classified into acute and chronic leukaemias. In acute leukaemia, there is a 
predominance of immature cell types, blasts and pro stages, whereas in chronic leukaemia Introduction  4
the cell types are relatively mature (Crans et al., 2001). In acute leukaemias chromosomal 
abnormalities frequently activate transcription factors. These are encoded by so-called 
master genes which in turn control the expression of responder genes and can be positive or 
negative transcriptional regulators. In contrast, chromosomal abnormalities in chronic 
leukaemia often do not encode nuclear proteins. In chronic leukaemias genes activated 
appear to have roles in proliferation and survival, whereas acute leukaemia associated genes 
have a role in transcription and differentiation (Rabbitts et al., 1991).  
Chromosomal abnormalities have been found in more than 60% of patients with acute 
myelogenous leukaemia (AML) and 65% of those with acute lymphoblastic leukaemia (ALL). 
Chromosomal rearrangements lead to the unnatural juxtaposition of genes, which give rise to 
the aberrant expression of transcription factors resulting in uncontrolled cell proliferation. This 
can occur in one of two ways: most commonly, by gene fusion joining exons from normally 
disparate genes to encode a novel fusion protein and less commonly, by the juxtaposition of 
a cellular oncogene with the enhancer of a lineage specific gene, leading to an increase in 
expression of the oncogene. 
In T or B lymphoid progenitors such genes are frequently mobilized into the vicinity of genes 
encoding discrete chains of the T-cell receptor (TCR) or immunoglobulin (Ig) molecules, 
respectively, resulting in inappropriate expression of the translocated protooncogenes. The 
oncoproteins produced by these chromosomal translocations specifically interfere with 
transcriptional networks that normally function in concert with growth factors and their 
receptors to regulate haematopoiesis. This often produces a block in differentiation with 
subsequent accumulation of lymphoid precursors in the bone marrow or thymus (Look et al., 
1997).  
Although convincing evidence supports an essential role for oncogenic transcription factors in 
leukaemogenesis, the molecular events leading to malignant transformation upon 
deregulation or mutation of the corresponding oncogenes are not well understood. The 
oncogenic transcripton factors must cross talk with the general transcription machinery to 
activate or suppress gene transcription (Tjian et al., 1994). They presumably also interact 
with other known or unknown factors to regulate their target genes and modulate the status of 
cell proliferation and differentiation. Elucidation of the molecular events leading to leukaemia 
formation may lead to identification of new molecular targets for the design of more effective 
and less toxic therapies against leukaemia (Look et al., 1997). 
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1.2.1  Childhood Leukaemia (Acute Lymphoblastic Leukaemia) 
ALL is the most prevalent type of leukaemia in children (Uckun et al., 1998). ALL is regarded 
as a childhood disease with a peak at 2-5 years of age with an annual incidence in different 
western countries varying between 0.9 to 4.7 per 100,000 children. ALL is also the most 
common form of cancer in children overall, accounting for approximately one third of all 
juvenile neoplasms (under 16 years in developed countries). Bone and joint pain, fever, 
hepatosplenomegaly and lymphadenopathy are relatively common presenting features   
(Uckun et al., 1998; Ma et al., 1999; Harrison et al., 2001).  
The outcome for children with ALL is now extremely favourable. Initial remission rates exceed 
90% with greater than 70% of patients achieving long term event free survival (EFS) 
(Harrison et al., 2001). Despite the intensity of first line chemotherapy in the treatment of ALL, 
this strategy is not able to cure all patients so that roughly 25% of all children suffer from 
relapse, mostly within the first 5 years from diagnosis (Uderzo et al., 2001). 
Based on the expression of surface antigens, ALL can be broadly classified as either B- or T- 
lineage. Markers include immunoglobulin and CD79 for B-lineage ALL and T-cell receptor 
and cytoplasmic CD3 for T-lineage ALL. B-lineage ALLs can be further sub-classified as early 
pre B-, pre B-, transitional pre B- or B-cell and T-lineage ALLs as early, mid or late 
thymocyte. ALLs are grouped as either `high risk’ or `standard risk’. Risk classification is 
based in part on clinical features, the most important of which have been presenting age and 
leukocyte count. White blood cell (WBC) count at diagnosis is a standard prognostic feature, 
with children with WBC above 50,000/ul being at higher risk. Immunophenotyping is also 
used in risk classification. It is proposed, however, that genetic factors may more accurately 
predict outcome than do age, immunophenotype and leukocyte count (Rubnitz and Pui, 
1997). For example, the DNA index (ploidy), which was found to be the strongest predictor of 
treatment outcome when compared to age, WBC, sex and immunophenotype. Ploidy, is the 
ratio of DNA content of leukaemic cells to that of normal cells and can be measured by flow 
cytometry. Hyperploidy, defined as a DNA index greater than 1.16 (which correlates with 
more than 50 chromosomes per leukaemic cell) is present in about 20% of patients over one 
year of age and is associated with a very favourable prognosis regardless of age and 
presenting WBC. Along the same lines, hypodiploidy has been repeatedly found to be an 
adverse prognostic feature (Friedmann et al., 2000).  
The DNA index is closely related to other prognostic features such as unfavourable 
chromosomal abnormalities. Chromosomal abnormalities can be detected using standard 
cytogenetic analysis. Some recently discovered structural abnormalities are diagnosed 
through other techniques, such as fluorescence in situ hybridization (FISH) or reverse 
transcriptase polymerase chain reaction (RT-PCR) (Friedmann et al., 2000). Table 1.1 Introduction  6
outlines the distribution of translocations prevalent in childhood ALL. Genetic alterations in 
childhood leukaemia are powerful prognostic indicators. TEL-AML1 fusion is associated with 
a good prognosis in B-lineage childhood acute lymphoblastic leukaemia, whereas BCR-ABL 
fusion and MLL rearrangements are associated with poor prognosis (Ma et al., 1999). 
Although cells from the majority of paediatric patients express B-lineage associated antigens, 
those from approximately 15% of patients express the T-lineage associated antigens. T-
lineage ALL in children is associated with numerous unfavourable presenting features, 
consequently, paediatric T-lineage ALL is frequently reported to have a worse prognosis than 
paediatric B-lineage ALL (Uckun et al., 1998). 
Karotype Dysregulated  Gene  Frequency 
B precursor ALL 
t(12;21)(q13;q22) 
t(1;19)(q23;q13) 
t(9;22)(q34;q11) 
t(4;11)(q21;q23) 
Other 11q23 
Hyperdiploid 
 
TEL-AML1 
E2A-PBX1 
BCR-ABL 
MLL-AF4 
MLL fusions 
- 
 
25% 
6% 
4% 
4% 
<1% 
20% 
B-cell ALL 
t(8;14)(q24;q32) 
t(2;8)(q12;q24) 
t(8;22)(q24;q11) 
 
MYC  
MYC 
MYC  
 
2% 
 
T-cell ALL 
Basic helix loop helix 
t(1;14)(p32;q11) 
t(1;7)(p32;q35) 
t(7;9)(q34;q32) 
t(7;19)(q34;p13) 
t(8;14)(q24;q11) 
t(14;21)(q11;q22) 
LIM proteins 
 
 
TAL1/SCL 
TAL1/SCL 
TAL2  
LYL1  
MYC  
BHLHB1 
 
 
 
3-6% 
<1% 
<1% 
<1% 
1% 
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t(11;14)(p15;q11) 
t(11;14)(p13;q11) 
Homeobox proteins 
t(10;14)(q24;q11) 
t(7;10)(q35;q24) 
t(5;14)(q35;q32) 
Other 
t(1;7)(p34;q34) 
t(7;9)(q34;q34) 
inv(14)(q11q32) 
LMO1 
LMO2 
 
HOX11  
HOX11  
HOX11L2 
 
LCK  
NOTCH 
IGH  
1-4% 
7% 
 
5% 
<1% 
20% 
 
<1% 
  2% 
<1% 
TABLE 1.1 DISTRIBUTION OF TRANSLOCATIONS IN CHILDHOOD ALL (Bernard et al., 
2001; Ballerini et al., 2002; Harrison et al., 2000; Rubnitz and Pui, 1997; Ma et al., 1999; 
Thandla et al., 1997; Wang et al., 2000). 
1.2.2  T-cell Acute Lymphoblastic Leukaemia (T-ALL) 
T-ALL is associated with high WBC, male gender, higher age at presentation in children, 
presence of a mediastinal mass, high incidence of CNS disease and relatively poor 
prognosis. Genetic changes in T-ALL involve the T-cell receptor (TCR) genes in 
approximately 30% of T-ALL cases. The alpha and delta genes (TCRA and TCRD) have 
been mapped to 14q11-q13 and the beta and gamma chains (TCRB and TCRG) to 7q32-q36 
and 7q15 respectively. Rearrangements most frequently involve the TCRAD and TCRB loci 
(Harrison et al., 2001). It can clearly be seen from Table 1.1, which outlines the distribution of 
translocations observed in both T-ALL and B-lineage ALL, that chromosomal translocations 
associated with ALL also frequently involve transcription factors. 
Leukaemic transformation may occur at distinct stages of T-cell ontogeny in T-ALL in different 
patients which results in leukaemic cells with immunophenotypes that correspond to less or 
more mature T-cell progenitors (Heerema et al., 1998). Contemporary intensive therapies 
have resulted in the improvement of outcome for T-ALL patients, with 5 year relapse free 
survival rates now in the range of 60-75%. Nevertheless, despite the gains achieved with risk 
adjusted therapy programs, relapse continues to be the major cause of treatment failure for 
approximately 20% of T-lineage cases (Heerema et al., 1998; Pui and Evans, 1998; 
Silverman et al., 2001).  Introduction  8
1.3 Homeobox  Genes 
One family of transcription factor genes that can be deregulated in ALL are the homeobox 
genes. The term homeobox takes its origin from the Drosophila homeotic mutations in which 
the identity of one body segment was transformed into the likeness of another. Many of the 
genes involved in these mutations share a conserved 180 nucleotide homeobox which 
encodes a 60 amino acid DNA binding motif called the homeodomain. The homeodomain 
region forms a helix-turn-helix structure with 3 distinct α helical regions (Gehring et al., 1994). 
The third helix contacts DNA through the major groove and makes specific base pair 
contacts. Homeobox proteins tend to bind to DNA in complexes with partner proteins, such 
as PBX and MEIS (Piper et al., 1999). 
Homeobox genes are expressed in precise temporal and spatial patterns to guide the 
morphogenesis of the Drosophila embryo. In Drosophila homeotic genes are organized as a 
complex called HOM-C or the homeotic cluster that is expressed in ordered domains along 
the anterior-posterior axis of the embryo. This expression parallels the linear 3’ to 5’ order of 
the genes in the cluster. This cluster shares significant homology to the four mammalian HOX 
clusters (HOXA-HOXD) (Mark et al., 1997; Ravid et al., 2001). Human homeobox genes are 
located on chromosomes 2, 7, 12 and 17 and presumably have arisen by local gene 
duplications followed by duplication of entire gene clusters (Mark et al., 1997). 
The family of homeobox containing genes is subdivided into classes. Those that are of 
particular importance in haematopoetic cells include the hexapeptide group, including the 
HOX family, which have an N-terminal PBX protein interaction domain, the POU group, 
containing N-terminal POU domain, the LIM group, with an N-terminal LIM domain and the 
TALE group, including PBX and MEIS proteins (Ravid et al., 2001). 
1.3.1  HOX Genes and Development 
In mammals, 39 HOX genes are organized into four conserved clusters (A-D) of 9-11 genes 
each situated on a different chromosome. Numbered according to their 3’ to 5’ order on the 
chromosome, this order correlates with the spatial and temporal order of expression of these 
genes along body axes during development. Retinoic acid stimulation has also been 
implicated to cause a cascade of HOX gene expression that proceeds in a 3’ to 5’ direction 
along the HOX cluster. Genes in the same position on different clusters are called paralogs 
and have particularly high homology to each other. None of the clusters contain a gene from 
every paralog group indicating that gene loss has occurred during evolution (Ravid et al., 
2001).  
During embryogenesis HOX genes are expressed in overlapping temporal and spatial 
patterns along the body axis including anterior-posterior axis of the spine and limbs, the Introduction  9
proximal distal axis of the limbs, gastrointestinal tract and urogenital system. Anterior to 
posterior order of expression follows the 3’ to 5’ order of genes within the cluster. HOX 
knockout mice therefore display multiple morphogenic, spatially restricted abnormalities 
(Ravid et al., 2001). 
Besides these clustered HOX genes, unclustered, more divergent homeobox genes have 
been assigned developmental roles in growth control, organogenesis and the establishment 
of cellular phenotypes (Lin et al., 1992; Jonsson et al., 1994; Lyons et al., 1995; Hentsch et 
al., 1996). 
1.3.2  HOX Genes and Haematopoiesis 
In general HOX genes tend to be expressed in lineage-restricted patterns. In haematopoiesis 
HOXA genes tend to be expressed in the myeloid lineage, HOXB genes are active in the 
erythroid lineage, HOXC genes are active in lymphoid cells and HOXD genes are generally 
silent (refer to Table 1.2). Complex patterns of coordinated HOX gene expression occur in 
normal haematopoietic cells. In normal CD34+ marrow cells which contain haematopoietic 
stem cells and committed progenitors, 9 of the 11 HOXA genes, 8 of the 10 HOXB genes and 
4 of the 9 HOXC genes, but no HOXD genes, were expressed (Giampaolo et al., 1994; 
Moretti et al., 1994; Sauvageau et al., 1994; Ravid et al., 2001). These CD34+ marrow cells 
can be sorted into three populations: primitive haematopoietic cells, granulocyte/macrophage 
progenitors and erythroid progenitors. HOX gene expression is highest in the most primitive 
subpopulations (Sauvageau et al., 1994; Ravid et al., 2001). Generally HOX genes at the 3’ 
region of clusters, such as HOXB3 and HOXB4, are down-regulated at the committed 
progenitor stage, while genes at the 5’ end of each cluster, such as HOXA9, HOXB9 and 
HOXA10, continue to be expressed until cells differentiate past the CD34+ compartment. 
Therefore a large set of HOX genes are involved very early on in haematopoiesis and play 
their most important role early on in haematopoietic proliferation and differentiation (Ravid et 
al., 2001). Introduction  10
 
HOX GENE  ROLE IN HAEMATOPOIESIS 
HOXA10    Overexpression in haematopoietic stem cells perturbs myeloid 
and B-cell differentiation. Megakaryocyte progenitor population 
is expanded (Thorsteinsdottir et al., 1997) 
HOXA9    Overexpression in primary bone marrow leads to defective T-
cell development 
  Knockout mice have lower lymphocytes, granulocytes and 
committed progenitors 
(Izon et al., 1998; Kroon et al., 1998) 
HOXA5    Overexpression in bone marrow and cord blood progenitors 
leads to a greater number of myeloid cells and lower levels of 
erythroid differentiation  
  Antisense oligonucleotides lead to high numbers of erythroid 
progenitors and fewer myelomonocytic cells 
      (Crooks et al., 1999; Fuller et al., 1999) 
HOXB6    Targeted disruption results in an expansion of erythroid 
progenitors 
  Antisense methodology decreases erythroid differentiation 
  Also been detected in myelomonocytic cells 
(Kappen et al., 2000; Shen et al., 1989; Ohnishi et al., 1998) 
HOXB4    Overexpression leads to expansion of the stem cell 
compartment in transplanted mice 
(Thorsteinsdottir et al., 1999) 
HOXB3    Overexpression in bone marrow leads to disruption of lymphoid 
differentiation, greater granulopoiesis and myeloproliferative 
disease  
(Sauvageau et al., 1997) 
HOXC6    Antisense treatment inhibits late erythroid colony formation 
(Kongsuwan et al., 1988) 
TABLE 1.2 THE ROLE OF HOX GENES IN HAEMATOPOIESIS as demonstrated by loss of 
function studies and overexpression studies (Adapted from Owens et al., 2002). 
1.3.2.1  HOX Genes and T-cell Development 
The complex pattern of HOX gene expression which is associated with the development of 
lymphoid cells is yet to be fully characterized. However, it has been determined that distinct 
patterns of HOXB and HOXC expression are apparent during lymphoid cell development. 
HOXB genes are not normally expressed in peripheral blood cells, however activation of T-
cells with phytohaemagglutinin (PHA) resulted in the sequential activation of HOXB1-7 and 
HOXB9 (Care et al., 1994). Additionally, the expression of HOXB3 in T-cell progenitors 
resulted in the skewing of the T-cell progenitors toward the γδ T-cell lineage (Sauvageau et 
al., 1997). HOXC4 and HOXC8 expression have also been detected in resting lymphocytes 
and expression is increased with PHA activation (Meazza et al., 1995). A crucial role for 
HOXA9 in the development of T-cells has been identified as the corresponding knockout 
mice possess thymocytes that are blocked at an early stage of differentiation (Izon et al., Introduction  11
1998). Overall, expression of HOX genes is low in quiescent mature cells, but stimulated by 
mitogen induced activation (Ravid et al., 2001). 
A recent study used RT-PCR and microarray analysis to analyze the expression patterns of 
HOX genes in stem cells from the fetal liver and adult bone marrow as well as T-cell 
progenitors from thymus tissue in children. The study found that HOXA cluster genes were 
expressed at high levels in fetal liver, adult bone marrow stem cells and paediatric thymus T-
cell precursors (Taghon et al., 2003). They demonstrated that as immature thymocytes 
migrated from the fetal liver and adult bone marrow into the thymus there was a drastic 
change in HOX gene expression. A sequential loss of expression of the 3’ region of the 
HOXA cluster genes was observed upon entry to the thymus and during T-cell development. 
Expression of HOXB4,  a gene associated with stem cell renewal and HOXA9, a gene 
expressed in early T-cell committed cells, were also found to be down-regulated upon entry 
to the thymus. The study also examined HOX gene expression in the thymus. HOXB3 was 
found to be expressed by TCRγδ T-cells as well as TCRαβ T-cells while HOXC4  and 
HOXA11 were found to be expressed at all stages of T-cell development. HOXA10 and 
HOXA7 were found to be expressed in immature thymocytes, but not in mature thymocytes 
(Taghon et al., 2003). 
1.3.3  HOX Genes and Leukaemia 
Aberrant  HOX  gene expression has been linked to leukaemia in humans and in mouse 
models. For example, Hoxb8 was found to cause AML when co-expressed with IL3 in mice 
(Perkins et al., 1990). Further work showed that overexpression of Hoxb8, Hoxa9, Hoxa10 or 
Hoxa3, but not Hoxb4 in mice eventually caused AML over several months. This finding 
suggested that a second genetic event in addition to Hox gene overexpression was required 
for leukaemogenesis (Thorsteinsdottir et al., 1997, 1999; Sauvageau et al., 1995, 1997; 
Kroon et al., 1998). 
It has also been shown that collaborator molecules are required to cooperate with HOX 
genes for the most effective regulation of a set of critical target genes required for the onset 
of leukaemia. Examples include IL3 and Meis1 collaborating with Hoxb8 and a9 respectively 
in transformation (Moskow et al., 1995; Kroon et al., 1998) and Pbx1 transforming Rat-1 
fibroblasts when expressed together with Hoxb3 or Hoxb4 (Krosl et al., 1998). It has also 
been suggested that Meis1 and Pbx1 induce transformation when co-expressed with distinct 
Hox partners. The pattern of interaction is thought to be such that HOX paralog groups 1 
through to 10 interact with PBX proteins and HOX paralogs 9 through to 13 interact with 
MEIS protein partners (Ravid et al., 2001). Thorsteinsdottir et al., (2001) demonstrated that 
HOXA9 and HOXB3 genes play key roles in establishing all the main characteristics of the 
AML, while MEIS1 functions only to accelerate the onset of leukaemic transformation Introduction  12
(Thorsteinsdottir et al., 2001). It has also recently been demonstrated in haematopoietic cell 
lines that the HOXA9 protein is part of a trimeric complex with both PBX2 and MEIS1 (Shen 
et al., 1999). 
In humans, HOXA9 fused to the nucleoporin NUP98 gene by the t(7;11)(p15;p15) 
translocation has been found to be associated with myeloid leukaemia (Nakamura et al., 
1996; Borrow et al., 1996).The oncogenic potential of NUP98-HOXA9 has been attributed to 
the FG repeats which are capable of interacting with the transcriptional co-activator 
CBP/p300 as well as the loss of the HOXA9 repressor domain in the fusion event (Kasper et 
al., 1999). HOXD13 fused to NUP98 has also been implicated in AML (Raza-Egilmez et al., 
1998). Additionally, the HOX DNA binding partner PBX1 is involved in the t(1;19) 
translocation which results in the production of the E2A-PBX1 fusion protein (Chang et al., 
1997). Importantly, however, HOXA9 has recently been shown to be a gene highly correlated 
with poor prognosis in human AML (Golub et al., 1999; Ravid et al., 2001). 
Several major mechanisms by which protein dependent transcriptional dysregulation of HOX 
genes can occur leading to the onset of leukaemogenesis have been proposed. In normal 
settings, homeodomain proteins interact with co-activators and other components of the 
basal transcriptional machinery in the presence of cofactors and DNA target binding 
sequences. In these situations gene expression is tightly regulated. In cases of leukaemia, 
homeodomain genes are frequently activated by chromosomal translocations, leading to 
dysregulated gene expression or production of fusion genes that encode chimaeric proteins 
with altered transactivating potential. Additionally, overexpression of cofactor proteins such 
as PBX or MEIS can alter HOX protein function. The probability of formation of HOX 
containing complexes capable of transcriptional activation or repression increases with the 
presence of cofactors (Owens et al., 2002).  
Transcriptional repression has also been implicated in leukaemogenesis, for example, 
aberrant expression of homeodomain proteins may result in inhibition of normal downstream 
target genes. This may occur through mechanisms involving competition for binding sites or 
interactions with transcriptional co-repressors such as CBP/p300 (Owens et al., 2002). It has 
been demonstrated that a direct interaction between HOX proteins and CBP could result in a 
block of CBP histone acetyltransferase activity and thus induce repressive HOX activity 
(Shen et al., 2001). Other mechanisms of homeodomain protein mediated repression have 
been described, including direct repression by interference with components of the basal 
transcriptional machinery, competition with cofactors for DNA binding sites and quenching of 
transcriptional co-activators by blocking their transactivating ability (Li et al., 1998; Um et al., 
1995; Owens et al., 2002). Introduction  13
 
Genes  Genetic Anomalies  Types of Disease 
Human Diseases 
PBX1  t(1;19) E2a-PBX1 Pre  B-ALL 
HOX11  t(10;14) TCRδ-HOX11  T-ALL 
HOX11L2  t(5;14) CTIP2-HOX11L2 T-ALL 
HOXA9  t(7;11) NUP98-HOXA9 AML 
HOXD13  t(2;11) NUP98-HOXD13 AML 
Mouse Models 
Hoxb8  Proviral activation  AML 
Hoxb3  Retroviral overexpression  AML 
Hoxa10  Retroviral overexpression  AML 
Hoxa9  Retroviral overexpression  AML 
TABLE 1.3 HOX GENES IMPLICATED IN LEUKAEMIA. Adapted from Ravid et al., 2001 Introduction  14
1.3.4  HOX11 as a Homeobox Protein 
Upon molecular cloning, HOX11 was found to contain a homeobox DNA binding domain 
within its second exon (Dube et al., 1991; Kennedy et al., 1991; Hatano et al., 1991; Lu et al., 
1991). The HOX11 gene was revealed to share significant homology with known homeotic 
genes such as the Drosophila 311 gene, which is involved in the control of insect muscle 
development (Dear et al., 1994). HOX11 was also found to be closely related, but not 
identical to the clustered murine and human homeobox genes. However, unlike previously 
identified human homeobox genes, HOX11 was not found on chromosomes 2, 7, 12 and 17 
and was therefore designated as being a nonclustered homeobox gene (Kennedy et al., 
1991).  
In contrast to being clustered with other adjacent homeobox genes, HOX11 was originally 
thought to be an orphan homeobox gene (Kennedy et al., 1991). However, the LBX1 
homologue of the Drosophila  lady bird genes was found to map to the q24 region of 
chromosome 10. Thus LBX1 and HOX11 map to a common chromosomal region as do their 
Drosophila counterparts. The HOX11 and LBX1 genes both belong to the NKL cluster which 
is believed to have diverged early during vertebrate evolution. The NKL cluster has 
disintegrated during evolution, presumably since there was no selection for it to remain intact, 
unlike the clustered HOX genes. The relatively intact 93D/E cluster in Drosophila which is 
equivalent to the NKL cluster in mammals contains the 93Bal and ladybird late genes that are 
homologous to the HOX11 family of genes and LBX family of genes in the human genome. 
Other corresponding members of the NKL cluster appear to have become redundant in 
humans (Jagla et al., 1995; Owens et al., 2002). 
1.3.5 The  HOX11 Family of Homeobox Genes 
HOX11 has been found to belong to a three member family of homeobox encoding genes 
within the NKL group. HOX11 along with HOX11L1 and HOX11L2 make up this family which 
have presumably arisen due to duplication events involving the entire NKL cluster. The 
homeobox domain is highly conserved amongst the genes of this family. All members of the 
HOX11 family contain a threonine residue in place of the more common isoleucine or valine 
in helix 3 of the homeodomain (refer to Figure 1.1). This is thought to contribute to binding 
specificity. The high degree of conservation of the homeodomain suggests that these 
proteins may bind to similar DNA target sequences in vivo. Shimizu et al., (2000) found that 
HOX11L1 was able to bind the same target sequence as HOX11 (Shimizu et al., 2000). 
Overall, murine Hox11L1 and Hox11L2 have 61.3% and 66.3% amino acid homology to 
Hox11 respectively (Dear et al., 1993). Introduction  15
Interspecies conservation of the primary sequences of these proteins is observed both within 
and outside the homeodomain, suggesting common important biological functions (Bernard 
et al., 2001). In addition to the homeodomain, HOX11 family proteins contain several other 
highly conserved motifs. The FIL domain (so named for its consensus sequence, FXIXXIL, 
where X= any amino acid) has been shown to actively mediate transcriptional repression by 
acting as an interaction motif for Groucho family co-repressors, raising the possibility that 
HOX11 proteins may function as transcriptional repressors under certain conditions (Cheng 
et al., 1993; Logan et al., 1998). The acidic glutamine rich region (Gln-Rich Region) is also 
conserved in the family and is thought to possibly function as a transcriptional activation 
domain. Finally, a glycine rich region at the amino terminus (Gly-Rich) and a PBX interaction 
motif (PIM), which is thought to facilitate the binding of PBX proteins, are also homologous 
amongst members of the family (Zhang et al., 1996). 
The DNA sequence for HOX11 encodes a 330 amino acid homeobox protein. A lysine rich 
stretch bordered by prolines (PPKKKKP) exists at the NH2-terminal portion of the 
homeodomain. All homeodomain proteins to date have a nuclear localization motif and this 
sequence highly resembles such a motif. HOX11 has a 5 amino acid PIM that is similar to the 
conserved pentapeptide motif IYPWM often found upstream of the homeodomain of HOX 
proteins. The NH2- terminal variable sequence of HOX11 has several extremely glycine rich 
regions, some of which were interspersed with prolines. Similar glycine rich regions have 
been observed in other homeobox proteins, although these are largely absent from HOX11L1 
and L2. Overall the HOX11 protein was found to be basic while the COOH terminus was 
found to be acidic. Other homeobox proteins have also been reported to have acidic COOH 
terminal domains rich in serine and threonine residues. Such domains have been implicated 
in transcriptional activation (Hatano et al., 1991). 
All three HOX11 family members exhibit a restricted pattern of expression in development. 
The different family members either individually or in combination play very similar roles in 
the differentiation of distinct neuronal populations (Logan et al., 2002). Introduction  16
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FIGURE 1.1 THE HOX11 FAMILY OF HOMEOBOX PROTEINS 
The HOX11, HOX11L1 and HOX11L2 proteins are represented. The FIL repression domain (FIL), 
glycine rich regions (Gly-Rich Regions), PBX interaction motif (PIM), homeodomain (HD), with 
threonine residue at position 47 (T47) and acidic, glutamine rich region are all indicated. Adapted 
from (Dear et al., 1993). 
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1.4  The HOX11 Gene and Its Regulation 
HOX11 was originally discovered through the sequencing of breakpoints in chromosome 10 
that occur within a 15kb breakpoint cluster region. The transcript encoded by the gene at 
10q24 was independently cloned by four laboratories (Dube et al., 1991; Kennedy et al., 
1991; Hatano et al., 1991; Lu et al., 1991). The gene is made up of three exons and two 
introns. The transcriptional start site was reported to be 725bp upstream of the ATG start site 
in the mouse. A typical TATA box was also identified 35bp upstream from the start site and a 
negative regulatory region was located in the –1240 to –540 region (Arai et al., 1997). 
Multiple negative regulatory elements (NRE1 to NRE4) have also been identified in the 
promoter of human HOX11 (Brake et al., 1998). These elements have differential function in 
different leukaemic cell lines and three are conserved between the human and murine 
genomes. It is proposed that the combined action of these negative regulatory elements 
contributes to the overall repression of HOX11 in normal cells. The T-ALL associated HOX11 
translocation may remove HOX11 from the long range negative elements and place the gene 
in a region where it is activated by positive elements. In addition, it is also possible that 
mutation or deletion of negative elements may release the gene from short range repression 
effects leading to its up-regulation (Brake et al., 1998). This may account for the high 
proportion of T-ALL patient samples that express HOX11 in the absence of a translocation 
(Salvati et al., 1999). In fact a recent study by Ferrando et al., (2004) used allele specific 
mRNA analysis to demonstrate that transacting mechanisms lead to the biallelic 
overexpression of HOX11 in 17% of 12 HOX11 positive T-ALL cases. In these cases single 
nucleotide polymorphisms were identified in the 3’UTR region of HOX11, which suggests that 
aberrant expression of HOX11 in T-ALL may result from loss of upstream transcriptional 
mechanisms that normally down-regulate HOX11 gene expression (Ferrando et al., 2004). 
A study by Brake et al., (2002) identified a region of the promoter which contributes 
significantly to HOX11 activation and identified two regulatory elements in K562 leukaemic 
cells. The first (at –1048bp) was found to bind PBX2 and PREP1. These findings were 
confirmed in HOX11 expressing T–ALL cell lines PER-255 and ALL-SIL. A second regulatory 
element (at –1019) was found to be a novel sequence that binds an as yet unidentified factor 
mediating the activation of HOX11. These two elements appear to contribute significantly to 
activation of the HOX11 proto-oncogene (Brake et al., 2002). 
Recent work described the identification of three alternative transcripts of HOX11 in primary 
patient T-ALL specimens and cell lines. All samples also expressed the canonical 2.3kb 
transcript and harboured chromosomal translocations involving the HOX11 locus (Watt et al, Introduction  18
2003). This finding suggested that the alternative transcripts are co-expressed with the 
canonical HOX11 transcript. It is conceivable that these alternative transcripts play a role in 
the oncogenesis of T-cells, since the expression of the canonical transcript has not been 
shown to be effective in animal models of T-cell leukaemia (Hawley et al., 1997; Hough et al., 
1998). It is possible that full transformation of T-cells may require the co-expression of 
alternative domains of HOX11. This study also established that alternative HOX11 transcripts 
contained all three exons, but utilized alternative splice sites within the intronic sequence. In 
addition, these alternative transcripts contained exons expressed in T-ALL which are not 
expressed in normal T-cells. These alternative transcripts were also detected in 
neuroblastoma and primitive neuroectodermal tumour cell lines (Watt et al, 2003). 
1.4.1  The Role of HOX11 as a Transcription Factor 
The first direct evidence to indicate that the HOX11 protein acts as a transcription factor was 
the demonstration that HOX11 could bind DNA and transactivate a CAT reporter gene linked 
to a promoter containing the specific target sequence TAATGG (Dear et al., 1993). Further 
work by Dear et al., (1993) utilized a GST-HOX11 homeodomain fusion protein to identify 
TAAT as the dominant HOX11 binding sequence in vitro, with TAAC being a possible variant. 
The third helix of the homeodomain of HOX11 has a threonine instead of the usual isoleucine 
or valine. The threonine in the HOX11 homeodomain could potentially hydrogen bond with 
cytosine in this position making TAAC a possibility. The threonine can also contact thymine 
residues via a methyl-methyl interaction thus accounting for TAAT (Dear et al., 1993). 
Tang et al., (1995) predicted the recognition motif of the HOX11 protein using the Engrailed 
(En) homeodomain protein as a model. The presence of Thr47 and Lys3 in HOX11 instead of 
Ile47 and Arg3, respectively, lead to the predicted binding sequence. The En  binding 
sequence TAATTG was modified to TAANTG in the case of HOX11. In order to further refine 
the optimal in vitro DNA binding sequence of the HOX11 protein, a PCR based random 
oligonucleotide selection strategy to select specific oligonucleotides that are bound by full 
length recombinant HOX11 was employed. The most common binding sequence identified by 
this method was GGCGGTAAGTGG while another less specific form GGCGGTAAGCCG 
was also identified. The optimal core binding sequence was identified as TAAGTG. The G at 
nucleotide position four is variable from previously identified binding sequences, but it is 
possible for threonine to use its hydroxyl or methyl side chain to bind guanine, cytosine or 
thymine. However, the TAAT sequence showed that it was unable to compete efficiently with 
the TAAGTG binding sequence in bandshift experiments, indicating that TAAGTG was the 
optimal HOX11 binding sequence in vitro (Tang et al., 1995). 
Recent work by Shimizu et al., (2000) found that a GST-HOX11 fusion protein was able to 
bind TAAT and TAAG core oligonucleotides in vitro. Further investigation showed that Introduction  19
HOX11 was only able to efficiently transactivate reporter genes linked to the TAAT core 
sequence, but not the TAAG core sequence. This result suggests that HOX11 may act as a 
transcriptional transactivator by binding to the CGGTAATTGG target sequence (Shimizu et 
al., 2000). 
Studies by Zhang et al., (1996) investigated the importance of transactivation domains within 
HOX11. By deletion analysis the glycine proline rich region at the amino terminus, the 
homeodomain and the glutamine rich region at the carboxyl terminus were all found to act in 
concert for optimal transactivation of promoters in reporter assays in mammalian and yeast 
cells (Zhang et al., 1996). Further work by Masson et al., (1998) examined the functional 
characteristics of HOX11 in a reporter assay. The transcription of the HOX11-dependent 
gene  Aldh1a1 in NIH3T3 cells was examined. An intact homeodomain was shown to be 
essential for induction of endogenous Aldh1a1 by HOX11. In addition, the NH2 terminal 50 
amino acid stretch including a conserved FIL motif was also shown to be crucial for optimal 
function of the HOX11 protein in vivo. Finally, the COOH terminal region of HOX11 was not 
required for Aldh1a1 induction and deletions in the area were found to have little effect 
(Masson  et al., 1998). Altogether, these findings indicate that HOX11 can function as a 
transcription factor and regulate gene expression. 
1.4.2 Co-factors  of  HOX11 
1.4.2.1  HOX11 and TALE Homeodomain Proteins 
Members of the three amino acid loop extension (TALE) homeodomain superfamily have 
been implicated as acting as co-factors in tumourigenesis and are known to cooperatively 
bind DNA with HOX homeoproteins (Kroon et al., 1998; Shen et al., 1997; Thorsteinsdottir et 
al., 1999; Mann et al., 1996). Co-operative interaction between homeodomain proteins and 
PBX proteins has been shown to be mediated by the conserved PIM motif which is usually 
found upstream of the homeodomain. The mammalian PBX and MEIS proteins belong to the 
TALE superfamily of homeodomain-containing transcription factors (Allen et al., 2000). Also 
of interest is the fact that MEIS proteins have also been found to interact with PBX proteins 
(Chang et al., 1997). More recent studies have revealed the existence of HOX/PBX/MEIS 
trimeric complexes which are integral to the oncogenic potential of HOX proteins (Schnabel 
et al., 2000). 
PBX homeoproteins have been shown to cooperatively bind to DNA with HOX11 in vitro. The 
PBX recognition site was found to have the sequence TGATTGAT and while all three PBX 
proteins were able to heterodimerize with HOX11 at this site, MEIS1 was not, nor was it able 
to heterodimerize at another previously identified MEIS1 target site. Nevertheless, incubation 
of HOX11, PBX and MEIS1 effected DNA binding at both these sites which was interpreted Introduction  20
as indicating the possible formation of a HOX11/PBX/MEIS1 trimeric complex (Allen et al., 
2000). 
Association with TALE homeoproteins is also thought to add selectivity to HOX11 
homeodomain DNA interactions. Heterodimerization with PBX1a was shown to change the 
way HOX11 interacts with various putative HOX11 binding sites. It is thought that such 
heterodimerization alters the way the HOX homeodomain makes specific contacts with DNA 
via the major groove. This finding adds further weight to the notion that TALE proteins may 
be necessary co-factors for HOX11 in oncogenesis (Allen et al., 2000). 
In an attempt to identify the role that TALE proteins may play in HOX11 
immortalization/transformation, Allen et al., (2000) examined the co-expression of PBX and 
MEIS homeobox genes together with HOX11 in a panel of T-ALL cell lines by Northern and 
Western blot. PBX2 transcripts were detected in two human T-ALL t(10;14) HOX11 
expressing cell lines. EMSA assays confirmed that PBX proteins are involved in the formation 
of higher order multiprotein complexes in t(10;14) T-ALL cells. Finally, HOX11 and PBX2 
were found to cooperatively induce focus formation in NIH3T3 cells when they were 
retrovirally expressed. Both experiments provided additional evidence that PBX proteins may 
act as HOX11 binding partners in T-ALL (Allen et al., 2000). 
TALE homeobox proteins may also play a role in controlling the transcriptional regulation of 
the HOX11 gene itself. In a search for trans-acting factors that control transcriptional activity 
from a distal 5’ region of the HOX11 promoter Brake et al., (2002) identified two distinct 
regulatory elements of the HOX11 promoter. The first of these elements was a PBX2 
regulatory element which was found to mediate activation of HOX11 in K562 cells. The 
PREP1 protein was also shown to be part of this binding complex. This binding complex was 
also confirmed in the HOX11 expressing T-ALL cell lines PER-255 and ALL-SIL (Brake et al., 
2002). The findings are also in agreement with work performed by Hawley et al., (1997) that 
identified the PBX binding responsive sequence as being essential for HOX11 immortalizing 
ability (Hawley et al., 1997). Recent findings by Selleri et al., (2001) demonstrate that Pbx1-/- 
knockout mice show spleen agenesis, recapitulating the asplenic phenotype of HOX11 
knockout mice. This finding provides additional evidence in support of PBX transcriptional 
regulation of HOX11 (Selleri et al., 2001; Dear et al., 1995). Taken together, these findings 
strengthen the case for TALE homeoproteins not only playing a role in HOX11 mediated 
leukaemogenesis but also in HOX11 gene regulation. 
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1.4.2.2  HOX11 and CTF1 
Increasing evidence suggests that homeoproteins can also interact with transcriptional 
regulators that lack a homeodomain (Zhang et al., 1999; Shen et al., 2001). A DNA binding 
site selection assay was used by Zhang et al., (1999) to investigate the cooperative binding 
of HOX11 with other transcription factors. A sequence identified as the binding site of CTF 
(CCAAT-box-binding) transcription factors was identified and further work showed that 
HOX11 interacted ex vivo and in vitro with CTF1. The ex vivo interaction between HOX11 
and CTF1 was confirmed by the co-immunoprecipitation of HOX11 and CTF1 in 
haematopoietic precursor cells. In addition co-transfection of CTF1 fused to the GAL4 
activation domain and a HOX11 construct resulted in the transactivation of the GAL promoter 
in yeast cells. In later experiments, in vitro translated CTF1 protein was shown to bind to 
HOX11, and a series of experiments with HOX11 mutants showed that the glycine proline 
rich region of HOX11 was the only region required for the association with CTF1. The 
addition of PBX protein to a DNA binding site selection assay did not alter the selection of the 
CTF binding site. This suggests that HOX11 preferentially associates with CTF proteins over 
PBX. The general transcription factor TFIIB was previously shown to bind to the proline rich 
activation domain at the carboxyl terminus of CTF1. Further mapping showed that HOX11 
bound to a separate region of CTF1 and a model was proposed in which constitutive 
expression of HOX11 in haematopoietic precursor cells facilitated the formation of a multi-
protein transcriptional complex containing CTF1 and TFIIB, thereby initiating a series of 
events leading to leukaemic transformation (Zhang et al., 1999).   
1.4.3  HOX11 Functions as a Transcriptional Repressor 
A study by Owens et al., (2003) identified that HOX11 displayed a dose dependent 
repression of the SV40 (simian virus 40), the HSVtk (herpes simplex thymidine kinase) and 
the CMV (cytomegalovirus) TATA containing promoters and the rat neu TATA-less promoter 
in CAT reporter assays (Owens et al., 2003). Further investigation using HOX11 mutants 
showed that the HOX11 repressor activity was DNA binding independent, but did require an 
intact homeodomain. Homeodomain point mutants which were previously shown to stop DNA 
binding activity were found to act as repressors as efficiently as wild type HOX11. The PBX 
interaction motif was also shown not to be necessary for repression, whilst the NH2 and 
COOH terminal domains of HOX11 were necessary for maximal transcriptional repression 
(Owens et al., 2003).  
These findings suggest that the repressor activity of HOX11 is mediated through protein-
protein interactions rather than the homeodomain binding to a specific DNA binding 
sequence. Several mechanisms of HOX11 repression have been suggested, including 
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binding site, interaction with transcriptional machinery and quenching, where HOX11 may 
interfere with the function of an activator nearby. The study by Owens et al., (2003) proposed 
that HOX11 acts as a repressor by contacting the components of the basal transcriptional 
machinery.  In vitro transcription assays demonstrated that HOX11 exerts its repressor 
function by interacting with one or more components of the RNA polymerase II holoenzyme. 
This finding is in accordance with the behaviour of the Msx-1 and Msx-2 homeodomain 
proteins which repress TATA containing and TATA-less promoters through interactions with 
the basal transcriptional machinery (TBP, TFIIA and TFIIB for Msx-1 and TFIIF for Msx-2) 
(Owens et al., 2003; Newberry et al., 1997). 
The repressor activity of HOX11 was also found to be separate from the HOX11-induced 
process of haematopoietic progenitor immortalization and up-regulation of the HOX11 target 
gene  Aldh1a1 and both these processes require an intact DNA binding domain. It was 
concluded that pathways that mediate HOX11 oncogenicity require the dysregulated 
expression of target genes by the binding of the HOX11 homeodomain to DNA in a sequence 
specific manner (Owens et al., 2003). 
1.5   The Role of HOX11 in Normal Cells 
1.5.1  The Role of HOX11 in Development 
1.5.1.1 Embryonic  Expression 
In the embryo Hox11 is initially expressed at embryonic day 8.5 (E8.5) in the trigeminal 
ganglia and the surface ectoderm of the developing muscle plates of branchial arches 1 to 4 
and 6 and subsequently in the motor nuclei that innervate cranial nerves 5,7,9 and 10. 
Additionally Hox11 is expressed in the presumptive muscle and papillae of the tongue, tooth 
primordia, the developing ear, a longitudinal bilateral stripe in the hindbrain, the thoracic 
region, the presumptive pharynx and the outflow tracts of the heart (Logan et al., 1998; 
Roberts et al., 1994; Dear et al., 1995; Roberts et al., 1995). More importantly, however, by 
E11.5 Hox11 is expressed at a single site in the abdomen within the splanchnic mesoderm 
(Roberts et al., 1994). 
1.5.1.2  Hox11 Controls the Genesis of the Spleen 
Several different groups have studied Hox11 knockout mice in order to investigate the role 
that Hox11 plays in development. Roberts et al., (1994) generated Hox11(-/-) knockout mice 
and discovered that these mice showed no evidence of a spleen or a splenic primordium. 
Further examination revealed that the development of the pancreas and stomach was normal 
in these mice. A slight increase in the number of neutrophils and lymphocytes and the 
presence of Howell-Jolly bodies in erythrocytes was also observed in these mice, but these Introduction  23
conditions are known to be associated with asplenia. A later study by Karrer et al., (1997) 
found that Hox11 knockout mice displayed little difference in their immune responses except 
for a slight delay in antibody response which is normally associated with asplenia (Karrer et 
al., 1997). Consequently, it was inferred that Hox11 controls the genesis of a single organ, 
the spleen (Roberts et al., 1994).  
1.5.1.3  The Fate of the Spleen In Hox11 Knockout Mice  
The fate of the cells of the spleen anlage in the dorsal mesogastrium of Hox11(-/-) knockout 
mice is uncertain. Alternative hypothesizes have been proposed to explain the involution of 
the spleen. The first proposed hypothesis was based around the idea that the cells of the 
spleen anlage undergo cell death through a program of apoptosis. This theory is of particular 
interest as it suggests that Hox11 plays some role in the prevention of cell death by 
apoptosis. Accordingly, it can be inferred that ectopic expression of Hox11 may instigate a 
program of cellular immortalization, which leads to tumorigenesis (Dear et al., 1995).  
Dear et al., (1995) incorporated the lacZ gene into the Hox11 transcriptional unit creating a 
null mutation. The production of β-galactosidase from lacZ Hox11(-/-) knockout mutants 
allowed the identification of sites of Hox11 expression in the developing spleen. Spleen 
formation was found to commence normally at E11.5, but complete reabsorption occurred 
between E12.5 and E13.5. Dying cells were found to exhibit molecular features of apoptosis, 
increased numbers of free chromosomal DNA ends, suggesting that programmed cell death 
may be initiated at this stage of organ development (Dear et al., 1995). It is also possible that 
this observed apoptosis occurred due to the lack of activation of downstream Hox11 target 
genes required for cell survival in these knockout mice.  
Further work by Roberts et al., (1995) revealed that no increase in cell death was detected by 
TUNEL assay within the dorsal mesogastrium of Hox11 deficient mice. Instead the dorsal 
mesogastrium was found to fail to separate from the stomach of Hox11(-/-) knockout mice. 
These mice were found to have a larger stomach and pancreas which was taken as a 
suggestion that these mesodermal cells found a new differentiative fate in the absence of the 
genetic program for spleen development and contributed to other organs and did not in fact 
apoptose. Thus a second hypothesis was formulated around the idea that cells of the spleen 
in Hox11(-/-) knockout mice contribute to other organs in the absence of Hox11. Accordingly, 
Hox11 plays an important role in providing the genetic program for spleen development via 
downstream target genes in the normal mouse (Roberts et al., 1995). 
Kanzler  et al., (2001) further investigated the fate of the spleen anlage in the dorsal 
mesogastrium of lacZ Hox11(-/-) knockout embryos. They reasoned that if cell death was not 
responsible for the involution of the spleen anlage in Hox11 null mice the cells which Introduction  24
originally contributed to this anlage must still be present somewhere in the embryo. They 
traced  lacZ expressing cells to determine their fate. At E12.5 the developing spleen and 
pancreas could be differentiated from one another, Hox11 was detectable in both tissues. At 
E13.5 there appeared to be a gradient of intensity in pancreatic mesenchymal cells, with 
those cells closer to the developing spleen expressing more Hox11 mRNA. Hox11 
expression in the pancreas was no longer detectable by E16.5, but was still present in some 
parts of the spleen. It is likely that Hox11 expression is initiated in the mesenchymal cell 
population of the pancreas, a proportion of which goes on to form the spleen (Kanzler et al., 
2001). 
Hox11 may be a cell autonomous gene product necessary for differentiation of all or part of 
the splenic mesenchyme. Alternatively the involution of the spleen in knockout animals may 
result from the inability of the cells to attract and retain other cells. Another possibility is that 
Hox11  expressing cells secrete a factor that is autostimulatory and results in further cell 
proliferation. To discriminate between these possibilities, chimeras were generated consisting 
of wild type and Hox11 null cells and the contribution of Hox11 null cells to the spleen was 
examined between E12.5 and E18.5. A total of 102 chimeras were examined and the Hox11 
mutation was found to be cell autonomous as Hox11 null cells were found to be absent from 
the spleen anlage of chimeric embryos. There was no detectable increase in the proportion of 
TUNEL positive apoptoic cells in chimeric spleens relative to wild type spleens between 
E13.5 and E14.5, suggesting that the cells were not being removed by apoptosis. These 
observations suggest that altered cell fate and not cell death is the major mechanism 
accounting for involution of the Hox11 null spleen anlage. It is possible that selective affinity 
explains the phenomenon observed in the spleen anlage. Hox11 null cells may lack a factor 
or factors such as a cell adhesion molecule required for cellular aggregation and interaction 
by the cells of the spleen anlage. It is also possible that a signal is given to Hox11 expressing 
cells in order for them to become committed to spleen development. Hox11 null cells are 
unable to process this signal and thus they do not become committed to a splenic fate 
(Kanzler et al., 2001). 
1.5.1.4  The Role of the HOX11 Family in Development 
Hox11, Hox11L1 and Hox11L2 display overlapping and distinct sites of expression within the 
central nervous system and the genes are thought to display some functional redundancy. 
Hox11 is primarily expressed in a longitudinal bilateral stripe in the hindbrain (Logan et al., 
1988). Hox11L1 is expressed in a subset of neural crest derived tissues such as dorsal root 
ganglia, cranial nerve ganglia, sympathetic ganglia and enteric nerve ganglia in embryos 
between E9.5 and E13.5 (Shirasawa et al., 1997). Studies in chick embryos have shown that 
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system. Hox11L2 has been shown to be expressed in dorsal root and sympathetic ganglia of 
the neural crest, the hindbrain and the spinal cord. Its expression has also been detected in 
neural crest derived enteric ganglia and some neurons of the CNS. In addition Hox11L2 and 
Hox11 proteins have been found to be expressed in overlapping domains within cranial 
sensory ganglia. Hox11 in concert with Hox11L2 is required for proper development of most 
relay somatic sensory neurons and the formation of dorsal interneurons (Logan et al., 1998). 
Further work in chick embryos demonstrated a complex Hox11L2 expression pattern in 
cerebellar granule cells and demonstrated that it may play a role in the differentiation of 
specific neuronal populations in the cerebellum (Logan et al., 2002). Hox11L2 is thought to 
be implicated in fissure formation and the compartmentalization of the cerebellar cortex 
(Logan et al., 2002). 
Nevertheless, knockout phenotypes reflect some distinct sites of expression reflecting non-
redundant functions. Hox11 knockout mice show no evidence of a spleen or splenic primordia 
(Roberts et al., 1994). A study by Shirasawa et al., (1997) found that Hox11L1 knockout mice 
developed megacolon. Further analysis found that neuronal cells of enteric ganglia had 
degenerated and undergone cell death (Shirasawa et al., 1997). It was concluded that 
Hox11L1 is required for maintenance and proper formation and function of the enteric 
neurons of the nervous system (Hatano et al., 1997; Logan et al., 2002). Importantly, 
Hox11L2 has been shown to be essential for the development of the ventral medullary 
respiratory center, in that its deficiency in mice leads to respiratory failure resembling 
congenital hypoventilation syndrome in humans (Shirasawa et al., 2000). Further study 
demonstrated that Hox11L2 expression is required for proper formation of first order relay 
visceral sensory neurons and most of the (nor) adrenergic centres of the brain stem. These 
neurons play crucial roles in modulating cardiovascular and respiratory functions (Qian et al., 
2002). 
The role of Hox11 in neuronal differentiation has not been determined. However, Hox11 in 
concert with homeobox gene Hox11L2  is required for proper development of most relay 
somatic sensory neurons and the formation of dorsal interneurons. At the molecular level 
Hox11L2 and Hox11 have a unique function in maintaining expression of a variety of genes 
such as Drg11,  Ebf3,  Lmbx1b and Isl1. Comparison of Hox11/Hox11L2 double knockout 
mice to Hox11L2 single knockout mice demonstrates that Hox11 does indeed play and 
important role in neuronal differentiation during development (Qian et al., 2002). Introduction  26
1.6  Cellular Expression of HOX11 
1.6.1 T-cell  Expression 
HOX11 dysregulation is exclusively associated with T-cell leukaemias (Yamamoto et al., 
1995; Hatano et al., 1991; Salvati et al., 1995). Consequently, it has been postulated that 
HOX11 may play an important role in the process of T-cell development or proliferation 
(Yamamoto et al., 1995; Lu et al., 1992). Several groups have investigated expression of 
HOX11 in the T-cell lineage in an effort to determine whether it may play a role in these 
processes. The results of these investigations have been varied and thus the possibility of 
HOX11 expression occurring in normal T-cells remains controversial (Appendix 1). 
Zutter et al., (1990) examined normal human thymus, CD3- pre T-cell lines, γδ T-cell lines 
and  αβ T-cell lines for HOX11 expression by Northern blot. They failed to show HOX11 
expression in any of these T-cell lines and postulated that HOX11 is a candidate 
protooncogene which is ectopically expressed by translocation or some other event that 
contributes to its dysregulation (Zutter et al., 1990). The findings of Hatano et al., (1991) were 
in accordance, they did not detect HOX11 by Northern blot analysis in the thymus, resting T-
cells or T-cells activated with phytohemagglutin (PHA) or phorbol 12-myristate 13- acetate 
(PHA+ PMA). HOX11 was not present in αβ T-cell lines, γδ T-cell lines or CD3- T-cell lines 
(Hatano et al., 1991). 
Lu  et al., (1992) used a more sensitive quantitative RT-PCR assay to demonstrate the 
expression of HOX11 in normal human T-cell lines and in T-cell leukaemia lines which do not 
harbour a translocation involving the HOX11 locus (Lu et al., 1992). The expression of 
HOX11 in a sample of a heterogeneous population of CD3+ T-cells extracted from adult 
peripheral blood was seen as a strong argument that HOX11 plays a role in gene regulation 
in normal T-cells at a particular stage of differentiation. The expression levels of HOX11 
appeared to be much lower than levels found in leukaemia cell lines such as JURKAT and 
HBP-ALL. It was concluded that heightened expression of endogenous HOX11 by 
translocation or some other event contributes toward the formation of leukaemia (Lu et al., 
1992). 
HOX11 has also been detected in several tumorigenic T-cell lines such as CTLL-2, EL-4, 
3D0, RPMI 8402 and JURKAT (Yamamoto et al., 1995; Hatano et al., 1991). Expression in 
the JURKAT cell line was also found to be cell cycle dependent, it is however possible that 
the cell cycle machinery in these cell lines is abnormal (Zhang et al., 1993). Further work by 
Zhang et al., (1996) showed that a number of growth factors, including IL-1α, IL-1β, IL-2, IL-3, 
IL-4, IL-6, IL-8, GM-CSF, TGF-β and IFN-α, did not have any regulatory effect on HOX11 
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phytohemagglutin in both JURKAT and normal T-cells was observed. This up-regulation was 
suppressed by tyrosine kinase inhibitors which once again suggests that HOX11 may play a 
role in the cell cycle, however it is important to note that experiments were carried out on 
stimulated cells, not those in the normal resting state (Zhang et al., 1996). 
Conversely, Yamamoto et al., (1995) could not detect HOX11 in any normal T-cells of the 
spleen or thymus by RT-PCR. The gene was also not detected in T-cells after stimulation 
with the stimulants concanavalin A, ionomycin or stimulants of apoptosis such as 
glucocorticoids, gamma irradiation and anti-Fas stimulants (Yamamoto et al., 1995). A recent 
study by Kees et al., (2003) readdressed the issue of HOX11 expression in normal T-cells. 
Peripheral blood T-cells (composed of 91.3% T-cells by flow cytometric analysis) were 
isolated from 11 normal individuals and analyzed using real-time quantitative reverse 
transcriptase polymerase chain reaction. All of these samples were clearly negative for 
HOX11 expression (Kees et al., 2003). Thus, it is generally accepted that HOX11 is not 
expressed in T-cells at any stage of development and that ectopic expression of HOX11 by 
translocation or some other event is clearly linked to malignancy (Kees et al., 2003). 
1.6.2  HOX11 Expression in Other Haematopoietic Cells and Tissue Types 
The role that HOX11 plays in normal haematopoietic development, if any, is unknown. To 
date, the only significant studies undertaken have involved retroviral transduction of bone 
marrow (Hawley et al., 1994) or ES cells (Keller et al., 1998). In addition, Moretti et al., (1994) 
found that HOX11  is expressed in CD34+ bone marrow cells (Moretti et al., 1994). This 
finding suggests that HOX11 may play a role early on in blood cell development at a 
multipotential stage of development.  
Several groups have studied HOX11 expression in various haematopoietic cell lines and 
tissues. HOX11 expression was found to vary amongst distinct cell types and it is probable 
that HOX11 activates a separate set of target genes amongst different cell types in order to 
achieve different regulation (Lu et al., 1992). Expression of HOX11 in various haematopoietic 
cells and tissues is outlined in Appendix 2. 
Haematopoiesis takes place in the blood islands of the yolk sac of embryos at E8. From E12 
through to E16 the liver is the major site of fetal haematopoiesis. During this period 
lymphocyte precursors migrate and differentiate in primordiums of the thymus and spleen. 
Two forms of Hox11, a long and a short spliced form, were detected in the spleen and 
thymus, but not in the liver and yolk sac (Yamamoto et al., 1995). Hox11 was found to peak 
in its expression in the spleen at E13.5 and gradually decrease thereafter. Haematopoietic 
cells populate and expand in the spleen from embryos after E15.5. No distinct increase in 
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developing lymphocytes in the spleen do not express Hox11. Furthermore no Hox11 
expression was detected in early B-cells in culture. This data suggested that Hox11 plays a 
major role in spleen development, but not lymphocyte development (Yamamoto et al., 1995). 
Hox11 expression was not detected by Northern blot analysis in pre B-cell (Reh, Nalm-6) or 
mature B-cell lines (Raji) (Zutter et al., 1990). Similar analysis by Lu et al., (1992) and Hatano 
et al., (1991) found no expression in the Burkitt lymphoma B-cell lines Raji and BJAB, the pre 
B-cell line Nalm-6 or the Daudi B-cell line (Lu et al., 1992; Hatano et al., 1991). Finally, 
Salvati et al., (1995) failed to identify HOX11 expression in primary B-lineage ALL samples 
(Salvati et al., 1995). 
HOX11 has, however, been detected at a low level in the K562 cell line. The cell line is 
derived from a BCR-ABL positive chronic myeloid leukaemia that progressed to blast crisis. 
The cells have taken on the phenotype of an embryonic erythroleukaemia (Lu et al., 1992; 
Mukai et al., 2003). Perhaps HOX11 is in some way involved as a secondary event in the 
blockage of cell differentiation that leads to blast crisis.  
It is also significant that HOX11 has been detected in a neuroblastoma cell lines SK-N-SH 
and N417 (Lu et al., 1992; Kennedy et al., 1991). Additionally, a study by Watt et al., (2003) 
reported the expression of canonical and alterative HOX11 transcripts in a number of 
primitive neuroectodermal tumour (PNET) and neuroblastoma cell lines (Watt et al., 2003). 
This finding is consistent with the notion that HOX11 functions as a transcription factor in the 
central nervous system. 
1.7  The Role of HOX11 in Oncogenesis 
The exact role that HOX11 plays in the initiation, progression and/or malignant transformation 
of cells remains to be elucidated. Several lines of evidence suggest that HOX11 is oncogenic. 
Firstly, HOX11 dysregulation is associated with T-ALL. Following chromosomal translocations 
involving the HOX11 locus, HOX11 is overexpressed as an unaltered protein product. 
Moreover, HOX11 is not normally expressed in T lymphocytes (Kees et al., 2003; Salvati et 
al., 1999; Yamamoto et al., 1995; Zutter et al., 1990; Hatano et al., 1991). HOX11 mRNA 
expression has also been demonstrated in the tumour cells of many paediatric patients with 
T-ALL without translocations involving the HOX11 locus (Salvati et al., 1995). Secondly, the 
transforming ability of HOX11 has also been demonstrated in vitro. Murine haematopoietic 
precursors transduced with HOX11 expression vectors form myeloid cell lines (Hawley et al., 
1994) and HOX11 expression in embryonic stem cells leads to the immortalization of 
embryonic precursors with both primitive and definitive haematopoietic potential (Keller et al., 
1998). Thirdly, the immortalization function of HOX11 is not restricted to T-cells (Hawley et 
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ectopically expressed in B lymphocytes developed a non-transplantable lymphoproliferative 
disease (Hough et al., 1998). Ectopic expression of HOX11 has been linked to 
dedifferentiation of erythroid cells (Greene et al., 2002) and dysregulation of the cell cycle 
(Zhang et al., 1995; Kawabe et al., 1997). The activation or repression of distinct target genes 
involved in differentiation programs may contribute to cell transformation. To date three 
putative target genes have been reported (Greene et al., 1998; Dear et al., 1995). The exact 
nature of the cellular cascade involved in HOX11 mediated neoplastic transformation has yet 
to be determined. However, it has been postulated that HOX11 may substitute or antagonize 
the function of closely related endogenous homeobox proteins to perturb lymphoid specific 
gene expression (Lu et al., 1992; Cleary, 1991). 
1.7.1  HOX11 and T-ALL 
Ectopic expression of the HOX11 gene is associated with the development of T-ALL. Various 
studies report the frequency of HOX11 expressing cases among T-ALL patients to be 
between 10-30% (Kees et al., 2003; Ferrando et al., 2002; Ballerini et al., 2002). HOX11 
activation in paediatric ALL patients was examined by Salvati et al., (1995) and Kees et al., 
(2003). Both studies confirmed that HOX11 expression is exclusive to T-ALL and does not 
occur in B-lineage ALL (Salvati et al., 1995; Kees et al., 2003).  
In T-cell leukaemia, translocations involving HOX11 and TCR α/β/δ loci are frequent. In these 
cases the HOX11 gene is expressed under the control of the juxtaposed TCR locus 
(Kennedy et al., 1991; Dube et al., 1991; Hatano et al., 1991). HOX11 activation in T-ALLs 
can also occur in the absence of translocation of the gene to the T-cell receptor locus. This 
implies that activation mechanisms other than juxtaposition of the gene must be involved 
(Salvati et al., 1995; Ferrando et al., 2002; Ballerini et al., 2002; Kees et al., 2003). 
It appears that HOX11 translocations or HOX11 up-regulation may be associated with better 
survival, however the effect may be dependent on the therapy used (Kees et al., 2003). A 
recent study on 58 T-ALL patients treated at St Jude Childrens’ Hospital found that 
expression of HOX11 in leukaemic blasts is significantly associated with favorable progress 
(Ferrando et al., 2002). A study of 76 T-ALL patients by Kees et al., (2003) showed that 
patients with leukaemic cells expressing HOX11 at high levels have a better clinical outcome 
than other patients. This effect was statistically significant in patients treated for high risk 
disease on protocol CCG-1901, and not observed in patients treated with other regimes 
(Kees et al., 2003). Thus, the survival effect of HOX11 expression may be dependent on the 
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1.7.1.1  HOX11 Dysregulation Involving Translocation 
The HOX11 gene was cloned and sequenced from two translocation breakpoints discovered 
in T-ALLs, t(10;14)(q24;q11) and the t(7;10)(q35;q24) (Dube et al., 1991; Kennedy et al., 
1991; Hatano et al., 1991; Lu et al., 1991). Cytogenetic analyses have shown that 4-5% of T-
ALL cases contain a t(10;14)(q24;q11) translocation where the HOX11 gene is juxtaposed to 
the  Dδ2,  Dδ3 or Jδ1 gene segments of the TCRδ at locus 14q11 (Salvati et al., 1999; 
Raimondi  et al., 1993). In addition, Kagan et al., (1987) reported a T-cell leukaemia 
containing the t(10;14)(q24;q11) translocation which involved the HOX11 gene being 
juxtaposed to the Vα TCR locus (Kagan et al., 1987). A variant translocation t(7;10)(q35;q24) 
is associated with 1% of T-ALL, where the HOX11 gene is juxtaposed to the TCRβ gene at 
locus 7q35 (Kennedy et al., 1991; Hwang et al., 1995; Boehm et al., 1989). Sequence 
analysis of 15 out of 19 reported t(10;14)(q24;q11) translocations demonstrated that the 
breakpoints on the 10q24 locus were clustered within a 1kb region directly upstream of 
HOX11. In contrast, the t(7;10)(q35;q24) translocation reported had a breakpoint 12kb 
upstream of the HOX11 gene.  Other complex translocations have been identified. Salvati et 
al., (1999) identified a translocation which involved an inversion event of the TCRδ gene as 
well as a translocation. The translocation occurred 3.4kb upstream of HOX11 which 
demonstrated that HOX11 can be transcriptionally activated from a considerable distance 
(Salvati et al., 1999). 
Juxtaposition of the HOX11 gene to the TCR locus results in the abnormal expression of full 
length HOX11 under the control of the TCR locus. The translocations involving HOX11 and 
the  TCR  locus are thought to be the result of errors in the normal TCR rearrangement 
process. The variable region of the TCR is encoded by V(D)J DNA segments that are 
assembled into complete variable regions by recombination (Tonegawa et al., 1983; Lewis et 
al., 1989). Such DNA rearrangements are mediated by a recombinase system that 
recognizes short DNA segments termed signal sequences situated adjacent to coding 
segments. These signal sequences consist of conserved heptamer and nonamer sequences 
separated by conserved spacers of 12 or 23 nucleotides. Cleavage at the border between a 
signal heptamer and a coding segment followed by rejoining of DNA ends into a new 
formation of coding and signal joints occurs. Template independent nucleotides or N-
nucleotides are frequently inserted at coding and signal junctions during TCR 
rearrangements (Tonegawa et al., 1983; Alt et al., 1992). This process can occur between 
genes which are cis rearranged or trans rearranged (Kagan et al., 1994). Three lines of 
evidence suggest that HOX11 translocations are the result of a failed attempt at TCR gene 
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1)  The breakpoints on chromosomes 10 and 14 are flanked by heptamer and nonamer 
motifs known to be recognized by recombinases normally required for shuffling of Ig 
and TCR gene subunits. 
2)  The random insertion of short nucleotide sequences which are common at the 
junction of normally rearranged Ig  and  TCR subunits are observed at t(10;14) 
breakpoints (Lichty et al., 1995). 
3)  The breaks in chromosome 10 occur in close proximity to DNA sequences capable of 
adopting an accessible and nuclease sensitive DNA structure that allows 
recombinase mediated translocation (Lu et al., 1991; Lu et al., 1990). 
To examine the role that errors in V(D)J recombination play in HOX11 mediated T-ALL 
Raghavan et al., (2001) used a human extra-chromosomal substrate assay to investigate the 
role that misrecognition by the RAG complex plays in HOX11 chromosomal translocation. 
The RAG complex usually initiates breaks of V(D)J recombination at consensus 
heptamer/nonamer sequences. HOX11 was found to fail to undergo recombination as a 12 or 
23 signal and was at least 20,000 fold less efficient than consensus signals. These studies 
did not provide any definitive proof that the heptamer and nonamer sites of the HOX11 
translocation are cleaved by the RAG complex (Raghavan et al., 2001). The V(D)J 
recombinase system may not be the exclusive mechanism involved in generation of 
chromosomal translocations (Kagan et al., 1994). In approximately 50% of cases of 
translocation involving HOX11 there were no V(D)J signal sequences found flanking the 
breakpoint which suggests that the V(D)J recombination system is not the exclusive 
mechanism involved in translocation. Chromosome accessibility to recombination can also be 
provided by hypomethylation of CpG sequences or altered superhelicity which may result in a 
recombinogenic chromatin structure (Salvati et al., 1999; Hsieh et al., 1992). 
1.7.1.2 HOX11  Dysregulation Without Translocation 
A study by Salvati et al., (1995) reported on the HOX11 expression status of a panel of 12 
paediatric T-ALL specimens by Northern blot and RT-PCR analysis. Deregulation of HOX11 
expression had occurred, however, in some cases there was no cytogenetically detectable 
abnormality involving chromosome 10, suggesting that HOX11 can be activated in the 
absence of translocations at the 10q24 locus. This finding is also supported by an Affymetrix 
microarray and quantitative RT-PCR study by Ferrando et al., (2002) that demonstrated that 
HOX11 is often aberrantly expressed in the absence of chromosomal abnormalities. Four out 
of eight (50%) of T-ALL patient specimens demonstrated increased HOX11 expression 
without a HOX11 associated cytogenetic abnormality (Ferrando et al., 2002). Introduction  32
A study by Kees et al., (2003) measured HOX11 expression levels by real time quantitative 
reverse transcriptase polymerase chain reaction. Fifteen out of 76 (19.7%) of paediatric T-
ALL patients expressed the HOX11 gene at high levels and 22 out of 76 (28.9%) at low 
levels. Only 2 out of 16 specimens that showed abnormal HOX11 expression exhibited 
abnormalities at 10q24 by direct cytogenetic analysis. These finding are in accordance with 
those of Salvati et al., (1995) and Ferrando et al., (2002) such that mechanisms other than 
chromosomal translocation are implicated in HOX11 deregulation (Kees et al., 2003; Salvati 
et al., 1995; Ferrando et al., 2002). 
There are a number of alternative mechanisms that may account for the deregulation of 
HOX11. These include mutations in cis-regulatory sequences and the translocation of 
enhancer elements from other genes such as the TCR into the HOX11 locus (Kees et al., 
2003). Brake et al., (1998) hypothesized that HOX11 may be repressed in normal T-cell and 
erythroid cells by the action of several negative elements which may be inactive in leukaemia, 
however, they failed to find evidence of this mechanism in patient specimens (Brake et al., 
1998). A recent study by Ferrando et al., (2004) suggested that aberrant expression of 
HOX11 in T-ALL may result from loss of upstream transcriptional mechanisms that normally 
down-regulate HOX11 gene expression (Ferrando et al., 2004). Watt et al., (2000) postulated 
that demethylation of the HOX11 promoter is a prerequisite for alternative gene activation 
mechanisms and found evidence of demethylation in the proximal promoter of two primary 
patient samples that express HOX11 in the absence of a translocation (Watt et al., 2000). 
Thus, although the mechanisms leading to HOX11 deregulation other than via translocation 
are not known, future studies based around the involvement of chromatin configuration and 
trans-acting factors in this deregulation may also provide some insight (Kees et al., 2003). 
1.7.2   HOX11L2 and T-ALL 
Dysregulation of HOX11 family members is an important pathway in T-ALL leukaemogenesis 
with aberrant expression of HOX11 found in approximately 10-30% cases of T-ALL whilst 
aberrant expression of HOX11L2 occurs in approximately 15% of T-ALL cases. Altogether 
nearly half of all cases of T-ALL express either HOX11 or HOX11L2 (Kees et al., 2003). 
The HOX11L2 gene was first implicated in playing an important role in T-ALL in a study of 
twenty three patients which found that the translocation t(5;14)(q35;q32) was associated with 
T-ALL in 22% of childhood patients (Bernard et al., 2001). The HOX11L2 gene was found to 
be transcriptionally activated by this translocation placing it under the influence of 
transcriptional regulatory elements downstream of CTIP2, also known as BCL11B (MacLeod 
et al., 2003; Bernard et al., 2001). CTIP2 encodes a member of the zinc finger family of 
transcriptional regulators which is normally expressed in the thymus, peripheral blood T 
lymphocytes and the spleen. It is also known to be highly expressed during T-cell Introduction  33
differentiation (Bernard et al., 2001). Additionally, a study by Hansen-Hagge et al., (2002) 
described two adult patients with t(5;14)(q35;q11) whereby HOX11L2 was activated by 
juxtaposition with TCRD (Hansen-Hagge et al., 2002). 
Other studies have confirmed this initial finding although reporting varying frequencies. 
Overall it is estimated that the overexpression of HOX11L2 plays a role in approximately 15% 
of T-ALL cases. A microarray study of 59 samples by Ferrando et al., (2002) detected a 
group of 10% HOX11L2 overexpressing T-ALL lymphoblast samples that had expression 
profiles similar to that of HOX11 overexpressing lymphoblasts. The probability of survival at 5 
years for these patients was found to be 30% for the HOX11L2 group (Ferrando et al., 2002). 
A later study of 28 T-ALL samples using real time RT-PCR demonstrated expression of 
HOX11L2 in 21% of patients. This expression was associated with the previously described 
t(5;14)(q35,q32) translocation. In normal haematopoietic tissues, HOX11L2 expression was 
not detected in adult spleen, peripheral blood lymphocytes or control bone marrow (Ballerini 
et al., 2002). Finally, a study by Mauvieux et al., (2002) on 23 T-ALL samples by RT-PCR 
detected  HOX11L2 in 30% of cases. This expression was associated with the 
t(5;14)(q35;q32) translocation in all cases except one. The expression of HOX11L2 was not 
found to be strongly associated with poor outcome as previously reported by Ferrando et al., 
(2002) a finding indicative of differences in sample size and treatment regimes (Mauvieux et 
al., 2002). 
1.7.3  HOX11 Expression in T-ALL Causes Arrest at the Early Cortical 
Thymocyte Stage of Development 
Although the role of HOX11 dysregulation in leukaemogeneisis has not been definitively 
established, the result of HOX11 deregulation in T-cells shows a distinct trend. A panel of 59 
lymphoblast samples from patients with T-ALL were analyzed using GeneChip microarray 
technology. Analysis lead to the identification of a HOX11 gene expression signature which 
revealed that HOX11 positive samples showed increased expression of the CD1 family 
members,  LAR and CD10 genes in a pattern resembling T-cells at the early cortical 
thymocyte stage of development (Ferrando et al., 2002). This early cortical thymocyte 
immunophenotype was also reported in a study by Ballerini et al., (2002) (Ballerini et al., 
2002). In addition a number of genes involved in growth and proliferation were found to be 
part of the HOX11 gene expression signature (Table 1.4). Introduction  34
 
Cell Growth  Cell Proliferation 
ADENOSINE DEAMINASE  DNA POLYMERASE EPSILON 
DNA TOPOISOMERASE  CYCLIN A 
DIHYDROFOLATE REDUCTASE  TAX1 BINDING PROTEIN 
HYPOXANTHINE 
PHOSPHORIBOSYLTRANSFERASE 1 
REPLICATION PROTEIN A1  
THYMIDYLATE SYNTHETASE   
TABLE 1.4  GENES OF THE HOX11  GENE EXPRESSION SIGNATURE INVOLVED IN 
CELL GROWTH AND PROLIFERATION Adapted from Ferrando et al., 2002. 
These findings were in accordance with those of other groups who demonstrated the 
immortalization of haematopoietic precursors by HOX11 and the interaction of HOX11 with 
cell cycle regulatory proteins (Keller et al., 1998; Kawabe et al., 1997). 
A direct correlation was also found between HOX11 expression and the expression of genes 
involved in programmed cell death. High levels of HOX11 correlated with increased 
expression of MYC and the pro-apoptoic GLUCOCORTICOID RECEPTOR gene. It is 
thought that the responsiveness of HOX11 positive T-ALL cases to chemotherapy, may be 
due to the fact that anti-apoptotic survival factors are down-regulated (eg BCL2) and pro-
apoptotic factors are up-regulated in early cortical thymocytes (Ferrando et al., 2002). 
This study also identified a subset of T-ALL cases which were not HOX11 positive, but had 
very similar gene expression profiles. These cases of T-ALL were found to express the 
related HOX11L2 gene. This finding suggested some redundancy in the oncogenic pathways 
involving these two genes. The expression profiles of the HOX11 positive cases were found 
to differ in their gene expression pattern from the HOX11L2 cases by the constant up-
regulation of eight genes (Ferrando et al., 2002). These genes may represent important 
components in the unique oncogenic pathway controlled by the oncogene HOX11 (Table 
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GENE FUNCTION 
FBP2   Regulates alterative mRNA splicing 
BAF155  Regulates gene expression through chromatin remodeling, which is   
known to associate tumour supressors and cause cell cycle arrest 
FYB   Regulates T-cell activation  
TABLE 1.5  GENES MORE HIGHLY EXPRESSED IN HOX11+ T-ALL COMPARED TO 
HOX11L2+ T-ALL Adapted from Ferrando et al., 2002. Introduction  36
 
 
 
 
 
 
 
 
 
FIGURE 1.2 THE CORRELATION OF GENE EXPRESSION PROFILES OF HOX11+ T-ALL 
SAMPLES WITH THE EARLY CORTICAL STAGE OF THYMOCYTE DIFFERENTIATION 
Cell surface markers CD8+, CD4+, CD3- and CD1+ are normally associated with the early 
cortical stage of development. HOX11+ T-ALL samples were found to arrest at this stage of 
development. Additional genes found to be associated with HOX11 induced early cortical 
arrest CD1A, CD18, CD1C, CD1D, CD1E, LAR and CD10 are also indicated (Ferrando et al., 
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1.8  The Transforming Ability of HOX11 
1.8.1  Cell Immortalization by HOX11 Across Haematopoietic Lineages 
To better understand the oncogenic role of HOX11 in leukaemogenesis, murine bone marrow 
precursor cells were infected with a retrovirus bearing the HOX11 gene. Constitutive 
expression of HOX11 resulted in immortalization of haematopoietic precursors. The 
experiment yielded cell lines consisting of immature cells belonging to the myeloid lineage. 
These cells may have been of a primitive lineage of uncommitted progenitors with myeloid 
markers. The transformed cell lines displayed a dependence on IL-3 for survival and 
proliferation in culture. The immortalized cells exhibited two major characteristics, suggesting 
transformation had occurred, increased proliferative capacity and a block in differentiation 
(Hawley et al., 1994). This process of haematopoietic progenitor immortalization was later 
found by mutational analysis to require the DNA binding domain of HOX11 and was thought 
to occur through the dysregulated expression of HOX11 target genes through the binding of 
the homeodomain to specific DNA sequences (Owens et al., 2003). Lethally irradiated 
BALB/c mice were transplanted with infected bone marrow cell lines, but did not develop 
leukaemia within 10 months. These results support the hypothesis that the transforming 
capacity of HOX11 is derived from its ability to alter the expression of genes regulating 
haematopoietic differentiation and that secondary mutations promoting cell survival or 
stimulating proliferation are required for progression to malignancy (Hawley et al., 1994). 
These findings also suggest that the oncogenic activity of HOX11 is not restricted to T-cell 
leukaemia (Hawley et al., 1994). 
The detection of HOX11 expression in human K562 leukaemic cells adds credence to the 
possibility that the oncogenic activity of HOX11 is not restricted to T-cell leukaemia (Lu et al., 
1992). Although generally regarded as an erythroleukaemic cell line, K562 was derived from 
a patient with chronic myeloid leukaemia in blast crisis and showed evidence of differentiation 
towards monocytes and granulocytes as well as erythrocytes (Lozzio et al., 1981). It is also a 
possibility that HOX11 is in some way involved in the blockage in cell differentiation that leads 
to blast crisis. In addition, studies by Keller et al., (1998) found that overexpression of HOX11 
in ES cells lead to the immortalization of embryonic precursors with the potential to form 
definitive erythroid progenies and Hough et al., (1998) found that expression of HOX11 in B-
cells in transgenic mice lead to the onset of a lymphoma-like illness (Keller et al., 1998; 
Hough et al., 1998). 
Further studies by Hawley et al., (1997) found that two murine bone marrow transplant 
recipients of HOX11 transformed cell lines eventually developed T-ALL like malignancies at 7 
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additional mutations. Additional experiments were performed with bone marrow cells 
transduced with mutant retroviruses in order to determine that the FPWM motif of the 
homeodomain is essential for progression to a malignant state (Hawley et al., 1997). 
1.8.2  Ectopic Expression of HOX11 Leads to the Formation of Immature Cell 
Phenotypes 
ALL characteristically involves the accumulation of blast cells that fail to differentiate 
normally. It has been noted that T-cells which over express HOX11 due to chromosomal 
translocations are actually often of an immature phenotype. It appears that their 
differentiation has arrested early in the assembly of their TCR (Zutter et al., 1990). In 
addition, a GeneChip microarray study by Ferrando et al., (2002) demonstrated that HOX11 
expression in T-ALL is indicative of arrest at the early cortical thymocyte stage of 
development. Such observations lead to the hypothesis that ectopic expression of HOX11 
leads to the formation of an immature, dedifferentiated cell type (Ferrando et al., 2002). 
By retrovirally transducing murine bone marrow cells with HOX11 Hawley et al., (1994) were 
able to demonstrate a block in haematopoietic cell differentiation. This occurred at an early 
progenitor stage and yielded cell lines with a mutli-potential myeloid phenotype (Hawley et 
al., 1994). Regulation of blood cell development at an early stage may be a normal function 
of HOX11 since expression of this gene has been detected in CD34+ haematopoietic 
progenitor cells (Moretti et al., 1994). 
Keller  et al., (1998) also transduced embryonic stem cells with a retrovirus that over-
expresses the HOX11 gene. They found that the over-expression of HOX11 leads to the 
immortalization of embryonic precursors with both primitive and definitive haematopoietic 
potential. They established several factor dependent haematopoietic cell lines that were 
different from known stages of embryonic haematopoiesis. Two cell lines had the capacity to 
generate both primitive and definitive erythroid progeny. In addition, these cell lines were C-
Kit positive and appeared to morphologically represent early haematopoietic populations 
(Keller et al., 1998). 
A study by Yu et al., (2002) immortalized yolk sac precursors by the retroviral mediated 
expression of HOX11. Haematopoiesis initiates in the extra-embryonic yolk sac and the 
expression of HOX11 leads to the immortalization of yolk sac cell populations. Morphologic 
examination of cytospin samples of the cell population revealed that they consisted of a 
homogenous population of immature blast like cells. When placed into haematopoietic growth 
factor containing methylcellulose cultures, these cells formed erythroid cells, macrophages 
and undifferentiated blast like cells. The cells were found to express factors that play an 
important role in haematopoietic and endothelial development, however they did not express 
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cells. Collectively, the morphologic, phenotypic and functional properties of yolk sac cells 
immortalized by HOX11 suggest that they represent a transitional stage of early 
haematopoietic development (Yu et al., 2002).  
Recent research by Greene et al., (2002) also supports the concept that the expression of 
HOX11 leads to the formation of an immature cell type. Enforced HOX11 expression was 
found to induce a profound alteration in J2E cellular morphology and differentiation status. 
The J2E cell line is a murine erythroid cell line that has the capacity to terminally differentiate 
in response to erythropoietin (EPO). Analysis of HOX11 clones showed that they had the 
preponderance of less differentiated cells that were highly adherent to plastic. Increased 
adherence is indicative of an immature erythroid cell phenotype. Early red blood cell 
development usually occurs through contact with stromal cells and fibronectin in the bone 
marrow. As early precursors develop into reticulocytes which are released into the blood 
stream there is an apparent loss of adherence (Coulombel et al., 1991; Patel et al., 1984). 
Morphologically the cells over-expressing HOX11 were large and had increased globin levels 
as well as a reduction in hemoglobin synthesis in response to erythropoietin. 
Immunocytochemical analysis confirmed the immature erythroid phenotype imposed by 
HOX11, with clones transfected with HOX11 demonstrating the expression of the C-Kit stem 
cell marker. C-Kit is a marker of the progenitor/stem cell compartment which continues to be 
expressed in the erythroid lineage until the basophilic erythroblast stage. Levels of the 
HOX11 target gene Aldh1a1 which is normally expressed at higher levels in haematopoietic 
stem cells were also increased in J2E cells transfected with HOX11. Taken together, these 
results suggest that HOX11 functions to reverse erythroid differentiation towards a less 
mature progenitor like state (Greene et al., 2002). 
HOX11 may function at a very early multipotential stage as one of many HOX genes known 
to play a role in normal haematopoiesis. It is also possible that HOX11 may play a role in the 
molecular events that direct a multipotent progentior cell toward various committed lineages. 
Cell maturation would appear to require a down-regulation of HOX11 expression (Greene et 
al., 2002). 
1.8.3  HOX11 Transformation Involving Altered Gene Expression Through 
Cooperative Interaction with CTF1 
Work by Zhang et al., (1999) showed that HOX11 interacted with CTF1 in vivo and in vitro 
(Section 1.4.2.2). Therefore HOX11 may act as an oncogenic transcription factor in 
haematopoietic cell immortalization by directing distinct signal pathways in cell proliferation 
and differentiation (Zhang et al., 1999).  
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1.8.4  HOX11 Transgenic Mice and Oncogenesis 
Despite the association of HOX11 gene activation with human T-ALL there is little evidence 
that inappropriate expression of HOX11 leads to T-cell associated malignancies in mice. In 
order to properly assess the oncogenic potential of HOX11, the development of transgenic 
mice in which the expression of HOX11 is targeted to lymphoid lineages is important. To date 
the expression of HOX11 in transgenic mice has been targeted to lymphocytes by placing 
human HOX11 under the transcriptional control of Ig heavy chain regulatory sequences. 
IgHu-HOX11 mice produced by Hough et al., (1998) targeted HOX11 expression to B-cells 
(Hough  et al., 1998). Although these mice did appear to develop B-cell lymphomas, the 
relevance of this model to T-ALL is unclear. A preliminary report describing Lck-HOX11 
transgenic mice suggested that ectopic expression of HOX11 in developing thymocytes of 
some transgenic mice resulted in T-cell lymphoma (Hatano et al., 1992). A full detailed report 
was never published on these mice and attempts by other labs to generate Lck-HOX11 mice 
have proven unsuccessful (Hough et al., 1998). Two founder H2k-HOX11 transgenic mice 
were found to develop a lymphoproliferative disorder by Cheng et al., (1993), but once again 
detailed studies have not been published (Cheng et al., 1993). Finally attempts to produce 
CD2-HOX11 transgenic mice have been successful and high levels of HOX11 expression 
were detected in thymocytes. Nevertheless, tumours failed to develop in these mice (Greene 
and Rabbitts, unpublished observations). 
Rosic-Kablar et al., (2000) examined the immunology of the IgHu-HOX11 mice and found 
that the tumour associated antigens expressed by lymphoma cells from HOX11 transgenic 
mice elicit an immune response in naïve mice. However, transgenic mice with terminal 
lymphomas are not responsive to tumour antigens from lymphoma cells presented by 
dendritic cells suggesting that lymphomagenesis in HOX11 transgenic mice is associated 
with the induction of anergy to tumour antigen specific T-cells (Rosic-Kablar et al., 2000). The 
immunological model for lymphomagenesis in IgHu-HOX11 transgenic mice raises further 
questions as to the relevance of this model for human T-cell leukaemia. 
1.8.5  HOX11 and the Cell Cycle 
Although the bulk of evidence published to date suggests that HOX11 functions by altering 
cell differentiation, some studies have implicated HOX11 in cell cycle regulation. The first 
evidence that implicated HOX11 in the cell cycle was provided by Zhang et al., (1993). It was 
determined that the HOX11 protein appeared to be modulated during different phases of the 
JURKAT-cell cycle, with the greatest expression occurring at the G1/S phase boundary. This 
finding was taken to suggest that the HOX11 protein functions as a nuclear transcription 
factor which is involved in progression to S phase at the G1 restriction point. 
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appear to be the substrate for any protein kinase. Nevertheless, the fact that levels of the 
HOX11 protein oscillate in the cell cycle suggest that the HOX11 protein may be a critical 
limiting factor in cell cycle progression (Zhang et al., 1993). Further work by Zhang et al., 
(1995) showed that rapid accumulation of HOX11 occurred in normal and JURKAT human T-
cells upon stimulation with phytohaemagglutinin. This apparent up-regulation was shown to 
be inhibited by tyrosine kinase inhibitors. As previous studies indicate that HOX11 itself is not 
phosphorylated, it is likely that HOX11 acts as a transcription factor located downstream of a 
novel tyrosine phosphorylation signal. The exact nature of the signal transduction pathway 
that modulates HOX11 expression is currently unknown and the possibility of abnormal cell 
cycle machinery in the leukaemic JURKAT cell line also brings the results into question 
(Zhang et al., 1995). 
Kawabe et al., (1997) showed that HOX11 interacts with protein phosphatases; protein serine 
threonine phosphatase 2a (PP2A) and protein phosphatase 1 (PP1) leading to the disruption 
of the G2/M cell cycle check point. The interaction of PP2A with HOX11 was initially 
discovered by these authors using yeast twohybrid analysis. It was later confirmed by 
immunoprecipitation in mammalian cells, using recombinant GST-HOX11, that HOX11 binds 
directly to the catalytic subunit of PP2A and PP1 via the amino-terminal. In order to further 
assess the functional consequences of the interaction between HOX11 and PP2A the effects 
of HOX11 on germinal vesicle breakdown in Xenopus oocytes was assessed. Inhibition of 
PP2A can regulate the cell cycle and control the activation of maturation promoting factor in 
Xenopus oocytes. PP2A and PP1 usually maintain the G2 meiotic arrest of Xenopus oocytes 
by preventing activation of maturation promoting factor. Microinjection of HOX11 into oocytes 
arrested at the G2 phase of the cell cycle caused the oocytes to progress to M phase. This 
suggests that HOX11 may inhibit the action of PP2A and PP1. Further work investigating the 
effect of HOX11 on the mammalian cell cycle was also undertaken. The JURKAT T-cell line 
usually arrests at G2 when exposed to γ irradiation. The arrest is eliminated by expression of 
HOX11. BrdU labelling was also undertaken and results indicated that HOX11 expression 
can disrupt the G2 checkpoint and allow cells to progress through M phase. PP2A and PP1 
have been shown to be targets of oncogenic virus proteins and chemical tumor promoters. 
HOX11 may inhibit PP2A and PP1 abrogating a G2 checkpoint in the cell cycle. This action 
may lead to genomic instability and oncogenesis (Kawabe et al., 1997). Introduction  42
 
1.8.6  HOX11 and Promoter Demethylation 
Methylation of CpG residues found in gene promoters is frequently associated with 
transcriptional repression. This is thought to occur via a number of mechanisms such as 
alteration of chromatin structure and/or the direct blocking of positive transcription factor 
binding. These mechanisms involve the recruitment of histone deacetylases to methylated 
DNA via proteins such as MeCP2 (Tazi et al., 1990; Boyes et al., 1991). Global alterations in 
the methylation status of genes has been observed in cancer cells. Methylation of the 
promoters of certain tumor suppressor genes has been suggested as a mechanism for their 
silencing in leukaemia (Nakamura et al., 1999). In contrast, promoter demethylation of 
oncogenes has been associated with transcriptional activation in cancer cells (Counts et al., 
1994). 
The fact that HOX11 activation in T-ALL can occur in the absence of a translocation 
emphasizes the fact that activation mechanisms other than the juxtaposition of the gene next 
to enhancing sequences must be involved. In order to investigate the possible role of 
promoter demethylation, the methylation status of the proximal promoter was correlated with 
the HOX11 expression status in T-ALL (Watt et al., 2000). Bisulfite sequencing of genomic 
DNA obtained from a variety of T-ALL cell lines and primary patient specimens was used to 
determine the methylation status of every CpG residue within the proximal promoter. The 
expression of HOX11 in T-ALL was associated with extensive demethylation of the proximal 
HOX11 promoter regardless of the presence or absence of translocation. Samples which did 
not express HOX11 showed a more methylated pattern of CpG residues in the proximal 
promoter. Furthermore methylation of this sequence in vitro was sufficient to silence the 
proximal promoter. It is possible that demethylation of the HOX11 promoter is required as a 
prerequisite for additional gene activation mechanisms (Watt et al., 2000). 
1.9  Target Genes of HOX11 
HOX11 encodes a protein with a homeodomain suggesting that like other homeodomain 
proteins it regulates the transcription of a specific set of target genes. To date only three 
candidate target genes have been reported. Greene et al., (1998) utilized representational 
difference analysis (RDA) in the NIH3T3 fibroblast cell line to identify two possible target 
genes Aldehyde Dehydrogenase 1a1 (Aldh1a1) and Fhl1 (formerly Slim1). The third putative 
target gene to be identified is Wilm’s Tumour Gene (Wt1) which was found to act downstream 
of Hox11 in a transcription cascade involved in spleen development (Koehler et al., 2000). 
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1.9.1  Wt1 As a Target Gene of HOX11 
Dear et al., (1995) found that Hox11 mRNA expression precedes the expression of Wt1 in the 
developing spleen of mice. It was concluded that Wt1 could potentially act as a downstream 
target gene of Hox11 in a genetic cascade involved in spleen development. Initially, in situ 
hybridization analysis on Hox11-/- knockout mice found that the Wt1 signal was reduced by 
four fold in the spleen analage at E12.5. This finding suggested that the level of Wt1 activity 
is dependent on Hox11 levels in the developing spleen (Dear et al., 1995; Koehler et al., 
2000). 
In order to further investigate the relationship between Wt1 and Hox11 the ability of Hox11 to 
activate the Wt1 promoter was analyzed in a Hox11 null fibroblast cell line derived from the 
dorsal mesogastrium of a Hox11 null E12.5 embryo. Activation of a luciferase reporter 
construct containing the human Wt1 promoter, confirmed that Wt1 is dependent on Hox11 for 
transcriptional activation in the developing spleen. The exact nature of the interaction 
between Hox11 and Wt1 is yet to be determined. Hox11 may mediate Wt1 transcriptional 
activity via direct binding to the Wt1 promoter or alternatively via an indirect effect mediated 
via a protein regulated by Hox11 (Dear et al., 1995; Koehler et al., 2000). The status of Wt1 
as a Hox11 target gene remains controversial as the findings of Dear et al., (1995) are 
contrary to a recently published report by Herzer et al., (1999) that found no alteration in the 
Wt1 mRNA levels in the spleen analage of Hox11 -/- null mice. It is possible that differing 
genetic backgrounds may explain these differing observations (Herzer et al., 1999; Koehler et 
al., 2000). 
Wt1 has been classified as a tumour suppressor gene as well as an oncogene. The Wt1 
gene product acts as a regulator of gene expression depending on other cofactors it interacts 
with in different cell types. Wt1 contains a proline rich amino terminus which functions as a 
transcriptional repressor and four contiguous cys2-his2 zinc fingers at the carboxy end which 
bind DNA.  Wt1 expression has been found to be decreased in differentiated leukaemia cells 
both in vivo and in vitro and is up-regulated in fetal spleen and immature leukaemia cells. 
Additionally,  Wt1  exhibits oncogenic potential in specific cellular contexts through the 
transcriptional up-regulation of anti-apoptotic genes such as Bcl2. The Wt1 protein plays an 
essential role in the growth of leukaemic cells. Elevated expression of wild type Wt1 gene has 
been identified in almost all leukaemic cells, independent of the type of disease. Elevated 
levels of Wt1 have been seen in purified CD34+ cells from patients with AML and CML and 
increased  Wt1 expression has been shown to block normal differentiation and enhance 
proliferation of haematopoietic progentior cells. Accordingly, Wt1 may play and important role 
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1.9.2  Fhl1 As a Target Gene of HOX11 
Fhl1 was found by RDA to be activated in a proportion of Hox11 expressing NIH3T3 cells 
(Greene et al., 1998). Fhl1 is a novel LIM-only gene and belongs to a family of proteins that 
contain four and a half LIM domains in which the N-terminal domain consists only of the 
second half of the LIM consensus. When compared to other LIM-only proteins it is unique, as 
it possesses an odd number of zinc fingers. Fhl1 is normally expressed in skeletal and heart 
muscles, but not lymphoid tissues (Greene et al., 1999; Loughna et al., 2000). Fhl1 mRNA 
was found by Northern blot in most of the eleven T-ALL lines examined as well as the ACVA-
1 pre B-ALL cell line. Fhl1 is still only a putative Hox11 target gene as its status has not yet 
been functionally confirmed. In order to investigate a possible role in embryogenesis, in situ 
hybridization was performed on Hox11-/- null mutant mice and wild type embryos which failed 
to show a difference in Fhl1 expression levels (Greene et al., 1998).  
1.9.3  Aldh1a1 As a Target Gene of HOX11 
RDA was used to isolate cDNA clones corresponding to mRNA species activated following 
stable expression of HOX11 in NIH3T3 cells. The gene encoding the retinoic acid 
synthesizing enzyme Aldehyde Dehydrogenase 1a1 (Aldh1a1) was found to be ectopically 
activated by HOX11 in this system. A major function of Aldh1a1 appears to be the 
biosynthesis of retinoic acid by conversion of vitamin A to its biologically active form, retinoic 
acid. Retinoic acid is a local regulator of cellular proliferation, differentiation and death. To 
investigate functional correlations of HOX11 and Aldh1a1  expression, a further study of 
Aldh1a1 gene expression during spleen development was undertaken. The presence of 
Aldh1a1 mRNA inversely correlated with the presence of HOX11 mRNA. Hox11 null mouse 
embryos were found to have elevated Aldh1a1 mRNA in spleen primordia prior to atrophy, 
while Aldh1a1 appeared to be repressed by Hox11 during the organogenesis of the spleens 
of wild type mice. These results suggested that the expression of Aldh1a1 is negatively 
regulated by HOX11 and that abnormal expression of Aldh1a1 in Hox11 null mice may cause 
loss of splenic cells by aberrant retinoic acid metabolism (Greene et al., 1998). 
Transfection experiments were undertaken where HOX11 and a HOX11 mutant lacking the 
homeodomain were ectopically expressed in a number of NIH3T3 clones. Only HOX11 
positive clones showed transcriptional activation of the Aldh1a1 gene. A similar dependence 
of Aldh1a1 induction on the ectopic expression of HOX11 in NIH3T3 cells was found when 
HOX11 expression was controlled by a metallothionein promoter. The paradox of Aldh1a1 
regulation by HOX11 where Aldh1a1 is up-regulated by HOX11 in NIH3T3 fibroblasts and 
down-regulated in the developing spleen is most likely explained by the different physiological 
status of Aldh1a1 in these two situations. It is possible for homeodomain proteins to act as Introduction  45
both positive and negative regulators in differing situations depending on available cofactors 
(Greene et al., 1998). 
ALDH1A1 expression was investigated across a panel of leukaemic cell lines. ALDH1A1 
mRNA was surprisingly restricted to the HEL human erythroleukaemia cell line and a small 
cell lung carcinoma cell line. None of the T-ALL cell lines carrying the t(10;14) translocation 
expressed sufficient ALDH1A1 mRNA to be detected by Northern blot. Thus the role that 
ALDH1A1 plays in HOX11 mediated leukaemia induction is uncertain (Greene et al., 1998; 
Hawley et al., 1997).  
Work by Owen et al., (2003) suggests that the transcriptional pathways controlling Aldh1a1 
gene regulation by HOX11 are distinct from those mediating HOX11 oncogenesis. Murine 
bone marrow precursor cells were infected with a retrovirus bearing the HOX11 gene. 
Constitutive expression of HOX11 results in immortalization of haematopoietic precursors. 
This model was utilized in the examination of several HOX11 mutants. The deletion of the 
first 50 amino acids of the HOX11 protein reduced Aldh1a1 gene up-regulation, but had little 
or no effect on immortalization. The Gln-rich domain near the COOH terminus is important for 
Aldh1a1 gene expression, but not necessary for the establishment of immortalized 
haematopoietic precursors. Additionally, a HOX11 mutant where the HOX11 DNA target 
sequence within the homeodomain had been mutated was able to immortalize 
haematopoietic precursors, but unable to up-regulate Aldh1a1. Finally, a HOX11 mutant with 
a disrupted PBX interaction domain was still able to up-regulate Aldh1a1, but was unable to 
immortalize myeloid progenitors. Taken together, this evidence suggested that the pathologic 
action of HOX11, involves transcriptional pathways distinct from those controlling Aldh1a1 
(Owens et al., 2003). 
1.10 Searching for HOX11 Target Genes 
Given the role of HOX11 as a homeodomain transcription factor, it is likely that it regulates 
the transcription of a set of target genes. One possible way that ectopic expression of HOX11 
by translocation in T-ALL may cause leukaemia is through the dysregulated expression of 
such targets. Previous studies have identified three HOX11 target genes. It is likely that many 
more genes are regulated by HOX11 in the transcriptional cascade involved in cellular 
immortalization. RDA, cDNA microarray and Affymetrix GeneChip array are the three major 
technologies available for the identification of altered gene expression patterns. In this study, 
we initially chose RDA and then subsequently cDNA microarray and Affymetrix GeneChip 
technology as they became available, to identify potential HOX11 targets. Multiple cell lines 
were utilized in an effort to identify genes differentially regulated with HOX11 expression in a 
number of cellular backgrounds including, the J2E murine erythroid cell line and additionally 
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1.10.1 Representational Difference Analysis 
RDA allows the identification of a representative population of genes that differ in expression 
between two populations (Hubank et al., 1994). This technique can therefore be utilized in the 
identification of known and novel gene targets of oncogenic transcription factors (Boyd et al., 
1999).  RDA is based around subtractive hybridization. Subtractive hybridization involves the 
removal of cDNA fragments common to both control and experimental cDNA samples and 
the enrichment of differentially expressed cDNA species (Boyd et al., 1999). mRNA is 
isolated from control and experimental cells and used to generate two populations, one 
designated tester and the other driver. Other methodologies based on subtractive 
hybridization were found to be inadequate for finding differences in the sequences of two 
cDNA populations when 10
5 fold or greater enrichment of target sequences was required. 
RDA was devised to overcome this problem through the incorporation of two additional 
elements; enrichment via favourable hybridization kinetics and PCR amplification (Lisitsyn, 
1995). The exponential degree of enrichment of target sequences enables the detection of 
transcripts present in low concentrations, generating a high sensitivity technique (Hubank et 
al., 1994). The CLONTECH PCR Select Subtraction Kit used in this study differs 
significantly from the traditional RDA method as it incorporates a suppressive PCR 
(Diatchenko  et al., 1996). RDA also has some pitfalls and problems. Common problems 
include; 
1)  Cloning of an excessive number of false positives because low stringency has been 
applied or alternatively too high stringency resulting in no bands (Hubank et al., 
1994) 
2) Problems  with  sensitivity. A study by Braun et al., (1995) reported that most genes 
identified in a RDA assay were differential between tester and driver populations by 
10 fold or more when assayed using Northern blotting (Braun et al., 1995) 
3)  Genes identified by RDA can also be affected by hybridization conditions, changes in 
the restriction enzyme used and the expression levels of cell models used (Braun et 
al., 1995). 
Despite these pitfalls RDA is seen to be advantageous for the identification of putative target 
genes particularly because of its ability to identify unknown genes not found on microarrays. 
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1.10.1.1 Utilization  of  Representational Difference Analysis for the 
Identification of Target Genes Associated with Leukaemia 
RDA has been successfully utilized by several laboratories in the identification of genes 
regulated by oncogenes associated with leukaemia. A number of experiments have been 
based around discovering target genes of fusion proteins commonly found in leukaemias. 
RDA based around the method developed by Hubank and Schatz was used to identify 
transcripts up-regulated with the expression of the oncogenic EWS/FLI fusion gene in the 
NIH3T3 retrovirally transduced cell line. Stromelysin1 a metalloproteinase was later shown to 
be up-regulated within 8 hours of EWS/FLI-1 expression and was identified as a primary 
target gene. Indirect target genes Cytokeratin 15 and Cytochrome P-450 F1 were also 
identified (Braun et al., 1995). 
The technique has also been applied to various models in order to identify target genes of the 
E2A/PBX1 fusion gene often found in pre B cell leukaemias. McWhirter et al., (1997) applied 
RDA to NIH3T3 cells expressing the E2A/PBX1 fusion gene by retroviral infection and a 
control cell population. Once again the method developed by Hubank and Schatz identified a 
fibroblast growth factor FGF-15 as being differentially expressed. Reporter gene assays 
using deletion mutants indicated that E2A/PBX1 transactivates the FGF-15 gene through 
direct binding of the PBX1 homeodomain to a site in the promoter in combination with an 
endogenous factor (McWhirter et al., 1997). Subsequently, another study demonstrated a 
marked induction of the gene NDRG1 by enforced induction of the E2A/PBX1 gene in the 
bone marrow cell line Ba/F3. It was shown that DNA regulatory elements from the NDRG1 
promoter mediate gene induction by E2A/PBX1. NDRG1 was previously shown to be a target 
of repression by N-MYC and a target of induction by the tumour suppressor protein p53. 
Taken together this suggests that induction of NDRG1 is part of the cellular response to 
oncogene activation (Rutherford et al., 2001).  
Another fusion gene implicated in pro-B acute leukaemias E2A/HLF  has also been 
investigated using RDA. This fusion protein is thought to repress apoptotic pathways. 
Kurosawa et al., (1999) undertook RDA based around the Hubank and Schatz method on a 
pro B-cell leukaemia cell line and two transcripts encoding, ANNEXINVIII and a second 
fragment containing sushi repeat motifs named SRPUL, were found to be up-regulated by 
E2A/HLF. The role of these genes in leukaemogenesis was brought into question as neither 
protein prevented apoptosis in IL-3 dependent pro B cells (Kurosawa et al., 1999). Dang et 
al., (2001) also performed RDA to identify downstream targets of E2A/HLF using a murine 
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transcriptional co-repressor proteins, Grg2 and Grg6 were identified as being activated by 
E2A/HLF (Dang et al., 2001). 
Putative target genes of the AML/ETO gene fusion have also been discovered using RDA. 
Harada et al., (2001) performed an experiment on MEL cells where AML1/ETO or AML1 was 
overexpressed. They discovered through RDA the ART-1 gene, a novel transmembrane 
protein was up-regulated by AML expression and down-regulated by AML1/ETO expression. 
This protein was found to be down-regulated by AML1/ETO in both myeloid and erythroid 
cells and its expression was increased during erythroid cell differentiation (Harada et al., 
2001).  
A relevant study has also been undertaken to identify genes associated with ectopic LMO2 
expression. LMO2 is an oncogene known to play an important role in T-ALL. Davernport et 
al., (2000) utilized RDA to identify genes that were over-expressed in transgenic mice with 
enforced  LMO2 expression in their thymocytes. Six genes were identified as being up-
regulated in LMO2 induced leukaemia, Cyclin D1, IA-2 receptor type phosphotyrosine protein 
phosphatase,  Heat shock protein 73,  T- cell receptor  delta chain,  Neuropilin and mitotic 
check point gene Bub1 (Davernport et al., 2000). Also of note, downstream targets of the 
TAL1(SCL)/LMO complex known to play an important role in T-ALL were discovered using 
RDA. Both TAL1 and LMO1 were stably transfected into a T-ALL cell line and RDA was 
applied using a matched control cell line. Retinaldehyde dehydrogenase 2 (RALDH2, also 
known as ALDH1A2) was identified as being up-regulated by the complex. Promoter analysis 
suggested that RALDH2 is a direct target of a TAL1-LMO-GATA3 complex (Ono et al., 1998). 
RDA has also been used to elucidate genes involved in several haematopoietic 
developmental pathways. A number of groups have applied the method in order to identify 
genes which cause lineage switches. Johansen et al., (2001) were interested in genes 
involved in granulopoiesis. The CCAAT/enhancer binding element α (C/EBPα) is known to be 
an integral factor in granulocytic development. RDA based around the method of Hubank and 
Schatz was performed on RNA derived from a C/EBPα inducible myeloid cell line. C-MYC 
was identified as a C/EBPα negatively regulated gene. A E2F binding site in the C-MYC 
promoter was then identified by luciferase assay to be the cis-acting element critical for 
C/EBPα negative regulation. Further work showed that C/EBPα negative regulation of C-
MYC was critical for allowing early myeloid precursors to enter a granulocytic differentiation 
pathway (Johansen et al., 2001). Additionally Iwama et al., (1998) applied RDA to RNA 
extracted from livers of PU.1 and C/EBPα knockout mice and wildtype mice. Both 
transcription factors are known to play an important role in myeloid development in the 
pathways of monocyte/macrophage development and neutrophilic differentiation respectively. 
A set of differentially expressed genes specific to each cell type was identified (Iwama et al., Introduction  49
1998). Similarly, Williams et al., (1999) performed RDA on the J2E erythroleukaemic cell line 
in order to identify myeloid genes that are associated with a lineage switch. HLS7 a 
homologue of the novel human oncogene Myeloid  Leukaemia Factor 1 was identified as 
being an important differentially expressed transcript (Williams et al., 1999). 
The technique has also been applied to the oncogene c-Myc. A study by Prescott et al., 
(2001) identified a novel c-Myc responsive gene named Jpo1 by RDA of the Rat1a verus the 
Rat1a-Myc fibroblast cell lines. Jpo1 was found to respond to c-Myc induction in two inducible 
cell lines TGR and HO15. Additionally western blotting showed a correlation between c-Myc 
and JPO1 protein levels in human lymphoblastoid CB33 cells, Burkitt’s lymphoma cell lines 
and breast cancer cell lines. A estrogen receptor c-Myc fusion system utilized in combination 
with protein synthesis inhibitors was utilized in the identification of JPO1 as a direct c-Myc 
target (Prescott et al., 2001). 
In conclusion, previous studies demonstrate that RDA has been successfully applied to a 
number of experimental systems in order to identify putative target genes in pathways 
involved in oncogenesis. 
1.10.2 Microarray Technology 
Microarray technology involves the systematic screening of the expression a large number of 
known genes in parallel. Expression analysis can be performed using two different types of 
microarray chips. The competing technologies are high density in situ synthesized 
oligonucleotide arrays such as GeneChips from Affymetrix or cDNA microarrays which are 
produced by robotic spotting of cDNA or PCR products onto glass slides. Advantages and 
disadvantages are associated with the two techniques. Affymetrix technology requires very 
little total RNA and each sample including control samples are hybridized on a separate chip. 
This allows samples to be analyzed in several different permutations and means less material 
is required. cDNA microarrays are performed as a two colour competitive assay and control 
RNA must be included in each assay. There is also substantial difference in the quality of 
each type of array. There is considerable variability between batches of cDNA microarrays 
with regard to background and sensitivity which poses problems regarding reproducibility of 
experiments. Additionally the process of robotic spotting PCR products also adds to problems 
of reproducibility. Low complexity sequence induced non specific hybridization has also been 
reported with cDNA arrays (Duggan et al., 1999; Lipshutz et al., 1999; Brazma et al., 2001). 
Many investigators exclusively use Affymetrix technology in spite of higher expense as the 
data is seen to be of superior quality. Introduction  50
1.10.2.1 cDNA  Microarray 
cDNA microarray enables the analysis of expression levels of tens of thousands genes.   
Individual gene probes are produced by PCR amplification under high through put conditions. 
Inserts are amplified from cDNA and EST libraries. Before microarray printing the amplified 
probes are purified and analyzed by gel electrophoresis. The microarrays are formed by 
robotically depositing these gene probes onto a glass microscope slide. At least 400 spots 
can be printed from the single loading of the pin. The target is prepared by extracting total 
RNA. The target RNA is reverse transcribed into cDNA and labeled with fluorescent dyes. 
The cyanine dyes CY3 and CY5 are currently the most popular fluorochromes for DNA 
microarrays. These dyes are usually incorporated into the first strand cDNA product. 
Hybridization is performed under a coverslip in a heated humid chamber. Labeled target 
molecules hybridize to complementary probes with a frequency proportional to their relative 
abundance in the original mixture of targets. After hybridization and washing the fluorescently 
labeled targets are excited by scanning with laser light sources and visualized. Specialized 
software is then used to normalize, scale and standardize the signal intensities in order to 
eliminate systematic variations in intensity that are not related to changes in RNA abundance. 
Data from the hybridization experiment is then viewed as a normalized ratio of CY3/CY5 
which enables the gene to be classified as increased, decreased or no change compared to 
the reference preparation (Duggan et al., 1999; Deyholos et al., 2001). 
1.10.2.1.1  Utilization of cDNA Microarray Technology for Expression Profiling of 
Leukaemias 
cDNA microarray technology has been successfully applied to the profiling and classification 
of leukaemias. Ross et al., (2000) used microarray to profile leukaemic cell lines and 
Alizadeh  et al., (2000) performed similar experiments to molecularly classify two distinct 
forms of diffuse large B-cell lymphoma (Ross et al., 2000; Alizadeh et al., 2000). In addition, 
B-cell chronic lymphocytic leukaemia (B-CLL) profiles which correlate with patient prognosis 
have been established using cDNA microarray technology (Stratowa et al., 2001; Plate et al., 
2000). cDNA microarrays have also been used to classify the expression profiles of 51 bone 
marrow samples from children with acute leukaemia. This study provided expression profiles 
in each case which enabled the patients to be segregated into subgroups. The microarray 
findings were also confirmed using real time PCR for select genes and results were found to 
correlate. Overall cDNA microarray technology has enabled the classification of primary 
patient samples. This may aid future subclassifcation and diagnosis of leukaemia (Moos et 
al., 2002) Introduction  51
 
1.10.2.1.2  Utilization of cDNA Microarray Technology for the Identification of Target 
Genes Associated with Cancer 
Only a few studies to date have utilized cDNA microarray technology for the identification of 
target genes associated with leukaemia. cDNA microarray technology was used to elucidate 
a putative target gene of the PML-RARα gene in acute promyelocytic leukaemia (APL). The 
technology was used to identify genes induced in response to retinoic acid in TF1 myeloid 
leukaemia cells expressing PML-RARα. The haematopoietic gene B94 was found to be 
specifically induced by retinoic acid. Additionally a screen of patient samples found that this 
gene was repressed in marrow cells from APL patients. Treatment of APL blasts with retinoic 
acid resulted in up-regulation of B94 mRNA. These results reinforced the notion that B94 is a 
target of PML-RARα in APL (Rusiniak et al., 2000). A similar study by Witcher et al., (2003) 
used cDNA microarrays to investigate all trans retinoic acid regulated genes in an APL cell 
line NB4. It was found that all trans retinoic acid regulated several members of the tumor 
necrosis factor (TNF) pathway. Gel shift analysis demonstrated an increase in tumor necrosis 
factor induced NF-kB DNA binding within 2 hours of treatment with all trans retinoic acid. 
Further investigations demonstrated that other NF-kB target genes found to be up-regulated 
by cDNA microarray (BCL-3, DIF-3 and TNFR2) were synergistically induced in response to 
TNF and all trans retinoic acid (Witcher et al., 2003). 
Several other studies have utilized cDNA microarray technology for the identification of target 
genes in various cancers. One such study focused on the transcription factor NF-kB which is 
known to inhibit apoptosis. Ovarian and breast cancer cell lines OVCAR-3 and MCF7A/Z 
were stably transfected with an inhibitor IKBα known to sequester NF-kB in the cytoplasm. A 
set of control and IkBα expressing cell lines were then stimulated with IL-1B or TNF-α and 
subjected to cDNA microarray analysis. Upon comparison of data two previously unidentified 
NF-kB target genes EPHRIN-A1 and CAVEOLIN-1 were identified and confirmed by real time 
RT-PCR (Deregowski et al., 2002). 
Similarly, Ingram et al., (2002) used cDNA microrarrays to identify target genes of Sonic 
Hedgehog in the C3H/10T1/2 cell line. Sonic Hedgehog signaling pathways have been 
implicated in basal cell carcinomas and a range of other cancers. Eleven putative target 
genes were identified and later confirmed by Northern blot analysis, GLIZ,  BF-2,  Nr4a1, 
PMP22, LASP1, SFRP-1, SFRP-2, MIP1-γ and AMH. NR4A1, GLIZ, SFRP-1 and SFRP-2 
have putative roles in the process of apoptosis. PMP22 is implicated in development of 
peripheral nerves LASP1 is known to be involved in cytoskeletal changes involved in 
neoplastic transformation (Ingram et al., 2002). Introduction  52
cDNA microarrays have also been used to dissect c-myc apoptotic pathways. Nesbit et al., 
(2000) identified 35 transcripts up-regulated with c-myc expression in the 32Dcl.3 murine 
myeloid cell line and 25 down-regulated transcripts. Sixteen genes were confirmed by 
Northern blot analysis. Several differentially regulated ESTs and Small proline rich protein 2A 
were found to be regulated by IL-3. Additionally deletion experiments demonstrated that the 
transactivation domain of c-myc was found to be essential for c-myc regulation of a number 
of genes. Several of the differentially regulated transcripts were also found to be responsive 
to the proapoptotic cytokine IFN-γ, indicating the sensitivity of c-myc overexpressing cells to 
apoptosis (Nesbit et al., 2000). 
Finally, Takahashi et al., (2002) utilized cDNA microarray analysis to find genes regulated by 
the  β-catenin/T-cell factor complex known to play a role in colon cancer. The tumour 
repressor APC is known to interact with β-catenin and facilitate the degradation of β-catenin 
via the ubiquitin proteosome system. Mutations in APC commonly lead to the constitutive 
activation of the β-catenin/Tcf transcriptional complex. APC was transfected into SW40 colon 
cancer cells. Microarray experiments performed on these cells in comparison to normal 
SW40 cells lead to the identification of a novel gene APCDD1 which was down-regulated in 
cells expressing APC. Reporter gene assays using the 5’ flanking region of APCDD1 
indicated that a β-catenin/ T-cell factor complex increased reporter activity through interaction 
with putative Tcf/lymphoid enhancer factor binding motifs upstream of the transcriptional start 
site. Additionally expression of APCDD1 promoted growth of colon cancer cells in vitro and in 
vivo. Taken together, these data indicate that APCDD1 is directly regulated by the β-
catenin/Tcf complex and that this process plays and important role in colorectal 
tumorigenesis (Takahashi et al., 2002). 
In conclusion, cDNA microarray technology, when combined with techniques such as RT-
PCR, Northern blot analysis, screening of patient samples and functional assays, has been 
successfully utilized in the identification of putative target genes involved in oncogenesis. 
1.10.2.2 GeneChip  Microarray For Gene Expression 
The Affymetrix GeneChip probe arrays are manufactured using photolithographic methods, 
such that hundreds of thousands of different oligonucleotides are synthesized on each array.  
The arrays are used for the quantitative and highly parallel measurement of gene expression 
(Lipshutz  et al., 1999). The key to Affymetrix GeneChip technology is the use of probe 
redundancy which involves the use of multiple oligonucleotides of different sequence 
designed to hybridize to different regions of the same RNA. The use of multiple independent 
detectors for the same molecule greatly improves signal to noise ratios, improves the 
accuracy of RNA quantitation, increases the dynamic range, mitigates effects due to cross Introduction  53
hybridization and drastically reduces the rate of false positives and miscalls. An additional 
level of redundancy comes from the use of mismatch (MM) control probes that are identical to 
their perfect match (PM) partners except for a single base difference in the central position. 
The MM probes act as specificity controls that allow the direct subtraction of both background 
and cross hydridization signals and allow discrimination between real signals and those due 
to non-specific or semi-specific hybridization. In the presence of even low concentrations of 
RNA, hybridization to the PM/MM pairs produces recognizable and quantitative fluorescent 
patterns. The strength of these patterns directly relates to the concentrations of RNA 
molecules in the complex sample. A fluorescently tagged nucleic acid sample injected into 
the chamber hybridizes to complementary oligonucleotides on the array. Following washing, 
detection of hydribization occurs by, laser excitation entering through the back of the glass 
support, focused at the interface of the array surface and the target solution. Fluorescence 
emission is collected by a lens and passes through a series of optical filters to a sensitive 
detector. A quantitative two dimensional fluorescence image of hybridization intensity is 
obtained. GeneChip software is then used to calculate differential expression rates (Lipshutz 
et al., 1999). 
1.10.2.2.1  Utilization of GeneChip Microarray Technology for Expression Profiling of 
Leukaemias 
GeneChip microarray technology has been utilized in a number of studies for the gene 
expression profiling of patient leukaemia samples. Virtaneva et al., (2001) used 
oligonucleotide based microarrays to study global gene expression in AML trisomy 8 patients 
and cytogenetically normal AML patients (Virtaneva et al., 2001). Shipp et al., (2002) used 
GeneChip microarrays to link gene profiles with the clinical outcome of patients with diffuse 
large B-cell lymphoma (Shipp et al., 2002). Armstrong et al., (2002) utilized GeneChip 
microarray in order to establish that leukaemias involving MLL translocations demonstrate a 
characteristic, highly distinct gene expression profile which warrants their classification as a 
leukaemia distinct from ALL and AML. This study also found that MLL leukaemias often 
highly express individual HOX genes (Armstrong et al., 2002). 
Many studies have also been undertaken to identify predictor gene sets, for sub-classification 
of leukaemias. Golub et al., (1999) utilized cDNA microarray technology to profile ALL and 
AML and established 50 predictor genes which enable the molecular classification of 
leukaemia type (Golub et al., 1999). Similarly Kohlmann et al., (2003) used oligonucleotide 
microarrays to create expression signatures that can accurately discriminate acute leukaemia 
subgroups including t(8;21), t(15;17), t(11q23)/MLL, inv(16) for AML and t(9;22), t(8;14), 
t(11q23)/MLL for B-ALL and a separate precursor T-ALL subgroup (Kohlmann et al., 2003) 
Similarly, Schoch et al., (2002) and Debernardi et al., (2003) utilized GeneChip microarray 
technology to cluster AML cases into separate groups representing cytogenetic classes Introduction  54
(Schoch et al., 2002; Debernardi et al., 2003). Finally the technology has also been applied to 
the identification of a set of 35 genes associated with prognosis in AML (Yagi et al., 2003). 
B-cell leukaemias have also been the focus of expression profiling using oligonucleotide 
microarrays. The mechanisms by which integrins prevent apoptosis in B-cell leukaemias was 
investigated by Astier et al., (2003). REH and Nalm-6 precursor B-leukaemia cells were 
grown on plates coated with the ligand for the B1-integrin receptor or as a control an 
adhesive coating. This method induced B1-integrin expression. Microarray analysis was 
performed and several genes involved in adhesion and proliferation were identified as being 
up-regulated and confirmed using real time RT-PCR. Importantly however, the study showed 
that integrin stimulation up-regulated FBI-1 expression, but inhibited CD79A, REQUIEM, C-
FOS and CASPASE7 when the cells underwent apoptosis. Integrin stimulation also inhibits 
CASPASE3 activation, but increases XIAP and SURVIVIN expression. Similarly integrin 
stimulation prevents caspase activation induced by chemotherapeutic drugs. Thus, many 
genes modulated by the adhesion of human precursor B leukaemia cells regulate 
proliferation and apoptosis (Astier et al., 2003). Several studies have also been undertaken 
into B-CLL. Vallat et al., (2003) identified 16 genes whose expression varied between 3 
irradiation induced apoptosis resistant patient samples and 4 sensitive samples. Further 
analysis of these genes by real time RT-PCR across a panel of apoptosis sensitive and 
resistant patient samples identified 13 genes found to be specific in all cases (Vallet et al., 
2003). A similar study by Durig et al., (2003) demonstrated that B-CLL patient samples can 
be clustered according to high expression of ribosomal and other translation associated 
genes. High expression of these genes was also linked with favorable prognosis (Durig et al., 
2003). 
Another study applied GeneChip expression profiling to enhance the risk stratification of ALL 
patients. In order to determine whether gene expression profiling could enhance risk 
assignment, oligonucleotide microarrays were used to analyze the pattern of genes 
expressed in leukaemic blasts from 360 paediatric ALL patients. Distinct expression profiles 
identified each of the leukaemic subtypes T-ALL, E2A-PBX1, BCR-ABL, TEL-AML and MLL.  
Another novel ALL subgroup was identified based on its unique expression profile. 
Additionally, with some genetic subgroups, expression profiles identified patients that 
eventually failed therapy (Yeoh et al., 2002). 
Perhaps the study most relevant to T-ALL was undertaken by Ferrando et al., (2002). 
GeneChip microarray was used in order to use gene expression profiling to define novel 
oncogenic pathways in T-ALL (Section 1.7.3). Several significant findings were established in 
this study of 59 patient samples. HOX11 along with TAL1, LYL1, LMO1 and LMO2 were 
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addition LYL1 was found to be a gene expression signature of leukaemic arrest at the pro T-
thymocyte stage of development, HOX11 the early cortical stage of thymocyte development 
and TAL1 the late cortical stage of thymocyte development. HOX11L2 was also identified in 
this study as being associated with T-cell leukaemogenesis. Finally, the study was able to link 
HOX11 activation with favourable prognosis and TAL1, LYL1 or HOX11L2 activation with 
poor response to treatment (Ferrando et al., 2002). Expression profiling using GeneChip 
microarray technology has contributed to the identification of common highly expressed 
genes which play important roles in the pathogenesis of T-ALL and other leukaemias. 
1.10.2.2.2  Utilization of GeneChip Technology for the Identification of Target Genes 
Associated with Cancer 
GeneChip microarray technology enabled the identification of target genes of the receptor 
tyrosine kinase Flt3. Flt3 is usually expressed in early haematopoietic progenitor cells and 
mediates important functions for proliferation and survival. It is also expressed in the majority 
of cases of AML. Internal tandem duplications of Flt3 occur in 25% of cases of AML. These 
mutations activate the receptor and induce leukaemic transformation. The mouse myeloid 
progenitor cell line 32Dcl3 was stably transfected with either wild type or 3 different isoforms 
of tandem duplications of Flt3. Microarray expression analyses were then compared and 767 
genes were found to differ in expression between Flt3-mutated and wildtype cell lines. 
Eighteen of these genes were then confirmed as being differential using real time PCR 
analysis. It appeared that putative target genes of mutationally activated Flt3 closely 
resembled those of the IL-3 receptor. One putative target gene Pim-2 was investigated. It 
was found to be up-regulated on the mRNA and protein level in Flt3-mutated cells. 
Additionally it was found to be overexpressed in leukaemic bone marrow samples from 84 
patients with AML and was found to be important for the clonal growth of Flt3-mutated cells. 
Two genes PU.1 and C/EBPα were found to be repressed by Flt3 mutations. PU.1 plays a 
crucial role in monocytic and B-cell lineage differentiation and C/EBPα is important in myeloid 
differentiation.  Several expression assays using real time RT-PCR and western blotting 
confirmed this initial finding. In addition, the transcriptional activity of PU.1 was investigated 
using a PU.1 reporter luciferase construct. This experiment suggested that Flt3 mutations 
inhibit the induction of PU.1 expression and function. Thus GeneChip microarray technology 
lead to the identification of the transcriptional program of Flt3 mutations in AML (Mizuki et al., 
2003). 
The technology has also been utilized in the identification of putative target genes associated 
with transcriptional cascades involved in other types of cancer. Louro et al., (2002) used 
microarrays to identify transcripts regulated by GLI or c-Myc after retroviral transduction of 
epithelial RK3E cells. These genes are known to play an important role in epithelial malignant Introduction  56
transformation. GLI up-regulated 158 and repressed 52 genes on the GeneChip, while c-Myc 
repressed 424 genes. The up-regulation of 24 GLI regulated transcripts was confirmed by 
Northern blot analysis. The GLI induced expression of mesenchymal cell marker Snail, a zinc 
finger protein implicated in epithelial mesenchymal transition was further investigated using a 
GLI-estrogen receptor fusion protein. This system was shown to rapidly induce Snail 
expression, demonstrating that it is a putative direct transcriptional target gene of GLI (Louro 
et al., 2002). 
A novel application of GeneChip technology was utilized by Kannan et al., (2001) in order to 
identify primary and secondary target genes regulated by the tumor suppressor p53. 
Inhibition of protein synthesis by cycloheximide was used to distinguish between primary and 
secondary target genes regulated by p53. Thirty eight putative up-regulated direct target 
genes and 24 putative down-regulated direct target genes were identified. Cluster analysis 
was also used to distinguish the `primary target genes’ from the large pool of p53 regulated 
genes. Cell cycle (p21,  TGF-B,  CYCLIN E), apoptosis (FAS,  BAK,  IAP), cell adhesion 
(THYMOSIN, SMOOTHELIN), signaling (H-RAS, DIACYLGLYCEROL KINASE), transcription 
(ATF3,  LISCH7) and DNA repair (BTG2,  DDB2) related genes were identified as being 
putative p53 primary target genes (Kannan et al., 2001). Fontemaggi et al., (2002) utilized 
GeneChip technology to identify target genes of p73 in the H1299 cell line. Results were 
confirmed by RT-PCR. In addition, p73 was found to specifically bind the regulatory regions 
of CAN19, 14-3-3σ, p21 WAF1, α-ANTITRYPSIN, PTGF-B, PIG-3 and JAG2 in chromatin 
immunoprecipitation assays. These genes were identified as being putative direct targets of 
p73 (Fontemaggi et al., 2002). 
GeneChip microarray analysis was used to identify targets of Sonic hedgehog in granule cell 
precursors. This transcriptional pathway is thought to play a role paediatric 
medulloblastomas.  Cyclin D1 and N-myc were found to be robustly induced by Sonic 
hedgehog in microarray assays, this finding was confirmed by Northern blot analysis. N-myc 
transcription was also found to be induced in the presence of protein synthesis inhibitor 
cyclohexamide, indicating that it is a putative direct target of Sonic hedgehog. Retroviral 
transduction of N-myc into granule cell precursors induced the expression of Cyclin D1, E2F1 
and E2F2 and promoted proliferation. Dominant negative N-myc substantially reduced this 
proliferation.  Cyclin D1 and N-myc were also found to be overexpressed in murine 
medulloblastoma and are thought to be important Sonic hedgehog target genes in 
tumorigenesis (Oliver et al., 2003). 
Finally, the technology was used in the identification of E2F1 specific target genes. E2F1 is a 
key regulator of cell growth control. It has been implicated in cancer, such that loss of E2F1 
leads to tumour development in the reproductive tract, lungs and lymphoid system. Introduction  57
Overexpression of E2F1 leads to neoplasia in the skin and causes tumour formation in the 
liver of transgenic mice. Wells et al., (2002) profiled the gene expression of E2F1 nullizygous 
and wildtype mice and identified Pai-1,  Thioether S-methyl transferase,  Hydroxysteroid 
sulfotransferase and Carboxylesterase as putative target genes. Chromatin 
immunoprecipitation using chromatin from mouse kidney, spleen and testis was undertaken 
in order to demonstrated that E2F1 bound to the promoter of these putative target genes 
(Wells et al., 2002). 
Thus GeneChip microarray technology in conjunction with RT-PCR, Northern blot analysis, 
screening of patient samples, chromatin immunoprecipitation, functional reporter assays and 
protein synthesis inhibitor assays has also been successfully utilized in the identification of 
putative target genes. 
1.11 Models for Studying HOX11. The Paradox of HOX11 
Despite the role of HOX11 in human leukaemias, attempts to produce a relevant transgenic 
mouse model for the study of HOX11 associated T-ALL have proven unsuccessful. Cellular 
models for the study of HOX11 have been investigated as an alternative to the transgenic 
approach. The PER-117 human T-cell leukaemia line has been transfected with HOX11, 
however no phenotypic effect was observed (Greene, Ford and Kees, unpublished 
observations). The murine T-cell line EL4 and the human T-cell line JURKAT were also 
transfected with HOX11 however HOX11 expression was not tolerated (Greene, Ford and 
Kees, unpublished observations). Non-T-cell lines have also been employed as models for 
the study of HOX11. One example is the J2E cell line which is a murine erythroid cell line that 
has the capacity to terminally differentiate in response to erythropoietin (Epo) (Klinken et al., 
1988). This characteristic makes the phenotype of the J2E cell line `plastic’ and thus enables 
us to view the effect that HOX11 has on cell differentiation at both a phenotypic and genetic 
level. While the J2E cell line is not of the T-cell type, the study of the HOX11 oncogene in this 
model has additional relevance as HOX11 has been implicated in playing a role in both 
myeloid leukaemia and erythroleukaemia (Lu et al., 1992; Hawley et al., 1994). Introduction  58
 
1.12  Thesis Aims 
In this study I sought to further understand the role of HOX11 in tumorigenesis by; 
1) The identification of novel putative HOX11 target genes involved in T cell 
oncogenesis by profiling gene expression in response to HOX11 in a number of cell 
lines using a combination of RDA, cDNA microarray and GeneChip approaches and 
2) confirming target gene status by assessing whether the proximal promoters of the 
leading candidates identified are transcriptionally regulated by HOX11 in a T cell 
leukaemic cell line. 
These aims are addressed in Chapter Three by the application of RDA to a murine erythroid 
cell model, followed by the screening of candidate target genes across a panel of leukaemic 
cell lines by RT-PCR. Chapter Four outlines the application of cDNA microarray to the same 
cell model followed by the screening process outlined above. Chapter Five describes the 
utilization of Affymetrix microarray across murine erythroid, murine fibroblast and human T-
cell lines, followed by the same RT-PCR screening process. Finally functional studies 
involving a luciferase experimental system in a human T-cell line were undertaken to assess 
the regulation of the proximal promoters of leading candidate target genes by HOX11 in 
Chapter Six. 
 Materials and Methods  59
Chapter Two 
Materials and Methods Materials and Methods  60
 
2.1 MATERIALS 
2.1.1 Bacterial  Strains 
 
STRAIN    PHENOTYPE 
E.coli INVαF’ One Shot 
Competent Cells 
Invitrogen, CA, USA  F’ endA1, recA1, hsdR17 (rk-, 
mk+), supE44, thi-1, gyrA96, 
relA1, φ80lacZ∆M15, 
∆(lacZYA- argF) U169 λ- 
E.coli DH5α Competent Cells  Promega , MA, USA  φ80dlacZ∆M15, rec A1, end 
A1, gyrA96, thi-1, hsd R17(rk-, 
mk+), supE44, rel A1,deoR, 
∆(lacZYA-argF)U169 
 
2.1.2 Cell  Lines 
Name   Cell Type  Origin  Reference 
J2E Erythroid  Prof. S.P. Klinken, 
University of Western 
Australia, Perth, WA. 
Klinken et al., 1988 
J2EHOX11  J2E cell line stably 
transfected with 
pEFBOSHOX11 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Greene et al., 2002 
NIH3T3  Murine embryonic fibroblast  MRC Laboratory of 
Molecular Biology, 
Cambridge, U.K. 
Jainchill et al., 1969 
NIH3T3HOX11  NIH3T3 cell line stably 
transfected with 
pEFBOSHOX11 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Masson et al., 1998 
HEL  Erythroleukemic cell line  Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Martin and 
Papayannopoulou, 1982 
HELHOX11  HEL cell line stably 
transfected with 
pEFBOSHOX11 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
 
K562  Derived from a Philadelphia 
chromosome positive 
Chronic Myeloid 
Leukaemia. Embryonic 
erythroleukaemic 
phenotype 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
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PER-487III  Childhood T-cell Acute 
Lymphoblastic Leukemia 
cell line 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Kees et al., 1999 
PER-427I  Childhood T-cell Acute 
Lymphoblastic Leukemia 
cell line 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
 
JURKAT  Leukaemic T-cell line of a 
more mature phenotype 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Gillis et al., 1980 
MOLT4  T-cell Acute Lymphoblastic 
Leukemia cell line 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Sahai Srivastava et al., 
1973 
PER-550  Childhood T-cell Acute 
Lymphoblastic Leukemia 
cell line 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
 
RPMI 8402  T-cell Acute Lymphoblastic 
Leukemia cell line 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Srivastava et al., 1975 
PER-117  Childhood T-cell Acute 
Lymphoblastic Leukemia 
cell line bearing markers of 
a T-cell precursor 
phenotype 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Kees et al., 1987 
PER-117HOX11  PER-117 cell line stably 
transfected with 
pEFBOSHOX11 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
 
PER-255  Childhood T-Cell Acute 
Lymphoblastic Leukemia 
cell line with t(7;10) 
chromosomal translocation 
Prof. U. Kees,    
Institute for Child 
Health Research, 
Perth, WA. 
Kees et al., 1989 
ALL-SIL  Childhood T-Cell Acute 
Lymphoblastic Leukemia 
cell line with t(10;14) 
chromosomal translocation. 
Possesses and immature 
phenotype 
Dr J. Minowada, 
Fujisaki Cell Center, 
Okayama, Japan 
 
MKB-1 T-cell  Acute  Myeloblastic 
Leukemia 
MRC Laboratory of 
Molecular Biology, 
Cambridge, U.K. 
Matsuo et al., 1989 
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2.1.3 Tissue  Culture  Media 
Dulbecco’s modified medium (DMEM)  TRACE Biosciences, NSW, Australia 
Rosewell Park Memorial Institute Medium 1640 
(RPMI) 
TRACE Biosciences, NSW, Australia 
 
2.1.4  Chemicals and Reagents 
 
φ174HaeIII Standard  Promega, Madison, USA 
5 x Nucleic Acid Sample Loading Buffer  BioRad Laboratories, CA, USA 
ABI prism dGTP Big Dye Terminator v3.0 
Ready Reaction Cycle Sequencing Kit 
Perkin Elmer, MA, USA 
Advantage cDNA Polymerase Mix  Clontech Laboratories, CA, USA 
Aprotinin  ICN Biomedicals Inc., Ohio, USA 
Bacto Agar  Becton Dickinson, MD, USA 
Bactotryptone  Becton Dickinson, MD, USA 
Bradford Assay  BioRad Laboratories, CA, USA 
CaCl2  BDH AnalaR, Merck Pty Ltd, VIC, Australia 
Chemiluminescence Kit  AP Biotech, Little Chalfont, UK 
Chloroform   ICN Biomedicals Inc., Ohio, USA 
CLONTECH PCR Select Subtraction Kit  Clontech Laboratories, CA, USA 
Dextran Sulfate  Sigma Chemical Co., MO, USA 
Diaminofluorene (DAF)  Sigma Chemical Co., MO, USA 
Dithiothreitol (DTT)  ICN Biomedicals Inc., Ohio, USA 
DNA Free  Ambion, TX, USA 
DyNAzyme EXT  Finnzymes Oy, Finland 
Ethanol  Chem Supply, SA, Australia 
Ethylene Glycol-bis tetra acetic acid (EGTA)  ICN Biomedicals Inc., Ohio, USA 
Ethylenediamine tetra acetic acid (EDTA)  APS Chemicals Ltd, NSW, Australia 
Ficol 400  Sigma Chemical Co., MO, USA 
Foetal Bovine Serum (FCS)  TRACE Biosciences, NSW, Australia 
Fugene 6 Transfection Reagent  Roche, IN, USA 
Hydroxyethylpiperazine ethanesulfonic acid  
(HEPES) 
Roche, IN, USA 
Iodoacetamide  Sigma Chemical Co., MO, USA 
KCl  BDH AnalaR, Merck Pty Ltd, VIC, Australia 
Leupeptin  ICN Biomedicals Inc., Ohio, USA Materials and Methods  63
L-Glutamine  TRACE Biosciences, NSW, Australia 
Microspin G-25 columns  Amersham, Uppsala, Sweden 
NaCl  BDH AnalaR, Merck Pty Ltd, VIC, Australia 
Neomycin  Sigma Chemical Co., MO, USA 
Non Essential Amino Acids Soln.  TRACE Biosciences, NSW, Australia 
Nonidet P-40 (NP40)  ICN Biomedicals Inc., Ohio, USA 
32P-αdCTP  Amersham, Chalfont, UK 
Penicillin/Streptomycin Soln.  TRACE Biosciences, NSW, Australia 
Phenol  ICN Biomedicals Inc., Ohio,USA 
Phenol:Chloroform:Isoamylalcohol (25:24:1)  ICN Biomedicals Inc., Ohio,USA 
Phosphate Buffered Saline Tablets  ICN Biomedicals Inc., Ohio,USA 
p-nitrophenylguanidinobenzoate  Sigma Chemical Co., MO, USA 
Polyvinylpyrrolidone (PVP 360)  Sigma Chemical Co., MO, USA 
Primers (forward and reverse DNA primers)  Geneworks, SA, Australia 
Proteinase K  Sigma Chemical Co., MO, USA 
Puromycin  Sigma Chemical Co., MO, USA 
Pyruvate   TRACE Biosciences, NSW, Australia 
QIAamp DNA Blood Maxi Kit   QIAGEN, CA, USA 
QIAGEN Oligotex mRNA Extraction Kit  QIAGEN, CA, USA 
QIAGEN Plasmid Mega Purification Kit  QIAGEN, CA, USA 
QIAGEN Plasmid Midi Purification Kit  QIAGEN, CA, USA 
QIAGEN Plasmid Mini Purification Kit  QIAGEN, CA, USA 
Rediprime II- random prime labeling system  Amersham, Uppsala, Sweden 
Restriction Endonucleases  Promega, Madison, USA 
Sodium Acetate  APS Chemicals Ltd, NSW, Australia 
Sodium Dodecyl Sulfate (SDS)  BDH AnalaR, Merck Pty Ltd, VIC, Australia 
T4 DNA Ligase  Promega, Madison, USA 
Thermoscript  Gibco BRL, Auckland, New Zealand 
Triton X-100  BDH AnalaR, Merck Pty Ltd, VIC, Australia 
TRIZOL Reagent  Invitrogen, CA, USA 
Trypsin-Ethylenediaminetetra acetic acid 
(Trypsin-EDTA) 
TRACE Biosciences, NSW, Australia 
Water (for irrigation)  Baxter, NSW, Australia 
Yeast Extract  Becton Dickinson, MD, USA Materials and Methods  64
 
2.1.5  Materials and Equipment 
Fuji Medical X-ray Film  Fuji film, Tokyo, JAPAN 
Magna Nylon Transfer Membrane-discs  Magna, MSI, MA, USA 
Magna Nylon Membrane  Magna, MSI, MA, USA 
UV Stratalinker  BioRad Laboratories, CA, USA 
Ag501x8 Resin  BioRad Laboratories, CA, USA 
G50 Spin Chromatography Column  Amersham, Uppsala, Sweden 
Bioscan QC 200 counter  Bioscan Inc., Washington D.C., USA 
PTC-100 DNA thermal cycler  MJ Research, MA, USA 
Hybond-C Super Membrane  AP Biotech, Little Chalfont, UK 
Hyperfilm ECL  AP Biotech, Little Chalfont, UK 
Applied Biosystems 3730 Cycle Sequencer  Perkin Elmer, MA, USA 
Cryovial (1ml)  Nunc, Denmark 
 
2.1.6  Buffers and Solutions 
20 x Northern Running Buffer  Na2HPO4 122mM 
NaH2PO4 78mM 
20 x Saline Sodium Citrate (SSC)  NaCl 3M 
Na3C6H5O7.2H20 pH 7.0 300mM 
2YT Broth  Bactotryptone (w/v) 1.6% 
Yeast Extract (w/v) 1% 
NaCl 86mM 
Adjust to pH 7.0 
5 x RNA Loading Dye  Glycerol (v/v) 50% 
Bromophenol Blue (w/v) 0.2% 
in 5x Northern Running Buffer 
50xTAE Buffer  Tris-HCl (w/v) 24.4% 
Acetic acid (v/v) 1.14%  
EDTA 0.05M 
pH 8.0 
Deionized Glyoxal  Stir Glyoxal for 30min at RT filter through  
Ag501x8 resin, aliquot and store at -20°C 
Denhardt’s Solution  Dextran sulphate (w/v) 16.7%  
stir for 60min at RT. Materials and Methods  65
Add a mixture of; 
Ficol 400 (w/v) 0.8% 
BSA Fraction V (w/v) 0.8% 
PVP 360 (w/v) 0.8% 
Diaminofluorene (DAF) Stain  Diaminofluorene 1mg/ml in Tris-HCl Ph7.0 
200mmol/L 
H202 (v/v) 1.5% 
Freezing Medium   Foetal Calf Serum (v/v) 90% 
DMSO (v/v) 10% 
Gel Denaturing Solution  NaCl 1.5M 
NaOH 0.5M 
Gel Neutralizing Solution  NaCl 3M 
Tris 0.5M 
HCl 0.4M 
Genomic DNA Lysis Buffer  Tris-HCl (pH 7.4) 50mM 
EDTA 1mM 
SDS 0.5% 
Hybridization Buffer  SSC x 3 
Denhardt’s Solution x 10 
SDS 0.1% 
Salmon Sperm DNA 250mg/ml 
Hybridization Wash Buffer  SSC x 0.1 
SDS 0.1% 
Luria Bertoni Broth (LB)/Agar  Bactotryptone (w/v) 1% 
Yeast Extract (w/v) 0.5% 
NaCl 172mM 
Adjust to pH 7.0 
For agar Bactoagar 1.5% added to LB broth 
NP40 Lysis Buffer  Tris-HCl pH 7.4 10mM 
NaCl 150mM 
MgCl2 1mM 
NP40 (v/v) 0.5% 
Phosphate Buffered Saline (PBS)  KCl 2.68mM 
Na2HPO4 10.1mM 
KH2PO4 1.76mM 
NaCl 137mM 
Western Buffer A  Hepes pH7.9 10mmol/L Materials and Methods  66
KCl 10mmol/L 
EDTA 0.1mmol/L 
EGTA 0.1mmol/L 
Dithiothreitol 1mmol/L 
Leupeptin 10ug/ml 
Aprotinin 10ug/ml 
Western Buffer C   HEPES pH7.9 20mmol/L 
NaCl 400mmol/L 
EDTA 1mmol/L 
EGTA 1mmol/L 
DTT 1mmol/L 
Leupeptin 10ug/ml 
Aprotinin 10ug/ml 
Western Lysis Buffer  EDTA 2mmol/L 
Iodoacetamide 10mmol/L 
P-Nitrophenylguanidinobenzoate 25ug/ml 
Leupeptin 10ug/ml 
Aprotinin 10ug/ml 
Triton X-100 0.5% 
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2.1.7 Oligonucleotides 
Gene Primer 
Name 
Human
/Murine 
Forward/
Reverse 
Sequence 5’→3’ 
GENERAL 
HOX11  HOX417R  H R  CGG CCT GTG TGC CGG CAC CCG GAT 
  HOX290F  H F  TGA CCG GCT CCT ACA ACG TGA ACA 
  HOX11R4  H R  AGC AGC CAA GGC CGT ATT CTC CGT 
  EFIAFOR  H F  TCG CAA CGG GTT TGC CGC CAG ACC 
  HIOQ5  H F  CAT GCC CGG CGT CAA CAA CCT 
  HOXRW  H R  TCA CTC GCA GGC CGA CGC CAC 
ALDH1A1  MALDHF  M F  ATT GTG TTT GCA GAT GCC GAC TTG 
  MALDHR  M R  GCG CAT CTC ATC AGT CAC ATT GGA 
  HALDHF  H F  ATT GTG TTA GCT GAT GCC GAC TTG 
  HALDHR  H R  GCG CAT CTC ATC TGT AAC ATT AGA 
EXPRESSION ANALYSIS 
B-ACTIN  ACT F  H/M F  GCC CTG GAC TTC GAG CAA GAG ATG 
  ACT R  H/M R  CCT GCT TGC TGA TCC ACA TCT GCT 
GAPDH  GAPDHF  H/M F  CAT GAC CAC AGT CCA TGC CAT CAC 
  GAPDHR  H/M R  GAG GTC CAC CAC CCT GTT GCT GTA 
  G3PDH3’  H/M F  ACC ACA GTC CAT GCC ATC AC 
  G3PDH5’  H/M R  TCC ACC ACC CTG TTG CTG TA 
GATA-1  GATA1F  M F  GCA CTC TAC CCT GCC TCA AC 
  GATA1R  M R  CTC CCC ACA ATT CCC ACT AC 
NFE2  NFE2F  M F  GCT TGG AGA GAT GGA ACT GAC 
  NFE2R  M R  GCT CAA GAG ATT CTG CAT CAC 
EKLF  EKLFF  M F  CGG AGA GGA CGA TGA GAG G 
  EKLFR  M R  TGG AAG TGG CCT TGG TAC TG 
BMI-1  TBMIF  M/H F  TGG AGG GTA CTT CAT TGA TGC CAC 
  TBMIR  M/H R  CAT TGC TGC TGG GCA TCG TAA GTA 
Protein Tyrosine 
Phosphatase 
Non Receptor 
Type 21 
TPHOF  M F  CTG CAG CAG GAG ATT ACC AGG TAT 
  TPHOR  M R  CTG GGG TTT AGG CAG AGA CAT CCT 
Zinc Finger 67  TZF67F  M/H F  CCA GAG GAG CTG GGC TCA GAT GA 
  TZF67R  M/H R  GAA GGT GTC CAG GTG GCC ATT GGA 
Putative Ring 
Finger FLJ20329
MPRING  M/H F  ATT GAG AAG GAT GGT GGT TGT AAT Materials and Methods  68
  MPRINGR  M/H R  AGT CCT CAA TGT ACT CCC ACA GAT 
C-KIT  MCKITF2  M/H F  CTG GTC ATT ACA GAA TAT TGT TGC 
  MCKITR2  M/H R  TGG CTG CCA AAT CTC TGT GAA TAC 
Guanosine 
Diphosphate 
Dissociation 
Inhibitor 3 
TGDPF  M/H F  ACA AGG TTC CTT CCA CTG AAG CAG 
  TGDPR  M/H R  ATG ATC TGG CAG GAG TTG GCA TC 
  HGDP3’F  H F  GAG TGG CTA TTC AGC ATT GGC AGT 
  HGDP3’R  H R  ACC CGC TTT ATG TTC GCT TCC TCT 
Proliferation 
Associated 
Gene  
MOSF  M/H F  CCC TCT TGA CTT TAC TTT TGT GTG 
  MOSFR  M/H R  CTC TTT GCT CTT ATT GAC ATC AGG 
Hexoaminidase 
B 
THEXBF  M/H F  TAA TGT TCT TCA CTG GCA CAT AGT 
  THEXBR  M/H R  TAA GTA CCA AGG AGC AGA AAG GAT 
Osteopontin  TOSTF  M F  CCT GAC CCA TCT CAG AAG CAG ATT 
  TOSTR  M R  TGA CCT CAG AAG ATG AAC TCT CTA 
Tumour 
Rejection 
Antigen GP96 
3GP96F  M/H F  ATC AAG CTT GGT GTG ATT GAA GAC 
  3GP96R  M/H R  AAA CTG AGG CGA AGC ATT CTT TCT 
cGMP Phospho-
diesterase 
PDE9A1 
MPDE9A1F  M/H F  GTG CAT GAC AAC TAC AGG AAC AAC 
  MPDE9A1R  M/H R  CTC ACG GTC ACT CTG CAT AAA ATA 
Map Kinase 
Phosphatase 1 
MPHOSPF  M/H F  CCT AAC CAC TTT GAG GGT CAC TAC 
  MPHOSPR  M/H R  GAA ACA GGG AAG TTG AAG ACT GTG 
Interferon 
Gamma 
Receptor 
3MIFNGF  M F  CTG TAC AGG TAA AGG TGT ATT CGG 
  3MIFNGR  M R  CCA GGA TAA CTA CTG TAA AGA CGG 
  3HIFNGF  H F  ACG AGA TTC AGT GCC AGT TAG CGA 
  3HIFNGR  H R  TTG TCT TCG GTA TGC ATG CCT GGA 
Ras Binding 
Protein SUR-8 
3SUR8F  M/H F  GCC TGA CTC TCT TGA TAA CTT GAA 
  3SUR8R  M/H R  GGA AGT GAT GTT AAC TGA TTG TCC 
Cell Division 
Cycle 25A 
3CDC25AF  M/H F  TCA GGT TTC TGT CTA GAT TCT CCT 
  3CDC25AR  M/H R  GTC CAA AAT GTT CTC AAT GGT TCC 
Zinc Finger 
Protein X Linked
3ZFXF  M/H F  CTA AGC ATA GTA AAG AGA TGC CAT Materials and Methods  69
  3ZFXR  M/H R  TCT TTA TGA TGT CGC ATT ATG TGC 
Insulin Like 
Growth Factor 
Binding Protein 
10 (IGFBP10) 
3IGFBPF  M/H F  GGG ATC TGC AGA GCT CAG TCA GA 
  3IGFBPR  M/H R  GTC ATT GGT AAC TCG TGT GGA GAT 
Cdc-Like Kinase  MKINF  M/H F  ATA CTT TAG GTG AAG GTG CTT TCG 
  MKINR  M/H R  TTG ATA TGC CAT CTT CCT GAT ATG 
Vascular 
Endothelial 
Growth Factor C 
HVEGFC3’F  M/H F  TTT GCC AAT CAC ACT TCC TGC CGA 
  HVEGFC3’R  M/H R  CAG ACA GTT CTA CTG TGG CAA CAC 
Cdc5 Like 
Protein 
3CDC5F  M/H F  GAA CTT CGA GCT GGC ATA GA 
  3CDC5R  M/H R  CAG CTC CAT TAG AAG GAG TCC TGA 
Stra13  3STRA13F  M/H F  AGC TGA CCG GAT TAA CGA GTG CAT 
  3STRA13R  M/H R  TCC ATA GCC ACT GTC TGT GTC CGT 
Integrin Beta 2  3CD18F  M/H F  CTG GTG CCA GAA GCT GAA CTT CAC 
  3CD18R  M/H R  CCT CTG TCT GAA ACT GGT TGG ACT 
Idb2  TMID2AF  M/H F  AAA ACA GCC TGT CGG ACC ACA GC 
  TMID2AR  M/H R  GCC TGC AAG GAC AGG ATG CTG AT 
Type II cGMP- 
Protein Kinase 
MPRKG2F  M F  TAT CTG CAC CTA CTA GGC ATC ATC 
  MPRKG2R  M R  TGT CAG AAG TCT TTA TCC CAG CCT 
  HPRKG23’F  H F  ATG CCT CCA GAT GAG CTA TCA GGC 
  HPRKG23’R  H R  ACT GGG AGG CAA AAG CCT TCG CAA 
Hepatoma 
Transmembrane 
Kinase 
HHTKF  H F  GTG CCA GAC AAG AGC CAT GAA GAT 
  HHTKR  H R  GAC CTT GTA GGA CAT TAG GTG TCC 
  MHTKF  M F  TCA AGA ATT CAG CCC TAA CCT CTG 
  MHTKR  M R  GCT GTC TGC AGT CCT TAG TGG TAT 
Growth Arrest 
Specific Factor 3 
HGASF  H F  CAA TGG ACA CGC AAC TGA TCT CTG 
  HGASR  H R  CGC TCA GAG CCT CAG ACA GAC CGT 
  MGASF  M F  GAT CCT GTT CCT GCA CAT CGC GGT 
  MGASR  M R  TCC GCA GGA TCA CAT AGA TGA TAC 
Dihydrodiol 
Dehydrogenase 
HDDF  H F  TTC CAG TGT CTG TAA AGC CAG GTG 
  HDDR  H R  CAT CTA TGG CTT TCA TCT CCT CTG 
Nel-like 2  HNELF  H F  GTG CCT TAA GAA CTC ACA CCT GTT Materials and Methods  70
  HNELR  H R  CAC TAA GCC GTG AAA CAC CAT AGC 
Human Tumour 
Growth Antigen 
(L6) 
HL6F  H F  TGT GCT ATG GGA AGT GTG CAC GAT 
  HL6R  H R  CAC ATA TGC CTC CAA GCA CTC CAT 
VECTORS        
pCR2.1 VECTOR  PCR21F  - F  CCG CCA GTG TGC TGG AAT TC 
  PCR21R  - R  CCA GTG TGA TGG ATA TCT GCA 
GL3BASIC 
VECTOR 
GL3FOR  - F  CGA TAG TAC TAA CAT ACG 
  GL3REV  - R  TGT TTT TGG CGT CTT CCA 
PROMOTER 
ANALYSIS 
      
Promoter 
Region 
NOR1 
PRONORF  H F  GCG AGC TCG CCA ACC GCC GAA TTT AG 
  PRONORR  H R  GCG CTA GCT GTC TGT GTG TTC GAG TG 
Promoter 
Region 
VEGFC 
PROVEGFCF  H F  GCC TCG AGT AGC GTG GTC CTC TGT AA 
  PROVEGFCR  H R  GCA AGC TTT CAC AGG AAA CCG GAC AT 
Promoter  
Region 
Dihydrodiol 
Dehydrogenase 
PROHDDF  H F  GCG AGC TCG AAC GAA ATC AGG GCA TT 
  PROHDDR  H R  GCG CTA GCC TAG CAA ATG TTT GCT GC 
Promoter 
Region 
C-KIT 
PROCKITF  H F  GCG CTA GCC TTG GAG TAG GTC TTC CA 
  PROCKITR  H R  GCA AGC TTA GCT GCG ATG GGA TCC GA 
Promoter 
Region 
SMARCD3 
PROSMARCD
3F 
H F  GCG CTA GCA GTG TTG AAG GTG TGA CC 
  PROSMARCD
3R 
H R  GCC TCG AGG AGA CTG CCA GGC AGG GA 
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2.1.8 Vector  Contructs 
pSV-β-GALACTOSIDASE  Promega, Madison, USA 
pGL3BASIC  Promega, Madison, USA 
pGL3CONTROL  Promega, Madison, USA 
pEFBOS   MRC Laboratory of Molecular Biology, 
Cambridge, U.K. 
Mizushima and Nagata, 1990 
pEFBOSHOX11  MRC Laboratory of Molecular Biology, 
Cambridge, U.K. 
pEFBOS β-GALACTOSIDASE  Institute for Child Health Research, WA, 
Australia 
pCR2.1  Invitrogen, CA, USA 
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2.1.8.1 pEFBOS 
pEFBOS is a 5.8kb plasmid derived from pUC 119 (refer to Figure 2.1). It is a powerful 
mammalian expression vector which employs the promoter of polypeptide chain elongation 
factor 1 α (EF-1α) to drive expression of genes cloned into the multiple cloning site. The 
vector contains an SV40 replication origin, the promoter of the EF-1α gene and the 
polyadenylation signal of human G-CSF. The selectable marker for this plasmid is an Amp 
gene (Mizushima and Nagata, 1990). The pEFBOS plasmid vector was obtained from the 
MRC Laboratory of Molecular Biology, Cambridge, U.K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.8.2   pEFBOSHOX11 
pEFBOSHOX11 contains and expresses a 1044bp human HOX11 cDNA. It was originally 
derived from pEFBOS. The pEFBOSHOX11 plasmid vector was obtained from the MRC 
Laboratory of Molecular Biology, Cambridge , U.K. 
FIGURE 2.1 pEFBOS EXPRESSION VECTOR 
pEFBOS 
5800bp 
SV40 
STUFFER 
EF1α PROMOTER/ EXON1/ 
INTRON 1
G-CSF  3’ 
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2.1.8.3 pEFBOS  β-GALACTOSIDASE 
pEFBOS β-GALACTOSIDASE contains and expresses the lacZ gene which encodes the β-
galactosidase enzyme. It was originally derived from pEFBOS. The pEFBOS β-
GALACTOSIDASE plasmid vector was obtained from the Division of Childrens’ Leukaemia 
and Cancer Research, Institute for Child Health Research, WA, Australia. 
2.1.8.4 pCR2.1 
pCR2.1 is a 3.9kb TA cloning vector used to clone PCR products (refer to Figure 2.2). 
pCR2.1 has a single 3’T overhang enabling direct ligation of PCR products. The vector 
contains an F1 origin of replication, the lacZα gene as well as Amp and Kan resistance 
genes. The pCR2.1 vector was originally from Invitrogen. 
 
2.1.8.5 pGL3BASIC 
pGL3BASIC is a 4.8kb vector it lacks eukaryotic promoter and enhancer sequences allowing 
regulatory regions to be cloned into this vector (refer to Figure 2.3). Expression of luciferase 
activity in cells transfected with this plasmid depends on insertion and proper orientation of a 
functional promoter upstream from the luc+ gene. The vector contains F1 origin of replication, 
a SV40 late poly(A) signal and the selectable marker for this plasmid is an Amp gene. The 
pGL3BASIC vector was originally from Promega. 
FIGURE 2.2 pCR2.1CLONING VECTOR Materials and Methods  74
 
2.1.8.6   pGL3CONTROL 
pGL3CONTROL is a 5.3kb vector that contains a SV40 promoter and enhancer sequences, 
resulting in strong expression of the luciferase gene luc+ in mammalian cells. The vector 
contains F1 origin of replication, a SV40 late poly(A) signal and the selectable marker for this 
plasmid is an Amp gene. The pGL3CONTROL vector was originally from Promega. 
 
 
 
FIGURE 2.3 pGL3BASIC VECTOR 
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2.1.8.7 pSV-β-GALACTOSIDASE VECTOR 
pSV-β-GALACTOSIDASE is a 6.8kb vector. SV40 promoter and enhancer sequences drive 
transcription of the lacZ gene that encodes the β-Galactosidase enzyme. The selectable 
marker for this plasmid is Amp. The pSV-β-GALACTOSIDASE vector was originally from 
Promega. 
 
 
 
2.1.9  Luciferase Materials and Reagents 
Dual Light System Chemiluminescent 
Reporter Gene Assay System for the 
Combined Detection of Luciferase and β-
Galactosidase 
Applied Biosystems, MA, USA 
Luminoskan Ascent type 392   Labsystems, Helsinki Finland 
Microplate (White, Universal Binding)  Labsystems, Helsinki Finland 
Electroporation Cuvettes 0.4cm  BioRad Laboratories, CA, USA 
Gene-Pulser II  BioRad Laboratories, CA, USA 
2.1.10 Affymetrix Microarray Materials and Reagents 
5x Second Strand Buffer  Invitrogen, CA, USA 
Acetylated Bovine Serum Albumin  Sigma Chemical Co., MO, USA 
Agilent 2100 Bioanalyzer  Agilent Technologies, CA, USA 
Agilent RNA 6000 Nano Lab Chip Kit  Agilent Technologies, CA, USA 
Ammonium Acetate 7.5M  Sigma Chemical Co., MO, USA 
Antifoam 0-30  Sigma Chemical Co., MO, USA 
FIGURE 2.5 pSV-β-GALACTOSIDASE VECTOR Materials and Methods  76
Anti-streptavidin, Biotinylated Goat Antibody  Vector Laboratories, CA, USA 
DEPC Treated Water  Sigma Chemical Co., MO, USA 
DNA Ligase  Invitrogen, CA, USA 
DNA Polymerase I  Invitrogen, CA, USA 
DNTPs  Invitrogen, CA, USA 
EDTA 0.5M  Sigma Chemical Co., MO, USA 
ENZO RNA Transcript Labeling Kit  Affymetrix Inc., CA, USA 
Eukaryotic Hybridization Control Kit  Affymetrix Inc., CA, USA 
GeneChip Fluidics Station 400  Affymetrix Inc., CA, USA 
GeneChip Hybridization Oven 640  Affymetrix Inc., CA, USA 
Glacial Acetic Acid  Sigma Chemical Co., MO, USA 
Glycogen  Invitrogen, CA, USA 
Goat IgG Antibody  Sigma Chemical Co., MO, USA 
H5U95A GeneChip  Affymetrix Inc., CA, USA 
Herring Sperm  Promega, Madison, USA 
HP GeneArray Scanner  Affymetrix Inc., CA, USA 
Magnesium Acetate  Sigma Chemical Co., MO, USA 
MES Free Acid Monohydrate  Sigma Chemical Co., MO, USA 
MES Sodium Salt  Sigma Chemical Co., MO, USA 
Mu11KsubA GeneChip  Affymetrix Inc., CA, USA 
NaCl RNase/ DNase Free 5M  Ambion, TX, USA 
Phase Lock Gels  Eppendorf, NY, USA 
Phenol:Chloroform: Isoamylalcohol (25:24:1)  Ambion, TX, USA 
Potassium Acetate  Sigma Chemical Co., MO, USA 
RNase H  Invitrogen, CA, USA 
RNeasy Mini Kit  QIAGEN, CA, USA 
SSPE  Invitrogen, CA, USA 
Streptavidin, R-phycoerythrin conjugate  Invitrogen, CA, USA 
Superscript II  Invitrogen, CA, USA 
T4 DNA Polymerase  Invitrogen, CA, USA 
T7- (dT)24 HPLC Purified Primer  Proligo, CO, USA 
Trizma Base  Sigma Chemical Co., MO, USA 
Tween 20  Pierce Biotechnology Inc., IL, USA 
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2.1.10.1  Buffers and Solutions 
5x Fragmentation Buffer  Tris-acetate pH 8.1 200mM 
Potassium Acetate 500mM 
Magnesium Acetate 150mM 
MES Hybridization Buffer  MES 100mM 
[Na+] 1M 
EDTA 20mM 
Tween 20 0.01% 
12x MES Buffer  MES 1.22M 
[Na+] 0.89M 
Wash Buffer B  MES 100mM 
[Na+] 0.1M 
Tween 20 0.01% 
Wash Buffer A  SSPE X 6 
Tween 20 0.01% 
Antifoam 0-30 0.005% 
Stain Buffer  MES 100mM 
[Na+] 1M 
Tween 20 0.05% 
Antifoam 0-30 0.005% 
SAPE Solution  Stain Buffer x 1 
Acetylated BSA 2ug/ul 
Streptavidin, R-phycoerythrin conjugate 
10ug/ml 
Antibody Solution  Stain Buffer x 1 
Acetylated BSA 2ug/ul 
Goat IgG 0.1mg/ml 
Anti-streptavidin, Biotinylated Goat Antibody 
3ug/ml 
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2.1.11  cDNA Microarray Materials and Reagents 
Goldseal Microscope Slides  Erie Scientific Company, NH, USA 
EST clone library  Genome Systems, CA, USA 
Array-IT solution  Telechem, CA, USA 
CY3 or CY5-dUTP, dCTP, dGTP, dATP  Amersha, Uppsala, Sweden 
Superscript II  Gibco BRL, Auckland, New Zealand 
Micro-con 30 columns  Gibco BRL, Auckland, New Zealand 
Poly-L-Lysine  Sigma Chemical Co., MO, USA 
Succinic Anhydride  Sigma Chemical Co., MO, USA 
n-Methyl-Pyrrilidinone  Sigma Chemical Co., MO, USA 
Sodium Borate  Sigma Chemical Co., MO, USA 
 
2.1.11.1  Buffers and Solutions 
Poly-L-Lysine Poly-L-lysine  (w/v)  0.02% 
Slide Wash Solution  NaOH 2.25M 
95% Ethanol (v/v) 36.3%  
Coating Solution  Succinic Anhydride in n-Methyl-Pyrrilidinone 
(w/v) 1.59%  
Sodium Borate pH8.0 0.02M 
 
2.1.12 Antibodies 
HOX11, Sc-880  Santa Cruz Biotechnology, CA, USA 
Pan-globin anitserum  ICN, CA, USA 
v-Raf , Sc-133  Santa Cruz Biotechnology, CA, USA 
p42 MAP kinase, Sc-154  Santa Cruz Biotechnology, CA, USA Materials and Methods  79
2.2 Methods 
2.2.1   Cell Culture 
2.2.1.1   Growth and Maintenance 
Cells were stored frozen under liquid nitrogen. Prior to use, the cells were rapidly thawed to 
RT, washed in tissue culture media and pelleted at 200xg for 5min at RT. The pellet was 
resuspended in tissue culture growth media and the cells grown in 75cm
2 tissue culture flask 
at 37°C in 5%CO2. J2E, J2EHOX11, NIH3T3 and NIH3T3HOX11 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM). HEL, HELHOX11, K562, PER-487III, PER-
427I, JURKAT, MOLT4, PER-550, RPMI, PER-117, PER-117HOX11, PER-255, ALL-SIL and 
MKB-1 cells were cultured in Rosewell Park Memorial Institute Medium 1640 (RPMI). Growth 
media contained 10% foetal bovine serum, 0.03% L-glutamine, 0.03% pyruvate, 0.03% non-
essential amino acids and 1x penicillin/streptomycin antibiotic solution. PER-117, J2E and 
HEL cells stably transfected with pEFBOSHOX11 were also grown in growth media 
containing 0.2ug/ml, 0.6ug/ml and 1ug/ml of puromycin, respectively. Suspension cells were 
split 1/5 or 1/10 every 2 days and seeded into 75cm
2 tissue culture flasks containing 
appropriate growth medium and incubated at 37°C in 5% CO2. Cell monolayers were 
passaged every 5 days by washing with PBS before incubation with Trypsin-EDTA solution 
that was subsequently inactivated with the addition of growth medium containing fetal bovine 
serum. Cell monolayers were also split 1/5 or 1/10 every 2 days and seeded into 75cm
2 
tissue culture flasks containing appropriate growth medium and incubated at 37°C in 5% CO2. 
Culture conditions and the passage number of clones of the same cell line were kept 
constant for all RDA, microarray and RT-PCR experiments. All cells were harvested at 5-7 
x10
 5 cells/ml and all cell lines were judged to be phenotypically characteristic of the cell line, 
by Jette Ford, Division of Childrens’ Leukaemia and Cancer Research, Institute for Child 
Health Research. 
2.2.1.2 Cryopreservation 
 
2.2.1.2.1 Suspension  Cells 
Cells were grown to a density of 5x10
5cells/ml and harvested by centrifugation at 200xg for 
5min at RT. Pellets were resuspended in Freezing Medium, aliquoted into cryovials and 
stored at -80°C for 16h. The cryovials were transferred to liquid nitrogen the following day for 
long-term storage. 
2.2.1.2.2  Adherent Monolayer Cells 
Cells were harvested at 80% confluency by removing media, washing with PBS, trypsinising 
using Trypsin-EDTA solution and adding to an equal volume of fresh media. Cells were Materials and Methods  80
centrifuged at 200xg for 5 min at RT, washed with PBS and resuspended in freezing medium. 
The suspension was aliquoted into cryovials and stored at -80°C for 16h. The cryovials were 
transferred to liquid nitrogen the following day for long-term storage. 
2.2.1.3 Cytospin  Preparations 
J2E cell morphology was assessed by light microscopy of Wright’s stained cytocentrifuge 
preparations. Cells were prepared as previously described (Callus et al., 1995). Briefly, 100ul 
of cells at a density of 2.5 x10
5 cells/ml were pelleted onto glass slides in a cytocentrifuge at 
500rpm for 5min and allowed to air dry before staining with diaminofluorene (DAF) in which 
59ul of cell suspension and an equal volume of DAF stain were mixed before counting. 
2.2.2 Molecular  Biology 
2.2.2.1  Representational Difference Analysis 
Representational Difference Analysis was performed using the CLONTECH PCR Select 
Subtraction Kit according to manufacturer’s instructions. 
2.2.2.2   cDNA Microarray Analysis 
 
2.2.2.2.1  Total RNA Preparation 
Total cytoplasmic RNA was isolated by non-idet P-40 (NP-40) lysis, phenol extraction and 
ethanol precipitation (refer to section 2.2.13 RNA preparation). 
2.2.2.2.2  Preparation of Slides  
cDNA microarray analysis was carried out as previously described (Callow et al., 2000). 
Briefly, glass slides were washed using Slide Wash Solution with shaking for 2hrs at RT. 
Slides were rinsed three times with ddH20, coated with poly-L-lysine and dried at 40°C for 
5min.  
Colony purified and sequence verified EST clones were purchased from Genome Systems. 
The vector inserts were PCR amplified using primers designed to the vector sequence 
surrounding the expressed sequence insert and ethanol precipitated before resuspension in 
15ul of 3xSSC and 15ul of Array-IT solution. 
PCR amplified products were printed onto poly-L-lysine coated slides using a 16 pin print 
head constructed to specifications described by Schena et al., 1995. Arrays were then 
rehydrated by suspension over a dish of warm ddH20. Each slide was dried on a 100°C hot 
plate for 3sec and UV cross linked using a UV Stratalinker. Slides were then incubated in 
Coating Solution for 15min with shaking followed by incubation in a 95°C water bath for 2min. 
Slides were then washed in 95% Ethanol for 1min and spin dried. Materials and Methods  81
2.2.2.2.3  Staining of Slides 
CY3-dUTP or CY5-dUTP was used to label cDNA synthesized from the Oligo dT primed 
fraction of 60ug of total RNA with Superscript II enzyme. Superscript II buffer, dithiothreitol, 
CY3 or CY5 dUTP and the four unlabelled nucleotides were combined with the RNA and the 
reaction was allowed to proceed for 2-3h before termination by heat denaturation. 
The labeled cDNA mixture was concentrated on microcom-30 columns. After denaturation of 
the probe, the solution was added to the array and a coverslip was placed on top. The slide 
was then placed in a sealed, humidified chamber before being placed in a 65°C hybridization 
oven. After hybridization for 16h the slide was rinsed in 1xSSC, 0.05% SDS and then 
0.2xSSC followed by a rinse in 0.1xSSC and spin dried. 
2.2.2.2.4 Scanning  of  Microarrays   
Arrays were scanned using a purpose built dual laser scanner. Data from the dual laser 
scans was collected as graphics files for each of the two lasers. The dual images were 
combined and processed using the ScanAlyze program (written by Michael Eisen, 
http://rana.Stanford.edu/software) and positions on the images were assigned grid 
coordinates for the matching of spot identity with average pixel intensity at that region. The 
background was determined from pixel intensity at the edge of the bounding box. Background 
corrected, log converted red/green intensity ratios were determined for each element of the 
array. Variations in signal intensities of the fluorophores were normalized by subtracting the 
median value of log ratios from each log ratio determined for that array.  
2.2.2.3  Affymetrix Microarray Analysis 
 
2.2.2.3.1  Total RNA Preparation 
Total RNA was prepared using Trizol. Trizol (1ml) was added to 1x10
7 cells and incubated for 
5min at RT prior to suspension. Chloroform (0.2ml) was added and the mixture shaken 
vigorously for 15sec and incubated for 2-3min at RT. The samples were centrifuged at 
10,000xg for 15min at 4°C and the aqueous phase removed. Ethanol was added drop wise to 
the aqueous phase to give a final concentration of 35% Ethanol. This solution was then 
purified using a QIAGEN RNeasy mini column according to manufacturer’s instructions. 
The eluant was precipitated and resuspended in 20ul of DEPC treated ddH20. All RNA 
samples were screened using the Agilent 2100 Bioanalyzer and software using the RNA 
6000 Nano Lab Chip Kit according to manufacturer’s instructions. A rRNA ratio [28S/18S] 
greater than 1.8 was deemed to have acceptable quality. 
2.2.2.3.2 First  Strand cDNA Synthesis 
Total RNA (10ug) was incubated with 100pmoles of T7-(dT24) primer in a total reaction 
volume of 11ul. This reaction was denatured at 70°C for 10min and quenched on ice for 5 
min. A mixture of 1x first strand cDNA buffer, 10mM DTT, 0.5mM dNTPs and 400U of 
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volume to 20ul. The reaction was incubated at 42°C for 1h. The reaction was then placed on 
ice and the second strand cDNA synthesis commenced immediately. 
2.2.2.3.3  Second Strand cDNA Synthesis 
In a 150ul reaction 1x second strand buffer, 0.2mM dNTPs, 10U DNA ligase, 40U DNA 
polymerase I, 2U RNaseH were added to the 20ul first strand cDNA synthesis reaction and 
the reaction was gently mixed and incubated at 16°C for 2h. T4 DNA Polymerase (20U) was 
added and the reaction was incubated for 5min at 16°C. The reaction was made up to 31mM 
EDTA and stored at -20°C.  
2.2.2.3.4  Phase Lock Gel Cleanup of Double Stranded cDNA 
An equal volume of phenol:chloroform:isoamylalcohol was added to the double stranded 
cDNA reaction and vortexed. The mixture was then transferred to a phase lock gel tube and 
the tube was centrifuged at 12,000xg for 2min. The aqueous upper phase was then collected 
and 5mg of Glycogen, 0.5 volumes of 7.5M ammonium acetate and 2.5 volumes of ethanol 
were added. The reaction was then centrifuged at 12,000xg at RT for 20min, the supernatant 
removed and the pellet washed twice with 80% ethanol. The pellet was then resupsended in 
12ul of DEPC treated ddH20 and stored at -20°C. 
2.2.2.3.5  In Vitro Transcription 
The in vitro transcription reaction was performed using the ENZO BioArray High Yield RNA 
Transcript Labeling Kit according to manufacturer’s instructions. Briefly, in a 40ul reaction 1x 
Reaction Buffer, 1x Biotin labeled ribonucloetides, 1x DTT, 1x RNase Inhibitor mix and 1x T7 
RNA polymerase was added to a 5ul sample of purified double stranded cDNA. The reaction 
was incubated for 4h in a 37°C water bath and mixed gently every 30min. The reaction was 
stored at -20°C. The in vitro transcription reaction (20ul) was then purified using a QIAGEN 
RNeasy mini column according to manufacturer’s instructions. The eluant was precipitated, 
the pellet washed twice with 80% ethanol and resuspended in 20ul of DEPC treated ddH20. 
cRNA yield was calculated and concentration adjusted to 0.6ug/ml. 
2.2.2.3.6  Fragmentation of cRNA 
cRNA at a concentration of 0.6ug/ml was fragmented in a reaction containing 1x 
Fragmentation Buffer in a 40ul total reaction volume. The reaction was incubated for 35min at 
94°C. The sample was then analyzed using gel electrophoresis and then stored at -20°C. 
2.2.2.3.7  Target Preparation and Hybridization 
The Mu11KsubA or the HGU95A GeneChips were hybridized with 1xMES buffer for 10min at 
45°C, rotating at 60rpm in the GeneChip Hybridization Oven 640. A hybridization cocktail 
made up to; 1xMES Hybridization Buffer, 0.5 mg/ml Acetylated BSA, 0.1 mg/ml Herring 
Sperm DNA, 50pM Control Oligonucleotide B2, 1.5pM BioB control, 5pM BioC control, 25pM 
BioD control and 100pM Cre control and 0.05ug/ul Fragmented cRNA. The hybridization 
cocktail was then heated to 99°C for 5min and then incubated at 45°C for 5min and pipetted 
into the GeneChip. The hybridization was undertaken at 45°C for 16 h rotating at 60rpm. Materials and Methods  83
2.2.2.3.8  Washing and Staining 
The hybridization cocktail was removed from the GeneChip and stored at -20°C. Wash Buffer 
A was then pipetted into the GeneChip. The GeneChip Fluidics Station 400 was used to 
wash and stain the probe arrays. Briefly, 10 cycles were undertaken with Wash Buffer A at 
25°C, 4 cycles were then undertaken with Wash Buffer B at 50°C. The GeneChip was then 
stained using SAPE solution for 10min at 25°C followed by 10 cycles with Wash Buffer A at 
25°C. The probe array was then stained for 10min with Antibody Solution at 25°C, followed 
by SAPE solution for 10min at 25°C. Finally 15 cycles using Wash Buffer A were undertaken 
at 30°C. 
2.2.2.3.9 Scanning  of  GeneChips 
The GeneChips were scanned using the HP GeneArray Scanner and the Affymetrix 
Microarray Suite 5.0 software program according to maunfacturer’s instructions. 
2.2.3  DNA Sequencing and Database Searching 
Sequencing of constructs was performed with the Applied Biosystems 3730 cycle sequencer, 
using the ABI prism dGTP Big Dye Terminator v3.0 Ready Reaction Cycle Sequencing 
Kit. Searches for promoter region sequences were performed using the GENBANK database 
(www.ncbi.nlm.nih.gov). 
2.2.4  Plasmid DNA Preparation 
All DNA plasmid preparations were prepared using the QIAGEN Plasmid Mini Purification 
Kit, QIAGEN Plasmid Midi Purification Kit or QIAGEN Plasmid Mega Purification Kit 
according to manufacturer’s instructions. 
2.2.5 Restriction  Endonuclease Analysis 
All restriction endonuclease reactions were performed according to manufacturer’s 
instructions. Briefly, 1ug of DNA was cut with 10U restriction endonuclease in the 
corresponding 1x Reaction Buffer at 37°C for 1h. 
2.2.6 DNA/RNA  Quantitation 
The concentration and purity of DNA and RNA was determined by measuring the absorbance 
of solutions at 260 and 280nm. The DNA concentration of a solution with A260 of 1.0 was 
50ug/ml and the RNA concentration of a solution with A260 of 1.0 was 40ug/ml. DNA 
preparations with a ratio A260/A280 of above 1.8 were deemed pure. Similarly RNA 
preparations with a ration A260/280 of above 2.0 were deemed pure.  
2.2.7  Preparation of Competent Cells 
The DH5α strain or the INVαF’ of E.coli was streaked onto LB Agar and grown overnight at 
37°. A single colony was used to inoculate 5ml 2YT media and grown at 37°C with vigorous Materials and Methods  84
shaking for 16h. 1ml of this culture was used to inoculate a 100ml culture of 2YT medium and 
grown at 37°C with vigorous shaking for 2-3h until absorbance (A600) of 0.45-0.55 was 
reached. The culture was centrifuged at 2,000xg for 10min at 4°C. The pellet was 
resuspended in ice-cold 100mM CaCl2 and incubated on ice for 20min prior to centrifugation 
at 2,000xg for 10min at 4°C. The pellet was resuspended in 1/10 volume ice cold 100mM 
CaCl2 and glycerol added drop wise to a final concentration of 15%. The cells aliquoted and 
stored at -80°C. 
2.2.8 Ligation  Reactions 
The molar ratio used in ligation reactions varied between 3:1 and 6:1 insert: vector. DNA 
concentrations of insert were determined by comparison to a φ174HaeIII standard following 
agarose gel electrophoresis. The ligation mix comprised; vector DNA; insert DNA; 6U T4 
DNA ligase; 1x Ligation Buffer in a final volume of 20ul. The sample was incubated for 16hr 
at 15°C before transformation into competent cells. 
2.2.9  Transformation of Competent Cells 
Competent DH5α or INVαF’ E.coli cells were thawed on ice and dispensed into 200ul 
aliquots. Plasmid DNA (1ug) or 5ul of ligation reaction was gently mixed with the aliquoted 
cells. The cells were left on ice for 1h and then heat shocked at 42°C for 90sec and returned 
to ice. An aliquot of 300ul of 2YT was then added and the sample incubated at 37°C for 
10min. An aliquot of the transformation mix was then spread onto LB plates containing the 
correct antibiotic at 50ug/ml. The plates were incubated for 16h at 37°C. 
2.2.10 RT-PCR 
RNA was extracted using the Trizol or the NP40 Lysis methods (refer to 2.2.13 RNA 
preparation) and the RNA treated with DNase I using DNA Free according to manufacturer’s 
instructions. The cDNA was generated in a reaction containing 2ug of DNase-treated total 
RNA, 0.5ug of Oligo dT, in a 10.4ul reaction. This reaction was denatured at 65°C for 5min 
and quenched on ice for 15min. A mixture of 1x Thermoscript cDNA Synthesis Buffer, 5mM 
DTT, 1mM dNTPs, 40U RNase OUT, 15U Thermoscript Reverse Transcriptase was added 
and the reaction was gently mixed. The reaction was then incubated at 55°C for 1h following 
by incubation at 85°C for 5min. 2U RNase H was added to the reaction and it was incubated 
at 37°C for 20min. The reaction volume was then made up to 100ul with ddH20. An aliquot of 
2.5ul of the resulting cDNA was amplified by PCR. 
In a 25ul PCR reaction, 2.5ul cDNA, 1x Tth DNA Polymerase Buffer, 1.5mM MgCl2, 0.2mM 
dNTP mix, 0.8U Tth DNA Polymerase, 10pmoles Forward Primer, 10pmoles Reverse Primer, 
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thermal cycler as follows: 1min at 94°C, 1min at 63°C with a decrease every second cycle 
down to 55°C and then 55°C for the remaining cycles and 1.5min at 72°C. All RT-PCR 
reactions were performed in the linear range of amplification (typically 30 cycles or less). In 
some cases the denaturation temperature was changed from 94°C to 97°C. 
2.2.11 PCR  
Human Genomic DNA was extacted from whole blood using QIAamp DNA Blood Maxi Kit 
Protocol Kit according to manufacturer’s instructions. In a 50ul PCR reaction 450ng of 
Genomic DNA, 1X Dynazyme Buffer (with 1.5mM MgCl2), 20pmoles Forward Primer, 
20pmoles Reverse Primer, 0.2 mM dNTP mix, 0.5U Dynazyme and 0-5%DMSO. This 
reaction was then subjected to thermal cycling in a PTC-100 DNA thermal cycler as follows: 
1min at 97°C, 1min at 63°C with a decrease every second cycle down to 55°C and then 55°C 
for the remaining cycles and 1.5min at 72°C. All PCR reactions were performed for 30 cycles. 
2.2.12 Radiolabelling Probes 
DNA probes were prepared by random priming using Rediprime II labeling kit according to 
the manufacturer’s instructions to high specific activity (>1x10
6 cpm). Briefly, 25ng of DNA 
was denatured by heating to 100°C for 5min in a boiling water bath. DNA was placed on ice 
and added to reaction tube containing Klenow Enzyme and dATP, dGTP, dCTP provided and 
5ul of α
32P-dCTP (3,000Ci/mMol) was added. The reaction was incubated at 37°C for 10min. 
Labelled probe was purified using G50 Spin Chromatography Column and specific activity 
determined using Bioscan QC 200 counter. Denatured and sheared salmon sperm DNA 
(125ug) was added to the labelled probe prior to use in hybridization. 
2.2.13 RNA Preparation 
2.2.13.1 Trizol 
Total RNA was prepared using Trizol according to manufacturer’s instructions. Trizol (1ml) 
was added to 1x10
7 cells and incubated for 5min at RT prior to suspension. Chloroform 
(0.2ml) was added and the mixture shaken vigorously for 15sec and incubated for 2-3min at 
RT. The samples were centrifuged at 10,000xg for 15min at 4°C and the aqueous phase 
removed and an equal volume of isopropyl alcohol added prior to incubation for 10min at RT 
and centrifugation at 10,000xg for 10min at 4°C. The pellet was washed in 70% ethanol and 
centrifuged at 13,000xg for 5min at 4°C. The pellet was dried and resuspended in ddH20. 
2.2.13.2 NP40  Lysis 
Cells were centrifuged at 1,000xg for 5min at 4°C and washed twice with ice cold PBS. Non-
idet P-40 (NP40) Lysis Buffer (200ul) was used to resuspend 1x10
7 cells and incubated for Materials and Methods  86
5min on ice prior to centrifugation at 12,000xg for 10min at 4°C. The supernatant was 
collected and 25ul of 10%SDS was added. The supernatant was extracted twice with 100ul of 
buffered phenol. 0.1 volumes of 2M sodium acetate and 2.5 volumes of 100% ethanol was 
added to the supernatant and placed at -20°C for 2h prior to centrifugation at 12,000xg for 
15min at 4°C. The pellet was washed in 70% ethanol and centrifuged at 13,000xg for 5min at 
4°C. The pellet was dried and resuspended in ddH20. 
2.2.13.3 mRNA  Extraction 
mRNA was extracted using the QIAGEN Oligotex mRNA Extraction Kit according to 
manufacturer’s instructions. 
2.2.14 Northern Analysis 
2.2.14.1 Total  RNA Preparation 
Total cytoplasmic RNAs were isolated by non-idet P-40 (NP-40) lysis, phenol extraction and 
ethanol precipitation. Alternatively, Trizol was used to prepare total cytoplasmic RNA (refer 
2.2.13 RNA preparation). 
2.2.14.2 Northern  Blotting 
Total RNA (10ug) was incubated with 1x Northern Running Buffer, 1.1 M Deinoized Glyoxal 
in a final volume of 20ul. Samples were incubated at 50°C for 1h, placed on ice and made up 
to 1x RNA Loading Dye. RNA samples was then electrophoresed at 100mA constant current 
for 3h on a 1.4% agarose gel made up in 1x Northern Running Buffer. The RNA was then 
transferred to Magna membrane using 20xSCC overnight. The membrane was UV cross-
linked using UV Stratalinker. 
2.2.14.3 Hybridization 
Membranes were pre-wet in 2xSSC, rolled and placed in hybridization bottles. Hybridization 
Buffer (15ml) was added to the bottle and incubated at 65°C in the hybridization oven for 2h. 
The α
32P radiolabelled DNA probes were denatured prior to addition to hybridization buffer. 
Membranes were incubated for 16h at 65°C. Following hybridization membranes were 
washed to high stringency using Hybridization Wash Buffer and visualized by 
autoradiography. 
2.2.15 Southern Analysis 
2.2.15.1  Genomic DNA Preparation 
Cells were centrifuged at 1,000xg for 5min at 4°C and washed twice with ice-cold PBS. 
Genomic DNA Lysis Buffer (7ml) was used to resuspend 5x10
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to a final concentration of 100ug/ml and the sample incubated at 55°C for 16h. The sample 
was extracted once with an equal volume of Phenol and once with an equal volume of 
Phenol:Chloroform:Isoamylalcohol (25:24:1). The supernatant was collected and extracted 
once with Chloroform:Isoamylalcohol (24:1). 0.1 volumes of 2M sodium acetate and 2.5 
volumes of 100% ethanol was added to the supernatant and placed at -20°C for 2h prior to 
centrifugation at 12,000xg for 15min at 4°C. The pellet was washed in 70% ethanol and 
centrifuged at 12,000xg for 5min at 4°C. The pellet was dried and resuspended in ddH20. 
2.2.15.2 Southern  Blotting 
Genomic DNA (10ug) was incubated at 37°C for 16h with 1x Restriction Enzyme Buffer, 10-
20U of Restriction Enzyme in a 30ul total volume. The reactions were made up to 1x DNA 
Loading Dye. The samples were then electrophoresed for 16h at 1V/cm gel length on a 1% 
agarose gel made up in 1xTAE buffer. The gel was incubated twice with 0.2M HCl for 15min 
and rinsed with ddH20 in order to depurinate the DNA. The gel was then incubated for 30min 
with Gel Denaturing Solution and rinsed with ddH20 to denature the DNA followed by two 
incubations in Gel Neutralizing Solution in order to neutralize the DNA. The gel was then 
rinsed with ddH20 and the DNA transferred to Magna membrane using 20xSSC overnight. 
The membrane was UV crosslinked using UV stratalinker. 
2.2.15.3 Hybridization 
Membranes were pre-wet in 2xSSC, rolled and placed in hybridization bottles. Hybridization 
Buffer (15ml) was added to the bottle and incubated at 65°C in the hybridization oven for 2h. 
The α
32P radiolabelled DNA probes were denatured prior to addition to hybridization buffer. 
Membranes were incubated for 16h at 65°C. Following hybridization membranes were 
washed to high stringency using Hybridization Wash Buffer and visualized by 
autoradiography. 
2.2.16 Western Analysis 
Whole cell extracts were prepared with 100ul of ice-cold Western Lysis Buffer per 10
7 cells 
washed twice with PBS. Nuclear extracts were prepared by resuspending 10
7 cells in 1ml of 
Western Buffer A and incubating on ice for 15min. NP40 was added to a final concentration 
of 1% and the cells vortexed. The nuclei were pelleted by centrifugation at 14,000xg for 1min 
and resuspended in 100ul of ice cold Western Buffer C. The nuclear suspension was agitated 
vigorously at 4°C for 15min and cleared by centrifugation at 14,000xg for 10min at 4°C. 
Protein concentrations were determined by the Bradford Assay. Western Blotting was 
performed with 100ug of whole cell or 50ug of nuclear extract by 12 or 15% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a Hybond-C 
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(BSA) and incubated with either a polyclonal rabbit anti-HOX11 antiserum raised against the 
c-terminus, Sc-880, or a pan-globin antiserum for 1h at room temperature. To control for 
loading the blots were also probed with either a v-Raf or p42 MAP kinase antiserum. The 
membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibodies for 1h at RT before visualization of bands by enhanced chemiluminescence.  
2.2.17 Luciferase and β-Galactosidase Reporter Gene Assays 
2.2.17.1 Preparation  of  DNA for Transfections 
For all transfections into eukaryotic cell lines, DNA from each construct was prepared using 
the QIAGEN Plasmid Maxi Plasmid Purification Kit according to manufacturer’s instructions. 
The plasmid yield being between 0.3-0.5mg was resuspended in ddH20 to give a working 
concentration of 1.0ug/ul. 
 
2.2.17.2  Cell Culture and Transfection 
Cell culture and transfections were carried out as previously described (Brake et al., 1998). 
Briefly, the PER-117 cell line was grown in RPMI containing 0.03% w/v L-glutamine, 0.03% 
pyruvate and 0.03% non-essential amino acids, 1x penicillin/streptomycin solution and 10% 
foetal calf serum, at 37°C in a humidified atmosphere with 5% CO2. Cultured cells were 
grown to a density of 5-6 x 10
5 cells/ml. Each transfection used 1.2 x10
7 cells. Prior to their 
transfection the cells were washed twice in 5ml of RPMI with centrifugation at 1,500xg for 5 
min at RT and resuspended in 400ul of the same solution. After incubating the cells and 
plasmid preparations at RT for 10min, electroporation was performed using the Gene-Pulser 
II set at 300V, 960uF capacitance. Transfections contained 15ug of test plasmid and 5ug of 
control plasmid in a 0.4 centimetre gap electroporation cuvette. After electroporation, the cells 
were resuspended in 7ml of growth medium and incubated at 37ºC in 5% CO2 for 22hrs. All 
transfections were performed a minimum of three times. Results were confirmed with an 
additional independent DNA preparation. 
2.2.17.3 Luciferase  and  β-Galactosidase Reporter Gene Assays 
Luciferase and β-galactosidase reporter gene assays were carried out as previously 
described (Brake et al., 1998). Briefly, the Dual Light System Chemiluminescent Reporter 
Gene Assay System for the Combined Detection of Luciferase and β-Galactosidase was 
used for detection of both luciferase and β-galactosidase activity from the same lysate 
sample. Post transfection the transfected cells were washed three times in 5ml of phosphate 
buffered saline (PBS) with centrifugation at 1,500xg for 5min at 4°C. After the final wash the 
excess fluid was removed and the cells resuspended in 250ul of Dual Light Kit Lysis Solution 
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by centrifugation at 13,000xg for 5min at 4°C. The cell lysate was then stored at -80ºC. A 20ul 
aliquot of the cell lysate was then assayed in an opaque 96 well microtitre plate using the 
Dual Light System Chemiluminescent Reporter Gene Assay System for the Combined 
Detection of Luciferase and β-Galactosidase according to the manufacturer’s instructions. 
The relative light units (RLU) of the luciferase reaction were then read in counts per second 
using the Luminoskan Ascent Type 392 and Ascent Software Version 2.4. The microtitre 
plate was then incubated at RT in the dark for exactly 60min before the addition of 100ul of 
Accelerator II which facilitates the β-galactosidase reaction. Again light emission was 
measured in RLUs in c.p.s. using the same equipment and software. 
 
2.2.17.4 Statistical  Analysis 
Statistical analysis was performed by Dr Ross Taplin of Murdoch University using random 
effect models in SPLUS. The raw relative light unit (RLU) values for luciferase and β-
galactosidase for each of the replicate wells were examined and clear outliers were removed 
in two cases. A ratio of RLUs for luciferase over RLUs for β-galactosidase was taken for each 
well in order to gain normalized values. Logs to the base 2 were taken of these normalized 
RLU values. Ratios of the normalized RLUs were then taken comparing the ratio of pairs of 
wells from three independent experiments performed on separate days; (promoter + 
pEFBOSHOX11), (promoter + pEFBOS), (promoter + pEFBOSHOX11∆H3). Each ratio was 
expressed by subtracting the corresponding ratio for the pGL3BASIC empty vector control. 
Results are expressed on the logarthimic (to the base 2) scale. Two sided p-value testing 
using the null hypothesis of no difference was undertaken for each comparison. The 
experiment was repeated with a set of independent plasmid preparations and differences in 
results were not statistically significant. Chapter Three  90
Chapter Three 
Utilization of Representational Difference Analysis to Investigate the 
Dedifferentiation of the J2E Erythroid Cell Line by the Ectopic 
Expression of HOX11 Chapter Three  91
3.1 INTRODUCTION 
HOX11 is a divergent member of the homeodomain family of DNA binding transcription 
factors. These transcription factors regulate cellular commitment and development via 
modulation of downstream effector genes (Lawrence et al., 1992). HOX11  has been 
implicated in playing a vital role in the developmental process of splenogenesis (Roberts et 
al., 1994; Dear et al., 1995). HOX11 has also been found to be expressed in adult CD34+ 
bone marrow stem cells, however to date its expression has not been detected in any other 
normal haematopoietic tissues (Moretti et al., 1994; Hatano et al., 1991;Yamamoto et al., 
1995). Its expression has, however, been linked to leukaemic transformation and it has been 
detected in the tumour cells of patients with T-cell acute lymphoblastic leukemia (T-ALL) and 
neural tumours (Salvati et al., 1995; Watt et al., 2003). It is hypothesized that the aberrant 
expression of HOX11 in committed haematopoietic cell lineages may therefore predispose 
the cell to neoplastic transformation by deviation from the normal maturational pathway. 
The precise mechanism by which HOX11 transforms cells is yet to be determined. However, 
Hawley et al., (1994) demonstrated that HOX11 transformed cells exhibited a block in cellular 
differentiation. The activation or repression of distinct target genes involved in differentiation 
programs may contribute to cell transformation. To date only three candidate target genes 
have been reported. Greene et al., (1998) utilized representational difference analysis (RDA) 
in the NIH3T3 fibroblast cell line in order to discover possible HOX11 target genes. Aldehyde 
dehydrogenase1 a1 (Aldh1a1), which encodes an enzyme known to be involved in the 
synthesis of retinoic acid was discovered and found to be physiologically regulated by 
HOX11. A second target gene Fhl1, a novel LIM-only gene was identified as a target gene in 
the same experiment (Greene et al., 1998). The final putative target gene to be identified is 
Wilm’s tumour gene, Wt1 which was found to act downstream of HOX11 in a transcriptional 
cascade that is essential for spleen development (Dear et al., 1995; Koehler et al., 2000). 
Given the marked phenotypic effects involved in the onset of tumourigenesis, it is unlikely 
that ALDH1A1, Fhl1 and Wt1 are the only HOX11 target genes involved. In an attempt to 
identify other genes whose expression correlates with HOX11,  HOX11 was forcibly 
expressed in J2E cells. The J2E cell line is a haematopoietic cell line that has the capacity to 
terminally differentiate in response to erythropoietin (Epo) (Klinken et al., 1988). This 
characteristic in effect makes the phenotype of the J2E cell line somewhat `plastic’ and thus 
provides a relatively simple and cost effective model to examine the effect that HOX11 has 
on cellular differentiation at both a phenotypic and genetic level. 
HOX11 was expressed in the J2E erythroid cell line for a number of reasons. Attempts to 
produce a phenotypically relevant transgenic mouse model have proven difficult as CD2-
HOX11 mice do not develop tumours (Greene and Rabbitts, unpublished observations). Chapter Three  92
Hough  et al., (1998) produced Lck-HOX11 transgenic mice where HOX11 expression 
appeared not to be tolerated (Hough et al., 1998). The PER-117 human T-cell line has been 
transfected with HOX11, however no phenotypic effect was observed (Greene, Ford and 
Kees, unpublished observations). The murine T-cell line EL4 and the human T-cell line 
JURKAT were also transfected with HOX11, however HOX11 expression was not tolerated 
(Greene, Ford and Kees, unpublished observations). The J2E cell line on the other hand can 
be easily transfected and cultured and has the capacity to terminally differentiate (Klinken et 
al., 1988). This model was studied, therefore, in an effort to ascertain the effect that HOX11 
has on the cellular phenotype of the J2E cell and secondly in order to provide a model for the 
identification of possible HOX11 target genes. 
In this chapter, RDA was applied to this cellular model. RDA is a technique that enables the 
identification of differentially expressed genes, however, unlike microarray technology, it has 
the added benefit of being able to identify unknown genes. It employs subtractive 
hybridization in order to compare two populations of cDNA. Subtractive hybridization involves 
the removal of cDNA fragments common to both control and experimental cDNA samples 
and the enrichment of differentially expressed cDNA species (Hubank et al., 1994). RDA 
incorporates two additional elements in order to identify target genes, favourable 
hybridization kinetics and PCR amplification (Lisitsyn, 1995). The exponential degree of 
enrichment of target sequences enables the detection of transcripts present in low 
concentrations generating a high sensitivity technique (Hubank et al., 1994). 
The investigation into the effects of HOX11 expression in the J2E cell lines in this study was 
aimed at not only revealing the effects of HOX11 expression on cellular phenotype, but also 
the effects at the genetic level. Specifically, the aims of this chapter were to firstly, employ 
RDA to identify genes whose expression was altered as a result of HOX11 expression in J2E 
cells. It was expected that at least some of these genes, which may play important roles in 
signal transduction, metabolism, the cell cycle and transcription, may be transcriptional 
targets of HOX11. As a second aim, a northern blot and semi-quantitative RT-PCR screening 
technique was to be applied across a panel of HOX11 and non-HOX11 expressing cell lines 
in order to identify putative HOX11 target genes potentially relevant to T-cell 
leukaemogenesis. Chapter Three  93
 
3.2 RESULTS 
3.2.1  Production of J2E Cell Lines Which Express HOX11 
The J2E cell line is a murine erythroid cell line that is immortalized at the proerythroblast 
/basophilic erythroblast stage of erythroid maturation. J2E cells can be induced to terminally 
differentiate, proliferate and remain viable following Epo stimulation (Klinken et al., 1988). 
J2E cells were stably co-transfected with the expression vector pEFBOS containing human 
HOX11 cDNA and the pPGKPuro vector containing a gene for puromycin selection by Jette 
Ford, Division of Childrens’ Leukaemia and Cancer Research, Institute for Child Health 
Research. Control cells were transfected with pPGKPuro alone. Following selection with 
puromycin, expression of HOX11 in transfected cells was confirmed by RT-PCR. These cells 
were then cloned by repeat limiting dilution. Their HOX11 expression status was confirmed 
by Northern blot analysis. Figure 3.1 shows a Northern filter hybridization of 10ug of total 
RNA from 18 J2EHOX11 clones. RNA from ALL-SIL and HELHOX11, which are cell lines 
known to express HOX11, were used as positive controls. Two HOX11 negative clones 1 and 
19 and four HOX11 positive clones (3,11,18 and 44) were chosen for further study. Each of 
these clones demonstrated different levels of HOX11 expression and a total of four positive 
clones were selected in order to rule out phenotypic effects due to clonal variation and not 
HOX11 expression.  
The protein expression status for the clones 1, 19, 3, 11, 18 and 44 was confirmed by 
Western blot by Jette Ford, Division of Childrens’ Leukaemia and Cancer Research, Institute 
for Child Health Research as shown in Figure 3.2A. The integration of the pEFBOSHOX11 
into the genome of the clones was then demonstrated by Southern blot. This was performed 
by digesting genomic DNA with the enzyme Xba I (Figure 3.2B). Clones 3, 11, 18 and 44 all 
produced an expected 999bp fragment corresponding to the introduced gene when 
hybridized to a HOX11 probe. Chapter Three  94
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FIGURE 3.1: NORTHERN BLOT ANALYSIS OF J2E CELL LINES 
HOX11 EXPRESSION IN J2E CLONES Northern filter hybridization of 10ug total RNA from 
ALL-SIL, HELHOX11, J2E clones 1, 4, 19, 34 and J2E HOX11 clones 3, 6, 10, 11, 16, 18, 
22, 28, 29, 30, 32 41, 44, 45 and hybridized with HOX11 and Atp Synthase control. Red 
stars refer to clones selected for further analysis. 
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FIGURE 3.2 WESTERN BLOT AND SOUTHERN BLOT ANALYSIS OF J2E CELL LINES 
 
A. WESTERN BLOT FOR THE DETECTION OF HOX11 PROTEIN J2E control 
transfectants (clones 1 and 19) and J2E clones stably transfected with HOX11 (clones 
3,11,18 and 44). Each lane contains 100ug whole cell extract. Expression of v-raf served as 
the loading control. The experiment was completed by Jette Ford, Division of Childrens’ 
Leukaemia and Cancer Research, Institute for Child Health Research. 
 
B. SOUTHERN BLOT FOR THE DETECTION OF THE pEFBOSHOX11 CONSTRUCT
Southern filter hybridization of 10ug genomic DNA from J2E, J2E clones 1, 2, 19 and 
J2EHOX11 subclones 3, 11, 18, 44 and hybridized with HOX11. Genomic DNA was digested 
with Xba I resulting in the production of a 999bp fragment as shown on the pEFBOSHOX11 
restriction map above. This fragment is highlighted on the Southern blot with a red arrow. 
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3.2.2  HOX11 Induces An Immature Morphology in J2E Erythroid 
Cells 
In order to assess the effect of HOX11 expression on the phenotype of J2E cells, HOX11 and 
control clone cultures were examined using cytospin preparations shown in Figure 3.3. 
Clones 1 and 19 retained the proerythroblast/basophilic erythroblast morphology of the 
parental J2E cell line. The HOX11 positive clones 3, 11, 18 and 44 on the other hand were 
strikingly different. In all cases the HOX11 positive clones tended to be larger, have high 
nucleus to cytoplasm ratios and euchromatic nuclei which is indicative of an immature 
erythroid morphology. Clone 18 was heterogeneous as it contained both immature erythroid 
cells and large gigantoblasts. Chapter Three  97
 
3.2.3  The Effect of HOX11 on the Expression of Known Target 
Genes 
Several genes have already been identified as putative HOX11 target genes in other cell 
lines. One gene, Aldh1a1, which had previously been identified as a target gene in the 
NIH3T3 cell line as well as in the developing spleen, was found to be expressed at 
significantly higher levels in the positive clones than the control J2E clones. However, one 
HOX11 positive clone (clone 11) showed an undetectable level of Aldh1a1 gene expression, 
suggesting that HOX11 may also repress transcription of this gene in some circumstances. 
Transcripts of other putative target genes Fhl1, a novel LIM-only gene (Greene et al., 1998) 
and Wt1, found to act downstream of Hox11 in a transcriptional cascade that is essential for 
spleen development (Dear et al., 1995; Koehler et al., 2000) were not detectable at the 
Northern filter hybridization level (Figure 3.4). 
3.2.4  The Effect of HOX11 on the Expression of Genes Associated 
with the Erythroid Lineage 
Certain genes are known to play an important role in erythroid differentiation. Given the 
striking phenotypic change which had occurred in HOX11 expressing J2E cells (Figure 3.3), 
Northern blot analyses were also performed on such genes, namely, Gata-1, β-Globin, Nf-e2 
and Eklf in order to confirm that these cells had retained an erythroid phenotype. β-Globin is 
essential for erythroid differentiation and is usually expressed at low levels by J2E cells with 
levels of expression increasing following Epo stimulation. GATA-1 is a zinc finger protein that 
is a key regulator of erythroid differentiation. Without its expression erythroid precursors 
arrest at the proerythroblast stage of development and then undergo apoptosis. Erythroid 
lineage selection, survival and terminal maturation of erythroid precursors is dependent on 
GATA-1 (Shivadasani et al., 1996). Eklf or erythroid kruppel-like factor is known to bind to the 
CACCC site found in the β-Globin promoter and is essential for its production (Shivadasani et 
al., 1996; Spadaccini et al., 1998). Finally, NFE2 is a leucine zipper family nuclear protein 
that mediates enhancement of globin gene expression (Shivadasani et al., 1996). In all cases 
Northern filter hybridizations were not sensitive enough to detect these transcripts and thus 
no patterns of regulation could be identified using this technique alone (Figure 3.5). 
In the case of globin, pan-globin levels were determined by Western blot analysis and 
haemoglobin production was determined in our laboratory by DAF staining (data not shown). 
HOX11 positive clones tended to have reduced basal haemoglobin synthesis, even after 
exposure to Epo. RT-PCRs were performed in order to detect Eklf and Nfe2 (Figure 3.6). No 
clear difference in expression levels were detected between HOX11 positive and control cell 
clones, however the presence of these transcripts did contribute to phenotypic identification. Chapter Three  98
It was conceivable that the low levels of globin expression in the HOX11 positive clones may 
be indicative of the emergence of megakaryocytic precursors. However, Nfe2 and Eklf are 
erythroid lineage specific markers and the presence of these transcripts indicated that the 
HOX11 transfectants were indeed erythroid. 
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FIGURE 3.3 HOX11 INDUCES AN IMMATURE MORPHOLOGY IN J2E ERYTHROID 
CELLS  
Modified Wright’s stained cytospin preparations of control transfected clones 1 and 19 and 
J2E clones stably transfected with HOX11 (clones 3, 11, 18 and 44). A J2E control is also 
included. A gigantoblast is marked with an arrow in clone 18. Original magnification x400. The 
experiment was completed by Jette Ford, Division of Childrens’ Leukaemia and Cancer 
Research, Institute for Child Health Research. 
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FIGURE 3.4 THE EFFECT OF HOX11 ON THE EXPRESSION OF KNOWN TARGET GENES IN 
J2E CELLS 
Northern filter hybridization of 10ug total RNA from J2E clones 1, 19 and J2EHOX11 clones 3, 11, 
18, 44 and hybridized with HOX11, Aldh1a1, Fhl1, Wt1 and Gapdh control. Positive controls (C) 
undertaken as probe hybridizations are shown for Fhl1 and Wt1. 
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FIGURE 3.5 EXPRESSION OF GENES ASSOCIATED WITH THE ERYTHROID LINEAGE IN 
J2EHOX11 CELLS 
Northern filter hybridization of 10ug total RNA from J2E, J2E clones 1, 19 and J2EHOX11 clones 
3, 11, 18, 44 and hybridized with Gata1, β-Globin, Nfe2, Eklf and Gapdh control. J2E total RNA 
was included as a positive control (C).
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FIGURE 3.6 RT-PCR ANALYSIS FOR TRANSCRIPTION FACTOR EXPRESSION IN J2E CLONES 
RT-PCR analysis for the expression of erythroid transcription factors Eklf, Nfe2 in J2E control clones 
(1 and 19) and HOX11 transfected J2E clones (3, 11, 18 and 44). β-Actin was amplified as a control 
for the amount of cDNA used in each reaction. J2E total RNA was included as a positive control (C). A 
negative control (C-) was also included.  
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3.2.5  Searching for Genes Whose Expression is Altered in J2E Cells 
as a Result of Enforced HOX11 Expression 
The mechanism by which HOX11 transforms cell is yet to be determined, however the 
regulation of distinct target genes involved in differentiation programs may contribute to cell 
transformation. RDA was therefore employed in order to identify genes involved in the 
genetic cascade that is responsible for the effects that HOX11 expression has on the J2E 
phenotype. The technique sought to identify genes whose expression was differential as a 
result of HOX11 expression, some of which may be transcriptional targets of HOX11. 
3.2.5.1  The CLONTECH PCR Select cDNA Subtraction Kit for 
Representational Difference Analysis 
The CLONTECH PCR Select Subtraction Kit used in this study differs significantly from the 
traditional RDA method as it incorporates a suppressive PCR (Diatchenko et al., 1996). 
Figure 3.7 outlines the method. Firstly, mRNA is isolated from control and experimental cells 
and used to generate two populations, one designated tester and the other driver. The 
cDNAs are then digested with Rsa I a four base cutting restriction enzyme in order to yield 
blunt ends. The tester cDNA is then divided into two populations and each is ligated to a 
different adaptor. The first round of subtractive hybridization involves the mixing of the tester 
cDNA sample with a large excess of driver. The samples are denatured and then allowed to 
hybridize, differentially expressed sequences remain as single stranded molecules (Type a 
molecules, first hybridization, Figure 3.7). It is also important to note that equalization of high 
and low abundance molecules also occurs at this step as high abundance molecules are 
more likely to form double stranded hybrids which are effectively removed from the process 
of amplification  (Type b molecules, first hybridization, Figure 3.7) (Clontech Laboratories 
Incorporated, 1999; Diatchenko et al., 1996). In the second hybridization the two tester 
populations with different ligated adaptors are mixed with fresh denatured driver. Hybrids of 
single stranded differentially expressed sequences with different adaptors at each end form 
(Type e, second hybridization, Figure 2.7). After filling in the 3’ ends with Taq polymerase a 
suppressive PCR is performed using adaptor 1 as a forward primer and adaptor 2 as a 
reverse primer. The differentially expressed sequences are amplified. Non-differentially 
expressed sequences form hybrids with driver DNA or with each other, these hybrids have 
the same primer sequence at both ends and they fail to exponentially amplify due to the 
formation of pan- like structures (PCR product b Figure 3.7). A second PCR amplification is 
performed using a nested primer set to further reduce any background PCR products. The 
differentially expressed cDNA are then directly inserted into a cloning vector (Clontech 
Laboratories Incorporated, 1999). Chapter Three  104
 
 
FIGURE 3.7 SCHEMATIC DIAGRAM OF PCR-SELECT cDNA SUBTRACTION  
Solid lines represent the Rsa I digested tester or driver cDNA. Solid boxes represent the 
outer part of Adaptor 1 and 2R and corresponding PCR primer 1 sequence. Clear boxes 
represent the inner part of Adaptor 1 and the corresponding Nested PCR primer 1 sequence; 
shaded boxes represent the inner part of Adaptor 2R and the corresponding Nested PCR 
primer 2R sequence. See text for explanation of technique (Clontech Laboratories 
Incorporated, 1999). Chapter Three  105
 
3.2.5.2  Optimization of cDNA Synthesis / Adaptor Ligation for 
Representational Difference Analysis 
The HOX11 positive J2E clone 3 and the control J2E clone 1 were selected for use in the 
RDA experiment. Initially, RDA was undertaken using the Clontech PCR Select-cDNA 
Subtraction Kit. Total RNA was isolated using the NP40 lysis method (Sections 2.2.13.2 and 
2.2.13.3). The cDNA synthesis protocol provided in this kit (Appendix 3 TABLE A) did not 
result in cDNA of a high enough quality to undergo Rsa I digestion. Figure 3.8A demonstrates 
the results of an unsuccessful digest. An alternative cDNA synthesis protocol was then 
applied (Appendix 3 TABLE B) which yielded a successful Rsa I digest as indicated by the 
decrease in average fragment size (Figure 3.8B). This cDNA was then used to complete the 
process. 
It was also important to ensure that the adaptor ligation to Rsa I cut cDNA populations was 
successful prior to continuing with the RDA protocol. A low ligation efficiency at this step can 
greatly reduce subtraction efficiency. Figure 3.9 outlines a PCR experiment that was 
performed in order to verify that at least 25% of the cDNA population had adaptors 
successfully ligated to both ends. In this experiment, primers amplified a fragment that 
spanned the adaptor/cDNA junction of the Gapdh gene within tester populations. The 
intensity of these bands was compared to those of a PCR control experiment where the 
Gapdh gene alone was amplified (Figure 3.9A) (Clontech Laboratories Incorporated, 1999). 
The intensity of the bands of these two different PCR products was found to differ by 
approximately two fold (Figure 3.9B) and thus the efficiency of the ligation was judged to be 
greater than 25% and sufficient for the RDA protocol to continue. Chapter Three  106
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.8 OPTIMIZATION OF cDNA SYNTHESIS FOR THE CLONTECH PCR SELECT-
cDNA SUBTRACTION KIT  
 
A. Analysis of Rsa I digestion of cDNA produced from kit protocol 
Lane 1 φ174Hae III 250ng 
Lane 2 cDNA undigested 
Lane 3 cDNA unsuccessfully digested with Rsa I 
 
B. Analysis of Rsa I digestion of cDNA produced from optimized protocol 
Lane 1 φ174Hae III 250ng 
Lane 2 λHind III 250ng 
Lane 3 cDNA undigested 
Lane 4 cDNA successfully digested with Rsa I 
 A.  B.
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FIGURE 3.9 DETERMINATION OF EFFICIENCY OF ADAPTOR LIGATION TO RSA I CUT 
J2E cDNA 
A. Diagrammatic representation of the PCR products produced using PCR Primer 1, G3PDH 
3’ and G3PDH 5’ in the ligation efficiency analysis PCR from the Clontech PCR Select-
cDNA Subtraction Kit. 
 
B. Gel electrophoresis of ligation efficiency analysis 
Lane 1 φ174Hae III 250ng 
Lane 2 Tester Ligation J2E clone 3, PCR Primer 1/ G3PDH 3’  
Lane 3 Tester Ligation J2E clone 3, G3PDH 5 ‘/ G3PDH 3’ 
Lane 4 Tester Ligation J2E clone 1, PCR Primer 1/ G3PDH 3’ 
Lane 5 Tester Ligation, J2E clone 1, G3PDH 5 ‘/ G3PDH 3’ 
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3.2.6 Results  of  Representational  Difference Analysis to Identify 
Genes Whose Expression is Altered by Enforced Expression 
of HOX11 in J2E Cells 
In this study, RDA subtractive hybridization between J2EHOX11 positive clone 3 and control 
clone 1 was undertaken in both forward and reverse directions. Gel electrophoresis of the 
RDA populations is shown in Figure 3.10. The forward subtracted populations seen in lanes 2 
and 3 indicate experiments where J2EHOX11 positive cDNA was designated tester and J2E 
control cDNA driver. Thus adaptors were ligated to the HOX11 positive cDNA and the 
fragments amplified in the analysis should arise from genes whose expression is up-
regulated in the presence of HOX11. The reverse subtracted populations seen in lanes 6 and 
7 indicate experiments where J2E control cDNA was designated tester and J2EHOX11 cDNA 
driver. In this case, adaptors were ligated to the J2E control cDNA and the fragments 
amplified in the analysis should arise from genes whose expression is down-regulated in the 
presence of HOX11. 
The banding patterns seen in both the forward and reverse subtracted populations were 
indicative of a successful experiment where differential transcripts have been amplified. By 
contrast, the unsubtracted control populations in lanes 4, 5, 8 and 9 were a smear with no 
defined bands. In parallel, a control was run where skeletal muscle cDNA was `spiked’ with 
φ174Hae III DNA. After a round of RDA was performed, bands of the φ174Hae III marker 
were clearly present in this control population, confirming that the experiment had been 
successfully conducted. The individual bands were slightly larger than those of a normal 
φ174Hae III ladder due to the ligated adaptors. 
In order to confirm the subtraction efficiency of the RDA experiment, PCR analysis was 
performed (Figure 3.11). This was done by comparing the abundance of known cDNAs 
before and after subtraction. A presumptive non-differentially expressed housekeeping gene, 
Gapdh, was used for this analysis. Several Gapdh PCR reactions were performed using 18, 
23, 28 and 33 cycles. This allowed the visualization of the Gapdh  PCR product every 5 
cycles. By comparing lanes 2-5 of the forward subtracted population to lanes 6-9 of the 
unsubtracted control population it is clear that Gapdh products of equal intensity in the 
subtracted population appear at least 5 cycles later. A similar result is observed when 
comparing lanes 10-13 of the reverse subtracted population to lanes 14-17 of the 
unsubtracted control population. In both cases the decrease in Gapdh abundance indicates 
that this gene has been successfully subtracted from the test populations and the subtraction 
efficiency of this experiment was deemed high enough to continue. Chapter Three  109
Given that HOX11 was ectopically expressed at high levels in the J2E clones used for this 
experiment, it is a gene known to be differentially expressed between the driver and tester 
populations. Potentially, therefore, it could help confirm if the RDA selection procedure had 
been successful. For this reason, PCR analysis of the subtracted and unsubtracted 
populations for HOX11 was performed. Figure 3.12 shows the results of this analysis. Two 
separate sets of primers outlined in Figure 3.12A were utilized. Firstly, EF1AFOR, a pEFBOS 
sense primer was used in conjunction with HOX11R4, an antisense primer specific for 
HOX11. These primers spanned a vector–encoded intron which enabled mRNA expressed 
from the introduced construct to be differentiated from integrated plasmid DNA. The results of 
the PCR performed using the EF1AFOR/ HOX11R4 primers are shown in lanes 2-6 of Figure 
3.12B. As expected, HOX11 is present in the unsubtracted control of the forward subtraction 
(lane 3) as this population is known to consist entirely of J2EHOX11 positive cDNA. HOX11 
is not present in the unsubtracted control of the reverse subtraction (lane 5) as this population 
is known to consist entirely of HOX11 negative control cDNA. Surprisingly, HOX11 was not 
detected in the forward subtracted population seen in Lane 2. The lack of the EF1AFOR, 
HOX11R4 fragment was probably due to the fact that this fragment is unlikely to be amplified 
by PCR unless under conditions including a 97°C denaturation step due to the high G+C 
content of this fragment. It is also possible that unfavorable hybridization kinetics prevented 
the amplification of this fragment. 
A second HOX11 PCR was performed using the HOX290F and HOX417R primers. The 
results of this PCR are shown in lanes 7-11 of Figure 3.12B. In this case HOX11, was 
detected in the forward subtracted population (lane 7) as expected, as well as in the 
unsubtracted control population (lane 8). Once again HOX11 was not present in the 
unsubtracted control of the reverse subtracted population (lane 10). Surprisingly, HOX11 was 
also detected at a low level in the reverse subtracted population (lane 9). HOX11 would not 
be expected to be amplified in this case, however its low level presence is understandable 
given the excess of J2EHOX11 positive driver present in this population. Nevertheless, the 
conclusion again, was that no significant enrichment of HOX11 cDNA fragments had 
occurred. 
To confirm and extend these findings, Southern filter hybridization analysis on the RDA 
populations was performed for Gapdh,  HOX11 and Aldh1a1 (Figure 3.13). Aldh1a1 was 
found by previous RDA analysis to be a putative HOX11 target gene in the NIH3T3 fibroblast 
cell line (Greene et al., 1998). Gapdh  transcripts were found to be subtracted from the 
forward and reverse subtracted test populations shown in lanes 2 and 4 and present in great 
quantities in unsubtracted control populations in lanes 1 and 3. This result was in accordance 
with expectation and with the findings of the subtraction efficiency test shown in Figure 3.11. 
Also as expected, HOX11 and Aldh1a1 were detected in the forward unsubtracted control Chapter Three  110
population (lane 1). This population is known to consist entirely of J2EHOX11 positive cDNA. 
Surprisingly however, neither HOX11 nor Aldh1a1 were detected in the forward subtracted 
population indicating that neither of these genes had been selectively enriched. In the case of 
HOX11 this is probably due to issues related to hybridization kinetics and PCR conditions 
mentioned above. In the case of Aldh1a1 poor hybridization kinetics due to a low number of 
Rsa  I  sites throughout this gene may have contributed to this result. Alternatively, since 
Aldh1a1 was only up-regulated by about three fold in J2EHOX11 positive clone 3 when 
compared to control clone 1, the RDA procedure may not have been sensitive enough to 
enrich fragments of Aldh1a1 cDNA (Figure 3.4). Thus, in summary, neither HOX11 nor 
Aldh1a1 were found to be enriched by the RDA procedure. This is not altogether surprising 
given that the technique is representational and does not enrich for all differentially expressed 
genes due to its inherent biases. Nevertheless, the selection against the housekeeping gene 
Gapdh observed, indicated that the procedure itself had been successful. Chapter Three  111
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.10 RESULTS OF REPRESENTATIONAL DIFFERENCE ANALYSIS 
Gel electrophoresis of Representational Difference Analysis (RDA) populations. J2E control clone 1 
and J2EHOX11 clone 3 were subjected to RDA using the CLONTECH PCR-Select cDNA Subtraction 
Kit. Numbers indicate PCR cycle number used to amplify the population.  
M= φX174 Hae III marker (250ng).  
FS= forward subtracted populations where J2EHOX11 clone 3 cDNA was used as tester and J2E 
control clone 1 was used as driver.  
RS= reverse subtracted populations where J2EHOX11 clone 3 cDNA was used as driver and J2E 
control clone 1 was used as tester.  
US= unsubtracted control population.  
C= RDA kit control subtracted population where skeletal muscle cDNA which has been spiked with 
φ174Hae III DNA was used as tester and skeletal muscle cDNA was used as driver. 
 
Population:   M    FS    FS     US   US   RS   RS     US   US      C   
Cycle N
o:       12    13    12    13     12   13     12    13       14     Chapter Three  112
 
 
 
 
FIGURE 3.11 SUBTRACTION EFFICIENCY TEST FOR REPRESENTATIONAL 
DIFFERENCE ANALYSIS 
PCR analysis to estimate the efficiency of subtraction of the RDA experiment. The 
Glyceraldehyde-3-phosphate dehydrogenase gene (Gapdh), a housekeeping gene, 
was used for this purpose. Numbers indicate PCR cycle number used to amplify the 
Gapdh gene. M= φX174 Hae III marker (250ng). 
 
Cycle N
o :         18   23   28  33     18   23   28  33    18   23   28   33    18  23   28   33  
    M 
Population: 
Unsubtracted
Control 
Forward 
Subtracted 
Reverse 
Subtracted 
Unsubtracted
Control Chapter Three  113
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.12 DETECTION OF HOX11 IN REPRESENTATIONAL DIFFERENCE 
ANALYSIS POPULATIONS BY PCR 
PCR analysis for the expression of HOX11 transcripts outlined in PART A above 
A. 
Diagrammatic representation of the HOX11 transcripts produced using the EF1AFOR, 
HOX11R4 and HOX290F, HOX417R primers. 
B. 
Lane 1 250ng φ174 HaeIII 
Lane 2 Forward Subtraction, primers EF1AFOR, HOX11R4 
Lane 3 Unsubtracted control, primers EF1AFOR, HOX11R4 
Lane 4 Reverse Subtracted, primers EF1AFOR, HOX11R4 
Lane 5 Unsubtracted control, primers EF1AFOR, HOX11R4 
Lane 6 J2EHOX11 positive control, primers EF1AFOR, HOX11R4 
Lane 7 Forward Subtraction, primers HOX290F, HOX417R 
Lane 8 Unsubtracted control, primers HOX290F, HOX417R 
Lane 9 Reverse Subtraction, primers HOX290F, HOX417R 
Lane 10 Unsubtracted control, primers HOX290F, HOX417R 
Lane 11 J2EHOX11 positive control, primers HOX290F, HOX417R Chapter Three  114
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
Lane     1          2     3     4    5    6        7     8    9   10   11 
EF1AFOR/HOX11R HOX290F/HOX417R 
 FS   UC   RS   UC   +  FS   UC   RS   UC   + 
A. 
SV40 ORI 
EF1α  PROMOTER AND 
EXON 1 
HOX11 
G-CSF 
NONCODING 
REGION 
EF1AFOR HOX11R4 
HOX290F HOX417R 
ATG STOP 
198bp PRODUCT 
127bp PRODUCT Chapter Three  115
 
 
 
 
 
 
 
FIGURE 3.13 DNA HYBRIDIZATION ANALYSIS OF REPRESENTATIONAL 
DIFFERENCE ANALYSIS POPULATIONS 
Southern filter hybridization analysis of RDA populations for HOX11, Aldh1a1 and 
Gapdh control 
Lane 1 Unsubtracted control 
Lane 2 Forward Subtracted population 
Lane 3 Unsubtracted control 
Lane 4 Reverse Subtracted population 
Aldh1a1 
HOX11 
Gapdh 
Lane                1           2          3           4 
      UC        FS        UC       RS Chapter Three  116
 
3.2.7  Analysis of Individual Forward Subtracted Representational 
Difference Analysis Clones 
The focus was then shifted to the identification of genes present in the forward subtracted 
population of the RDA. Genes amplified in this population are putatively up-regulated in the 
J2EHOX11 cells. In order to identify these genes, the amplified fragments were cloned into 
the pCR2.1 vector and transformed into the INVαF’ strain of E.coli. Colony hybridizations 
were then performed, probing sequentially with both the forward subtracted and reverse 
subtracted populations (Figure 3.14). These populations were chosen as probes, as 
differentially expressed cDNAs are amplified in these populations. In total, sixty-five colonies 
were classified as being differentially expressed using the colony hybridizations. Four clones 
that appeared to be differentially expressed after taking into account slightly different 
exposure times, are indicated with red arrows on filter hybridizations in Figure 3.14A. In each 
case the signal from the colony probed with the forward subtracted population was more 
intense than the signal produced when the same colony was re-probed with the reverse 
subtracted population. A panel of further examples of clones identified as being differentially 
expressed is also shown (Figure 3.14B). A Gapdh control was also included which produced 
no signal due to the fact that this housekeeping gene has been subtracted from both probe 
populations. Three clones (2, 5, 100) are also shown where the difference in the intensity of 
signals from probing with the forward and reverse subtracted populations was judged not to 
be great enough for them to be classified as differentially expressed (Figure 3.14B). 
The gene fragment inserts of the sixty-five clones classified as being differentially expressed 
were amplified by PCR. Southern filter analysis was then carried out using the reverse 
subtracted and forward subtracted populations as probes in order to confirm the colony 
hybridization results (Figure 3.15A and Figure 3.15B, respectively), equal labeling of different 
probes was assumed, as 25ng of both forward and reverse subtracted populations were 
labeled with a high specific activity of approximately 33000cpm.In all cases the signals 
produced through probing with the forward subtracted population were more intense than 
those produced with same amount of labeled probe of the reverse subtracted population. As 
expected, no signals were observed for HOX11, Aldh1a1 or Gapdh since these genes were 
not enriched by the RDA procedure. As further confirmation of their differential expression 
status, Southern filter analysis was then carried out using J2E control cDNA from clone 1 and 
J2EHOX11  positive cDNA from clone 3 as probes (Figure 3.16A and Figure 3.16B 
respectively). In this case Gapdh serves as a labeling control, note that the Gapdh signal for 
Figure 3.16B is slightly more intense than that 3.16A, this was taken into account when 
comparing sample intensities. This analysis only clarified the differential status of high 
abundance transcripts. In addition to HOX11 as a control, clones 17, 32, 37, 41, 75, 79, 92, Chapter Three  117
93, 99, 106, 108, 115, 121, 191, 208, 211 and 212 appeared differentially expressed in this 
analysis.  
The RDA study was concluded by the sequencing of the 65 clones of interest. In some cases 
clones could not be identified due to the low standard of sequencing from some PCR 
products. Table 3.1 outlines the identity of 46 putative differentially expressed genes. Chapter Three  118
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.14 IDENTIFICATION OF CLONES REPRESENTING DIFFERENTIALLY 
EXPRESSED GENES USING COLONY HYBRIDIZATION   
An example of a colony hybridization probed with both the Forward Subtracted and 
Reverse Subtracted populations is shown.  Red arrows indicate colonies which were 
deemed to be differentially expressed. 465 colonies were processed this way (A). Ten 
other differentially expressed colonies are shown below. Gapdh and VECTOR colony 
controls are included as are three colonies deemed to be non-differentially expressed (B). Chapter Three  119
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FIGURE 3.15 CONFIRMATION OF DIFFERENCE CLONES BY SOUTHERN ANALYSIS 
Inserts of Representational Difference Analysis Clones were amplified by PCR and run on an 
agarose gel. Southern filter analysis was then carried out using the Reverse Subtracted 
population as a probe (A) and the Forward Subtracted population as a probe (B). Clone 
identities are indicated. HOX11, Aldh1a1 and Gapdh controls are included.  Chapter Three  121
 
 1     4    7    10   11   15  17   22   23  28   30   31   32   34   37  41   45  46  52  58 
 61  75  79  80    81   86   87   89  92  93   99  102 103 106 108 110 115 116 120 121 
 122 124 128 129 154 167 180 183 184 186 187 191 202 208 209 211 212 223 227 239 
250 273 387 429 454       HOX11   Aldh1a1  Gapdh                  
A. 
B. 
  1    4     7    10   11   15   17  22  23    28   30   31  32   34   37  41   45  46  52   58
 61  75   79   80  81   86   87   89  92   93  99  102 103 106 108 110 115 116 120 121 
 122 124 128 129 154 167 180 183 184 186 187 191 202 208 209 211 212 223 227 239 
250  273 387 429 454       HOX11   Aldh1a1  Gapdh                Chapter Three  122
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.16 CONFIRMATION OF DIFFERENCE CLONES BY SOUTHERN ANALYSIS 
USING cDNA PROBES 
Inserts of Representational Difference Analysis clones were amplified and run on an 
agarose gel. Southern filter analysis was then carried out using a population of cDNA 
produced from the J2E control clone 1 as a probe  (A) and a population of cDNA produced 
from J2EHOX11 clone 3 as a probe (B). Clone identities are indicated. HOX11, Aldh1a1 
and Gapdh controls are included.  Chapter Three  123
 
  1    4    7     10   11  15   17   22   23   28   30  31  32   34   37   41   45   46    52   58 
 61   75   79   80  81   86   87   89   92   93  99 102 103 106 108 110 115 116 120 121
 122 124 128 129 154 167 180 183 184 186 187 191 202 208 209 211 212 223 227 239 
250  273  387 429 454   HOX11   Aldh1a1  Gapdh        
  1    4    7    10   11   15   17    22   23    28    30   31 32  34  37  41   45   46  52 58 
 61   75  79   80   81   86   87  89  92   93   99 102 103 106 108  110 115 116 120 121 
122 124 128 129 154 167 180 183 184 186 187 191 202 208 209 211 212 223 227 239 
250  273  387 429 454  HOX11  Aldh1a1  Gapdh         
A. 
B.  
Clone   Identity  Homo-
logy 
Genbank 
Accession 
Expression 
Figure 
Transcription Factors 
11  Murine zinc finger protein (Bmi-1)  99% M64068.1  Figure  3.19 
209  Murine zinc finger protein 67  98% NM_009565.1  Figure  3.21 
180  Homosapiens putative ring finger FLJ20329  90% AK000336.1  Figure  3.23 
99  Murine Sui1 homologue  97%  J01420.1    
37  Rat electron transfer flavoprotein (ETF)  94%  M22030.1   
Signal Transduction Molecules 
387  Murine Ral guanine nucleotide dissociation 
stimulator (Rgds) 
100% NM_009058.1   
61  Murine protein tyrosine phosphatase, non 
receptor type 21 
97% NM_011877.1  Figure  3.22 
87  Murine guanosine diphosphate dissociation 
inhibitor 3 
99% NM_008112.1  Figure  3.26 
122  Murine SH-3 domain binding protein 2 (Sh3 bp2)  99%  NM_011893.1   
108  Murine proliferation associated gene 
(PAG)/Peroxiredoxin 1 
98% NM_011034.1  Figure  3.27 
22, 
129 
Murine Hexosaminidase B  99-100% NM_010422.1  Figure  3.18 
121  Murine homologue of human ftp-3  94%  NM_019868.1   
79 Murine  Thioredoxin  100% NM_011660.1   
Cytoskeleton/ Structural 
115  Murine gamma cytoplasmic actin   100%  NM_009609.1   
120 Rat  nexlin  92%  AF056035.1   
 
Metabolism 
75, 
167 
Murine Mitochondrial genome  100%  J01420.1   
46  Murine Spermidine N1- acetyl transferase  93%  NM_009121.1   
Transcription/ Repair/ Replication 
15 Homosapiens  splicing  factor  83%  AF107463   
23  Murine telomerase binding protein p23  99%  NM_019766.1   
Translational Regulation 
184, 
186 
Murine DEAD box peptide 3  100%  NM_010028.1 
 
 
45  Rat eukaryotic initation factor 5  92%  L11651.1   
17  Murine translational repressor  98%  MMU76112   
Cell Surface Receptor 
81  Murine major histocompatability complex class I  95%  AF111102.1   
Secreted Protein 
102, 
211 
Murine Osteopontin  90-95% J04806.1  Figure  3.25 
 
Chromatin Structure 
106  Murine H3 histone, family 3B  98%  NM_008211.1   
Other 
4  Human mRNA for KIAA0183  88%  D80005.1   
86, 
202 
Murine tumour rejection antigen gp96   100% NM_011631.1  Figure  3.20 
89  Murine Mex 67 homologue  95%  NM_016813.1   
187 Murine  Sid6061p  93%  AB025048.1   
212, 
250 
Rattus N. subtractive clone N27  90%  U30789.1   
429  Murine SCID complementing gene 2  100%  D78188   
 
80, 1, 227, 7, 32, 41, 208, 58, 
116, 28, 31, 34, 103, 110, 273 
Unknown with homolgy to 
some ests. Clones 32 and 116 
are identical, clones 110 and 
273 are identical 
    
 
TABLE 3.1 SEQUENCE IDENTITY OF REPRESENTATIONAL DIFFERENCE ANALYSIS 
CLONES 
Clone identity number, sequence identity, percentage homology of clone sequence to Genbank 
sequence,Genbank accession number are included. Genes in bold represent those genes 
selected for further analysis. Gene expression patterns of genes in leukaemic cell lines are 
shown in the figures indicated. 
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3.2.8  Expression of HOX11 Up-Regulated Genes in Leukaemic Cell 
Lines 
RDA identified 46 genes whose expression was altered as a result of HOX11 expression in 
J2E cells. The expression levels of these genes were up-regulated in J2EHOX11 expressing 
clone 3 as compared to the J2EHOX11 negative clone 1. The CLONTECH PCR Select 
Subtraction Kit used to undertake RDA analysis differs from the traditional RDA method 
(Clontech Laboratories Incorporated, 1999; Hubank et al., 1994). The traditional RDA 
technique involves the selective degradation of material common to both tester and driver 
populations using mung bean nuclease (Hubank et al., 1994). The CLONTECH PCR Select 
Subtraction Kit does not incorporate selective degradation and instead relies on subtractive 
PCR to suppress the amplification of non-differential products (Diatchenko et al., 1996). The 
disadvantage of this technique over traditional RDA is the fact that non-differential transcripts 
may be cloned and sequenced resulting in the identification of many `background’ genes. It is 
important that these genes are removed from the analysis in order to identify putative HOX11 
target genes. 
The panel of genes identified by the RDA is also likely to include all genes up-regulated in the 
HOX11 transcriptional cascade, including those at the furthest end of the cascade. HOX11 
target genes at the beginning of this transcriptional cascade are more likely to be of interest. 
Given the phenotypic changes observed when HOX11 is introduced into the J2E cell line, it is 
likely that many of the genes identified are further down the HOX11 transcriptional cascade 
and are linked with phenotypic changes. Additionally, thirteen transcripts with homology to 
ESTs were identified by RDA analysis (Table 3.1). These transcripts may represent novel 
genes. Further analysis was not undertaken on these ESTs as their promoters were not 
characterized, which is important in the functional confirmation of putative target genes. In 
order to identify putative HOX11 target genes potentially involved in leukaemogenesis, nine 
genes that are known to be transcription factors and/or previously implicated in cancer were 
chosen for further analysis. The genes BETA-HEXOSAMINIDASE, BMI-1, putative ring finger 
FLJ20329, tumour rejection antigen GP96, TYROSINE PHOSPHATASE NON-RECEPTOR 
TYPE 21, OSTEOPONTIN, zinc finger ZF67, GUANOSINE DIPHOSPHATE DISSOCIATION 
INHIBITOR 3 and  PAG were analyzed for their expression in leukaemic cell lines. 
Additionally, in initial experiments, the cell surface phenotype of the J2E clones transfected 
with  HOX11 were determined by flow cytometry. Significantly, the transfectants over-
expressing HOX11 were characterized by increased surface expression of C-Kit (Greene et 
al., 2002). Although this gene was not identified by RDA, it was included in the analysis as 
being a differentially expressed gene of interest. 
A Northern blot and RT-PCR based screening method across a panel of cell lines was 
employed. These cell lines are outlined in Table 3.2 and include a number of HOX11 and Chapter Three  126
 
M       20     24     26      28               20     24     26     28 
J2EHOX113 K562 
Cycle N°: 
FIGURE 3.17 OPTIMIZATION OF PCR CYCLE NUMBER FOR SEMI-QUANTITATIVE RT-PCR 
An example of PCR analysis for β-ACTIN on the HOX11 positive cell lines J2EHOX113 and K562 
in order to establish the optimal cycle number to identify the linear range of amplification. This 
experiment was undertaken for all genes analysed on the HOX11 positive cell lines including 
J2EHOX113, NIH3T3HOX115, HELHOX115, K562 and PER255. In this case 20 cycles was 
deemed optimal. Chapter Three  127
 non-HOX11 expressing cells of erythroleukaemic, T-ALL and fibroblast phenotypes of both 
murine and human origin. Culture conditions and the passage number of clones of the same 
cell line were kept constant for all RDA, microarray and RT-PCR experiments. All cells were 
harvested at 5-7 x10
 5  cells/ml and all cell lines were judged to be phenotypically 
characteristic of the cell line, by Jette Ford, Division of Childrens’ Leukaemia and Cancer 
Research, Institute for Child Health Research. Ideally, a putative HOX11 target gene would 
be expected to demonstrate consistently altered expression (either up-regulation or down-
regulation) in HOX11-expressing cell lines when compared to matched control cell lines. This 
effect would also be present in the majority, if not all, clones from each cell line. This criterion 
was established from the example of the known HOX11 target gene Aldh1a1.  ALDH1A1 
expression was found to be consistently up-regulated with the expression of HOX11 in the 
PER-117, J2E and NIH3T3 cell line clones and consistently down-regulated with the 
expression of HOX11 in HEL cell clones (Greene et al., 1998; Greene et al., 2002; Greene 
and Kees, unpublished observations). The down-regulation observed in the case of the HEL 
cell line may be due to the availability of different co-factors and/or competition for binding 
sites within the Aldh1a1 promoter. HOX-PBX complexes have been demonstrated to act as 
repressors or activators of transcription via association with corepressors or coactivators 
(Saleh et al., 2000). Nevertheless, in all cases the expression of HOX11 had a marked effect 
(either up-regulation or down-regulation) on Aldh1a1 and therefore it was conceivable that a 
similar pattern of behaviour would apply to other target genes. It would also be expected that 
putative HOX11 target genes involved in leukaemogenesis would demonstrate altered 
expression in T-ALL cell lines known to express HOX11 (PER-255, ALL-SIL and MKB-1) and 
the K562 cell line also known to express HOX11 when compared to other T-ALL and 
leukaemic cell lines known not to express HOX11. The genes would also be of interest if they 
were to display an altered expression in an overall comparison of normal thymocytes and 
leukaemic T-cell lines. 
Initially, quantitative Northern blot analyses were undertaken for each gene, 
autoradioradiographs were then analyzed using densitometry and values normalized to 
matched β-ACTIN controls. However, this technique was not sensitive enough to detect the 
expression of many of the genes. As a result, a highly sensitive semi-quantitative RT-PCR 
based screening technique was applied to all genes that could not be successfully analyzed 
by Northern blot. Whilst it is possible that this method may not account for all differences in 
specific cDNA concentrations the technique was also cost effective in comparison to Taqman 
based RT-PCRs and did not require access to specialized equipment. Where possible, 
intron-spanning primers were designed in regions known to be homologous between the 
murine and human forms of the gene. The reactions were first optimized with regard to 
amplification cycle number in order to utilize the linear range of amplification (Figure 3.17). Chapter Three  128
This experiment was undertaken for all candidate HOX11 target genes on the HOX11 
positive cell lines including J2EHOX113, NIH3T3HOX115, HELHOX115, K562 and PER255, 
as it was thought that these samples would be most likely to demonstrate the highest levels 
of expression of up-regulated HOX11 target genes. Products were separated on an ethidium 
bromide agarose gel and the intensity of the bands produced were analyzed using a 
phosphoimager. Values were normalized to matched β-ACTIN controls. The screening 
technique was undertaken once for each gene analysed mainly because of time constraints 
and the fact the process was a basic screening technique. Initially, GAPDH and β-ACTIN 
were utilized as housekeeping genes for the RT-PCR and northern blot analyses. The 
GAPDH RT-PCR appeared to give highly variable results and additionally, normalized values 
for HOX11 expression across the panel of leukaemic cell lines produced questionable results. 
Accordingly a decision was made to utilize β-ACTIN  as the housekeeping gene for 
normalization. 
The expression levels of HOX11 itself  in the leukaemic cell lines was first analyzed by 
Northern blot and RT-PCR and the results are shown in Figure 3.17. The quantitative 
Northern blot data concurred with the results gained from the semi-quantitative RT-PCR 
based technique, which indicated that the use of the RT-PCR assay for the investigation of 
levels of gene expression was valid. In the case of the HEL cell clones, HOX11 expression 
was detected at the level of RT-PCR not Northern blot. Additionally, a second RT-PCR for 
HOX11, using HOX11-specific primers rather than those used to detect expression from the 
pEFBOSHOX11 construct, was undertaken on the panel of PER-117 HOX11 transfected cell 
clones. It had previously been reported that PER-117 clone 2 expressed low levels of HOX11 
(Greene, unpublished observations). Although the Northern blot result for PER-117 clone 2 
was negative, a RT-PCR was undertaken which independently confirmed this finding. Due to 
the low level of HOX11 expression observed, PER-117 clone 2 was classified as a low-level-
HOX11 expressing cell line, nevertheless, and this was taken into consideration during data 
analysis (Figure 3.17). 
A summary of gene expression levels in cell lines for the nine genes of interest is presented 
in Table 3.3. Four main categories of genes were established: 1) Background genes 
generated as artifacts of the RDA technique which appeared to be non-differential in their 
expression 2) J2E Clone 3 specific genes which appeared to be specifically up-regulated with 
HOX11 expression in J2E clone 3 cells only 3) Genes consistently up-regulated in clones of 
the J2E cell line only with HOX11 expression 4) Genes affected by HOX11 expression in 
more than one cell line. 
Firstly,  BETA-HEXOSAMINIDASE,  BMI-1, tumour rejection antigen GP96 and zinc finger 
ZF67 all demonstrated no correlation of gene expression levels with HOX11 expression and Chapter Three  129
thus were deemed to be background genes as a result of the RDA procedure (Figures 3.18, 
3.19, 3.20 and 3.21 respectively). Secondly, Tyrosine Phosphatase Non-receptor Type 21 
appeared to be up-regulated in J2E clone 3 only (Figure 3.22). This gene represented a 
differentially regulated gene that was specific to this particular clone and thus was unlikely to 
be related HOX11 expression. Thirdly, putative ring finger Flj20329 and C-Kit are genes 
which were up-regulated in three out of four HOX11 positive clones of the J2E cell line but, 
there appeared to be no clear correlation of these genes with HOX11 expression in any of the 
other leukaemic cell lines screened (Figure 3.23 and 3.24 respectively). These genes may be 
putative HOX11 target genes specific to the J2E murine erythroid cell line or genes 
associated with the HOX11-induced dedifferentiation of the J2E cell line. Finally, 
OSTEOPONTIN,  GUANOSINE DISSOCIATION  INHIBITOR 3 and PAG expression was 
found to correlate with HOX11 in more than one cell line which implicates each of these 
genes as putative HOX11 targets (Figures 3.25, 3.26 and 3.27 respectively). 
Osteopontin clearly appeared to be down-regulated in all HOX11 positive J2E clones (Figure 
3.25). Given that the RDA screen was performed in a forward direction to identify genes up-
regulated in J2EHOX11 clone 3, this result was unexpected and puzzling. This gene may 
have been a background clone that fortuitously demonstrated differential expression. 
Nevertheless, Osteopontin appeared to correlate inversely with HOX11 expression in the J2E 
murine erythroid cell line. Additionally, if the low level of HOX11 expression exhibited by 
PER-117 clone 2 is taken into account, this gene also showed a negative correlation with 
HOX11 in the PER-117 cell line. However, the gene could not be detected in any HOX11 
positive T-cell leukaemia cell line nor in normal thymocytes (data not shown). 
OSTEOPONTIN may potentially be a HOX11 target gene, however, the gene expression 
profile was not suggestive of it being important in T-ALL. Guanosine Diphosphate 
Dissociation Inhibitor 3 was found by Northern blot to be up-regulated with HOX11 
expression in both the J2E murine erythroid cell line and the NIH3T3 murine fibroblast cell 
line (Figure 3.26). Similarly, PAG was found to be up-regulated with HOX11 expression in the 
J2E cell line and the NIH3T3 cell line and down-regulated with HOX11 expression in the HEL 
human erythroid cell line (Figure 3.27). In both cases, no correlation of gene expression with 
HOX11 in the leukaemic T-cell lines was found. Given the fact that both Guanosine 
Diphosphate Dissociation Inhibitor 3 and PAG are differentially expressed with HOX11 in 
more than one cell line, it is possible that, like OSTEOPONTIN, they represent putative 
HOX11 target genes. Chapter Three  130
 
PHENOTYPE CELL  LINE  HOX11 
EXPRESSION 
MURINE ERYTHROID  J2E Clone 1, J2E Clone 2, J2E Clone 19   
  J2EHOX11 Clone 3, J2EHOX11 Clone 
11, J2EHOX11 Clone 18, J2EHOX11 
Clone 44 
✓ 
MURINE FIBROBLAST  NIH3T3 Clone 11   
  NIH3T3HOX11 Clone 1, NIH3T3HOX11 
Clone 5  ✓ 
HUMAN 
ERYTHROLEUKAEMIA 
HEL Clone 1   
  HELHOX11 Clone 4, HELHOX11 Clone 5  ✓ 
HUMAN T-ALL  PER-117 Clone 1, PER-117 Clone 2   
  PER-117 Clone 9, PER-117 Clone 10, 
PER-117 Clone 11, PER-117 Clone 12  ✓ 
    
PHENOTYPE  CELL LINE  HOX11 
EXPRESSION 
HUMAN 
ERYTHROLEUKAEMIA 
HEL   
HUMAN CML IN BLAST 
CRISIS. EMBRYONIC 
ERYTHROLEUKAEMIC 
PHENOTYPE 
K562  ✓ 
NORMAL THYMOCYTES  THY6, THY7, THY8, THY9   
T-ALL  PER-487III, PER-427I, JURKAT, MOLT4, 
PER-550, RPMI 8402, PER-117 
 
T-ALL  PER-255, ALL-SIL, MKB-1  ✓ 
 
 
 
 
B. 
TABLE 3.2 THE PANEL OF CELL LINES UTILIZED FOR SCREENING OF PUTATIVE HOX11 
TARGET GENES 
PART A Outlines the phenotype and HOX11 expression status of the J2E, NIH3T3, HEL and 
PER-117 cell line clones produced by transfection with the pEFBOSHOX11 construct. 
 
PART B Outlines the phenotype and HOX11 expression status of a panel of erythroleukaemic 
and T-ALL cell lines, normal thymocytes are also included.  
A.  
GENE P/
N 
CELL LINE COMPARISON 
   J2E  
(HOX11 vs 
non-HOX11) 
NIH3T3 
(HOX11 vs 
non-HOX11) 
HEL  
(HOX11 vs 
non-HOX11) 
PER117 
(HOX11 vs 
non-HOX11) 
(PER-255, ALL-SIL, 
MKB-1) vs non-HOX11 
leukaemic cells  
Leukaemic vs 
Normal Thymocyte 
1) BACKGROUND 
BETA 
HEXOSAMINIDASE 
P  NP  NP NP NP NP  NP 
BMI-1  P  NP  NP NP NP NP  ↑ 
Tumour Rejection 
Antigen GP96 
P  NP  NP NP NP NP  NP 
Zinc Finger ZF67  P  NP  NP NP NP NP  NP 
2) J2E CLONE 3 SPECIFIC 
PROTEINTYROSINE 
PHOSPHATASE NON-
RECEPTOR TYPE 21 
P NP  NP  •  •  •  • 
3) J2E SPECIFIC 
FLJ20329  P  ↑  NP NP NP NP  ↑ 
C-KIT  P  ↑  NP NP NP NP  NP 
4) DIFFERENTIAL IN MORE THAN ONE CELL LINE 
OSTEOPONTIN  P  ↓  NP  •  ↓  •  • 
GUANOSINE 
DIPHOSPHATE 
DISSOCIATION 
INHIBITOR 3 
N  ↑  ↑  NP NP NP  - 
PAG  P  ↑  ↑  ↓  NP NP  ↓ 
TABLE 3.3 SCREENING OF GENE EXPRESSION LEVELS BY NORTHERN BLOT AND RT-PCR ANALYSIS 
P = PCR screening normalized to β-ACTIN expression 
N = Northern Blot densitometric analysis normalized to β-ACTIN expression 
NP = No Pattern (no correlation of gene expression levels with expression levels of HOX11) 
↑ = Increase in gene expression (with expression of HOX11) 
↓ = Decrease in gene expression (with expression of HOX11) 
− = Not undertaken 
• = Not detectable  
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1
3
1FIGURE 3.18 HOX11 EXPRESSION IN LEUKAEMIC CELL LINES
A) The levels of expression of HOX11 were also analyzed by Northern blot analysis. 
10ug of total RNA was hybridized with HOX11 and a β-ACTIN control. Densitometric 
analysis was then performed on autoradiographs. The results of this analysis are 
displayed in graphical form in A, B, C and D. Black bars indicate cell lines which 
express HOX11 and grey bars indicate cell lines which do not express HOX11. The 
corresponding autoradiographs of the HOX11 and  β-ACTIN Northern blots are 
displayed in E, F, G, H and I.
B) The levels of expression of HOX11 measured across a panel of cell lines by semi-
quantitative RT-PCR using EFIAFOR-HOXR4 primers (pEFBOSHOX11). The 
intensity of the resulting bands on an ethidium bromide agarose gel were measured 
in photostimulated luminescence units using a phosphoimager. The values were then 
normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in duplicate 
and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in J, K, L, M and N.  Black bars 
indicate cell lines which express HOX11, grey bars indicate cell lines which do not 
express HOX11 and hatched bars indicate cell lines which express a low level of 
HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding
agarose gels of the HOX11 RT-PCR are displayed in O, P, Q, R and S. An additional 
RT-PCR using HIOQ5-HOX11R4 primers (HOX11) was undertaken for the PER-117 
cell clones and the panel of human erythroleukaemia, normal T-cell and T-cell
leukaemia cell lines.
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HOX11 EXPRESSION IN LEUKAEMIC CELL LINES BY NORTHERN BLOT
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HOX11 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR
S. LEUKAEMIC 
CELL LINES Chapter Three  137
FIGURE 3.19 BETA HEXOSAMINIDASE EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of BETA HEXOSAMINIDASE were measured across a panel of cell 
lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium
bromide agarose gel were measured in photostimulated luminescence units using a
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-
ACTIN were performed in duplicate and an average value was used for normalization.The 
normalized expression levels of one experiment are displayed in graphical form in A, B, C, D 
and E.  Black bars indicate cell lines which express HOX11, grey bars indicate cell lines 
which do not express HOX11 and hatched bars indicate cell lines which express a low level 
of HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding
agarose gels of the BETA HEXOAMINIDASE RT-PCR are displayed in F, G, H, I and J.  A. J2E
B. NIH3T3 
C. HEL
D. PER-117 
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BETA-HEXOSAMINIDASE EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR 
NORMALIZED TO β-ACTINF. J2E
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BETA-HEXOSAMINIDASE EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR FIGURE 3.20 BMI-1 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of BMI-1 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which  express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the   BMI-1 RT-
PCR are displayed in F, G, H, I and J. 
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BMI-1 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR 
J. LEUKAEMIC 
CELL LINESFIGURE 3.21 GP96 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of GP96 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the GP96 RT-
PCR are displayed in F, G, H, I and J.  
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J. LEUKAEMIC 
CELL LINES
GP96 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR FIGURE 3.22 ZF67 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of ZF67 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the ZF67 are 
displayed in F, G, H, I and J.  
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ZF67 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR Chapter Three  149
FIGURE 3.23 TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 21 EXPRESSION IN 
LEUKAEMIC CELL LINES
The levels of expression of TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 21 were 
measured across a panel of cell lines by semi-quantitative RT-PCR. The intensity of the 
resulting bands on an ethidium bromide agarose gel were measured in photostimulated
luminescence units using a phosphoimager. The values were then normalized to a β-ACTIN
control. RT-PCRs for β-ACTIN were performed in duplicate and an average value was used 
for normalization.The normalized expression levels of one experiment are displayed in 
graphical form in A and B.  Black bars indicate cell lines which express HOX11 and grey bars 
indicate cell lines which do not express HOX11. Refer to Section 2.1.2 for the phenotype of 
each cell line. The corresponding agarose gels of the TYROSINE PHOSPHATASE NON-
RECEPTOR TYPE 21 RT-PCR are displayed in C and D.  
TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 21 was found to not be expressed at 
the RT-PCR level in the HEL cell lines, the PER-117 cell lines or the panel of human 
erythroleukaemia, normal T-cell and T-cell leukaemia cell lines. Accordingly, this data is not 
shown. D. NIH3T3 
A. J2E
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TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 21 EXPRESSION IN LEUKAEMIC CELL 
LINES BY RT-PCR NORMALIZED TO β-ACTIN
TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 21 EXPRESSION IN LEUKAEMIC CELL 
LINES BY RT-PCR FIGURE 3.24 FLJ20329 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of FLJ20329 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRS for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the FLJ20329 
and β-ACTIN RT-PCR are displayed in F, G, H, I and J.  
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β-ACTINFIGURE 3.25 C-KIT EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of C-KIT were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B and C. Black bars indicate cell 
lines which express HOX11 and grey bars indicate cell lines which do not express HOX11. 
Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding agarose gels of 
the C-KIT RT-PCR are displayed in D, E, F, G and H. 
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C-KIT EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR FIGURE 3.26 OSTEOPONTIN EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of OSTEOPONTIN were measured across a panel of cell lines by 
semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide
agarose gel were measured in photostimulated luminescence units using a phosphoimager. 
The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were 
performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B and C.  Black 
bars indicate cell lines which express HOX11 and grey bars indicate cell lines which do not 
express HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding
agarose gels of the OSTEOPONTIN RT-PCR are displayed in D, E and F.  OSTEOPONTIN 
was found to not be expressed at the RT-PCR level in the HEL cell lines or the panel of 
human erythroleukaemia, normal T-cell and T-cell leukaemia cell lines. Accordingly, this data 
is not shown. 
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OSTEOPONTIN EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR NORMALIZED 
TO β-ACTIN
OSTEOPONTIN EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR FIGURE 3.27 GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 3 EXPRESSION 
IN LEUKAEMIC CELL LINES
The levels of expression of GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 3
were analyzed by Northern blot analysis. 10ug of total RNA was hybridized with 
GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 3 and a β-ACTIN control. 
Densitometric analysis was then performed on autoradiographs. The results of this analysis 
are displayed in graphical form in A, B, C, D and E. Black bars indicate cell lines which 
express HOX11, grey bars indicate cell lines which do not express HOX11 and hatched bars 
indicate cell lines which express a low level of HOX11. The corresponding autoradiographs of 
the  GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 3 and  β-ACTIN Northern 
blots are displayed in F,G,H,I and J.
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GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 3 EXPRESSION IN 
LEUKAEMIC CELL LINES BY NORTHERN BLOT
J. LEUKAEMIC
CELL LINES FIGURE 3.28 PAG EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of PAG were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRS for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the PAG and β-
ACTIN RT-PCR are displayed in F, G, H, I and J.  
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3.3 DISCUSSION 
HOX11 is a DNA binding transcription factor which has been implicated in playing a vital role 
in splenogenesis (Roberts et al., 1994; Dear et al., 1995). HOX11 expression has been 
detected in adult CD34+ bone marrow stem cells, however to date its expression has not 
been detected in any other normal haematopoietic tissues (Moretti et al., 1994; Hatano et al., 
1991; Yamamato et al., 1995; Kees et al., 2003). Aberrant expression of HOX11 in a 
committed haematopoietic lineage may predispose a cell to neoplastic transformation by 
preventing maturation and/or causing deviation away from a normal maturational pathway. 
In order to investigate this phenomenon, HOX11 was constitutively expressed in the J2E 
erythroleukaemic cell line. This cell line was chosen, as attempts to investigate the effects of 
HOX11 in transgenic mice have proven unsuccessful. Additionally, other T-cell lines which 
have been transfected with HOX11 either demonstrate no phenotypic effect or do not tolerate 
gene expression (Section 3.2.1).. The J2E cell line is amenable to transfection, easily 
cultured and possesses the ability to terminally differentiate (Klinken et al., 1998). In addition, 
this cell line demonstrated a marked change in phenotype upon transfection with HOX11. 
The enforced expression of HOX11 in murine J2E cells resulted in an apparent 
dedifferentiation to a primitive erythroid phenotype (Greene et al., 2002). Differentiation status 
was measured by cell morphology, which was characterized by the generation of cells with 
the morphology of immature erythroblasts. The expression of Nfe2 and Eklf lineage specific 
markers confirmed that the HOX11 transfectants were of an erythroid phenotype. These 
findings were confirmed by further work which found that the transfectants displayed a 
decrease in haemoglobin synthesis even after stimulation with Epo (Greene et al., 2002). In 
addition, the expression of C-Kit, a marker of progenitor and stem cells, which continues 
expression until the basophilic erythroblast stage in the erythroid lineage was found to be 
increased (Greene et al., 2002). A study by Dolzing et al., (2001) on immortalized fetal liver 
erythroid progenitors found that high levels of the C-Kit receptor were present on the cell 
surface which were down-regulated to undetectable levels within 42 hours after induction of 
differentiation with Epo (Dolzing et al., 2001). Accordingly, the increase in C-Kit expression 
seen with HOX11 expression is indicative of an immature erythroid phenotype. Finally, the 
J2E cells ectopically expressing HOX11 were found by cell adhesion assays to be highly 
adherent (Greene et al., 2002). Increased adherence is also indicative of an immature 
phenotype. Early red blood cell development usually occurs through contact with stromal 
cells and fibronectin in the bone marrow. As early precursors develop into reticulocytes which 
are released into the blood stream there is an apparent loss of adherence (Coulombel et al., 
1991; Patel et al., 1984). Chapter Three  166
The ectopic expression of HOX11 in J2E cells resulted in elevated Aldh1a1 gene expression 
in clones 3, 18 and 44. Clone 11 did not follow this expression pattern. This finding may be 
due to clonal variation such that clone 11 expressed lower levels of HOX11 protein. It is 
known that HOX11 can activate or repress Aldh1a1 gene expression depending on the cell 
line, most probably due to the availability of co-factors or co-regulatory molecules and/or 
competition for binding sites within the Aldh1a1 promoter (Greene et al., 1998). The fact that 
Aldh1a1 was found to be up-regulated in three out of four cases is significant given the role 
that Aldh1a1 plays in retinoic acid synthesis, a key regulator of the process of differentiation 
(Purton et al., 1999). In primitive haematopoietic precursor cells expression of high levels of 
ALDH1A1 appears to favour stem cell maintenance and renewal (Purton et al., 2000). 
Taken together, these observations suggest that ecotopic expression of HOX11 in the J2E 
erythroid cell line leads to dedifferentiation. This process of dedifferentiation would suggest 
that HOX11 has the capacity to function at the very early progenitor or stem cell stage in 
haematopoiesis. This theory is supported by previous work which investigated the effects of 
HOX11 on haematopoiesis. Hawley et al., (1994) retrovirally transduced murine bone marrow 
cells with HOX11 and were able to demonstrate a block in the early progenitor stage of 
haematopoietic differentiation (Hawley et al., 1994). This work was continued when 
embryonic stem cells were transduced with HOX11 and these cell lines were C-Kit positive 
and appeared to represent early haematopoietic precursor populations (Keller et al., 1998). 
These findings in conjunction with those outlined in this study support the idea that HOX11 
may function early on in the set of molecular events that eventually direct a cell to 
differentiate toward a committed lineage. It follows that HOX11 expression is then down-
regulated as the cell continues down this maturational pathway. 
In order to investigate the effect that the expression of HOX11 in the J2E cell line has at the 
genetic level and to identify putative HOX11 target genes, RDA was undertaken. Forty-six 
genes whose expression was up-regulated as a result of HOX11 expression in the J2E cell 
line were identified. It is interesting to note that the technique identified 15 clones which 
possess sequences of unknown genes with homology to previously described ESTs (refer to 
Table 3.1). Neither HOX11 nor Aldh1a1 were enriched in this experiment. This indicates that 
gene enrichment is dependent on variables including, hybridization kinetics, the location of 
Rsa I sites within a gene and the G and C content of a gene segment. In the case of HOX11 
in particular, the high G and C content of the gene is known to affect successful PCR 
amplification. Thus, one disadvantage of RDA is that some differentially expressed genes 
may not have been isolated using this technique. 
The population of genes identified by RDA was likely to consist of all genes involved in the 
transcriptional cascade which occurs when HOX11 is expressed in the J2E cell line. Many of Chapter Three  167
the genes identified would be associated with the apparent erythroid `dedifferentiation’. 
These genes would be expected to be at the lower end of the transcriptional cascade and are 
less likely to be HOX11 target genes. Several of the identified genes; Murine Sui1 
Homologue,  Electron Transfer Flavoprotein (ETF),  Thioredoxin,  Nexlin,  Spermidine N1-
Acetyltransferase,  DEAD Box Peptide 3,  Eukaryotic Initiation Factor 5,  Major 
Histocompatability Complex Class I, H3 Histone 3B and tumour rejection antigen GP96 have 
previously been found to be associated with differentiation of erythroid progenitors with Epo 
using cDNA array filters and suppression subtractive hybridization (Gubin et al., 1999; 
Dolznig  et al., 2001). It follows that these genes may be associated with the observed 
phenotypic changes. 
In order to identify putative HOX11 target genes implicated in leukaemogenesis, genes that 
are known to be transcription factors and those previously implicated in cancer were chosen 
for further analysis. The genes BETA-HEXOSAMINIDASE,  BMI-1, putative ring finger 
FLJ20329, tumour rejection antigen GP96, TYROSINE PHOSPHATASE NON-RECEPTOR 
TYPE 21, OSTEOPONTIN, zinc finger ZF67, GUANOSINE DIPHOSPHATE DISSOCIATION 
INHIBITOR 3 and PAG were analyzed. Additionally, in initial experiments the cell surface 
phenotype of the J2E clones transfected with HOX11 were determined by flow cytometry. 
Significantly, the transfectants over expressing HOX11  were characterized by increased 
surface expression of C-Kit (Greene et al., 2002). Although this gene was not identified by 
RDA, it was included in the analysis as being a differentially expressed gene of interest.  
A quantitative Northern blot and semi-quantitative RT-PCR based screening method across a 
panel of leukaemic cell lines was employed. The cell lines included a number of HOX11 and 
non-HOX11 expressing cells of erythroleukaemic, T-cell leukaemic and fibroblast phenotypes 
of both murine and human origin. A putative HOX11 target gene would be expected to 
demonstrate consistently altered expression (either up-regulation or down-regulation) in 
HOX11 expressing cell lines when compared to matched control cell lines. Additionally a 
HOX11 target gene involved in leukaemogenesis would be expected to demonstrate altered 
expression in T-ALL cell lines known to over-express HOX11 (PER-255, ALL-SIL and MKB-1) 
when compared to other T-ALL cell lines known not to express HOX11. 
The screening method had the additional benefit of identifying `background’ genes generated 
by the analysis. The CLONTECH PCR Select Subtraction Kit does not incorporate selective 
degradation and instead relies on subtractive PCR to suppress the amplification of non-
differential products (Diatchenko et al., 1996; Hubank et al., 1994). The disadvantage of this 
technique over traditional RDA is the fact that non-differential transcripts may be cloned and 
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Four categories of genes were established from the screening. The first included background 
genes which appeared to be non-differential in their expression with relation to HOX11. 
Secondly, there were genes which appeared to be differentially up-regulated in J2E clone 3 
only. Genes in either of these two categories were not considered to be of interest and in 
particular, are unlikely to represent HOX11 target genes. Thirdly, there were genes 
consistently differentially up-regulated in all HOX11 positive clones of the J2E cell line. 
Finally, there were genes which were differentially expressed with HOX11 in more than one 
cell line. Genes in the final category are most likely to represent genes whose expression is 
regulated by HOX11. 
OSTEOPONTIN,  GUANOSINE  DIPHOSPHATE DISSOCIATION INHIBITOR 3 and PAG 
were all found to be differentially expressed with HOX11 in more than one cell line. 
OSTEOPONTIN was down-regulated in both the J2E murine erythroid cell line and the PER-
117 T-cell leukaemic line with HOX11 expression. However, the gene was not detected in the 
HOX11 positive leukaemic T-cell lines (PER-255, ALL-SIL and MKB-1) or normal thymocyte 
samples. OSTEOPONTIN is a secreted adhesive glycoprotein that has been associated with 
tumourigenesis and metastasis in several cancers including hepatocellular carcinoma, breast 
cancer, colon cancer, ovarian cancer and prostate carcinoma (Gotoh et al., 2002; Furger et 
al., 2001; Yeatman et al., 2003; Carlinfante et al., 2003; Kim et al., 2002). Elevated 
OSTEOPONTIN expression levels often correlate with increased metastatic potential of 
transformed cells (Denhardt et al., 2003). Whilst the expression profile of OSTEOPONTIN 
suggested that it may be a HOX11 target gene, it appeared that the gene cannot be linked to 
T-cell leukaemogenesis and thus it was not chosen for further analysis. 
Guanosine Diphosphate Dissocation Inhibitor 3 appeared to be up-regulated with the 
expression of HOX11 in the murine erythroid J2E and murine fibroblast NIH3T3 cell lines. 
GUANOSINE DISPHOSPHATE DISSOCATION  INHIBITOR 3 is a ubiquitously expressed 
Ras-related small GTP binding protein, that plays an important role in the regulation of 
vesicle-mediated cellular transport. It modulates the activity of G-proteins of the rab family 
(Sedlacek et al., 1999; Nishimura et al., 1995; Janoueix-Lerosey et al., 1995). This gene is 
thus of some interest as a potential HOX11 target gene, however, there was no clear 
correlation with HOX11 expression in the T-cell leukaemic PER-117 cell line and there 
appeared to be no correlation of gene expression in the HOX11 positive leukaemic T-cell 
lines (PER-255, ALL-SIL and MKB-1) in comparison to HOX11 negative leukaemic cell lines 
(refer to Table 3.3). 
PAG was up-regulated with the expression of HOX11 in the J2E cell line and the murine 
fibroblast NIH3T3 cell line and down-regulated in the HEL human erythroid cell line. Mice 
lacking PAG also known as Perioxiredoxin1 (Prdx1) have a shortened life span due to the Chapter Three  169
development of severe haemolytic anemia and malignant cancers. The haemolytic anemia is 
characterized by an increase in erythrocyte reactive oxygen species leading to haemoglobin 
instability and decreased erythrocyte life span. The malignancies include lymphomas, 
sarcomas and carcinomas and are frequently associated with loss of PAG expression in 
heterozygotes suggesting that PAG is an important tumour suppressor. PAG is an antioxidant 
protein that uses thioredoxin (also identified in the RDA) as an electron donor to scavenge 
peroxide in the cellular response to reactive oxygen species. Loss of PAG increases the 
susceptibility of tissues to cancer, by causing heightened sensitivity to oxidants (Neumann et 
al., 2003). Additionally, PAG has been shown to inhibit the function of c-Abl and c-Myc 
proteins associated with lymphoma and sarcoma respectively (Wen et al., 1997; Mu et al., 
2002). No correlation of PAG gene expression with HOX11 expression, however, was found 
in the PER-117 T-cell clones or the HOX11 positive leukaemic T-cell lines (PER-255, ALL-
SIL and MKB-1). Thus PAG, like GUANOSINE DISSOCIATION  INHIBITOR 3 and 
OSTEOPONTIN may be a HOX11 target gene, but it could not be implicated in T-cell 
leukaemogenesis based on the expression analyses performed and thus was not chosen for 
further analysis. 
Putative Ring Finger Flj20329 and C-Kit were differentially up-regulated only in all HOX11 
positive clones of the J2E cell line. The biological role of Putative Ring Finger FLJ20329 is 
unknown. It is possible that this gene is a HOX11 target that requires a combination of 
cofactors exclusive to the J2E cell line or alternatively it may be a gene involved in the 
HOX11-associated dedifferentiation to a primitive erythroid phenotype. In either case its 
expression profile suggests that the gene does not appear to be relevant to T-cell 
leukaemogenesis. Similarly, C-Kit expression appeared to be up-regulated with HOX11 
expression in the J2E cell line. This was consistent with the results of a flow cytometric 
analysis of C-Kit receptor expression in J2E clones transfected with HOX11, which showed 
consistent up-regulation in all clones analyzed (Greene et al., 2002). Despite these promising 
findings, there appeared to be no correlation of C-KIT expression with HOX11 expression 
within any of the long-term T-cell line models studied using the semi-quantitative RT-PCR 
assay. Nevertheless, C-KIT was considered worthy of further investigation because, a study 
of 18 T-ALL primary patient samples using the same technique suggested a correlation of 
HOX11 expression with C-KIT expression (Greene, D’Souza and Kees, unpublished 
observations).  
C-KIT is a receptor tyrosine kinase that is expressed in early haematopoietic stem cells, 
clonogenic myeloid, erythroid, megakaryocytic and dendritic progenitor cells, pro B and pro T 
cells and mature mast cells (Lyman et al., 1998; Scheijen et al., 2002). Together with its 
ligand SCF, C-KIT plays an important role in the survival and self renewal of haematopoietic 
stem cells (Scheijen et al., 2002). C-KIT is thought to play an important role in the early Chapter Three  170
stages of T lymphoid development. Pro T-cells which have not yet undergone TCR 
rearrangement and are CD4-/CD8-/CD3- express a high level of C-KIT. Additionally, C-KIT 
positive cells derived from the bone marrow and thymus have been shown to differentiate into 
CD4/CD8 double positive T-cells (Tomeczkowski et al., 1998; Godfrey et al., 1994; Matsuzaki 
et al., 1993). 
Increased  C-KIT expression has been linked with T-ALL and T-cell lymphoma. 
Tomeczkowski et al., (1998) detected C-KIT receptors in three out of seven T-lymphoblastic 
cell lines and nine out of twenty-one biopsy tumour preparations from children with T-ALL or 
T-cell lymphoma. A growth stimulatory signal was transduced in three out of eleven C-KIT 
positive T-lymphoblastic cells with the addition of SCF (Tomeczkowski et al., 1998). C-KIT 
expression was also confirmed in three out of five T-ALL cell lines and a SCF proliferative 
effect was observed in one case (Kees et al., 1995). The SCL/LMO complex of transcription 
factors which play an important role in T-ALL has been shown to directly regulate the 
ALDH1A2 and C-KIT genes (Ono et al., 1998; Lecuyer et al., 2002). Similarly, ALDH1A1 is a 
known HOX11 target gene (Greene et al., 1998). It is therefore intriguing that a correlation 
between C-KIT and HOX11 expression has been found since if C-KIT can also be confirmed 
as a HOX11 target gene, a common transcriptional pathway would be implicated in the 
pathogenesis of T-ALL.  
In conclusion, C-KIT plays an important role in haematopoiesis and T-cell development, 
substantial evidence also links its expression to T-ALL. Additionally, the gene has been found 
to be up-regulated with the expression of HOX11 in the J2E and NIH3T3 cell lines and some 
evidence exists in primary patient samples. These findings highlight the need for functional 
assays to be undertaken examining the putative regulation of C-KIT by HOX11. 
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Utilization of cDNA Microarray to Investigate the Dedifferentiation of the 
J2E Erythroid Cell Line by the Ectopic Expression of HOX11 Chapter Four  172
4.1 INTRODUCTION 
The enforced expression of HOX11 in murine J2E cells resulted in an apparent 
dedifferentiation to a primitive erythroid phenotype (Greene et al., 2002). In the previous 
chapter, RDA was applied to the J2E cellular model in order to identify genes whose 
expression was differentially altered as a result of HOX11 expression. It was expected that at 
least some of these genes may be transcriptional targets of HOX11 and a screening 
technique was employed in order to identify putative target genes potentially relevant to T-cell 
leukaemogenesis. RDA employs subtractive hybridization and a suppressive PCR to identify 
differentially expressed genes. The technique does not require dedicated equipment and 
enables the identification of novel genes. Nevertheless, the representative nature of RDA 
means that key genes involved in the HOX11-mediated perturbation of J2E differentiation 
may have been overlooked. The fact that RDA relies on restriction digestion and PCR 
amplification means that many genes may have been excluded from successful amplification. 
Indeed, both HOX11 and Aldh1a1 failed to be enriched in the RDA confirming the inherent 
biases of the procedure. 
In recent years microarray technology has emerged, which currently complements RDA (and 
should eventually eclipse it once a complete panel of genes can be arrayed). cDNA 
microarray technology allows for the systematic screening of a large number of genes in 
parallel. The utility of cDNA microarray technology for the identification of genes involved in 
transcriptional cascades is illustrated in several studies. For example, Ingram et al., (2002) 
successfully used cDNA microarray to identify target genes of Sonic Hedgehog while another 
study by Nesbit et al., (2000) utilized the technology to dissect c-myc apoptotic pathways 
(Ingram et al., 2002; Nesbit et al., 2000). 
It was expected that cDNA microarray technology would complement the RDA already 
undertaken in a two major ways. Firstly, the technology may identify genes not detected by 
the RDA. Secondly, it enables a large number of genes and gene pathways to be examined. 
This is of particular importance as HOX11 may affect the expression of numerous genes, as 
is the case for the T-ALL oncogene MYC (Facchini et al., 1998; Nesbit et al., 2000). 
Moreover, it is likely that a large number of genes are involved in the J2E dedifferentiation 
associated with enforced expression of HOX11. 
In an attempt to understand the molecular basis of HOX11-induced dedifferentiation in J2E 
cells, as well as identify putative HOX11 target genes, cDNA microarray analysis was applied 
to the J2E cellular model. The cDNA microarray technology utilized in this chapter enabled 
screening of 11663 EST and cDNA clones. Individual gene probes had been previously 
produced by PCR amplification from a library of cDNA and ESTs. cDNA microarrays were 
produced by robotically spotting gene probes onto glass microscope slides. The target was Chapter Four  173
prepared by extracting total RNA from respective J2E clones and reverse transcribing it into 
cDNA labeled with fluorescent dyes. The cyanine dyes CY3 and CY5 were incorporated into 
the first strand cDNA. Hybridization was then performed and labeled target molecules 
hybridized to complementary gene probes at a frequency proportional to their relative 
abundance. After washing, the amount of target bound to each probe was quantified by 
scanning with a laser light source. Software was then used to normalize, scale and 
standardize the signal intensities. The ratio of CY3 to CY5 then enables each gene to be 
classified as increased, decreased or no change (Duggan et al., 1999; Deyholos et al., 2001). 
The specific aims of this chapter were firstly, to employ cDNA microarray technology to 
identify genes whose expression was altered as a result of HOX11 expression in J2E cells. 
As a second aim a quantitative Northern blot and a semi-quantitative PCR screening 
technique was to be applied across a panel of HOX11 and non-HOX11 expressing leukaemic 
cell lines in order to identify putative HOX11 target genes potentially relevant to T-cell 
leukaemogenesis. Chapter Four  174
4.2 RESULTS 
4.2.1 Utilization  of  cDNA  Microarray Technology on the J2E 
Erythroid Cell Line to Identify Genes Whose Expression is 
Altered as a Result of Enforced Expression of HOX11 
cDNA microarray analysis was undertaken on total RNA extracted from the J2EHOX11 
positive clone 3 and the J2E control clone 1 (Figure 4.1). The method utilized to undertake 
the cDNA microarray analysis is outlined in section 2.2.2.2. The cDNA microarray experiment 
was completed with total RNA provided by the author by Dr Matthew Callow, Genome 
Sciences Department, Lawrence Berkeley National Laboratory. Dual laser scans of the cDNA 
microarray slides were collected and the spots on the images were assigned grid coordinates 
corresponding to individual probe identities. Pixel intensities for each of the 11663 probes 
were assigned and the background was determined from an area at the edge of each 
individual grid. The CY3/CY5 labeling of the cDNA was performed in both directions in order 
to prevent bias, such that one experiment was performed with J2EHOX11 cDNA labeled with 
CY3 and J2E control cDNA labeled with CY5 and a second experiment was performed with 
J2EHOX11 cDNA labeled with CY5 and J2E control cDNA labeled with CY3. Background 
corrected, normalized, log converted CY3/CY5 intensity ratios were determined for each 
probe and the genes listed in order of most up-regulated with HOX11 expression to least up-
regulated with HOX11 expression.  
The panel of genes identified by cDNA microarray as being up- or down-regulated with 
HOX11 expression is likely to include all genes regulated in the HOX11 transcriptional 
cascade within the J2E cell line, including those at the furtherest end of the cascade. Given 
the marked phenotypic changes observed when HOX11 is introduced into the J2E cell line, it 
is likely that many of the genes identified are further down the HOX11 transcriptional 
hierarchy and do not play  key roles in the pathway of HOX11 induced tumorigenesis. In the 
first instance, therefore, genes known to be transcription factors, those associated with the 
cell cycle and those previously implicated in cancer were prioritized and chosen for further 
analysis. Specifically, nine genes whose expression was up-regulated and six genes whose 
expression was down-regulated in response to HOX11 expression were selected.  It is 
unfortunate that neither Hox11 nor Aldh1a1 probes were included on the cDNA microarray. 
The 15 genes chosen for further analysis together with their signal intensities from the 
microarray data are displayed in Figure 4.2. All were ranked in the top 100 up- or down-
regulated genes, with one, C-Kit, having been identified previously in Chapter Three as a 
differentially expressed gene of interest. Two data sets are shown for C-Kit, Idb2 and Prkg2. 
The background corrected net signal intensities for the experiment where the J2EHOX11 
cDNA is stained with CY5 (green) and the J2E CONTROL cDNA is stained with CY3 (red) Chapter Four  175
and the alternative experiment where J2EHOX11 cDNA is stained with CY3 and the J2E 
CONTROL cDNA is stained with CY5 are graphed adjacently. In all cases the signals 
obtained from the J2EHOX11 cDNA are represented by black bars and J2E CONTROL 
cDNA by white bars. Tables 4.1 and 4.2 outline the known functions of these genes. FIGURE 4.1  cDNA MICROARRAY ANALYSIS OF J2E CELLULAR MODEL 
A. Gel electrophoresis of total RNA extracted from the J2EHOX11 clone 3 (lane 1) and J2E 
control clone 1 (lane 2) using the NP40 Lysis method (refer to Section 2.2.13.2)
B. An example of a panel of a cDNA microarray performed on the J2E cellular model. J2E 
cDNA was labelled with CY3 red fluorescent dye and J2EHOX11 cDNA was labelled with 
CY5 green fluorescent dye. Clones that hybridized most strongly with J2E appear red, while 
those hybridized most strongly with J2EHOX11 appear green. This experiment was 
completed by Dr Matthew Callow, Genome Sciences Department, Lawrence Berkeley 
National Laboratory. 
A.
B.
Lane 1    2
Chapter Four                                                176FIGURE 4.2 cDNA MICROARRAY ANALYSIS OF A J2EHOX11 CELL LINE VERSUS A J2E 
CONTROL CELL LINE
The normalized net signal intensities of the selected genes found to be up-regulated with 
HOX11 expression by  cDNA microarray are shown in panels A and B. The normalized net 
signal intensities of the selected genes found to be down-regulated with HOX11 expression by 
cDNA microarray are shown in panels C and D.  The results obtained where J2EHOX11 cDNA
is stained with CY5 (green) and J2E CONTROL cDNA stained with CY3 (red) are paired with 
the results obtained where J2EHOX11 cDNA is stained with CY3 (red) and J2ECONTROL 
cDNA stained with CY5 (green). Black bars represent, J2EHOX11 positive cDNA and white 
bars J2E CONTROL cDNA. Two probes were included on the cDNA microarray for C-Kit, Idb2 
and Prkg2. The normalized net signal intensities represented in each case are shown in parts 
E and F.
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   J2ECONTROL LABELED RED J2EHOX11 LABELED GREEN  J2ECONTROL LABELED GREEN J2EHOX11 LABELED RED 
NAME ACCESSION  GREEN  GREEN 
BG 
GREEN 
NET 
RED RED  BG  RED 
NET 
GREEN GREEN 
BG 
GREEN 
NET 
RED RED  BG  RED 
NET 
Mouse c-kit mRNA  AI020663 1869 1243 626 950 543 407  2434 2023 411 1360 598 762 
Kit  c-kit  AA739426 1748 1246 502 678 546 132  1916 1804 112 766 529 237 
ESTs, Highly 
similar to Cdc5-like 
protein   AA466838 2057 1285 772 1293 608 685  2368 1964 404 1802 638 1164 
Mus musculus 
Stra13 mRNA, 
complete cds  AA064241 8029 1180 6849 4443 528 3915  6525 1965 4560 9476 582 8894 
Mus musculus 
cGMP 
phosphodiesterase 
(Pde9A*1) mRNA, 
complete cds  AA498410 5456 1239 4217 2293 566 1727  5531 2028 3503 5370 621 4749 
Insulin-like growth 
factor binding 
protein 10 
(Igfbp10)  AA423149 8025 1243 6782 4336 563 3773  3928 1836 2092 5079 562 4517 
Integrin beta 2  AA467489 3238 1243 1995 1779 580 1199  2570 1887 683 2375 608 1767 
CDC-like kinase  AA108933 8119 1226 6893 2808 568 2240  3618 1915 1703 3997 572 3425 
Zinc finger protein 
X linked  AA155377 27798 1325 26473 9737 661 9076  7763 1932 5831 11960 586 11374 
Cell division cycle 
25A  AA008925 4736 1249 3487 1270 574 696  3017 2108 909 4091 660 3431 
GENES UP-REGULATED WITH HOX11 EXPRESSION 
BG= BACKGROUND 
NET VALUES= NORMALIZED SIGNAL INTENSITIES - BACKGROUND 
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   J2ECONTROL LABELED RED J2EHOX11 LABELED GREEN  J2ECONTROL LABELED GREEN J2EHOX11 LABELED RED 
NAME  ACCESSION GREEN GREEN  BG  GREEN 
NET 
RED RED  BG RED 
NET 
GREEN GREEN  BG  GREEN 
NET 
RED RED  BG  RED 
NET 
Prkg2 cyclic 
GMP-dependent 
protein kinase II  AA636342 1973 1145 828 12129 513 11616  16336 1959 14377 1793 569 1224 
Prkg2   Mouse 
cyclic GMP-
dependent 
protein kinase II 
mRNA and 
flanking regions  AA636342 1949 1232 717 16833 613 16220  19413 2012 17401 2031 642 1389 
Idb2  AI607409 1712 1248 464 3501 569 2932  4783 1784 2999 1178 572 606 
Idb2  AI786496 1705 1217 488 3323 580 2743  4717 1871 2846 1171 557 614 
Interferon 
gamma receptor  AA541842 9202 1278 7924 10524 543 9981  14815 1816 12999 8012 527 7485 
Mus musculus 
Ras-binding 
protein SUR-8 
mRNA, complete 
cds   3162 1213 1949 3943 540 3403  5532 1832 3700 1585 529 1056 
Map Kinase 
Phosphatase-1  AA125367 2945 1279 1666 3275 598 2677  6031 2000 4031 3575 654 2921 
Vegfc   Vascular 
endothelial 
growth factor C  AA726944 1545 1145 400 1526 512 1014  3722 1960 1762 988 570 418 
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GENES DOWN-REGULATED WITH HOX11 EXPRESSION 
BG= BACKGROUND 
NET VALUES= NORMALIZED SIGNAL INTENSITIES - BACKGROUND 
F  
 
GENE  MOLECULAR FUNCTION  BIOLOGICAL PROCESS 
C-KIT    Transmembrane receptor protein tyrosine kinase 
activity 
 
  Cell Growth /maintenance 
 Signal  transduction 
  Transmembrane receptor protein tyrosine kinase 
signaling 
 Oncogenesis 
CDC5-LIKE PROTEIN   Transcription  factor   mRNA  splicing   
  Similar to CDC5 a cell cycle positive regulator 
STRA13      Stimulated by retinoic acid 
PDE9A1    cGMP specific phosphodiesterase activity   Signal  transduction 
INSULIN LIKE GROWTH 
FACTOR BINDING 
PROTEIN 10 
    Embryogenesis and morphogenesis 
 Cell  proliferation 
 Angiogenesis 
 Oncogenesis 
INTEGRIN BETA 2    Cell adhesion receptor activity    Integrin mediated signaling pathway 
 Cell  adhesion 
 Immune  response 
CDC-LIKE KINASE    Non-membrane spanning protein tyrosine kinase 
activity 
 Cell  proliferation 
  Regulation of cell cycle 
  Protein tyrosine kinase signaling 
 mRNA  splicing 
ZINC FINGER PROTEIN 
X LINKED 
 Transcription  factor 
 Transcription  co-activator 
  Regulation of Transcription 
CDC25A    Protein tyrosine phosphatase activity    Protein amino acid dephosphorylation 
  Cell cycle regulation, regulation of CDK activity 
 Mitosis 
 Oncogene 
TABLE 4.1 FUNCTION OF GENES UP-REGULATED WITH HOX11 EXPRESSION 
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GENE MOLECULAR  FUNCTION  BIOLOGICAL PROCESS 
CGMP DEPENDENT 
PROTEIN KINASE II 
  Protein serine/threonine kinase activity    Protein amino acid phosphorylation 
 Signal  transduction 
 Cell  cycle 
IDB2   Transcriptional  regulator    Negative regulation cell differentiation 
 Development 
 Oncogenesis 
INTERFERON GAMMA 
RECEPTOR 
 Cytokine  binding 
  Haematopoietin cytokine receptor activity 
 Immune  response 
 Signal  transduction 
  Chronic lymphocytic leukaemia cell survival 
SUR8      RAS protein signal transduction pathway 
  FGF receptor signaling pathway 
MAP KINASE 
PHOSPHATASE 1 
  Protein serine/ threonine phosphastase activity    Protein amino acid dephosphorylation 
 Cell  Cycle 
  Response to oxidative stress 
VEGFC   Growth  factor    Regulation of cell cycle 
 Angiogenesis 
  Lymph gland development 
  Positive regulator of cell proliferation 
 Signal  transduction 
 Oncogenesis 
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4.2.2  Expression of Genes of Interest From the cDNA Microarray in 
a Panel of Leukaemic Cell Lines 
It is important to verify cDNA microarray expression profiles by an independent method in 
order to confirm differential gene expression in the cell line utilized. Additionally, examining 
expression levels in a panel of leukaemic cell lines is a first step towards the identification of 
differentially expressed genes that are potentially relevant to leukaemogenesis. As in Chapter 
Three, a quantitative Northern blot and semi-quantitative RT-PCR based screening method 
was employed for this purpose. The cell lines examined are outlined in Table 3.2 and include 
a number of HOX11 and non-HOX11 expressing cells of erythroleukaemic, T-ALL and 
fibroblast phenotypes of both murine and human origin. As in Chapter Three a set of criteria 
were established based on the behaviour of the HOX11 target gene Aldh1a1 (Section 3.2.9). 
The expression levels of genes of interest were initially analyzed by quantitative Northern blot 
analysis. Autoradiographs were then analyzed using densitometry and values normalized to 
matched  β-ACTIN controls. However, as found for the genes identified by RDA, this 
technique was not sensitive enough to detect the expression of many of the genes. A 
sensitive semi-quantitative RT-PCR based screening technique was therefore applied to all 
genes that could not be detected by Northern blot. Where possible, intron-spanning primers 
were designed in regions known to be homologous between the murine and human forms of 
the gene. The PCR reactions were optimized in order to utilize the linear range of 
amplification. Completed reactions were run on ethidium bromide agarose gels and the 
intensity of the bands produced analyzed using a phosphoimager. Values were normalized to 
matched β-ACTIN controls.  
A summary of the cell line comparisons of gene expression levels for the genes of interest is 
presented in Tables 4.3 and 4.4. The results for C-Kit are not shown since this gene was 
examined in the previous chapter (Figure 3.24 and Table 3.3). Four categories of genes were 
established: 1) Background genes which appear to be non-differential in their expression 2) 
Genes which appeared to be correlated with HOX11 expression in J2EHOX11 clone 3 
comparisons with J2E CONTROL clone only 3) Genes consistently correlated with HOX11 
expression in clones of the J2E cell line 4) Genes whose expression status remains 
uncertain. 
Firstly,  CDC5-LIKE PROTEIN,  STRA13,  IGFBP10,  ZINC FINGER PROTEIN X LINKED, 
CDC25A,  cGMP DEPENDENT PROTEIN KINASE II,  IDB2,  INTERFERON GAMMA 
RECEPTOR and SUR8 all demonstrated no clear correlation of gene expression levels with 
HOX11  expression and thus could not be confirmed as differentially expressed genes 
(Figures 4.3-4.7 and 4.11-4.14). Worthy of note however, in the cases of SUR8 and IGFBP10 Chapter Four  185
there was significant down-regulation which correlated with HOX11 expression in the PER-
117 T-cell line and HEL cell line respectively (Figures 4.5 and 4.14). Whilst these two genes 
strangely could not be confirmed to correlate with HOX11 expression in J2E cells, they 
remain potentially of interest. This is particularly so for SUR8 which also displayed a lower 
level of expression in all of the T-ALL cell lines as compared to the normal thymocyte 
samples (Figure 4.14). Belonging to the second category, INTEGRIN BETA 2 was up-
regulated with HOX11 in comparisons of J2EHOX11 clone 3 with J2E CONTROL clone 1 
only (Figure 4.8). This gene thus appeared to be a clonal artifact within the J2E cell line. 
Interestingly, it also appeared to be up-regulated with HOX11 expression in the HEL cell line 
as well as in HOX11 positive T-ALL cell lines. INTEGRIN BETA 2 is therefore also potentially 
worthy of further investigation. 
In the third category, PDE9A1, CDC-LIKE KINASE and MAP KINASE PHOSPHATASE 1 
(MKP1) are all genes that were differentially expressed in the majority of HOX11 positive 
clones of the J2E cell line, but had no clear correlation of their gene expression with HOX11 
in any of the other leukaemic cell lines examined (Figures 4.9, 4.10 and 4.15). These genes 
may be HOX11 target genes that require a cellular milieu specific to the J2E murine erythroid 
cell line or alternatively they may be more generally associated with the HOX11 
dedifferentiation of the J2E cell line observed in Chapter 3. Intriguingly, however, MKP1 
expression, like SUR8, was lower compared to normal thymocyte samples in all T-ALL cell 
lines examined. Alone in the fourth category, Vascular Endothelial Growth Factor C (VEGFC) 
could not be detected by Northern blot in the J2E or NIH3T3 murine cell lines and attempts to 
amplify this gene by RT-PCR were unsuccessful. However, it was found to be differentially 
expressed in the T-ALL cell line PER-117 as it was down-regulated in the majority of HOX11-
positive PER-117 clones. In addition, it displayed elevated levels in the HOX11 positive 
erythroleukaemic K562 cell line and the ALL-SIL T-ALL cell line (Figure 4.16). Thus, whilst 
VEGFC may be of interest, its expression status is uncertain.  
 
 
 
GENE P/
N 
CELL LINE COMPARISON 
   J2E  
(HOX11 vs 
non-HOX11) 
NIH3T3 
(HOX11 vs 
non-HOX11) 
HEL  
(HOX11 vs 
non-HOX11) 
PER117 
(HOX11 vs 
non-HOX11) 
(PER-255, ALL-SIL, 
MKB-1) vs non-HOX11 
leukaemic cells  
Leukaemic vs Normal 
Thymocyte 
1) UNCONFIRMED 
CDC5-LIKE PROTEIN   P  NP NP NP ↓  NP NP 
STRA13  P  NP NP NP NP NP  NP 
IGFBP10  P NP  NP  ↓  •  NP NP 
ZINC FINGER PROTEIN 
X LINKED 
N  NP NP NP NP NP  - 
CDC25A  N NP  ↑  NP NP NP  NP 
2)J2E CLONE SPECIFIC 
INTEGRIN BETA 2  N NP  •  ↑  NP  ↑  - 
3) J2E SPECIFIC 
PDE9A1  P  ↑  NP  •  NP NP  NP 
CDC-LIKE KINASE  P  ↑  NP NP NP NP  NP 
TABLE 4.3 SCREENING OF GENE EXPRESSION LEVELS BY NORTHERN BLOT AND RT-PCR ANALYSIS FOR GENES UP-REGULATED 
WITH HOX11 EXPRESSION 
P = PCR screening normalized to β-ACTIN expression 
N = Northern blot densitometric analysis normalized to β-ACTIN Expression 
NP = No Pattern (no correlation of gene expression levels with expression levels of HOX11) 
↑ = Increase in gene expression (with expression of HOX11) 
↓ = Decrease in gene expression (with expression of HOX11) 
− = Not undertaken 
• = Not detectable  
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GENE P/
N 
CELL LINE COMPARISON 
   J2E  
(HOX11 vs 
non-HOX11) 
NIH3T3 
(HOX11 vs 
non-HOX11) 
HEL  
(HOX11 vs 
non-HOX11) 
PER117 
(HOX11 vs 
non-HOX11) 
(PER-255, ALL-SIL, 
MKB-1) vs non-HOX11 
leukaemic cells  
Leukaemic vs Normal 
Thymocyte 
1) UNCONFIRMED 
cGMP DEPENDENT 
PROTEIN KINASE II 
N NP  ↑  NP  •  NP - 
IDB2  P  NP NP NP NP NP  NP 
INTERFERON GAMMA 
RECEPTOR 
P  NP NP NP  NP NP  NP 
SUR8  P  NP NP NP ↓  NP  ↓ 
2) J2E SPECIFIC 
MAP KINASE 
PHOSPHATASE 1 
P  ↓  NP  •  •  NP  ↓ 
3) GENES AFFECTED IN THE PER-117 T-CELL LEUKAEMIC LINE 
VEGFC  N  •  •  NP  ↓  NP - 
TABLE 4.4 SCREENING OF GENE EXPRESSION LEVELS BY NORTHERN BLOT AND RT-PCR ANALYSIS FOR GENES DOWN-REGULATED 
WITH HOX11 EXPRESSION 
P = PCR screening normalized to β-ACTIN expression 
N = Northern blot densitometric analysis normalized to β-ACTIN expression 
NP = No Pattern no correlation of gene expression levels with expression levels of HOX11) 
↑ = Increase in gene expression (with expression of HOX11) 
↓ = Decrease in gene expression (with expression of HOX11) 
− = Not undertaken 
• = Not detectable  
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FIGURE 4.3 CDC-5 LIKE PROTEIN EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of CDC-5 LIKE PROTEIN were measured across a panel of cell 
lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium
bromide agarose gel were measured in photostimulated luminescence units using a
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-
ACTIN were performed in duplicate and an average value was used for normalization.The 
normalized expression levels of one experiment  are displayed in graphical form in A, B, C, D 
and E.  Black bars indicate cell lines which express HOX11, grey bars indicate cell lines 
which do not expressing HOX11 and hatched bars indicate cell lines which express a low 
level of HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding
agarose gels of the CDC-5 LIKE PROTEIN RT-PCR are displayed in F, G, H, I and J.  A. J2E
B. NIH3T3 
C. HEL 
D. PER-117
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FIGURE 4.4 STRA13 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of STRA13 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the STRA13 RT-
PCR are displayed in F, G, H, I and J.  A. J2E 
B. NIH3T3
C. HEL 
D. PER-117
E. 
Chapter Four                                                      192
0
0.5
1
1.5
2
2.5
3
12 1 9 3 1 1 1 8 4 4
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
11 1 5
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
145
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
129 1 0 1 1 1 2
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
HEL
K562
THY7
THY8
THY9
PER487III
PER427I
JURKAT
MOLT4
PER550
RPMI
PER117
PER255
ALL-SIL
MKB-1
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
STRA13 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR NORMALIZED TO β-ACTIN
E. LEUKAEMIC
CELL LINES Chapter Four                                                   193
F. J2E
1         2       19      3      11      18     44
STRA13
G. NIH3T3
11    1     5
STRA13
H. HEL
1     4     5
STRA13
I. PER-117 
1         2      9       10      11     12
STRA13
STRA13 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR
K
5
6
2
T
H
Y
7
T
H
Y
8
T
H
Y
9
P
E
R
-
4
8
7
I
I
I
P
E
R
-
4
2
7
I
J
U
R
K
A
T
M
O
L
T
4
P
E
R
-
5
5
0
R
P
M
I
P
E
R
-
1
1
7
P
E
R
-
2
5
5
A
L
L
-
S
I
L
M
K
B
-
1
H
E
L
STRA13
J. LEUKAEMIC 
CELL LINES Chapter Four                                                   194
FIGURE 4.5 IGFBP10 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of IGFBP10 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment  are displayed in graphical form in A, B, C and D.   Black bars indicate cell 
lines which express HOX11 and grey bars indicate cell lines which do not express HOX11. 
Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding agarose gels of 
the IGFBP10 RT-PCR are displayed in E, F, G, H and I.  A. J2E
B. NIH3T3
C. HEL 
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FIGURE 4.6 ZINC FINGER PROTEIN X LINKED  EXPRESSION IN LEUKAEMIC CELL 
LINES
The levels of expression of ZINC FINGER PROTEIN X LINKED were analyzed by Northern 
blot analysis. 10ug of total RNA was hybridized with ZINC FINGER PROTEIN X LINKED and 
a  β-ACTIN control. Densitometric analysis was then performed on autoradiographs. The 
results of this analysis are displayed in graphical form in A,B, C, D and E. Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. The corresponding
autoradiographs of the ZINC FINGER PROTEIN X LINKED and β-ACTIN Northern blots are 
displayed in F,G,H,I and J.A. J2E
B. NIH3T3
C. HEL  
D. PER-117
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FIGURE 4.7 CDC25A EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of CDC25A were analyzed by Northern blot analysis. 10ug of total 
RNA was hybridized with CDC25A and a β-ACTIN control. Densitometric analysis was then 
performed on autoradiographs. The results of this analysis are displayed in graphical form in 
A,B, C, D and E. Black bars indicate cell lines which express HOX11 and grey bars indicate 
cell lines which do not express HOX11. The corresponding autoradiographs of the CDC25A
and β-ACTIN Northern blots are displayed in F,G,H,I and J.A. J2E 
B. NIH3T3
C. HEL 
D. PER-117
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FIGURE 4.8 INTEGRIN BETA 2 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of INTEGRIN BETA 2 were analyzed by Northern blot analysis. 
10ug of total RNA was hybridized with INTEGRIN BETA 2 and a β-ACTIN control.
Densitometric analysis was then performed on autoradiographs. The results of this 
analysis are displayed in graphical form in A,B, C and D. Black bars indicate cell lines 
which express HOX11, grey bars indicate cell lines which are do not express HOX11 and 
hatched bars indicate cell lines which express a low level of HOX11. The corresponding
autoradiographs of the INTEGRIN BETA 2 and β-ACTIN Northern blots are displayed in 
E,F,G,H and I.Chapter Four  204
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FIGURE 4.9 PDE9A1 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of PDE9A1 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A and B.  Black bars indicate cell lines 
which express HOX11 and grey bars indicate cell lines which do not express HOX11. Refer 
to Section 2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the 
PDE9A1 RT-PCR are displayed in C and D. PDE9A1 was found not to be expressed at the 
RT-PCR level in the NIH3T3, HEL and PER117 cell lines. Accordingly, this data is not shown.  A. J2E
B. LEUKAEMIC 
CELL LINES 
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FIGURE 4.10 CDC-LIKE KINASE EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of CDC-LIKE KINASE were measured across a panel of cell lines by 
semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide
agarose gel were measured in photostimulated luminescence units using a phosphoimager. 
The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were 
performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B and C.  Black 
bars indicate cell lines which express HOX11 and grey bars indicate cell lines which do not 
express HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding
agarose gels of the CDC-LIKE KINASE RT-PCR are displayed in D, E, F, G and H.  Chapter Four                                                              209
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FIGURE 4.11 cGMP DEPENDENT PROTEIN KINASE II EXPRESSION IN LEUKAEMIC CELL 
LINES
The levels of expression of cGMP DEPENDENT PROTEIN KINASE II were analyzed across a 
panel of cell lines by Northern blot analysis. 10ug of total RNA was hybridized with cGMP
DEPENDENT PROTEIN KINASE II and a β-ACTIN control. Densitometric analysis was then 
performed on autoradiographs. The results of this analysis are displayed in graphical form in A, B, 
C and D. Black bars indicate cell lines which express HOX11 and grey bars indicate cell lines 
which do not express HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The 
corresponding autoradiographs of the cGMP DEPENDENT PROTEIN KINASE II and β-ACTIN
Northern blots are displayed in E, F, G, H and I.Chapter Four                                                              212
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FIGURE 4.12 IDB2 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of IDB2 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the IDB2 RT-
PCR are displayed in F, G, H, I and J.  A. J2E
B. NIH3T3
C. HEL 
D. PER-117
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FIGURE 4.13 IFNγ RECEPTOR EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of IFNγ RECEPTOR were measured across a panel of cell lines by 
semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide
agarose gel were measured in photostimulated luminescence units using a phosphoimager. 
The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were 
performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B, C, D and E.  
Black bars indicate cell lines which express HOX11, grey bars indicate cell lines which do not 
express HOX11 and hatched bars indicate cell lines which express a low level of HOX11. 
Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding agarose gels of 
the IFNγ RECEPTOR RT-PCR are displayed in F, G, H, I and J.  Chapter Four                                                              218
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FIGURE 4.14 SUR8 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of SUR8 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose
gel were measured in photostimulated luminescence units using a phosphoimager. The 
values were then normalized to a β-ACTIN control. RT-PCRS for β-ACTIN were performed in 
duplicate and an average value was used for normalization.The normalized expression levels 
of one experiment are displayed in graphical form in A, B, C, D and E.  Black bars indicate 
cell lines which express HOX11, grey bars indicate cell lines which do not express HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the SUR8 RT-
PCR are displayed in F, G, H, I and J.  A. J2E 
B. NIH3T3
C. HEL
D. PER-117
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FIGURE 4.15 MAP KINASE PHOSPHATASE 1 EXPRESSION IN LEUKAEMIC CELL 
LINES
The levels of expression of MAP KINASE PHOSPHATASE 1 were measured across a panel 
of cell lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium
bromide agarose gel were measured in photostimulated luminescence units using a
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-
ACTIN were performed in duplicate and an average value was used for normalization.The 
normalized expression levels of one experiment are displayed in graphical form in A, B and 
C.  Black bars indicate cell lines which express HOX11 and grey bars indicate cell lines which 
do not express HOX11. Refer to Section 2.1.2 for the phenotype of each cell line. The 
corresponding agarose gels of the MAP KINASE PHOSPHATASE 1 RT-PCR are displayed 
in D, E, F, G and H.  Chapter Four                                                      224
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FIGURE 4.16 VEGFC EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of VEGFC were analyzed across a panel of cell lines by Northern 
blot analysis. 10ug of total RNA was hybridized with VEGFC and a β-ACTIN control.
Densitometric analysis was then performed on autoradiographs. The results of this analysis 
are displayed in graphical form in A, B and C. Black bars indicate cell lines which express 
HOX11, grey bars indicate cell lines which do not express HOX11 and hatched bars indicate 
cell lines which express a low level of HOX11. Refer to Section 2.1.2 for the phenotype of 
each cell line. The corresponding autoradiographs of the VEGFC and β-ACTIN Northern blots 
are displayed in D, E, F, G and H.Chapter Four                                                227
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4.3 DISCUSSION 
The function of HOX11 as a transcription factor involved in both activation and repression is 
well documented and the domains necessary for HOX11 transactivation have been identified 
(Dear et al., 1993; Masson et al., 1998; Owens et al., 2003). HOX11 has been established as 
a critical gene involved in the genetic cascade controlling the formation of the spleen during 
development (Dear et al., 1995; Roberts et al., 1994; Roberts et al., 1995). The role of 
HOX11 in leukaemogenesis remains enigmatic, but a number of studies have provided 
strong evidence for its role in oncogenesis (Hawley et al., 1994; Hawley et al., 1997; Hough 
et al., 1998, Keller et al., 1998). In order to better describe the role that HOX11 plays in 
normal development and in particular leukaemogenesis, cDNA microarray technology was 
applied to the J2E erythroid cell model in an effort to identify genetic pathways disrupted by 
HOX11. Identification of HOX11 transcriptional targets, in particular, is an important step in 
establishing an understanding of the pathway by which HOX11 exerts its function, particularly 
with relation to oncogenesis. 
cDNA microarray technology potentiates the global investigation of expression patterns and 
thus the identification of a range of putative target genes. The fact that a large number of 
differentially regulated genes was identified by cDNA microarray is consistent with the role of 
HOX11 as a homeodomain protein. Homeodomain proteins are known to be able to act as 
transcriptional regulators of many genes with a range of cofactors (Abate-Shen et al., 2002). 
The idea that HOX11 may affect the expression of numerous genes, is indirectly supported 
by the T-ALL oncogene MYC for which numerous targets have been identified (Facchini et 
al., 1998; Nesbit et al., 2000). The large number differentially expressed genes identified by 
cDNA microarray is likely to consist of all genes involved in the transcriptional cascade which 
occurs when HOX11 is expressed in J2E cells. Many of these genes would be associated 
with the apparent erythroid `dedifferentiation’ and would be more likely to be at the lower end 
of the transcriptional cascade. It is likely that direct target genes and other target genes of 
importance would be positioned at the upper end of such a cascade. For this reason, 
following ranking according to differential expression, a panel of 14 genes known to be 
transcription factors, those associated with cell cycle regulation and those previously 
implicated in cancer were chosen for further analysis.  
In order to independently verify the expression patterns of selected genes identified by cDNA 
microarray a Northern blot and semi-quantitative RT-PCR based screening method across a 
panel of cell lines was employed. The cell lines included a number of HOX11 and non-
HOX11 expressing cells of erythroleukaemic, T-ALL and fibroblast phenotypes of both murine 
and human origin. As outlined in the previous chapter, a putative HOX11 target gene would 
be expected to demonstrate consistently altered expression in HOX11-expressing cell lines Chapter Four  230
when compared to matched control cell lines. Additionally, HOX11 target genes involved in 
leukaemogenesis would likely demonstrate altered expression in T-ALL cell lines (PER-255, 
ALL-SIL and MKB-1) known to over express HOX11 when compared to other T-ALL and 
leukaemic cell lines known not to express HOX11. Genes of general interest to 
leukaemogenesis may display an altered expression in an overall comparison between 
normal thymocytes and leukaemic T-cell lines. 
In the case of several genes, the differential expression identified by cDNA microarray on the 
J2E HOX11 expressing clone 3 and J2E matched control clone 1 could not be confirmed by 
the Northern blot/ semi-quantitative RT-PCR screening. In fact, nine out of fourteen genes 
tested, could not be confirmed as differential in that they showed no clear correlation with 
levels of HOX11 expression by either Northern blot or RT-PCR. It is possible that this finding 
is a result of inaccuracies in the screening technique employed, in particular, the fact that it 
can be difficult to detect small differences with PCR and it is possible that in some cases due 
to differences in specific cDNA concentrations the PCR may have been slightly out of the 
linear range. Alternatively, it has recently been discovered that considerable variability 
between batches of cDNA microarrays with regard to background and sensitivity can pose 
problems regarding reproducibility of experiments. The process of robotic spotting of PCR 
products during the creation of the cDNA microarrays also adds to problems associated with 
reproducibility as can nonspecific hybridization and problems associated with ambiguous 
probe identity (Duggen et al., 1999; Brazma et al., 2001; Ross et al., 2000). A combination of 
these factors might contribute to increased background and false positives associated with 
cDNA microarray technology. It is now commonplace for investigators to repeat cDNA 
microarray experiments independently on three separate occasions or to utilize GeneChip 
technology in order to minimize such variation (Ross et al., 2000; Lipshutz et al., 1999). 
Accordingly, GeneChip technology was incorporated into the present studies as outlined in 
Chapter Five. 
Despite of the shortcomings of cDNA microarray technology, this study identified several 
genes of interest. One gene, INTEGRIN BETA 2, was found to be up-regulated with HOX11 
with respect to J2E CONTROL clone only. Thus, this gene appeared to be a clonal artifact 
within the J2E cell line. The isolation of this type of clonal artifact is not surprising given the 
fact that only two clones of the J2E cell line (J2EHOX11 clone 3 versus J2E CONTROL clone 
1) were examined by cDNA microarray. Nevertheless, this gene is potentially of interest since 
it was found to be up-regulated with HOX11 expression in the human erythroid HEL cell line, 
while amongst the T-ALL cell lines, its expression was highest in those that were HOX11 
positive. It therefore remains a possibility, that this gene, which encodes a cell adhesion 
molecule, may be a HOX11 target gene in at least some cell types. A second gene, SUR8, 
while not being confirmed to be down-regulated by the presence of HOX11 in J2E cells, was Chapter Four  231
found to be down-regulated with HOX11 in PER-117 T-cells. Moreover, all T-ALL cell lines 
examined, displayed a significantly lower level of SUR8 expression than the normal human 
thymocyte specimens. Although the molecular function of SUR8 in not well understood, it is 
involved in the regulation of Ras-mediated signal transduction, and growth receptor signaling 
pathways (Selfors et al., 1998; Sieburth et al., 1998). 
The expression of three genes, namely PDE9A1, CDC-LIKE KINASE and MKP1, were found 
to be altered by the enforced expression of HOX11 in the J2E cell line only. In the case of 
PDE9A1 and CDC-LIKE KINASE there was an apparent up-regulation while MKP1 appeared 
to be down-regulated in the presence of HOX11. There was no clear correlation of their 
expression with HOX11 in any of the other leukaemic cell lines tested (refer to Tables 4.4 and 
4.5). For these genes, the screening process recapitulated the results of the cDNA 
microarrays although the signal for J2EHOX11 positive clone 3 was unexpectedly low in 
some cases. PDE9A1 is involved in the high affinity hydrolysis of cGMP regulators of signal 
transduction pathways that concern activation of guanylyl cyclase activity. Little is known 
about its exact function, however it is highly expressed in immune tissues and T-cells and is 
thought to play a pivotal role in signal transduction (Soderling et al., 1998; Guipponi et al., 
1998; Wang et al., 2003). CDC-like Kinase belongs to a family of dual-specificity kinases 
implicated in the regulation of cellular growth and differentiation and pre-mRNA splicing. 
CDC-like Kinase contains a distinctive LAMMER motif and auto-phosphorylates itself at 
serine, threonine and tyrosine residues. The actual cellular mechanism that regulates cell 
growth, differentiation and development by the Clk/Sty family is not entirely clear. Both 
increased and decreased expression of CDC-like Kinase has been reported in 
erythroleukaemia, embryonal carcinoma and normal T-cells (Tang et al., 2003; Menegay et 
al., 2000). MKP1 possesses intrinsic phosphatase activity and inactivates MAP kinases by 
dephosphorylation of phosphothreonine and phosphotyrosine residues. Its expression plays 
an important role in the human cellular response to environmental stress and also acts as a 
negative regulator of cellular proliferation and differentiation. In this regard, it was intriguing 
that  MKP1 was expressed at a much lower levels in all T-ALL cell lines examined as 
compared to normal human thymocytes. By contrast MKP1 up-regulation has been detected 
in primary human ovarian carcinomas and breast cancer patients. In both cases, MKP1 
expression is thought to play a role in suppressing apoptosis (Denkert et al., 2002; Wang et 
al., 2003). PDE9A1, CDC-LIKE KINASE and MKP1 may be HOX11 target genes specific to 
the J2E cell line or may play a role further down the HOX11 transcriptional cascade in 
association with the observed HOX11-induced phenotypic change. In either case, no 
evidence directly linking these genes with T-cell leukaemogenesis has been reported to date. 
Significantly, C-KIT was found to be up-regulated with the expression of HOX11 in the J2E 
cell line by cDNA microarray analysis. This finding is in accordance with results outlined in Chapter Four  232
the previous chapter and by published findings (Greene et al., 2002). Interestingly, another 
receptor tyrosine kinase was identified in this microarray study, VEGFC expression appeared 
to be down-regulated in three out of four of the PER-117 T-cell leukaemia cell lines with 
HOX11 expression. Its differential expression, however, could not be confirmed in J2E cells 
owing to technical difficulties with RT-PCR. Nevertheless, its expression appeared to be up-
regulated in the HOX11 positive ALL-SIL T-ALL cell line and the K562 erythroleukaemia cell 
line when compared to other HOX11 negative leukaemic cell lines. VEGFC is a platelet 
derived growth factor which functions in angiogenesis and lymphangiogenesis. It is known to 
activate the VEGFR-2 and VEGFR-3 receptors. VEGFC and its receptors have been 
implicated in a wide range of tumours including; gall bladder cancer, lymph node metastasis, 
cervical carcinoma, malignant mesothelioma, breast cancer, colorectal adenocarcinoma and 
thyroid cancer (Nakashima et al., 2003; Ueda et al., 2002; Masood et al., 2003; Tsai et al., 
2003; Witte et al., 2002; Hung et al., 2003). More importantly however, VEGFC has been 
implicated in haematological malignancies (Orpana et al., 2002). Studies have shown that its 
ligand VEGFR-3 is expressed in over one third of human primary acute myeloid leukaemias 
(Fielder et al., 1997). Endothelial cells normally express the VEGFR-3 receptor and produce 
VEGFC in response to pro-inflammatory cytokines such as IL-1 and tumour necrosis factor. It 
is thought that this pathway may also function in tumourigenesis. Once up-regulated, VEGFC 
is then thought to play a role in an angiogenic paracrine loop involving VEGFR-3 which may 
contribute to cancer cell survival and proliferation (Oprana et al., 2002; Dias et al., 2003). 
This pathway may also provide resistance to chemotherapeutic agents as demonstrated by a 
study by Dias et al., 2003 which also linked increased VEGFC expression with increased Bcl-
2 induction and an increased Bcl-2/Bax ratio. Examination of VEGFR-3 null cells and a 
mutant known to only signal through the VEGFR-3 receptor demonstrated that the these 
observations were linked to a pathway involving VEGFC and VEGFR-3 (Dias et al., 2003).  
Other vascular endothelial growth factors have been implicated in acute lymphoblastic 
leukaemia (Perez-Atayde et al., 1997; Pule et al., 2002) thus it is of interest that HOX11 may 
regulate VEGFC in T-ALL. Whilst this study implicates VEGFC as a possible HOX11 target 
gene in a T-ALL cell line, the results are not conclusive. As with C-KIT, a more detailed 
analysis of the functional relationship, if any, of VEGFC with HOX11 is required. 
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5.1 INTRODUCTION 
In the previous two chapters RDA and cDNA microarray technology identified many genes 
which appeared to be differentially expressed in the presence of HOX11. The differential 
expression of a significant proportion of these genes, however, could not be confirmed by 
independent methods such as Northern blot and semi-quantitative RT-PCR. During the 
course of this study, the more reproducible GeneChip technology (Affymetrix) became 
available. GeneChip probe arrays are manufactured using photolithographic methods, such 
that hundreds of thousands of different oligonucleotide probes are synthesized on each array. 
Biotin labeled RNA fragments are hybridized to the probe array which is then stained with a 
streptavidin phycoerythrin conjugate and scanned by a Gene Array scanner. GeneChip 
technology has a number of advantages over other array technologies. Firstly, probe sets 
designated to detect a gene consist of 16-20 probe pairs, each of which spans a different 
section of a gene. Signal intensities of all probe pairs are taken into account when analyzing 
a gene. The use of multiple independent probes greatly improves signal to noise ratios, 
improves the accuracy of RNA quantitation, increases the range of detection, minimizes 
effects due to cross hybridization and drastically reduces the rate of false positives and 
miscalls often seen with cDNA microarray technology (Lipshutz et al., 1999). Further key 
advantages of GeneChip technology include that it requires very little total RNA and each 
sample, including the control, is hybridized on a separate chip. This allows samples to be 
more readily analyzed in a number of permutations. In the case of this study, it facilitated the 
global analysis of gene expression across a range of clones from different cell lines with 
different HOX11 expression status, but identical genetic backgrounds.  
On account of its advantages over other available technologies, GeneChip technology was 
utilized in this study. The strategy of using the J2E system produced some genes that may be 
targets of HOX11, however overall, relatively few genes of interest were identified from the 
RDA and cDNA microarray studies. The use of the J2E cell model may result in the 
identification of many differential genes that are associated with the phenotypic effects 
observed with HOX11 dedifferentiation of the J2E cell line. Most of these genes would be 
expected to be further down the genetic cascade and thus less likely to be direct HOX11 
target genes. It was anticipated that this experiment would complement the RDA and cDNA 
microarray analyses as it was expected to produce fewer false positives. In addition, due to 
the user-friendly nature of GeneChip technology, it could more readily be applied to multiple 
systems in order to facilitate the identification of genes like Aldh1a1 whose expression in 
different cell backgrounds correlates with HOX11 (Greene et al., 1998). Thus it was more 
likely to find bone fide transcriptional targets. Accordingly, this technique was used for the 
analysis of the J2E murine erythroid cell line, the NIH3T3 fibroblast cell line and the PER-117 Chapter Five 
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human leukaemic T-cell lines for global gene expression. The MU11KsubA and the HGU95A 
GeneChips utilized in this analysis represent 11,000 murine genes and EST clusters and 
12,000 human full-length genes respectively.  
It was postulated that further candidate HOX11 target genes could be identified on the basis 
of their expression being consistently altered in response to HOX11 in these cell lines. In this 
study, emphasis was placed on genes up-regulated with the expression of HOX11 across all 
three cell lines. Genes up-regulated in at least two of the three cell lines were also deemed to 
be of interest, as were genes up-regulated with HOX11 expression in the PER-117 T-cell line 
only on the basis that HOX11 is one of the most frequently deregulated genes in T-ALL (Kees 
et al., 2003).  
The specific aims of this chapter were to employ GeneChip technology to identify genes 
which are differentially expressed with HOX11 in the J2E, NIH3T3 and PER-117 cell lines. As 
a second aim a quantitative Northern blot and semi-quantitative RT-PCR screening technique 
was applied across a panel of leukaemic cell lines in order to confirm the GeneChip data. Chapter Five 
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5.2 Results 
5.2.1  Utilization of Affymetrix GeneChip Technology to Identify 
Candidate HOX11 Target Genes 
Microarray technology was employed to assess the global transcriptional profiles of clones 
with different HOX11 expression status, but identical genetic backgrounds. It was postulated 
that HOX11 target genes could be identified on the basis of their expression being 
consistently altered in response to HOX11 in multiple cell lines. Clones of the J2E murine 
erythroid cell line, the NIH3T3 murine fibroblast cell line and the PER-117 human leukaemic 
T-cell line were analyzed using Affymetrix GeneChip technology. 
In the case of the J2E cell line, total RNA from HOX11 positive clone 3 was used to generate 
target cRNA, which was hybridized to the MU11KsubA GeneChip and compared to the 
HOX11 negative clone 1 as a baseline. For the NIH3T3 cell line HOX11 positive clone 5 was 
compared to HOX11 negative clone 11 as a baseline. Finally, for the PER-117 T-cell line total 
RNA from HOX11 positive clones 9 and 11 was used to generate target cRNA, which was 
hybridized to the HGU95A GeneChip and compared to the control clones 1 and 2 as 
baselines. The target generation and Affymetrix microarray experiments for the PER-117 T-
cell lines were undertaken by Dr Katrin Hoffmann. In the case of the PER-117 cell line, the 
analysis of two HOX11 positive clones and two control clones allowed a four way cross 
comparison to be undertaken. Two comparisons were undertaken in each case such that 
PER-117 clone 9 was compared to control clones 1 and 2 and in a separate analysis PER-
117 clone 11 was compared to control clones 1 and 2 (Table 5.1).  
In order to identify genes up-regulated with HOX11 expression across all three cell lines, a 
list of genes up-regulated when HOX11 positive clones were compared to matched control 
clones was compiled for each cell line using Affymetrix Microarray Suite 5.0 software. In the 
case of the PER-117 cell line, two lists were complied one comparing HOX11 positive clone 9 
to control clones 1 and 2 and another comparing HOX11 positive clone 11 to control clones 1 
and 2, these lists were complied in collaboration with Dr Katrin Hoffmann. The signal log 
ratios and gene identities of the top 50 up-regulated genes in each case are shown in 
Appendices 4, 5, 6 and 7. Separate analysis was undertaken in order to identify genes up-
regulated with HOX11 expression in both the J2E and NIH3T3 cell lines. Due to the fact that 
both murine and human cell lines were compared, Locus Link (www.ncbi.nlm.nih.gov) was 
used to identify human homologues for genes identified as being up-regulated with HOX11 
expression in the J2E and NIH3T3 murine cell lines. All lists were then searched for 
corresponding gene matches. Accordingly, whilst high signal log ratios indicating fold 
increase in expression were deemed to be of importance, for this particular study whether or Chapter Five 
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not a gene was up-regulated across the panel of cell lines, was the main indicator used in the 
identification of genes of interest (Figure 5.1). Positive 5
Control 11 Mouse NIH3T3
Positive 3
Control 1 Mouse J2E
Positive 9, 11
Control 1, 2 Human PER-117
HOX11 Status Clone Species Cell Line
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TABLE 5.1 CELL LINES USED FOR AFFYMETRIX GENECHIP ANALYSIS
Several HOX11 expressing clones and control clones of the J2E murine erythroid cell line, 
the NIH3T3 murine fibroblast cell line and the PER117 human T-cell leukaemia cell line were 
chosen for gene chip analysis. FIGURE 5.1 UTILIZATION OF AFFYMETRIX GENECHIP TECHNOLOGY TO IDENTIFY 
PUTATIVE HOX11 TARGET GENES
A list of the genes up-regulated with HOX11 expression in the J2E murine erythroid cell line, 
the NIH3T3 murine fibroblast cell line and the PER-117 human T-cell leukaemia cell line was 
complied using Affymetrix Microarray Suite 5.0 software. The program Locus Link 
(www.ncbi.nlm.nih.gov) was used to identify human homologues for genes identified in the 
J2E and NIH3T3 cell lines. A list of genes commonly up-regulated with HOX11 expression in 
all three cell lines was then complied.
Chapter Five                                                              239Identification of differentially expressed genes in the PER-117 human T-
cell leukaemia cell line, the J2E murine erythroid cell line and the 
NIH3T3 murine fibroblast cell line using Affymetrix Microarray Suite 5.0 
Software
Locus Link used to identify human-murine
homologues (top 50 genes in each case)
Common genes up-regulated with HOX11
expression  in both murine and human cell 
lines
J2E genes up-
regulated with HOX11
expression
(MU11KSUBA GENECHIP)
NIH3T3 genes up-
regulated with HOX11
expression    
(MU11KSUBA GENECHIP)
PER-117 up-
regulated with HOX11 
expression
(HGU95A GENE CHIP)
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5.2.2  Optimization of the Affymetrix GeneChip Technology Protocol 
An overview of the steps involved in the Affymetrix GeneChip protocol is presented in Figure 
5.2. Briefly, total RNA extracted from the cell clone of interest was converted to single 
stranded cDNA using a T7-(dT24) primer. In vitro transcription of biotin labeled cRNA using 
double stranded cDNA as a template was then undertaken. The cRNA was fragmented and 
mixed with a cocktail of hybridization controls Oligo B2, bioB, bioC, bioD and cre. This target 
was then hybridized to the GeneChip. Following hybridization the GeneChip is washed and 
stained with a streptavidin phycoerythrin solution and an antibody solution and scanned. 
Initially, the NP40 lysis total RNA extraction method was employed (refer to Section 2.2.13 for 
further details). However, this method lead to low cRNA yields (Figure 5.2 part A), despite 
appearing intact by standard gel electrophoresis. Agilent Bioanalyzer analysis demonstrated 
low [28S/18S] rRNA ratios and gel analysis indicated poor quality total RNA as indicated by 
the multiple peaks (Figure 5.2 part B). The TRIZOL total RNA extraction method was then 
employed (refer to Section 2.2.13). The utilization of this method greatly increased cRNA 
yields and [28S/18S] rRNA ratios, which should ideally be 2.0. Additionally, gel analysis 
indicated good quality RNA with strong 18S and 28S peaks (Figure 5.2 part A, B). 
Accordingly, this technique was utilized for all GeneChip analyses. Prior to target preparation 
fragmented cRNA was electrophoresed in order to ensure the distribution of RNA fragment 
sizes from 35 to 200 bases and to confirm a final cRNA concentration of 0.5ug/ul to 2ug/ul. 
An example is shown in Figure 5.3. 
A number of parameters were utilized as quality control guidelines in order to ensure that the 
Affymetrix GeneChip analyses were successful. Firstly, hybridization control bioB  was 
required to be deemed present at least 50% of the time while hybridization controls bioC, 
bioD and cre needed to be confirmed present with increasing signal values reflecting their 
relative spike concentrations. Secondly, Oligo B2 which also served as a hybridization 
control, was checked to ensure labeling of cells at the edges of the array which indicated 
consistent hybridization intensities across the array. Thirdly, the Scaling Factor, Noise, 
Background and Percentage Present values (refer to Figure 5.4) were all confirmed to be in 
accordance with the guidelines and showed minor variation between arrays which is essential 
when undertaking a multiple array comparison. Finally, the ratio of the 3’ to the 5’ probe sets 
for GAPDH and β-ACTIN varied from 0 to 1.5 and were always less than 3, indicating equal 
and efficient labeling of transcripts. Each microarray experiment was only undertaken once. A 
study undertaken by a collaborator using the same protocol and reagents as those used in 
this study demonstrated that replicates revealed an excellent overall correlation with on 
average only 0.04% of all probe sets showing a fold-change >2 between replicate 
experiments (Hoffmann et al., manuscript submitted). A.
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FIGURE 5.2 OPTIMIZATION OF RNA ISOLATION FOR AFFYMETRIX GENECHIP
ANALYSIS 
The cRNA yields and rRNA Agilent Bioanalyzer ratios of total RNA extracted from cell lines 
using the NP40 Lysis Method and the TRIZOL Method are outlined in part A. Refer to Section 
2.2.13 for detailed methods. The Agilent Bioanalyzer analysis for total RNA extracted from 
the J2E control Clone 1 cell line using both methods is shown in part B.
1.89-2.13 1.23-1.82 AGILENT 
BIOANALYZER
rRNA ratio [28S/18S]
26-79ug total 4-14ug total cRNA YIELDS
TRIZOL METHOD NP40 LYSIS 
METHOD
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FIGURE 5.3 ANALYSIS OF cRNA SAMPLES FOR INTEGRITY BY GEL ELECTROPHORESIS
Lane 1 1KB Ladder 250ng
Lane 2 100bp Ladder 250ng
Lane 3 cRNA J2EHOX11 clone 3
Lane 4 Fragmented cRNA J2EHOX11 clone 3FIGURE 5.4 QUALITY GUIDELINES FOR AFFYMETRIX GENECHIP ANALYSIS
Parameters utilized for Affymetrix GeneChip Analysis. All parameters were calculated by 
GeneChip software.
Noise is a measure of small variations in the digitized signal observed by the scanner.
The Scaling Factor is used to normalize a GeneChip’s average intensity to a set target intensity
Background is a measurement of the signal intensity by autofluorescence of the array surface 
and nonspecific binding
3’/5’ β-Actin and 3’/5’ GAPDH are ratios of the signal values of  3’ probe sets to the signal values 
of  the  5’ probe sets for these internal control genes. A high 3’ to 5’ ratio indicates degraded RNA 
or insufficient transcription.
Percentage Present represents the number of probe sets called `present’ relative to the total 
number of probe sets on the array. Low values indicate poor target quality.
30-50 Percentage Present
≤3 3’/5’ GAPDH
≤3 3’/5’ β-Actin
≤70 Background
≤20 Scaling Factor
1.5-3.0 Noise
Value Parameter
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5.2.3  Genes Up-Regulated With HOX11 Expression By GeneChip 
Analysis 
Following the successful GeneChip hybrdization of clones from all three cell lines, a 
comparison analysis was undertaken using Affymetrix Microarray Suite 5.0 software. Arrays 
were normalized to a panel of housekeeping genes (β-ACTIN, GAPDH, 18SRNA, pyruvate 
carboxylase, transferrin receptor) and expression profiles of each HOX11 expressing clone 
were compared to the expression profile of each control clone using the latter as a baseline. 
Following this analysis we focused on genes showing an increase in expression with a Signal 
Log Ratio cut off of 1 for cell lines analyzed with the human HGU95A GeneChip. In the case 
of cell lines analyzed with the murine MU11KsubA GeneChip, we focused on genes showing 
an increase in expression with a Signal Log Ratio cut off of 0.5. These parameters were 
employed in order to account for intrinsic differences between the human and murine 
GeneChips. A Hox11 probe was not present on the murine MU11KsubA GeneChip, but in the 
case of the human HGU95A GeneChip HOX11 was detected as the human G-CSF non-
coding region associated with the pEFBOSHOX11 vector. Signal Log Ratios varied from 2.8 
to 5.8 when PER-117 HOX11 positive cell lines were compared to control clones. 
This analysis provided a list of the 50 genes most up-regulated with HOX11 expression in the 
J2E cell line (Table 4, Appendix 4). This result allowed the comparison of genes found to be 
up-regulated by RDA, cDNA microarray and Affymetrix GeneChip technologies. Somewhat 
surprisingly, the GeneChip analysis failed to identify any of the genes analyzed in Chapter 
Three from the RDA or Chapter Four from the cDNA microarray. This finding may be due to 
intrinsic differences between the technologies, or alternatively, differences in data analysis 
techniques. The aim of this chapter was also to examine other cellular models, in order to 
overcome the restriction of examining the J2E system in isolation. Overall, this enabled the 
identification of genes up-regulated with the expression of HOX11  in all three cell lines. 
Additionally, a list of genes up-regulated with HOX11 expression in both the murine NIH3T3 
and J2E cell lines was compiled (Tables 4 and 5 of Appendices 4 and 5 respectively show 
raw Affymetrix data used for the analysis). This strategy increased the likelihood of the 
identification of candidate HOX11 target genes, as it seems highly unlikely that a gene’s 
expression would be altered in two or three cell lines as a result of a random events. Finally, 
genes up-regulated with HOX11 expression in the PER-117 T-cell line only were also 
identified (Tables 6 and 7 of Appendices 6 and 7 respectively show raw Affymetrix data used 
for the analysis). This category of genes was considered of importance as HOX11 is one of 
the most frequently deregulated genes in T-ALL (Kees et al., 2003). The PER-117 cellular 
model provided a T-lymphocyte cellular milieu, which could facilitate the identification of 
candidate HOX11 target genes relevant to T-ALL. Chapter Five 
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Once again the panel of genes identified as being up-regulated with HOX11 expression by 
GeneChip analysis was likely to include all genes regulated in the HOX11 transcriptional 
cascade, including those at the furtherest end of the cascade. In order to focus on putative 
HOX11 target genes involved in the early stages of the HOX11 transcriptional cascade, 
genes known to be transcription factors, those associated with the cell cycle and those 
previously implicated in carcinogenesis were chosen for further analysis (Figure 5.5). The 
molecular function and biological processes of the genes of interest identified in this analysis 
are outlined in Table 5.2. FIGURE 5.5 GENES UP-REGULATED WITH HOX11 EXPRESSION BY AFFYMETRIX 
GENECHIP ANALYSIS
Genes up-regulated with the expression of HOX11 in both the NIH3T3 murine fibroblast cell 
line and the J2E murine erythroid cell line are shown in part A. Genes up-regulated with 
HOX11 expression in the NIH3T3 murine fibroblast cell line, the J2E murine erythroid cell line 
and the PER-117 human T-cell leukaemia cell line are shown in part B. Finally genes up-
regulated with the expression of HOX11 in the PER-117 human T-ALL cell line only are 
shown in part C. Signal Log Ratio estimates the magnitude of change of a transcript when 
the HOX11 expressing clone was compared to the control clone as a baseline. It is calculated 
by comparing each probe pair on the experimental array to the corresponding probe pair on 
the baseline array. A log scale to the base 2 is used, such that a signal log ratio of 1.0 
indicates an increase in the level of transcript by 2 fold. Dashes indicate cases where the 
gene was not included in the list of top 50 genes up-regulated with the expression of HOX11, 
but which were still classified as showing increased expression, due up-regulation in other 
cell lines.
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1.1 0.9 Hepatoma Transmembrane Kinase
J2E NIH3T3 GENE
SIGNAL LOG RATIO
GENES UP-REGULATED WITH HOX11 EXPRESSION IN BOTH MURINE 
(NIH3T3, J2E) CELL LINES
A.
0.6
-
1.1
NIH3T3
1.8
2.9
1.8
J2E
-
2.8
-
117-9 
vs
117-1
-
1.7
-
117-9 
vs 
117-2
2.8 3.4 Human Tumour Antigen (L6)
- - Nel-like 2
2.1 2.2 Dihydrodiol Dehydrogenase
117-11 
vs 
117-2
117-11 
vs 
117-1
GENE
SIGNAL LOG RATIO
B.
GENES UP-REGULATED WITH HOX11 EXPRESSION IN BOTH MURINE 
(NIH3T3, J2E) AND HUMAN (PER-117) CELL LINES
2.4
5.2
4
117-9 
vs       
117-1
1.9
3.5
2.8
117-9 
vs    
117-2
3 3.2 SMARCD3
- - NFKB2
- - NOR1
117-11 
vs    
117-2
117-11 
vs    
117-1
GENE
SIGNAL LOG RATIO
GENES UP-REGULATED WITH HOX11 EXPRESSION IN THE PER-117 
CELL LINE
C.
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GENE  MOLECULAR FUNCTION  BIOLOGICAL PROCESS 
HEPATOMA TRANSMEMBRANE KINASE   Receptor  tyrosine  kinase   Development 
  Receptor tyrosine kinase signal 
transduction 
 Angiogenesis 
  Megakaryocytic and erythroid 
differentiation 
GROWTH ARREST SPECIFIC FACTOR 3   Membrane  protein    Negative regulation of cell proliferation 
  Cell cycle arrest 
 Peripheral  nervous  system 
development 
DIHYDRODIOL DEHYDROGENASE   Oxidoreductase      Electron transport activity 
  Catalyzes the oxidation of 
transdihydrodiols 
NEL-LIKE 2      Cell growth  
 Differentiation 
 Cell  adhesion 
HUMAN TUMOUR ANTIGEN (L6)    Cell surface protein of the 
transmembrane 4 family 
 Cell  development 
 Cell  growth 
 Motility 
  Highly expressed in carcinomas 
NOR1    Steroid hormone receptor 
  Thyroid hormone receptor 
 Transcription  factor 
  Regulation of transcription 
  Cell growth and maintenance 
 Oncogenesis 
NFKB2   Transcriptional  coactivator 
 Transcription  factor 
  Regulation of transcription 
  Cell growth and maintenance 
 Oncogenesis 
 Apoptosis 
SMARCD3   Transcriptional  coactivator   Chromatin  remodeling 
  Regulation of transcription 
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5.2.4 Screening  of  Genes  From  the GeneChip Analysis Across a 
Panel of Cell Lines. The Correlation of Patterns of Gene 
Expression with HOX11 Expression 
In order to verify Affymetrix GeneChip expression profiles by an independent method, a semi-
quantitative RT-PCR based screening method similar to that utilized in Chapters Three and 
Four was used. The cell lines include a number of HOX11 and non-HOX11 expressing cells 
of erythroleukaemic, T-ALL and fibroblast cell types of both murine and human origin (refer to 
Table 3.2). All total RNA for screening experiments was isolated using the TRIZOL total RNA 
extraction method referred to in Section 5.2.2 and Section 2.2.13. 
Where possible, intron-spanning primers were designed in regions known to be homologous 
between the murine and human forms of the gene. All RT-PCR reactions were optimized 
within the linear range of amplification. Reactions were run on ethidium bromide agarose gels 
and the intensity of the bands produced quantitated densitometrically using a 
phosphoimager. Values were normalized to matched β-ACTIN controls. Genes were 
analyzed by RT-PCR analysis only and not by Northern blot analysis due to the sensitivity of 
GeneChip technology. 
Genes identified as being up-regulated with HOX11 expression in both the NIH3T3 and J2E 
murine cell lines were screened across murine and human cell lines, while genes up-
regulated with HOX11 expression in all three human and murine cell lines were screened by 
RT-PCR using human primers across human cell lines only. In the case of genes up-
regulated with HOX11 expression in the PER-117 cell line only, genes were screened by 
semi-quantitative RT-PCR analysis by collaborator Dr Katrin Hoffmann, Division of Childrens’ 
Leukaemia and Cancer Research, Institute for Child Health Research. As a consequence 
these genes were screened using a smaller panel of HOX11 and non-HOX11 expressing cell 
lines. In this case putative HOX11 target genes would be expected to demonstrate 
consistently altered expression in PER-117 cell clones when compared to matched control 
clones. HOX11 target genes potentially involved in leukaemogenesis might be expected to 
demonstrate altered expression in the PER-255 HOX11 positive T-ALL cell line compared to 
the PER-117 non-HOX11  expressing leukaemic cell line and also in the K562 
erythroleukaemic cell line known to express HOX11. 
The results of the RT-PCR screening of the various cell lines is summarized in Table 5.3 and 
shown in Figures 5.6 to 5.13. Five of the eight genes examined, namely HEPATOMA 
TRANSMEMBRANE KINASE,  NEL-LIKE 2,  HUMAN TUMOUR ANTIGEN (L6), 
DIHYDRODIOL DEHYDROGENASE and NFKB2, could not be confirmed as being 
differential as their expression either showed no correlation with HOX11 expression levels or Chapter Five 
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did so in only one cell line screened (Table 5.3 and Figures 5.6, 5.8, 5.9, 5.10 and 5.12). One 
gene demonstrated differential regulation in two of the cell lines, namely GROWTH ARREST 
SPECIFIC FACTOR 3 (GAS3), which was up-regulated with HOX11 expression in the 
NIH3T3, cell line and down-regulated with its expression in the HEL cell line (Figure 5.7). 
Additionally, if the low level of HOX11 expression exhibited by PER-117 clone 2 is taken into 
account, GAS3 also appeared to be down-regulated in PER-117 T-cells. The remaining two 
genes, NOR1 and SMARCD3 appeared to be up-regulated with HOX11 expression in the 
PER-117 leukaemic T-cell line and exhibited increased expression in the PER-255 T-cell line 
(HOX11 positive) as compared to the PER-117 cell line. Additionally. these genes were 
relatively highly expressed in the HOX11 positive K562 erythroleukaemic cell line (Figures 
5.11 and 5.13). 
  
GENE P  CELL  LINE  COMPARISON 
   J2E  
(HOX11 vs 
non-HOX11) 
NIH3T3 
(HOX11 vs 
non-HOX11) 
HEL  
(HOX11 vs 
non-HOX11) 
PER-117 
(HOX11 vs 
non-HOX11) 
(K562, PER-255, ALL-
SIL) vs non-HOX11 
leukaemic cells  
HEPATOMA 
TRANSMEMBRANE 
KINASE 
P NP  ↑  NP NP NP 
GROWTH ARREST 
SPECIFIC FACTOR 3 
P NP  ↑  ↓  ↓  NP 
DIHYDRODIOL 
DEHYDROGENASE 
P  -  -  ↓  NP NP 
NEL-LIKE 2  P  -  -  •  NP NP 
HUMAN TUMOUR 
ANTIGEN (L6) 
P  - - NP  ↓  NP 
NOR1  P  -  - - ↑  ↑ 
NFKB2  P -  -  -  NP NP 
SMARCD3  P  -  - - ↑  ↑ 
TABLE 5.3 SCREENING OF GENE EXPRESSION LEVELS BY RT-PCR OF GENES UP-REGULATED WITH HOX11 EXPRESSION 
P = PCR screening normalized to β-ACTIN expression 
N = Northern blot densitometric analysis normalized to β-ACTIN Expression 
NP = No pattern (no correlation of gene expression levels with expression levels of HOX11) 
↑ = Increase in gene expression (with expression of HOX11) 
↓ = Decrease in gene expression (with expression of HOX11) 
− = Not undertaken 
• = Not detectable  
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 FIGURE 5.6 HEPATOMA TRANSMEMBRANE KINASE EXPRESSION IN LEUKAEMIC CELL 
LINES
The levels of expression of HEPATOMA TRANSMEMBRANE KINASE were measured across a 
panel of cell lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an
ethidium bromide agarose gel were measured in photostimulated luminescence units using a
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN
were performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B, C, D and E.  Black 
bars indicate cell lines which express HOX11, grey bars indicate cell lines which do not express 
HOX11 and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the HEPATOMA 
TRANSMEMBRANE KINASE RT-PCR are displayed in F, G, H, I and J.  
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HEPATOMA TRANSMEMBRANE KINASE EXPRESSION IN LEUKAEMIC CELL LINES BY 
RT-PCR NORMALIZED TO β-ACTINF. J2E
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J. LEUKAEMIC 
CELL LINES FIGURE 5.7 GROWTH ARREST SPECIFIC FACTOR 3 EXPRESSION IN LEUKAEMIC CELL 
LINES
The levels of expression of GROWTH ARREST SPECIFIC FACTOR 3 were measured across a 
panel of cell lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an 
ethidium bromide agarose gel were measured in photostimulated luminescence units using a 
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN
were performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B, C, D and E.  Black 
bars indicate cell lines which express HOX11, grey bars indicate cell lines which are classified do 
not express HOX11 and hatched bars indicate cell lines which express a low level of HOX11. 
Refer to Section 2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the 
GROWTH ARREST SPECIFIC FACTOR 3 RT-PCR are displayed in F, G, H, I and J.  
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J. LEUKAEMIC 
CELL LINES FIGURE 5.8 DIHYDRODIOL DEHYDROGENASE EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of DIHYDRODIOL DEHYDROGENASE were measured across a panel 
of cell lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium 
bromide agarose gel were measured in photostimulated luminescence units using a 
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN
were performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B, C.  Black bars 
indicate cell lines which express HOX11, grey bars indicate cell lines which do not express 
HOX11 and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the DIHYDRODIOL 
DEHYDROGENASE RT-PCR are displayed in D,E and F.  
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F. LEUKAEMIC 
CELL LINES FIGURE 5.9 NEL-LIKE 2 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of NEL-LIKE 2 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose gel 
were measured in photostimulated luminescence units using a phosphoimager. The values were 
then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in duplicate and an 
average value was used for normalization.The normalized expression levels of one experiment 
are displayed in graphical form in A and B.  Black bars indicate cell lines which express HOX11
and grey bars indicate cell lines which do not express HOX11. Refer to Section 2.1.2 for the 
phenotype of each cell line. The corresponding agarose gels of the NEL-LIKE 2 RT-PCR are 
displayed in C,D and E.  
Chapter Five                                                              262Chapter Five                                                              263
A. PER-117
B. LEUKAEMIC 
CELL LINES 
0
1
2
3
4
5
6
129 1 0 1 1 1 2
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
20
40
60
80
100
120
HEL
K562
PER487III
PER427I
JURKAT
MOLT4
PER550
PER117
PER255
ALL-SIL
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
NEL-LIKE 2 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR NORMALIZED 
TO β-ACTINChapter Five                                                              264
C. HEL
1       4     5
NEL-LIKE 2
D. PER-117
1         2        9       10      11     12
NEL-LIKE 2
K
5
6
2
P
E
R
-
4
8
7
I
I
I
P
E
R
-
4
2
7
I
J
U
R
K
A
T
M
O
L
T
4
P
E
R
-
5
5
0
P
E
R
-
1
1
7
P
E
R
-
2
5
5
A
L
L
-
S
I
L
H
E
L
NEL-LIKE 2 E. LEUKAEMIC 
CELL LINES 
NEL-LIKE 2 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCRFIGURE 5.10 HUMAN TUMOUR ANTIGEN L6 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of HUMAN TUMOUR ANTIGEN L6 were measured across a panel of 
cell lines by semi-quantitative RT-PCR. The intensity of the resulting bands on an ethidium 
bromide agarose gel were measured in photostimulated luminescence units using a 
phosphoimager. The values were then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN
were performed in duplicate and an average value was used for normalization.The normalized 
expression levels of one experiment are displayed in graphical form in A, B, C.  Black bars 
indicate cell lines which express HOX11, grey bars indicate cell lines which do not express 
HOX11 and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 
2.1.2 for the phenotype of each cell line. The corresponding agarose gels of the HUMAN 
TUMOUR ANTIGEN L6 RT-PCR are displayed in D,E and F.  
Chapter Five                                                    265A. HEL
B. PER-117
Chapter Five                                                     266
0
0.05
0.1
0.15
0.2
0.25
145
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.02
0.04
0.06
0.08
0.1
0.12
1 2 9 10 11 12
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
0
0.2
0.4
0.6
0.8
1
1.2
1.4
HEL
K562
PER487III
PER427I
JURKAT
MOLT4
PER550
PER117
PER255
ALL-SIL
P
h
o
t
o
s
t
i
m
u
l
a
t
e
d
 
L
u
m
i
n
e
s
c
e
n
c
e
 
U
n
i
t
s
C. LEUKAEMIC
CELL LINES 
HUMAN TUMOUR ANTIGEN L6 EXPRESSION IN LEUKAEMIC CELL LINES BY RT-PCR 
NORMALIZED TO β-ACTINChapter Five                                                    267
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F. LEUKAEMIC
CELL LINES 
HUMAN TUMOUR ANTIGEN L6 EXPRESSION IN LEUKAEMIC CELL LINES BY 
RT-PCRFIGURE 5.11 NOR1 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of NOR1 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose gel 
were measured in photostimulated luminescence units using a phosphoimager. The values were 
then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in duplicate and an 
average value was used for normalization.The normalized expression levels of one experiment  
are displayed in graphical form in A.  Black bars indicate cell lines which express HOX11 and 
grey bars indicate cell lines which do not express HOX11. Refer to Section 2.1.2 for the 
phenotype of each cell line. RNA preparation, primer design and RT-PCR experiments were 
undertaken by Dr Katrin Hoffmann and Jette Ford, Division of Childrens’ Leukaemia and Cancer 
Research, Institute for Child Health Research.  
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A. NOR1 EXPRESSION IN LEUKAEMIC CELL LINES NORMALIZED TO β-ACTINFIGURE 5.12 NFKB2 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of NFKB2 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose gel 
were measured in photostimulated luminescence units using a phosphoimager. The values were 
then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in duplicate and an 
average value was used for normalization.The normalized expression levels of one experiment 
are displayed in graphical form in A.  Black bars indicate cell lines which are classified as 
expressing HOX11, grey bars indicate cell lines which are classified as not expressing HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 2.1.2 
for the phenotype of each cell line. Primers were designed by Dr Katrin Hoffmann, Division of
Childrens’ Leukaemia and Cancer Research, Institute for Child Health Research.  
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sFIGURE 5.13 SMARCD3 EXPRESSION IN LEUKAEMIC CELL LINES
The levels of expression of SMARCD3 were measured across a panel of cell lines by semi-
quantitative RT-PCR. The intensity of the resulting bands on an ethidium bromide agarose gel 
were measured in photostimulated luminescence units using a phosphoimager. The values were 
then normalized to a β-ACTIN control. RT-PCRs for β-ACTIN were performed in duplicate and an 
average value was used for normalization.The normalized expression levels of one experiment 
are displayed in graphical form in A.  Black bars indicate cell lines which are classified as 
expressing HOX11, grey bars indicate cell lines which are classified as not expressing HOX11 
and hatched bars indicate cell lines which express a low level of HOX11. Refer to Section 2.1.2 
for the phenotype of each cell line. RNA preparation, primer design and RT-PCR experiments 
were undertaken by Dr Katrin Hoffmann and Jette Ford, Division of Childrens’ Leukaemia and 
Cancer Research, Institute for Child Health Research.  
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5.3 DISCUSSION 
During the course of this study the user-friendly GeneChip technology (Affymetrix) became 
available which facilitated the global analysis of gene expression across a range of clones 
from multiple cell lines with different HOX11 expression status, but identical genetic 
backgrounds. The aim was to identify potential target genes of HOX11, that like Aldh1a1 can 
be regulated in different cellular backgrounds (Greene et al., 1998). This experiment was 
anticipated to complement the RDA and cDNA microarray analyses as it was expected to 
produce fewer false positives and thus was more likely to find transcriptional targets. The J2E 
murine erythroid cell line, the NIH3T3 fibroblast cell line and the PER-117 human T-cell 
leukaemia cell line were chosen for GeneChip analysis based on the behaviour of the 
putative HOX11 target gene ALDH1A1 across these cell lines (Greene et al., 1998 and 
Greene, unpublished observations). Genes that displayed differential regulation with HOX11 
expression in more than one cell line were of interest, particularly if their expression levels 
were altered in all three cell lines. This was based on the theoretical basis that such genes 
are unlikely to represent chance events unrelated to HOX11 expression. Having stated that, 
genes up-regulated with HOX11 expression in the PER-117 T-cell line only were also of 
interest since clinically HOX11 is a T-cell oncogene (Kees et al., 2003). Genes found to be 
up-regulated with the expression of HOX11 by GeneChip analysis in any of the above 
categories, were screened by semi-quantitative RT-PCR across a panel of additional HOX11 
and non-HOX11 expressing cell lines in order to identify candidate HOX11 target genes 
potentially relevant to T-cell leukaemogenesis. It is important to note that probes for the 
candidate HOX11 target genes c-Kit and Aldh1a1 were not present on the murine 
MU11KsubA GeneChip and thus their status could not be confirmed by this method in the 
J2E and NIH3T3 cell lines. In the case of the HGU95A GeneChip these genes were not 
detected in the top 50 genes up-regulated with HOX11 expression in the PER-117 cell line. 
A further three candidate HOX11 target genes were identified in this chapter. GAS3 was up-
regulated with HOX11 expression in the NIH3T3 cell line and down-regulated with its 
expression in the HEL and PER-117 cell lines. Nevertheless, there appeared to be no 
correlation of gene expression in the HOX11 positive T-ALL cell lines (PER-255, ALL-SIL) in 
comparison to HOX11 negative T-ALL cell lines. GAS3, also known as PMP22, is a 22kDa 
glycoprotein. Studies in cultured cells have demonstrated that this glycoprotein can regulate 
cell death and cell spreading in both fibroblasts and schwann cells. Its expression at the cell 
surface has also been shown to play an important role in the process of apoptosis in 
fibroblasts (Fabbretti et al., 1995; Brancolini et al., 1999; Brancolini et al., 2000). Genetic 
studies demonstrate that GAS3 is responsible for a set of inherited peripheral neuropathies in 
mice and humans and it is thought that it may play and important role in myelin membrane Chapter Five 
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formation and maintenance (Brancolini et al., 2000). Whilst no evidence exists linking this 
gene to T-cell leukaemogenesis, it is intriguing that GAS3 may be a candidate HOX11 target 
gene, especially since HOX11 has been linked to apoptosis (Dear et al., 1995). 
The genes NOR1 and SMARCD3 were consistently up-regulated with HOX11 expression in 
the T-ALL cell line PER-117 by GeneChip and semi-quantitative RT-PCR analysis. In 
addition, both genes were found to be expressed at a higher level by the semi-quantitative 
RT-PCR analysis in the HOX11-expressing PER-255 T-ALL cell line when compared to the 
non-HOX11 expressing PER-117 cell line. NOR1 is an orphan member of the nuclear 
hormone receptor super-family. The gene is a member of the NR4A subgroup implicated in 
cell proliferation, differentiation, T-cell apoptosis, neurological disorders, inflammation and 
chondrosarcomas (Wansa et al., 2003). NOR1 is induced by T-cell antigen receptor signaling 
in immature thymocytes and T-cell hybridomas leading to apoptosis. Whilst NOR1 is involved 
in TCR-mediated cell death and thymocyte negative selection, the clear function of the gene 
is unknown due to the functional redundancy of nuclear hormone receptors NUR77 and 
NOR1 (He et al., 2002; Cheng et al., 1997). Nevertheless, the activation of NOR1 by the 
purine antimetabolite 6-mercaptopurine suggests a role for the gene in the genotoxic stress 
response pathway (Wansa et al., 2003). Additionally, NOR1 has been implicated in 
carcinogenesis in a chromosomal translocation with Ewing’s sarcoma gene in extraskeletal 
myxoid chondrosarcoma. The role of the EWS/NOR1 fusion protein in carcinogenesis is not 
clear, however is has been shown to modulate pre-mRNA splicing and is a highly potent 
transcriptional activator (Ohkura et al., 2002; Laflamme et al., 2003). Finally, NOR1 has been 
implicated in the processes of angiogenesis and haematopoietic stem cell development, as 
VEGF has been shown to induce expression of the NOR1 receptor (Liu et al., 2003). Given 
its role in T-cell development and carcinogenesis an investigation into the functional 
relationship between NOR1 and HOX11 is warranted. 
SMARCD3 is a subunit of the SWI/SNF chromatin remodelling complex which is involved in 
transcriptional regulation. Members of this complex display helicase and ATPase activities 
which are thought to regulate transcription of certain genes by altering the chromatin 
structure around the genes, thereby allowing transcription factors to gain access to DNA. 
Specifically, cofactors such as SMARCD3 serve as transcriptional cofactors and alter the 
path of DNA around the nucleosomal histone core in an ATP dependent manner (Wang et 
al., 2003). The SWI/SNF complex has also been linked to malignant transformation, such that 
the complex participates in the inhibition or activation of several oncogenes and tumor 
suppressor genes (Klochendler–Yeivin et al., 2002; Muchardt et al., 2001). Primary deletions 
or truncations of genes involved in the SWI/SNF complex have been associated with 
malignant rhabdoid tumour, medulloblastoma, PNET and chronic myeloid leukaemia 
(Klochendler–Yeivin et al., 2002). Several studies have also provided evidience suggesting a Chapter Five 
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role for the SWI/SNF complex as a tumour suppressor (Klochendler–Yeivin et al., 2002). 
Evidence for the role of SWI/SNF complex in oncogenesis also exisits, suggesting that the 
complex facilitates the transcription of target genes of the oncogene c-myc and that the 
complex associates with c-Fos and c-Jun potentiating transactivating activity of a heterodimer 
(Ito et al., 2001; Cheng et al., 1999). The SWI/SNF complex has been shown to stimulate 
RAG1 and RAG2 mediated V(D)J recombination in vitro (Kwon et al., 2000; Klochendler–
Yeivin et al., 2002). Additionally, a study by Ferrando et al., 2002 demonstrated increased 
expression of BAF155, another component of the SWI/SNF complex, in T-ALL samples 
expressing  HOX11, thereby implicating the SWI/SNF complex in HOX11-related 
leukaemogenesis (Ferrando et al., 2002). Therefore, further studies investigating the 
regulation of SMARCD3 by HOX11 appear to be warranted. 
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6.1 INTRODUCTION 
Several novel putative HOX11 target genes were identified in this study. Among these was C-
Kit which showed increased surface expression in the J2E erythroid cell line (Greene et al., 
2002) (Chapter Three) and was also detected by cDNA microarray (Chapter Four). In 
addition, cDNA microarray analysis of the J2E cell line identified VEGFC as being down-
regulated with HOX11 expression (Chapter Four). Similarly, NOR1 and SMARCD3  were 
identified as being up-regulated with HOX11 expression in the PER-117 cell line by 
Affymetrix GeneChip microarray analysis (Chapter Five).  
While correlations in expression patterns provide some evidence to support the case that 
several of the genes identified in this study may be HOX11 targets, functional experiments 
are required to confirm that HOX11 actually regulates their expression. To address the role of 
C-KIT,  VEGFC,  NOR1 and SMARCD3  as potential transcriptional targets of HOX11 we 
therefore analyzed the ability of HOX11 to regulate the promoters of these genes in the PER-
117 T-cell line using transient transfection luciferase assays. DIHYDRODIOL 
DEHYDROGENASE was also included in the luciferase assay as a negative control, as, with 
the exception of the HEL cell line, the screening analysis demonstrated no clear correlation 
between the expression of this gene and HOX11 expression in the various cell lines 
examined. Therefore, it was expected that HOX11 would not regulate the DIHYDRODIOL 
DEHYDROGENASE promoter and thus it could act as a check of specificity.  
Luciferase reporter assays have been widely used and enable the investigation of the 
functional regulation of a gene at least in vitro (Gould et al., 1988). Promoter regions are 
cloned upstream of the luciferase gene, in a vector that lacks promoter and/or enhancer 
sequences. Expression of the 61kDa luciferase protein is dependent on the transactivation of 
a correctly oriented, functional promoter. This protein then catalyzes the oxidation of luciferin 
and light is produced by the conversion of the chemical energy of luciferin oxidation which is 
detected using a luminometer (Queen et al., 1984; Widen et al., 1986). In transient 
transfection luciferase assays luciferase reporter activity is used as a direct correlate for the 
promoter activity and the measured reporter activity depends on the level of transcriptional 
activity of the given promoter and also on the transfection efficiency, which is often evaluated 
with a control reporter construct. Whilst being a robust experimental system, problems such 
as the expression of the internal control reporter construct being modified by other co-
transfected factors have been reported, additionally, it is also important to note that when a 
promoter construct is transiently transfected, variables such chromatin configuration and 
missing distal elements may produce results which differ from those seen during native gene 
expression (Huszar et al., 2001).  Chapter Six 
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6.2 RESULTS 
6.2.1 Luciferase  Promoter  Constructs 
In order to investigate the role of C-KIT,  VEGFC,  NOR1 and SMARCD3  as potential 
transcriptional targets of HOX11 we analyzed the ability of HOX11 to regulate the promoters 
of these genes. Sections within the –1700bp to +300bp regions (as measured from the 
transcriptional start site, +1) of the C-KIT,  VEGFC,  NOR1  and DIHYDRODIOL 
DEHYDROGENASE promoters were amplified from human genomic DNA by high-fidelity 
PCR and cloned into the pGL3BASIC vector (Figure 6.1A, C, D, E, F,G). The pGL3BASIC 
vector lacks eukaryotic promoter and enhancer sequences allowing cloning of promoter 
regions into the vector. Expression of luciferase activity is dependent on insertion of a 
functional promoter upstream from the luciferase gene (Figure 6.1B). In the case of 
SMARCD3  the promoter region of this gene has not been previously characterized. 
Accordingly, sequences upstream from the SMARCD3 coding region on chromosome 7 were 
analyzed using algorithms provided by PROMOTER SCAN (www-
bimas.cit.nih.gov/molbio/proscan) and PROMOTER INSPECTOR (www.genomatix.de/cgi-
bin/promoterinspector_pd/promoterinspector) and a 971bp candidate promoter region was 
cloned into pGL3BASIC (Figure 6.1D). In all cases constructs were confirmed by sequencing. 
The cloned sections of the promoters were analyzed for the TAAGTG(CACTTA) and the 
TAATTG(CAATTA) putative HOX11 binding sites (Tang et al., 1995; Shimizu et al., 2000). 
Two putative binding sites were discovered in the C-KIT promoter as indicated in Figure 
6.1C. FIGURE 6.1 LUCIFERASE PROMOTER CONSTRUCTS
The  Genbank Accession numbers, promoter regions, fragment lengths, restriction sites and  
frequency of HOX11 binding sites of the promoter sequences used to construct the 
pGL3BASIC promoter constructs for the functional analysis are shown in Part A. The 
pGL3BASIC luciferase vector is shown in Part B. pGL3BASIC is a 4.8kb vector that lacks 
eukaryotic promoter and enhancer sequences allowing cloning of regulatory regions into the 
vector. Expression of luciferase activity in cells transfected with this plasmid depends on 
insertion of a functional promoter upstream from the luciferase gene. The -1108bp to +53bp 
region of the C-KIT promoter is shown in Part C. In the case of SMARCD3 the putative 
proximal promoter region was predicted using PROMOTER SCAN (www-
bimas.cit.nih.gov/molbio/proscan) and PROMOTER INSPECTOR (www.genomatix.de/cgi-
bin/promoterinspector_pd/promoterinspector). The 971bp fragment which was cloned into 
pGL3BASIC is indicated in Part D. The -1030bp to +288bp region of the VEGFC promoter is 
shown in Part E. The -1683bp to +148bp region of the NOR1 promoter is shown in F. The 
-965bp to +49bp region of the DIHYDRODIOL DEHYDROGENASE promoter is shown in G.
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+288bp
AF020393 VEGFC
0 Nhe I, Sma I 971bp - - SMARCD3
0 Sac I, Nhe I 1014bp -965bp to 
+49bp
U51676 DIHYDRODIOL 
DEHYDROGENASE
Sac I, Nhe I
Nhe I, Hind III
RESTRICTION 
SITES USED 
FOR CLONING 
INTO 
pGL3BASIC
E14965
S67773
GENBANK 
ACCESSION
0 1831bp -1683bp to 
+148bp
NOR1
2 1161bp -1108bp to 
+53bp
C-KIT
NUMBER OF 
PREDICTED 
HOX11 
BINDING 
SITES
FRAGMENT 
LENGTH
PROMOTER 
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GENE PROMOTER
A.
B.
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cttggagtaggtcttccaataagtgttcaagccctgggtcttccctcactacaataataaacatacc
tgctctaccctcctcacaaagctgttatcgtgagcatgaaaagacgagtcgctgtggggaagaacta
ttaacccctatacagatactgttgttgctttccgttcaaggatccaccatgagactgtgggtaaggc
actttctgggcagtgaaatcgggcttaagagaatcattgtacttttattttgctcctgggaccggca
agggcagttaagagccctagccctaaaactgtcgtctgttacagaggcagagaaatcattactgggg
ttggcagcgttggggggaggggggaaaacgtgtatgaaaacctgggctcccagagcaaacttcgcca
cgcgccctccatcgcccctgtctccacacaagtcccggcaggggcttcttgggcggaggccacgccg
accaataggaacccactgtgttcctacaggttacgaagcaggtggagaaattgagcagaaacaatta
gcgaaaccgggctcagcctttaccgcggtgccaggagctcctaacaggcctggaggggaatgtcggg
gctcaatttcctaacgctcccctccccatccccatgccacctccacgagcagcggcgtccagcctcc
tcccgcccgaacgtgctcgaggggcgggcagtcgacctttattgtctggggagcacctggcaggtgg
cgggcccgtgccctaacgtgtgcgtggtgcccagcttcacaaagcgagcgggcagcacctccttggt
ccgggaacggcctcagcctggccgtccacatcccaggggtggaaaggtggagagagaaaggggctcc
ggagtcaagagcggggagagagggcgcgcgccctcctcctcccggcgggcacagccccccggcatta
acacgtcgaaagagcaggggccagacgccgccgggaagaagcgagacccgggcgggcgcgagggagg
ggaggcgaggaggggcgtggccggcgcgcagagggagggcgctgggaggaggggctgctgctcgccg
ctcgcggctctgggggctcggctttgccgcgctcgctgcacttgggcgagagctggaacgtggacca
gagctcggatcccatcgcag 
+53bp
C.
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1+
C-KIT PROMOTER (ACCESSION NUMBER S67773)
The -1108bp to+58bp region of the C-KIT promoter. CG of CpG islands are shown in red, 
putative HOX11 putative binding sites are boxed, two overlapping initiation elements are 
underlined, two transcriptional start sites are indicated by  +1, A predicted downstream 
promoter element is underlined. Sp1, Myb and Ets binding sites of importance are shown in 
bold (Ratajczak et al., 1998; Park et al., 1998; Lecuyer et al., 2002)
Downstream Promoter Element
Initiation Elements
HOX11 Binding Site
HOX11 Binding Site
1+ Sp1 Binding Site
Myb Binding Site Ets Binding Site
Myb Binding Site Ets Binding SiteD.
agtgttgaaggtgtgacctggcctgggggagaggctggatatcggcaggggcagagacgggaacct
gagggagaaggacctgaccttgacctcagcctcagaccatgggtccctgctgcctgcctgcctcct
actgggggcctacgaggcccacctggccccaaatgcttggcaggctccctgcccgctggctgctta
gggaggtgctcccacttcccccgccgttgcctgagctctctagggctccttcactctgcaggtagg
ctggggtccccctctgtgctgggcactgtggtagctcagccgtgtgaggcggggccctggaagagc
ccatgagatggccagagctgggcttgtctggctggaagctgggaataggcttctccaagctgccaa
atttaagtattgagtacataaaaggaggagattggcattagtgagaacatggccctgaggcttgat
ggacccaaagcctcccagggtatgtgcgttttgagggggtggggggtgcacatgggtgtccgggac
ctcgtctaggtaatgtctgcagccacataggatgatctgactgaatctgtgtgaggacaaccgttt
gtgtgcctgtgtgtgcgcgcccacgtgcatgcgcgtgtgtggtcctagtgtaggtgatgtctgcgg
ccacacaggatgctgactgcgtgtgtgactcgtgggcgtgcagatgcaagcacaggcctacgacac
atctgtgtacaggctgaagatcacaacgggtctggccagggcccgccgagggcctccgagctggcg
agcacaccgacggctggatggggcgacgcttcctgctccggtccctaactcattattaagctcctc
gctctttgcagacgctccctgcgcctcccccgctccgggctgcagcggcgcaggcgccgggccgag
ccgagcgccgagcagggagcgggcggccgcgctccgggccggggtccc
SMARCD3 PUTATIVE PROMOTER FROM UPSTREAM SEQUENCE ON CHROMOSOME 7
A 971bp region of the SMARCD3 putative promoter. CG of CpG islands are shown in red. A 
predicted Multiple start site element downstream (MED1 Element) and a possible TATA box are 
underlined. 
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Multiple Start Site Element Downstream
TATA Box-1030bp
tagcgtggtcctctgtaacctgctcaccctgccccaaggaggcagctagccaatgccaccagcccaa
cggaaaccccagtgcttttccaatggggaaatgcagtcacttttctttggatgctacacatcctttc
tggaatatgtctcacacacatctctctttatcaccccctttttcaagtaaaccaacttcttgcagaa
gctgacaatgtgtctctttactctccacgaagattctggcccttctcttcacctgtcagaagtttag
gattccaaagggatcattagcatccatcccaacagcctgcactgcatcctgagaactgcggttcttg
gatcatcaggcaactttcaactacacagaccaagggagagaggggacccctccgaggtcccataggg
ttctctgacatagtgatgacctttttccaaactttgagcagggcgctgggggccaggcgtgcgggag
ggaggacaagaactcgggagtggccgaggataaagcgggggctccctccaccccacggtgcccagtt
tctccccgctgcacgtggtccagggtggtcgcatcacctctaaagccggtcccgccaaccgccagcc
ccgggactgaacttgcccctccggccgcccgctccccgcaggggacaggggcggggagggagagatc
cagaggggggctgggggaggtggggccgccggggaggaggcgagggaaacggggagctccagggaga
cggcttccgagggagagtgagaggggagggcagcccgggctcggcacgctccctccctcggccgctt
tctctcacataagcgcaggcagagggcgcgtcagtcatgccctgcccctgcgcccgccgccgccgcc
gccgccgctcagcccggcgcgctctggaggatcctgcgccgcggcgctcccgggccccgccgccgcc
agccgccccggcggccctcctcccgcccccggcaccgccgccagcgcccccgccgcagcgcccgcgg
cccggctcctctcacttcggggaaggggagggaggagggggacgagggctctggcgggtttggaggg
gctgaacatcgcggggtgttctggtgtcccccgccccgcctctccaaaaagctacaccgacgcggac
cgcggcggcgtcctccctcgccctcgcttcacctcgcgggctccgaatgcggggagctcggatgtcc
ggtttcctgtga
+288bp
+1
Initiation Element
Downstream Promoter Element
VEGFC PROMOTER (ACCESSION NUMBER AF020393)
The -1030bp to+288bp region of the VEGFC promoter. GC of CpG islands are shown in red, a predicted 
initiation element and downstream promoter element are underlined. The transcriptional start site is 
indicated by  +1 (Chilov et al., 1997).
E.
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gccaaccgccgaatttagtaacatcgcctgcgtcaatcacgcgcctcggtgcgtcaggccgcgcggc
tccaggtcctgctcccccccttcaagcctttgaatggatacaatgtagcagcgccctccttccttcc
gaggctggattggaaccgccgcagtgcagagactcggttgctctcggctgggtcaactttcggggca
ttctcccacgatcctctccgcaccaccgtgtctgaattggaagtggaggcgaagaaagatatacatg
ccatatttacctatatgtagtttgttttcaagtttctggtcctagctcgaaccttcttcgattctga
aatgtgtgctgtctacaaaggaatcttgtatctcccctcggcgcagccccccgccccgccacacaca
cacaaattgggacaggtcaaacatataaaacggtatttgtgattcaagcggaccacatggggaccac
tctatctgcattgtttcactcaaatattttctcctgtccaaaaattcatttctgaaagagactgcgt
tcactcagcagcaacctttgggactaggggtctttaactctgataaattttgttttcatcaagaaat
ttacacttaaatttatcatttccaggaagaaattgctctccttcatacagtcacccaggctttcggc
acaccatttcatgacaaatgtgtccgaggagaccaaagcaaatcccctagcgagggactgactaata
agtcctgttgattgatttcgaaatgtttaatttgggagatgtgggcggagggcatctacaaccatca
aaaagtgaaagtgctagttgagagttccatttctgacccggtgccggggaggaggaatgatttgcaa
tagtcagacccgctcagctgttcaacacgtgtgtgtttgttttacacacagagtagtttctgctgca
gccgcgtgtgcatgatggatgtgcacttcgctgggttataacgtgtccagttaagaaacccacgccg
tacgtgtaaagaaatcaaaccttatccccggaaccatctgcatccctgtgtgaacacgcacccagta
aatgatgcggggaggggggattagcctgggcgcagaggaccggagcaacgtaaacagctttagaacc
tatgcaagaggaaagtgcagctgcacctcagggcgtcttcgggctggtgccagacgccttctgcacc
ggctgccaggtcactggagctggtcagaagctggctggcggagcttccctttcggaagagctgtcct
ctcccttacccccctcgccctggctccgtgcctcggggcagcctcggaggcgcgccagcagcactcc
tccaactctactccacccgagcctgacagctgggcggtcccgcctgacccgtgggcaggccgctgca
ccctcccgcagacgcacgccctggcgagcggttccgctgcaaaaagagaagcccccaggccggggcc
ggccgtgcggcggagtttccattgtgcggccgtgcgactggccgaggaacgcgcgcgcgcgcgcaca
cgaacacacacaccctccctcgcacacgcggaaccggctgggccaggggagggaggaggagggtgac
gtagcgtcccatggcgtcacattgacgtctcgcattccaggcactctatggagaggccgctagggct
cctgtggcataaatgacgtgccgagagagcgagcgaacgcgcagccgggagagcggagtctcctgcc
tcccgccccccacccctccagctcctgctcctcctccgctccccatacacagacgcgctcacacccg
ctccctcactcgaacacacagac
+148bp
TATA-like Element
1+
CRE
CRE CRE
F.
NOR1  PROMOTER (ACCESSION NUMBER E14965)
The -1683bp to+148bp region of the NOR1 promoter. CG of CpG islands are shown in red, TATA-
like element is underlined, transcriptional start site is indicated by  +1, cAMP response elements 
(CRE) of importance are underlined (Ohkubo et al., 2000)
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gaacgaaatcagggcattgcaagtctgacaactccaagatgttgataatgtattgtgcaaactacat
tcatcatgttctaatctgccctccaaaggaaggaacaagtgaaaaactatcccacatgagaattatt
catccattatatgtaatttaatttccagtttttccttacaaataatgtttaacaagacgactagata
tataaaatggttatcagttttttggctagttacttcttgatagtctgtaataaacctggttgaagaa
caaatactattaaggcactgcttgcatatattaaatgatgtccaaactccaaaaactgttaataatt
aacactccaataaaaactacaccagaatttctttttatttgcaccctcatcaggattacagctttat
caggactgcatcttcttcagaaatgaatatttctcttacaacggtcaaggaaagaaaaatcaaaata
aattttctgattgaaaatgtaaaaaggcaaatatttttacagttttaactttaattttttattgagg
accaactatttgaaaaattctcattagtcattcctttaaattatgtgtatgtgagagaaagacgtaa
gatggttaattatttcaaatgatgcagtataaagaaggggcattatcacggcagaaacgaaaaaaga
tatttgtagctggaggtttttatagtctaacatatggttgctatttgttctacaaatccttttgaat
aatttaatatagagatttagaatagaaaataatactttagatagaaattaatgagtttattataacc
atatattataataatttacttaggaattctctttgataagaaacaaatgaactgaatgcaattttct
ccacagaccatataagactgcctatgtacctcctcctacatgccattggttaaccatcagtcagttt
gcaggggtggggggaggggtttccgtgcccattgtttttgtaatctctgaggagaagcagcagcaaa
catttgctag
+49bp
1+
AP-2 Binding Site
DIHYDRODIOL DEHYDROGENASE  PROMOTER (ACCESSION NUMBER U51676)
The -965bp to+49p region of the DIHYDRODIOL DEHYDROGENASE promoter. CG are shown in 
red, transcriptional start site is indicated by  +1, AP-2 binding site of importance is shown in bold 
(Ciaccio et al., 1996)
G.
Chapter Six                                                               286Chapter Six 
 
287
6.2.2  Optimization of Luciferase Reporter Gene Assays 
The PER-117 cell line, established from the leukaemic cells of a patient with T-ALL (Kees et 
al., 1987) and which does not express HOX11, was chosen as the system in which to test the 
functional HOX11 regulation of the C-KIT,  VEGFC and NOR1 promoter regions and the 
SMARCD3 putative promoter region. This cell line was considered appropriate given that 
HOX11 is one of the most frequently deregulated genes in T-ALL and thus it is plausible to 
assume that the PER-117 cell line provides a background which contains cofactors relevant 
to clinical cases of T-ALL (Kees et al., 2003). 
A transient transfection luciferase assay was developed using the parental PER-117 cell line. 
The PER-117 clones which had been stably transfected with HOX11 were not utilized due to 
the possibility of clonal discrepancies affecting results. In highly controlled experiments, 
promoter constructs together with either the HOX11-expressing pEFBOSHOX11 vector or the 
empty pEFBOS control vector were transfected into this cell line. The pSV-β-Galactosidase 
(pSVBGAL) control construct which expresses β-galactosidase was also included in order to 
account for differences in transfection efficiency and /or cell survival. The empty pGL3BASIC 
vector was also included in all experiments as a negative control. Western blot analysis of 
this transient transfection system consistently demonstrated the expression of the 36kDa 
HOX11 protein (Figure 6.2). 
Twenty-two hours post-transfection experimental cells were harvested using lysis buffer and 
the cell lysate assayed using the Dual Light Chemiluminescent Reporter Gene Assay 
System, which measures both luciferase and β-galactosidase reporter activity. In all cases a 
negative control reaction consisting solely of lysis buffer was assayed in parallel. Initial 
experiments undertaken with promoter constructs, pEFBOS  or  pEFBOSHOX11 and the 
pSVBGAL control construct provided questionable results with respect to the β-galactosidase 
internal control. Analysis of the raw β-galactosidase values consistently indicated examples 
where values were not more than 2 fold above the values for the lysis buffer negative control 
(Figure 6.3A). Moreover, a common pattern of lower β-galactosidase values in 
pEFBOSHOX11 samples when compared to matched control samples using pEFBOS was 
observed (Figure 6.3A). This observation raised concerns that HOX11 may be repressing the 
expression of the β-galactosidase internal control. These concerns were supported by Owens 
et al., 2003 who reported the repression of the SV40 promoter by HOX11 (Owens et al., 
2003). Given that this promoter controls the expression of β-galactosidase from pSVBGAL it 
was decided that an alternative construct should be used as the internal control. Utilization of 
the pEFBOS-β-Galactosidase (pEFBOSBGAL) construct which employs the EF-1α promoter 
to control expression of β-galactosidase demonstrated values that were consistently 8-17 fold 
above the values for the lysis buffer negative control (Figure 6.3B), thus overcoming Chapter Six 
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background interference. However, again HOX11 was observed to affect the expression of 
the internal control β-galactosidase. This time, a pattern of consistently increased β-
galactosidase values in pEFBOSHOX11 samples when compared to matched control 
samples using pEFBOS was observed (Figure 6.3B). Similar findings have been reported by 
Huszar et al., 2001, where co-transfected transcription factors were shown to modulate the 
activity of the internal control, thus affecting the interpretation of results (Huszar et al., 2001). 
In order to avoid any misinterpretation, the data was statistically analyzed. After log to the 
base 2 transformation, raw β-galactosidase values were expressed as a ratio of [promoter 
with HOX11] versus [promoter without HOX11]. Each ratio was then expressed by 
subtracting the corresponding ratio for the pGL3BASIC empty vector control. All experiments 
were repeated in triplicate in independent experiments performed on different days and a 
mean taken. Two sided p-value testing for the null hypothesis that the values were equal to 
zero demonstrated at the p<0.05 level of significance that the values were not significantly 
different from zero. This result demonstrated that the effect of HOX11 on the β-galactosidase 
internal control is independent of the promoter tested and can be accounted for by utilizing 
the pGL3BASIC empty vector control for normalization (Figure 6.4). Chapter Six                                                               289
FIGURE 6.2 ANALYSIS OF HOX11 PROTEIN EXPRESSION IN TRANSIENT 
TRANSFECTION ASSAYS
Western blot analysis of PER-117 cells transiently transfected with pEFBOSHOX11,
pEFBOSBGAL and pGL3BASIC. The  36kDa HOX11 protein in lane 2 is indicated with an 
arrow.  Lane 1 contains a control cell line transfected with pEFBOS,  pEFBOSBGAL and 
pGL3BASIC.
45kDa
31kDa
36kDa
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FIGURE 6.3 COMPARISON OF β-GALACTOSIDASE INTERNAL CONTROL 
CONSTRUCTS
PER-117 cells were transfected with promoter constructs A (NOR1) ,B (VEGFC) , C (C-KIT) 
or  pGL3BASIC  empty vector, in addition to pEFBOS or  pEFBOSHOX11  and a β-
Galactosidase control construct. The raw relative light units (RLU) for β-Galactosidase are 
presented graphically. Part A shows a set of experiments performed using the pSVBGAL
construct and Part B the same set of experiments performed using the pEFBOSBGAL
contruct. The NEGATIVE experiment refers to a lysis buffer control which was assayed for β-
galactosidase activity.Chapter Six                                                               291
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FIGURE 6.4 THE EFFECT OF HOX11 ON β-GALACTOSIDASE ACTIVITY IS 
INDEPENDENT OF THE PROMOTER TESTED AND CAN BE ACCOUNTED FOR BY 
EXPRESSING RATIOS OVER THE pGL3BASIC EMPTY VECTOR CONTROL
Statisical Analysis was performed using random effect models in SPLUS by Dr Ross Taplin, 
Division of Science and Engineering, Murdoch University. After log (base 2) transformation, 
raw  β-Galactosidase values were expressed as a ratio of [promoter with HOX11] versus 
[promoter without HOX11]. Each ratio was then expressed by subtracting the corresponding 
ratio for the pGL3BASIC empty vector control. Average values were taken for a set of three 
independent experiments performed on different days.Two sided p-value testing for the null 
hypothesis that the values equal zero was undertaken at the P< 0.05 level of significance. In all 
cases it was concluded that the values were not significantly different from zero.
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6.2.3  Luciferase Reporter Assays to Establish the Ability of HOX11 
to Transcriptionally Regulate Candidate Target Genes 
To address the role of C-KIT,  VEGFC,  SMARCD3 and NOR1 as potential transcriptional 
targets of HOX11, the ability of HOX11 to regulate the promoters of these genes in the PER-
117 cell line using transient transfection assays was assessed. DIHYDRODIOL 
DEHYDROGENASE was also included as a specificity control. The promoter constructs 
outlined in section 6.2.1 were cotransfected with pEFBOSHOX11  or  pEFBOS and the 
pEFBOSBGAL vector constitutively expressing β-galactosidase. The resulting transcriptional 
activity was normalized to β-galactosidase and expressed as a ratio of HOX11 experiments 
versus pEFBOS empty vector experiments. All values were then expressed as a ratio of the 
empty reporter construct pGL3BASIC for reasons outlined in Section 6.2.2. All experiments 
were repeated in triplicate and a mean taken. Two sided p-value testing for the null 
hypothesis of no difference at the p<0.05 level of significance was undertaken. A statistically 
significant repression with HOX11 expression of around two-fold was observed for the C-KIT 
and VEGFC promoters. Whilst a slight repression was also observed for the SMARCD3 and 
NOR1 promoters, neither was statistically significant. In the case of the negative control 
promoter,  DIHYDRODIOL DEHYDROGENASE, the observed repression was also not 
statistically significant (Figures 6.5 and 6.6).  
To assess whether HOX11 can regulate transcription in a manner independent of DNA 
binding,  pEFBOS∆H3-HOX11 was also used in the transient transfection assays. This 
construct contains the HOX11 coding sequence with the deletion of the third helix (aa242-
251) of the homeodomain which is essential for DNA binding. The HOX11∆H3 mutant had no 
effect on the DIHYDRODIOL DEHYDROGENASE and  SMARCD3  promoters.  However 
surprisingly, activation was observed in the cases of C-KIT,  VEGFC and NOR1 and this 
activation was statistically significant in the case of VEGFC. Moreover, a statistically 
significant difference between experiments performed using HOX11 and those performed 
using the homeodomain mutant was observed for C-KIT, VEGFC and NOR1 suggesting that 
the repression observed with HOX11 in all cases was linked to the presence of an intact 
homeodomain (Figures 6.5 and 6.6). Chapter Six                                                               294
FIGURE 6.5 ANALYSIS OF THE TRANSCRIPTIONAL REGULATION OF THE CKIT, 
VEGFC AND DIHYDRODIOL DEHYDROGENASE PROMOTERS AND BY HOX11 AND THE 
∆H3-HOX11 MUTANT
Statisical analysis was performed using random effect models in SPLUS by Dr Ross Taplin, 
Division of Science and Engineering, Murdoch University. The raw RLU values for luciferase
and β-galactosidase for each of the replicate wells were examined and clear outliers were 
removed in two cases. A ratio of RLUs for luciferase over RLUs for β-galactosidase was taken 
for each well in order to gain normalized values. After log to the base 2 transformation, values 
were expressed as a ratio of [promoter with HOX11] versus [promoter without HOX11] or 
alternatively as a ratio of [promoter with ∆H3-HOX11] versus [promoter without HOX11]. All 
values were then expressed by subtracting the corresponding ratio for the pGL3BASIC empty 
vector control. Two sided p-value testing using the null hypothesis of no difference was 
undertaken for each comparison. The experiment was repeated in triplicate using independent 
experiments on different days. Values are presented graphically in log format and the 
corresponding fold change is presented in a table. 
DD = DIHYDRODIOL DEHYDROGENASE
** = P-VALUES refering to a significant difference between experiments 
performed using HOX11 and the homeodomain mutant ∆H3-HOX11
• = P-VALUES refering to a significant difference between experiments 
performed using HOX11 and those performed using no HOX11 
° = P-VALUES refering to a significant difference between experiments 
performed using homeodomain mutant ∆H3-HOX11 and those performed 
using no HOX11
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1.021 increase DD + ∆H3-HOX11
1.310 decrease DD + HOX11
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1.693 increase C-KIT + ∆H3-HOX11
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FIGURE 6.6 ANALYSIS OF THE TRANSCRIPTIONAL REGULATION OF THE NOR1
PROMOTER AND THE SMARCD3 PUTATIVE PROMOTER BY HOX11
Statisical analysis was performed using random effect models in SPLUS by Dr Ross Taplin, 
Division of Science and Engineering, Murdoch University. The raw RLU values for luciferase 
and β-galactosidase for each of the replicate wells were examined and clear outliers were 
removed in two cases. A ratio of RLUs for luciferase over RLUs for β-galactosidase was taken 
for each well in order to gain normalized values. After log to the base 2 transformation values 
were expressed as a ratio of [promoter with HOX11] versus [promoter without HOX11] or 
alternatively as a ratio of [promoter with ∆H3-HOX11] versus [promoter without HOX11]. All 
values were then expressed by subtracting the corresponding ratio for the pGL3BASIC empty 
vector control. Two sided p-value testing the null hypothesis of no difference was undertaken 
for each comparison. The experiment was repeated in triplicate using independent 
experiments performed on different days. Values are presented graphically in log format and 
the corresponding fold change is presented in a table.
** = P-VALUES referring to a significant difference between experiments
performed using HOX11 and the homeodomain mutant ∆H3-HOX11
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6.3 DISCUSSION 
In clinical cases of T-ALL inappropriate expression of HOX11 through translocation could 
result in persistence of downstream target gene expression, thus perpetuating signals 
preventing differentiation and or creating greater proliferation of haematopoietic cells (Owens 
et al., 2002). The identification of putative HOX11 target genes is therefore of great interest. 
In this chapter, luciferase reporter assays were utilized in order to investigate whether HOX11 
can functionally regulate four leading candidate target genes identified in this study. Transient 
co-transfection assays using the proximal promoter sequences of C-KIT, VEGFC, SMARCD3 
and  NOR1 together with HOX11 were performed. Included in this analysis was 
DIHYDRODIOL DEHYDROGENASE which acted as a negative control. As might have been 
expected the DIHYDRODIOL DEHYDROGENASE proximal promoter region was not 
significantly transactivated or repressed by HOX11. This gene was included in this analysis 
as a negative control as the semi-quantitative RT-PCR screening technique only 
demonstrated the down-regulation of gene expression with HOX11 with the HEL human 
erythroid cell line. The fact that DIHYDRODIOL DEHYDROGENASE was not significantly 
affected by HOX11 confirmed its status as a negative control and demonstrated that HOX11 
was not acting non-specifically on any promoter used in the assay. 
As with DIHYDRODIOL DEHYDROGENASE, no significant transactivation or repression was 
observed by HOX11 on the NOR1 and SMARCD3  promoters. By contrast, transient 
transfection assays using the proximal promoter sequences of C-KIT and VEGFC revealed a 
significant repression by HOX11 of approximately 2 fold in each case. In combination with the 
microarray, semi-quantitative RT-PCR and Northern blot data, this strongly suggests that 
both C-KIT and VEGFC lie downstream of a HOX11 transcriptional cascade. At this stage it is 
unclear whether these genes are directly regulated by HOX11 or indirectly via other 
intermediary factors regulated by HOX11. However, consistent with the notion that at least C-
KIT may be a direct target, two consensus HOX11 binding sites (TAAGTG and CAATTA; 
reverse complement TAATTG) were observed within its proximal promoter region (Figure 
6.1C) (Tang et al., 1995; Shimizu et al., 2000). It is important to note that, although the NOR1 
and SMARCD3 proximal promoters were not significantly affected by HOX11, this does not 
rule them out as potential HOX11 targets since HOX11 or a factor downstream of HOX11 
may require distal regulatory elements, in addition to, or exclusive of, the proximal promoter 
region, in order to influence their transcription. 
In the case of C-KIT, original characterization of the J2E erythroid cell line by flow cytometric 
and RT-PCR analysis indicated increased expression of C-KIT with HOX11 expression 
(Greene et al., 2002). The luciferase reporter assays in the PER-117 T-ALL cell line outlined 
in this chapter indicate repression of the C-KIT proximal promoter region with HOX11 Chapter Six 
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expression. This discrepancy may be a result of differences in the cellular context or due to 
the region of the promoter that was cloned. It should be noted that both activation and 
repression by HOX11 have been demonstrated in the case of the putative HOX11 target 
gene Aldh1a1 depending on the cellular context (Greene et al., 1998). The availability of co-
factors in different cellular milieu can affect gene regulation. For example, association with 
TALE homeoproteins is thought to add selectivity to HOX11 homeodomain interactions such 
that heterodimerization of HOX11 with PBX1a was shown to alter the way HOX11 interacts 
with various binding sites (Allen et al., 2000). In addition, different HOX11 phosphorylation 
states in different cell lines may affect whether HOX11 acts as an activator or repressor. 
Several model systems have shown that protein phosphorylation can induce a rapid 
modulation of transcriptional activity. Phosphorylation is known to affect the DNA binding 
activity of transcription factors, their sub-cellular localization or their interaction with 
transcriptional machinery (Yokoyama et al., 2002; Weiss et al., 2004). Distal regulatory 
elements, in addition to, or exclusive of, the proximal promoter region may also be important 
in the regulation of transcription. Distal elements may recruit co-activators or co-repressors 
that may determine transactivation or repression and this provides yet another explanation for 
the discrepancies in C-KIT regulation. By contrast, in the case of VEGFC, luciferase reporter 
assays correlated with cDNA microarray and Northern blot results. All assays indicated a 
repression of VEGFC gene expression with HOX11 expression. 
Many possible molecular mechanisms may account for the observed repression of VEGFC 
and C-KIT by HOX11 and a repression function for HOX11 has previously been suggested 
for Aldh1a1 in the spleen and ALDH1A1 in HEL human erythroid cells (Greene et al., 1998; 
Greene, unpublished observations). Several indirect mechanisms of repression may be 
responsible, for example, certain homeodomain proteins can interact with transcriptional co-
activators or co-repressors depending on their availability, potentially providing an 
explanation for differences in gene expression observed in different cellular milieu (Owens et 
al., 2002). To date, no HOX11 co-repressors have been identified, however, HOX11 
possesses a FIL repression motif (FXIXXIL) required for interaction with Groucho related co-
repressors. Several HOX proteins are known to interact with Groucho proteins including 
Engrailed and Hesx1 (Jimenez et al., 1997;Carvalho et al., 2003). Intriguingly for HOX11 this 
same motif has been implicated in transcriptional activation (Masson et al., 1998). Similarly, 
occlusion, whereby another protein competes for a HOX11 DNA binding site is another 
example of indirect repression.  CCAAT displacement protein (CDP) is an example of a 
homeodomain protein which functions as a transcriptional repressor through competition for 
binding site occupancy (Nepveu et al., 2001). The role of HOX11 as a transcriptional activator 
or repressor may be dependent on such competition for transcription factor binding sites. 
Quenching of transcriptional activators by the blocking of their transactivating ability is also a Chapter Six 
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well known indirect mechanism of repression. A direct interaction between HOX proteins and 
CBP, often through the homeodomain, can result in a block of CBP histone acetyltransferase 
activity, thus mediating repression (Shen et al., 2001). Additionally, HOX cofactors may form 
complexes that can determine whether HOX proteins act as repressors or activators. Saleh et 
al., 2000 report that HOX-PBX complexes can be switched from repressors to activators by 
interaction of PBX with histone deacetylases (Saleh et al., 2000). Other mechanisms of 
repression include direct repression by interference with components of the basal 
transcriptional machinery. Owens et al., 2003 reported that HOX11 may exert a repressor 
function through interaction with the components of the RNA polymerase II holoenzyme 
(Owens et al., 2003). This finding is in accordance with the behaviour of the Msx-1 and Msx-2 
homeodomain proteins which repress promoters through interactions with components of the 
basal transcriptional machinery (TBP, TFIIA and TFIIB for Msx-1 and TFIIF for Msx-2) (Zhang 
et al., 1996; Newberry et al., 1997). Additionally, HOX11 has been shown to interact with 
CTF1 a transcription factor that associates with TFIIB and the basal transcriptional machinery 
(Zhang et al., 1999). Accordingly, HOX11 may also interact with the basal transcriptional 
machinery through indirect mechanisms. It is also possible that increased HOX11 levels may 
lead to the sequestering of all cofactors by excess HOX11, thus leading to a environment 
where no cofactors are available to bind HOX11 and effect gene expression. Accordingly, the 
differences in C-KIT gene expression between the stabily transfected J2E erythroid cell line 
and the transiently transfected PER-117 cell line may be explained by slight differences in 
levels of HOX11 expression. Whatever the molecular mechanism of HOX11 induced 
repression, C-KIT and VEGFC appear to be transcriptional targets downstream of HOX11.  
To assess whether HOX11 can regulate transcription in a manner independent of DNA 
binding, a HOX11∆H3 mutant was also used in the transient transfection assays. Activation 
was observed when C-KIT and VEGFC proximal promoters were transfected with the HOX11 
mutant lacking the third helix of the homeodomain. In contrast, the DIHYDRODIOL 
DEHYDROGENASE and NOR1 proximal promoters and the SMARCD3 putative proximal 
promoter were not significantly transactivated by the homeodomain mutant. In the cases of 
VEGFC, C-KIT and NOR1 a significant difference was noted when HOX11 experiments were 
compared to HOX11 homeodomain mutant experiments, highlighting the importance of an 
intact homeodomain in the observed HOX11 related repression (Figures 6.5, 6.6). HOX11 
appears to be bi-functional depending on whether it binds DNA or not, alternatively the 
homeodomain mutant may affect co-factor binding or putative homodimerization since 
HOX11 has been shown to be capable of homodimerization (Rice and Greene, unpublished 
observations). Several possible mechanisms may account for these observations. HOX11 
may be a repressor upon DNA binding, thus occluding the binding of possible activators 
leading to repression. The homeodomain mutant is unable to bind DNA (Heidari et al., 2002) Chapter Six 
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leaving the transcriptional activator free to bind DNA, resulting in activation. Secondly, 
HOX11 may bind a co-factor or homodimerize after DNA binding leading to repression, whilst 
the homeodomain mutant is unable to do so, leaving it free to interact with the basal 
transcriptional machinery in a different context thus allowing activation. The importance of the 
homeodomain in the observed repression is in accordance with the findings of Owens et al., 
2003 who reported that a fully intact homeodomain was required for HOX11 to inhibit 
promoter activity. 
C-KIT is a receptor tyrosine kinase that is expressed in early haematopoietic stem cells. It 
plays an important role in the survival and self renewal of haematopoietic cells and is also 
thought to play an important role in the early stages of T-cell development (Tomeczkowski et 
al., 1998; Godfrey et al., 1994; Matsuzaki et al., 1993). Increased expression of C-KIT has 
previously been linked with T-ALL and T-cell lymphoma with the receptor being up-regulated 
in 9 out of 21 T-ALL samples (Tomeczkowski et al., 1998). Additionally, a study of eighteen 
T-ALL patient samples showed a correlation of HOX11 and C-KIT expression in one patient 
sample (Greene, D’Souza and Kees, unpublished observations). Similarly, four our of eight 
HOX11 positive T-ALL samples were found to have up-regulated C-KIT expression in a 
microarray study by Ferrando et al., 2002 (Ferrando et al., 2002, see supplementary data). 
Although the role that HOX11 plays in the direct transcriptional regulation of C-KIT in T-ALL is 
unclear, especially given the discrepancies in regulation due to different cellular milieu, it 
seems clear from this study that HOX11 does act upstream to regulate the C-KIT proximal 
promoter region. Given the importance of C-KIT in the process of haematopoiesis and its link 
to T-ALL and other leukaemias it is an oncogenically relevant candidate HOX11 target gene.  
This study has also identified VEGFC as a putative HOX11 target gene. VEGFC is a receptor 
tyrosine kinase that functions in angiogenesis and lymphangiogenesis. VEGFC and its 
receptors a have been implicated in a wide range of cancers, the most relevant of which 
being primary acute myeloid leukaemias (Fielder et al., 1997; Orpana et al., 2002). Once up-
regulated, VEGFC is thought to play a role in an angiogenic paracrine loop involving its 
receptor VEGFR-3 which is thought to contribute to leukaemic cell survival through up-
regulation of the anti-apoptotic gene Bcl-2 (Oprana et al., 2002; Dias et al., 2002). Once 
again the role that HOX11 plays in the transcriptional regulation of VEGFC in T-ALL is 
unclear. Northern blot analysis of the HOX11 positive T-ALL cell line ALL-SIL indicated 
increased levels of VEGFC expression, nevertheless analysis of the PER-117 cell line 
indicated down-regulation of VEGFC expression with HOX11 expression. Luciferase reporter 
assays also indicated that HOX11 negatively regulates the proximal VEGFC promoter. Given 
differences in the cellular milieu and the fact that only the proximal promoter region was 
analyzed in the functional assays, it is possible that HOX11 may positively or negatively 
regulate VEGFC in T-ALL.   Chapter Six 
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Although the repression was not statistically significant, NOR1 is also of interest as a putative 
target gene, in particular because a significant difference was noted when HOX11 
experiments were compared to HOX11 homeodomain mutant experiments (Figure 6.6).   
NOR1  belongs to the NR4A nuclear hormone receptor subgroup implicated in cell 
proliferation, differentiation, T-cell apoptosis and chondrosarcomas (Wansa et al., 2003). 
NOR1 has been identified as a mediator of TCR mediated cell death through apoptosis 
(Cheng  et al., 1997). It has been implicated in carcinogenesis through chromosomal 
translocation with the Ewing’s sarcoma gene associated with chondrosarcoma (Ohkura et al., 
2002). Additionally, a microarray expression study by Ferrando et al., 2002 indicated that 
NOR1 was up-regulated in five out of eight HOX11 positive T-ALL samples (Ferrando et al., 
2002, see supplementary data). Whilst functional studies were not conclusive about the role 
of  NOR1 as a putative HOX11 target gene, the results are of some interest. In order to 
establish the role of NOR1 as a candidate HOX11 target gene, further functional and 
expression analyses are required. 
In conclusion, this study has definitively identified two candidate HOX11 target genes. The 
data indicated that the function of HOX11 as a transcriptional regulator may be dependent or 
independent of DNA binding as well as being affected by the cellular context. Further 
experimentation is required to establish the exact nature of the HOX11 transcriptional 
regulation of VEGFC and C-KIT and the role of these pathways, if any, in T-ALL. 
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7.1 DISCUSSION 
HOX11 is a homeodomain transcription factor that has been implicated in T-ALL leukaemic 
transformation (Salvati et al., 1999; Kees et al., 2003). Its role in leukaemogenesis remains 
enigmatic, nevertheless, in vitro and in vivo studies provide additional evidence supporting 
the role of HOX11 as an oncogene (Hawley et al., 1994; Hawley et al., 1997; Hough et al., 
1998; Keller et al., 1998). The mechanism by which HOX11 transforms cells is yet to be 
elucidated and it is possible that a complex gene expression network is involved. The 
identification of transcriptional targets is critical to our understanding of the pathways 
controlled by this master regulator gene. Hawley et al., (1994) demonstrated that HOX11 
transformed cells exhibited a block in cellular differentiation. Aberrant expression of HOX11 in 
a committed haematopoietic lineage may predispose a cell to neoplastic transformation by a 
deviation from the normal maturational pathway.  
HOX11 was expressed in the J2E murine erythroid cell line in Chapter Three as attempts to 
model T-ALL experimentally have proven unsuccessful. The J2E cell line was easily 
transfected and maintained and had the capacity to terminally differentiate (Klinken et al., 
1988). Given such a `plastic’ phenotype, this cell line was considered a well controlled model 
to ascertain the effect that HOX11 might have on the cellular phenotype of a haematological 
cell line and, in particular, to observe the possible effects that this oncogene might have on 
the process of differentiation.  Secondly, the model helped to allow the identification of 
candidate HOX11 target genes that may be involved in gene expression pathways implicated 
in such phenotypic changes.  
The J2E cell line demonstrated a marked phenotypic change upon transfection with HOX11 
(Chapter Three). The enforced expression of HOX11 resulted in an apparent dedifferentiation 
to a primitive erythroid phenotype. Cells demonstrated the morphology of immature 
erythroblasts, they displayed decreased haemoglobin synthesis after stimulation with Epo 
and an up-regulation of C-Kit, a marker of progenitor and stem cells which is only expressed 
up to the basophilic erythroblast stage of development (Dolzing et al., 2001; Greene et al., 
2002). Finally J2E cells which ectopically express HOX11 were found in cell adhesion assays 
to be highly adherent (Greene et al., 2002). This is also indicative of an immature cell 
phenotype as early red blood cell development occurs through contact with stromal cells and 
matrix in the bone marrow  (Coulmbel et al., 1991). Thus, expression of HOX11 in the J2E 
erythroid cell line leads to an apparent dedifferentiation. This finding is suggestive of the fact 
that HOX11 has the capacity to function at the very early progenitor stage of haematopoiesis. 
This theory is supported by a study by Hawley et al., (1994), which demonstrated that murine 
bone marrow cells which had been retrovirally transduced with HOX11 displayed a block in 
the early progenitor stage of myeloid differentiation (Hawley et al., 1994). It is possible that 
HOX11 functions in a set of molecular events that eventually direct a cell to differentiate Chapter Seven 
 
303
toward a committed lineage, its expression is then down-regulated in normal development as 
the cell continues down this maturational pathway. This finding also has implications for the 
role of HOX11 in the process of tumorigenesis. HOX11 is one of the most frequently 
deregulated genes in T-ALL (Kees et al., 2003).  A study by Ferrando et al., (2002) examined 
a panel of T-ALL patient samples by GeneChip analysis and found that HOX11 caused an 
apparent arrest at the early cortical thymocyte stage of T-cell development (Ferrando et al., 
2002). Therefore, it is possible that the mechanism by which HOX11 transforms cells involves 
a block in cellular differentiation and/or a deviation from the normal maturational pathway 
toward a process of dedifferentiation. 
In order to identify HOX11 target genes that may play a role in this apparent dedifferentiation, 
RDA was initially undertaken and genes whose expression was up-regulated as a result of 
HOX11 expression in the J2E cell line were identified (Chapter Three). These genes were 
then screened across a panel of murine and human, HOX11 expressing and non-HOX11 
expressing leukaemic cell lines in order to identify candidate HOX11 target genes that may 
be involved in T-cell leukaemogenesis. C-KIT was also included in this analysis as the J2E 
transfectants were characterized by increased surface marker expression by flow cytometric 
analysis and increased gene expression by RT-PCR analysis. OSTEOPONTIN, 
GUANOSINE DISSOCATION INHIBITOR 3 and PAG were all found to be regulated with 
HOX11 in more than one cell line. However, from the available literature the genes could not 
be clearly linked to T-cell leukaemogenesis. C-KIT expression was found to be up-regulated 
with HOX11 expression in the J2E cell line and correlated with HOX11 in a small number of 
T-ALL primary patient samples. Similarly, four out of eight HOX11 positive T-ALL samples 
were found to have up-regulated C-KIT expression in a microarray study by Ferrando et al., 
(2002) (Ferrando et al., 2002, see supplementary data). Additionally, increased C-KIT 
expression has previously been linked to T-ALL and T-cell lymphoma (Tomeczkowski et al., 
1998, Ono et al., 1998, Lecuyer et al., 2002). As a result, C-KIT was thought to be a possible 
candidate HOX11 target gene and was considered worthy of further investigation. 
Due to the representative nature of RDA, concerns were raised that HOX11 target genes 
involved in the perturbation of J2E differentiation may have been overlooked. RDA relies on 
restriction digests, meaning that certain gene fragments cannot be amplified due to their size. 
Additionally, the PCR amplification component of the technique means that may genes that 
require specialized PCR conditions may also be excluded from amplification (Diatchenko et 
al., 1996). The RDA protocol utilized did not incorporate a selective degradation step 
associated with traditional methods and instead relied on a suppressive PCR to prevent 
amplification of non-differential products (Diatchenko et al., 1996; Hubank et al., 1994). As a 
result many `background’ non-differential genes were isolated. In fact four out of nine genes 
screened by Northern blot and/or semi-quantitative RT-PCR appeared to be background Chapter Seven 
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genes which did not appear to be differentially expressed with HOX11 in the J2E cell line. 
cDNA microarray technology was therefore employed during this study, which was likely to 
complement the RDA study on the J2E cell line, as it allows for the systematic screening of 
large numbers of genes in parallel. A large number of genes were identified as being 
differentially regulated with the expression of HOX11. This finding was consistent with the 
role of HOX11 as a homeodomain protein which are known to be able to act as 
transcriptional regulators of many genes with a range of cofactors (Abate-Shen et al., 2002). 
The best studied T-ALL oncogene, MYC, also has numerous target genes (Facchini et al., 
1998). Many of the genes identified would be expected to be associated with the apparent 
phenotypic dedifferentiation of the J2E cell line and would be at the lower end of the HOX11 
transcriptional cascade. In order to facilitate the identification of candidate HOX11 target 
genes associated with T-cell leukaemogenesis, the same Northern blot/ semi-quantitative 
RT-PCR screen across leukaemic cell lines was undertaken. Nine out of fourteen genes 
screened appeared to be non-differential and showed no correlation between levels of gene 
expression and HOX11 expression in the J2E cell line. While PDE9A1, CDC-LIKE KINASE 
and MKP1 were found to be altered with the expression of HOX11 in the J2E cell line, there 
was no clear correlation of their expression in the leukaemic cell lines. VEGFC could not be 
detected in the J2E cell line by Northern blot analysis and could not be assessed by semi-
quantitative RT-PCR and functional primers could not be designed. Nevertheless, it was 
down-regulated in the majority of the clones of the PER-117 T-cell line and its expression 
was up-regulated in two HOX11 positive T-ALL and erythroleukaemic cell lines. Whilst its role 
as a candidate HOX11 target gene was unclear from this analysis, it had previously been 
implicated in acute myeloid leukaemias and acute lymphoblastic leukaemias (Fielder et al., 
1997; Perez-Atayde et al., 1997; Pule et al., 2002) and a more detailed analysis of the 
functional relationship of VEGFC and HOX11 was undertaken. 
During the course of this study it was discovered that considerable variability between 
batches of cDNA microarrays with regard to background and sensitivity poses a problem 
regarding the reproducibility and comparability of cDNA microarrays. Problems associated 
with nonspecific hybridization and ambiguous probe-identity have also been reported 
(Duggan et al., 1999; Brazma et al., 2001; Ross et al., 2000). These factors may lead to 
increased background and false positives. It was also possible that the Northern blot and/or 
semi-quantitative RT-PCR screening methods may have contributed to the high number of 
genes that could not be confirmed as differential from the RDA and cDNA microarray 
experiments. In particular, due to the exponential amplification involved in the semi-
quantitative RT-PCR, it is possible that this technique may underestimate the differential 
expression of a gene between two samples. Additionally, it is possible that in some cases 
due to differences in specific cDNA concentrations the PCR may not have been in the linear Chapter Seven 
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range. Similarly, the quantitative Northern blot analysis had a shortcoming, in that it 
demonstrated low levels of sensitivity. Nevertheless, the semi-quantitative RT-PCR and/or 
Northern blot screening technique was considerably more affordable than real-time PCR 
technology and did not require specialized equipment, and in the case of the known 
difference gene HOX11, there was a good correlation between the two techniques (refer to 
Figure 3.19).   
The expression of many genes identified by RDA and cDNA microarray could not be 
confirmed by the screening technique employed. Affymetrix GeneChip technology became 
available during this study (Chapter Five). The use of multiple independent probe sets was 
thought to greatly improve signal to noise ratios, the accuracy of target quantitation, increase 
the range of detection and minimize effects due to cross hybridization (Lipshutz et al., 1999). 
Thus it was thought that the use of GeneChip technology would reduce the rate of false 
positives and miscalls. The J2E cellular model had identified two main candidate HOX11 
target genes, however, it was possible that many of the differential genes identified in this cell 
line were associated with the drastic phenotypic effects related to the HOX11 
dedifferentiation. Such genes would be expected to be at the lower end of the genetic 
cascade and thus would be less likely to be HOX11 target genes of importance. The user-
friendly nature of GeneChip technology meant that it could be readily applied to multiple cell 
lines in order to help identify target genes of HOX11. This experimental design was based on 
the premise that the previously identified HOX11 target gene ALDH1A1 can have its 
expression altered by HOX11 in different cellular backgrounds (Greene et al., 1998; Greene, 
unpublished observations). Thus, it was expected that genes whose expression was altered 
in more than one cell line would be more likely to be transcriptional targets. The same semi-
quantitative RT-PCR screening technique on the leukaemic cell lines utilized in Chapters 
Three and Four was employed once more. Similar to the other strategies, four out of eight of 
the genes analyzed by semi-quantitative RT-PCR once again appeared to be non-differential 
genes, indicating that there was a low level of correlation between GeneChip technology and 
the semi-quantitative RT-PCR. This finding suggests the need to utilize quantitative real-time 
PCR in order to improve the screening process. Nevertheless, three candidate HOX11 target 
genes were identified in this study. GAS3 was regulated with HOX11 expression in three cell 
lines, however there appeared to be no clear experimental or theoretical evidence linking this 
gene to T-cell leukaemogenesis. Two more genes of interest NOR1 and SMARCD3 were 
found to be consistently up-regulated with HOX11  expression in the PER-117 T-cell 
leukaemia cell line and two HOX11 expressing T-ALL and erythroleukaemic cell lines. 
Additionally, NOR1 was linked to T-cell development (He et al., 2002; Cheng et al., 1997) and 
SMARCD3 to SWI/SNF chromatin remodeling, an important process in oncogenesis Chapter Seven 
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(Klochendler-Yeivin  et al., 2002). Therefore, functional studies investigating the possible 
regulation of the NOR1 and SMARCD3 promoters by HOX11 was undertaken. 
The J2E cellular model was investigated using RDA, cDNA microarray and GeneChip 
technologies, in order to identify genes differentially expressed with HOX11. Surprisingly, 
there was no correlation between the genes identified as being up-regulated by RDA, the top 
100 genes found to be up-regulated by cDNA microarray and the top 50 genes found to be 
up-regulated by GeneChip technology. This finding can only be explained by the intrinsic 
differences between the technologies and differences in the total RNA extraction techniques 
utilized. RDA is a suppressive subtractive technique, which is biased by restriction digestion 
and set PCR conditions (Diatchenko et al., 1996). cDNA microarray involves PCR 
amplification of selected probes and robotic spotting. This technology has bee associated 
with varying background and sensitivity, non-specific hybridization and ambiguous probe 
identity (Duggan et al., 1999; Ross et al., 2000). GeneChip technology utilizes 
photolithographic methods to synthesize oligonucleotide probes for a larger number of genes. 
The process produces cDNA from total RNA and then converts this to biotin cRNA which is 
used as the target. Multiple independent probe sets are also thought to minimize false 
positives and miscalls (Lipshutz et al., 1999). However, all three methods appeared to have a 
false positive rate of at around 50% as judged by the screening methods employed. 
The candidate HOX11 target genes Wt1,  Flh1  and  Aldh1a1 and genes found to be 
associated with HOX11 gene expression signatures in T-ALL patients (Tables 1.4, 1.5) were 
not identified as putative HOX11 target genes by RDA, cDNA microarray or Affymetrix 
microarray in this study (Greene et al., 1998; Dear et al., 1995; Ferrando et al., 2002). These 
genes did not rate within the top 100 up-regulated genes of interest found by Affymetrix or 
cDNA microarray and in may cases the targets were not present on the microarrays. Whilst 
these findings are disappointing, in the cases where the targets were present, this difference 
may be explained by intrinsic differences in the models examined, especially with reference 
to differences between patient samples and cell lines. 
To address the role of C-KIT, VEGFC, NOR1 and SMARCD3 as potential targets of HOX11 
the ability of HOX11 to regulate the promoters of these genes in the PER-117 T-cell line was 
investigated using transient transfection luciferase assays (Chapter Six). Transient co-
transfection assays using proximal promoter regions together with HOX11 resulted in a 
statistically significant repression of the C-KIT and VEGFC proximal promoters. These results 
suggest that C-KIT and VEGFC function as transcriptional targets of HOX11 and lie 
downstream of a HOX11 transcriptional cascade. It is unclear whether these genes are 
directly regulated by HOX11 or if the results represent an indirect effect mediated by other 
factors transcriptionally regulated by HOX11. It is possible, though far from certain, that the Chapter Seven 
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HOX11 homeodomain directly binds DNA of the proximal C-KIT promoter at the TAAGTG 
and CAATTA putative HOX11 binding sites (Dear et al., 1993; Tang et al., 1995). 
Nevertheless, in the case of the VEGFC proximal promoter region, no putative HOX11 
binding sites were identified. In the case of VEGFC, the repression observed in the luciferase 
reporter assays correlated with the cDNA microarray and Northern blot results. For C-KIT, 
however, characterization of the J2E erythroid cell line by flow cytometry and PCR analysis 
indicated an increase in expression of C-Kit with HOX11 expression, while the luciferase 
reporter assays indicated down-regulation in the PER-117 T-cell line. This discrepancy may 
be due to a different cellular context which can affect cofactor availability and phosphorylation 
status, both of which can affect DNA binding sub-cellular localization and interaction with 
transcriptional machinery (Allen et al., 2000; Yokoyama et al., 2002; Weiss et al., 2004). 
Distal regulatory elements, absent from the luciferase constructs, may also be important in 
transcriptional regulation. Both activation and repression by HOX11 of the known HOX11 
target gene ALDH1A1, depending on the cellular context has been reported (Greene et al., 
1998; Greene, unpublished observations) suggesting that the function of HOX11 may be 
complex. 
Many possible molecular mechanisms of both a direct and indirect nature may account for 
the observed repression of VEGFC and C-KIT by HOX11. Indirect mechanisms include 
competition for transcription factor binding sites, quenching of transcriptional activators and 
interaction with transcriptional co-repressors (refer to Section 6.3) (Owens et al., 2002). Of 
note, HOX11 possesses a FIL repression motif required for interaction with Groucho related 
co-repressors. Several HOX proteins are known to interact with Groucho proteins and the FIL 
motif in HOX11 has been identified as being important in transcriptional activation (Masson et 
al., 1998). Other mechanisms include direct repression through interaction of HOX11 with 
components of the transcriptional machinery. Owens et al., (2003) reported that HOX11 is 
able to interact with the RNA polymerase II holoenzyme in order to repress the SV40, HSVtk, 
CMV and neu promoters (Owens et al., 2003). Intriguingly, activation was observed when C-
KIT and VEGFC proximal promoters were transfected with a HOX11 mutant lacking the third 
helix of the homeodomain. A significant difference was also noted when HOX11 experiments 
were compared to homeodomain mutant experiments in the case of the NOR1 proximal 
promoter. This finding suggests that the HOX11 homeodomain plays a crucial role in the 
regulation of NOR1, C-KIT and VEGFC gene expression. It is noteworthy, that these findings 
are in accordance with those of Owens et al., 2003 who reported that a fully intact 
homeodomain was required for HOX11 to repress a range of promoters (Owens et al., 2003). 
HOX11 may be bi-functional depending on whether it binds DNA or not or alternatively the 
homeodomain may affect cofactor binding or putative homodimerization (refer to Section 6.3). Chapter Seven 
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The role HOX11 plays in the regulation of the C-KIT and VEGFC promoter regions in T-ALL 
is unclear. The ideal cellular model for the study of HOX11-mediated T-cell leukaemogenesis 
is not yet available and given differences in the cellular millieu and the fact that only the 
proximal promoter region of these genes was analyzed in functional assays, it is possible that 
HOX11 may activate or repress these genes in T-ALL. Nevertheless, this study demonstrates 
the ability of HOX11 to regulate the proximal promoters of VEGFC and C-KIT, identifying 
them as putative target genes. 
C-KIT is known to be expressed in early haematopoietic cells and most importantly is thought 
to play a role in the early stages of T-cell development (Tomeczkowski et al., 1998; Godfrey 
et al., 1994; Matsuzaki et al., 1993; Reilly, 2003). It is thought to play and important role in the 
survival and self renewal of cells as the binding of C-KIT to SCF results in activation of JAK-
STAT, PI-3 kinases and MAP kinase pathways that promote cell growth and differentiation 
(Reilly, 2003). A number of studies have implicated its expression in leukaemia. In AML C-
KIT expression can be detected in 60-90% of de novo cases. Additionally SCF stimulation of 
leukaemic blasts has been shown to result in increased C-KIT tyrosine phosphorylation and 
proliferation, suggesting a functional role for C-KIT in AML (Ikeda et al., 1991; Broudy et al., 
1992). Notably, a study by Tomeczkowski et al., (1998) investigated the expression and 
regulation of C-KIT in cells from children with T-cell lymphoma and T-cell acute lymphoblastic 
leukaemia. C-KIT receptors were detected in three out of seven T-lymphoblastic cell lines 
and nine out of 21 biopsy tumour preparations. Additionally, a proliferative response by SCF 
was detected in three cell preparations, indicating that C-KIT is able to transduce a growth 
stimulatory signal in some T-lymphoblastic cells. A large study of C-KIT expression in fresh 
blast cells of 376 newly diagnosed cases of ALL reported that the C-KIT receptor is 
expressed in 10% of T-lineage cases (Legitimo et al., 1999). Finally, a study by Ferrando et 
al., 2002 also detected up-regulated C-KIT levels in four out of eight T-ALL patient samples 
(Ferrando et al., 2002, see supplementary data).  Thus abundant evidence exists to implicate 
the aberrant expression of both HOX11 and C-KIT in T-ALL and one fruitful line of 
investigation now would be to determine whether expression of these two genes correlates in 
a large sample of primary T-ALL specimens. Notably, the SCL/LMO complex of transcription 
factors which play an important role in T-ALL has been shown to directly regulate the 
ALDH1A2 and C-KIT genes (Ono et al., 1998; Lecuyer et al., 2002). Similarly ALDH1A1 is a 
known HOX11 target gene (Greene et al., 1998). If C-KIT can also be confirmed as a HOX11 
target gene a common transcriptional pathway of leukaemogenesis in T-ALL may be 
implicated. 
VEGFC or VASCULAR ENDOTHELIAL GROWTH FACTOR C, is a growth factor that 
functions in lymphangiogenesis. VEGFC activated VEGFR-3 and VEGFR-2, which are 
expressed in both blood vessel and lymphatic vessel endothelia. Proteolytic cleavage is an Chapter Seven 
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important regulator of the receptor binding and thus the biological activity of VEGFC 
(Karkkainen et al., 2004). VEGFC and its receptors have been implicated in acute myeloid 
leukaemias (Fielder et al., 1997; Oprana et al., 2002). Once up-regulated, VEGFC is thought 
to play a role in an angiogenic paracrine loop involving its receptor VEGFR-3 which is thought 
to contribute to leukaemic cell survival through up-regulation of the anti-apoptotic gene Bcl-2 
(Oprana et al., 2002; Dias et al., 2002). Vascularity and angiogenic factors are increased in 
acute and chronic leukaemias and myelodysplastic syndromes and may play a significant 
role in the course and disease process. The reported increased vascularity in pediatric ALL, 
AML and MDS, the prognostic importance of VEGFC in AML and the detection of angiogenic 
factor receptors, suggest that angiogenic factors may have a direct effect on marrow 
vascularity and leukaemic cells (Perez-Atayde et al., 1997; Hussong et al., 2000; Aguayo et 
al., 1999; Pruneri et al., 1999; Aguayo et al., 2000). The fact that HOX11 is expressed in the 
outflow tracts of the heart during development is suggestive of a possible role in the process 
of angiogenesis (Roberts et al., 1995; Dear et al., 1995). Additionally, in a study by Yu et al., 
(2002) they retrovirally transduced yolk sac cells with HOX11 in order to establish cell lines.  
Distinct types of yolk sac cell populations were immortalized including one which consisted of 
a plastic adherent, endothelial like cell and a non-adherent suspension cell. When these cells 
were seeded onto matrigel coated wells, a majority of the cells attached and differentiated 
into capillary like structures. Even though complete endothelial development could not be 
demonstrated, a low percentage of cells positive for VEGF receptors Flk-1 and Flt-1 were 
detected by flow cytometric analysis, suggesting that they have endothelial-like differentiation 
capacity (Yu et al., 2002). Accordingly, it is tempting to speculate that HOX11 may play a role 
in the process of angiogenesis through the regulation of target genes such as VEGFC. 
Whilst it appears that both C-KIT and VEGFC are transcriptionally regulated by HOX11, a 
number of additional studies could be undertaken in order to confirm their role as target 
genes. Functional studies within T-cells derived from transgenic mice or inducible T-cell 
systems in order to document the activation of these genes by HOX11 would be of great 
interest. Chromatin immunoprecipitation (ChIP) analysis could also be employed to determine 
whether C-KIT and VEGFC are direct target genes. In addition, expression analysis using 
GeneChip technology of a panel of primary T-ALL patient samples, including those that 
express high levels of HOX11 would clearly establish the role of these candidate target genes 
in T-cell leukaemogenesis. Of crucial importance would be to determine whether these 
transcriptional targets account for the oncogenic activity of HOX11, this could be 
accomplished by creating T-cell transgenic mice for C-KIT or VEGFC, or possibly by using 
siRNA to observe the effects of lowering C-KIT or VEGFC levels in HOX11 transgenic mice 
and cell models. Chapter Seven 
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Both C-KIT and VEGFC are involved in signal transduction pathways as a receptor tyrosine 
kinase and a tyrosine kinase ligand respectively. Tyrosine kinases, which catalyze the 
transfer of a phosphate group from ATP, play a key role in the regulation of signal 
transduction for a number of cellular functions including proliferation, differentiation, apoptosis 
and cell cycle progression. It is known that a number of receptor tyrosine kinases are 
expressed on normal haematopoietic tissue and that many have been linked to the 
pathogenesis of leukaemia (Reilly, 2003). Their importance is illustrated by the fact that, 
clinically, a number of small molecule tyrosine kinase inhibitors have been utilized as anti-
tumour therapies. The most notable of which is STI571 (imatinib mesylate, Gleevec) which 
was originally applied to CML to inhibit BCR-ABL in leukaemic cells and induce apoptosis. 
STI571 was found to be highly effective in the early stages of CML, however, at later stages 
of the disease mutations were found to arise. The action of ST571 extends to C-KIT and it 
has also been successfully applied to gastrointestinal stromal tumours (GISTs) which exhibit 
constitutive activation of the KIT receptor in 60-70% of cases (Weisberg et al., 2003). Trials 
are also underway for the use of this inhibitor for the treatment of C-KIT positive small cell 
lung cancers which are often characterized by a C-KIT and SCF autocrine loop (Vlahovic et 
al., 2003). Another small molecule vascular endothelial growth factor tyrosine kinase receptor 
inhibitor SU5416 has also been studied in AML. It was shown that the drug reduced 
expression of VEGFR-1 and 2 receptors in cell lines and was a potent inhibitor of VEGF 
endothelial cell sprouting. The drug also appeared to have a dual mode of action as it also 
directly inhibited C-KIT (Spiekermann et al., 2002). Studies were extended to leukaemic 
blasts from C-KIT positive AML patients, where the drug inhibited SCF induced 
phosphorylation of C-KIT and induced apoptosis (Smolich et al., 2001). Finally, a study of 
forty-two patients with advanced AML found that in eight cases a partial response occurred. 
Patients with high levels of VEGF expression were found to have a higher response rate in 
this study (Fielder et al., 2003). The involvement of active receptor tyrosine kinases in 
haematopoietic malignancies, targeted inhibition of active tyrosine kinases in combination 
with commonly used anti-leukaemic drugs is a therapeutic modality of promise, although it 
remains to be determined whether this is applicable to T-ALL (Kano et al., 2001). Further 
work should clarify the role of C-KIT and VEGFC as downstream effectors of HOX11 as well 
as characterize their exact mode or regulation. Nevertheless, the work outlined in this thesis 
tentatively implicates receptor tyrosine kinases in HOX11-mediated tumorigenesis and serves 
to underscore their importance in haematological malignancies. 
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Appendix 1 
Cell Type 
 
Description Expression 
Level 
Reference 
Murine Thymus  Embryonic Day 13.5  +  Yamamoto et al., 1995 
Thymus  Human 2 weeks old  -  Zutter  et al., 1990, 
Hatano et al., 1991 
T-cells  Thymocytes and Splenocytes  -  Yamamoto et al., 1995 
T-cells  Peripheral blood, adult, human 
91.3% T-cell purity 
- Kees  et al., 2003 
T-cells  Peripheral blood, adult, human   
76% T-cell purity 
++ Lu  et al., 1992 
ALL-SIL    Acute T-cell leukaemia T-cell line 
harbouring t(10;14) (q24;q11) 
translocation 
++++ Lu  et al., 1992 
1582  Acute T-cell leukaemia T-cell line 
harbouring t(10;14) (q24;q11) 
translocation 
+++ Hatano  et al., 1991 
996  Acute T-cell leukaemia T-cell line 
harbouring t(10;14) (q24;q11) 
translocation 
++++ Hatano  et al., 1991 
519    Acute T-cell leukaemia T-cell line 
harbouring t(10;14)(q24;q11) 
+++ Zutter  et al., 1990 
HPB-ALL  Acute T-cell leukaemia T-cell line  +++  Lu et al., 1992 
Jurkat  Acute T-cell leukaemia T-cell line  +++  Lu  et al., 1992, 
Yamamoto et al., 1995  
Zhang et al., 1993 
CTLL-2  Cytotoxic T-cell line  +  Yamamoto et al., 1995 
EL-4  T-cell lymphoma cell line  +  Yamamoto et al., 1995 
3D0 T-cell  line  +  Yamamoto  et al., 1995   313
RPMI 8402  T-cell line CD3- with translocation 
t(11;14)(p15;q11) 
- Zutter  et al., 1990, 
Hatano et al., 1991 
Hut 78  αβ T-cell line derived from T-cell 
lymphoma 
- Hatano  et al., 1991 
Det  αβ T-cell line  - Hatano  et al., 1991 
CEM  Acute lymphoblastic leukaemia T-
cell line CD3-, αβTCR 
- Zutter  et al., 1990, 
Hatano et al., 1991 
HSB-2  Acute lymphoblastic leukaemia T-
cell line CD3-, Arrested at δTCR 
deletion 
- Zutter  et al., 1990, 
Hatano et al., 1991 
Peer  γδT-cell line   - Zutter  et al., 1990, 
Hatano et al., 1991 
Mv  γδT-cell line  - Zutter  et al., 1990, 
Hatano et al., 1991 
702  γδT-cell line  - Zutter  et al., 1990, 
Hatano et al., 1991 
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Appendix 2 
Cell Line  Description  Expression 
Level 
Reference 
Haematopoietic Tissues 
Murine Thymus  Embryonic Day 13.5  +  Yamamoto et al., 1995 
Murine Spleen  Embryonic Day 13.5  ++++  Yamamoto et al., 1995 
Murine Liver  Embryonic Day 13.5  -  Yamamoto et al., 1995 
Murine Yolk Sac  Embryonic Day 13.5  -  Yamamoto et al., 1995 
Human Spleen  Adult  -  Hatano et al., 1991 
Murine liver  Adult  +  Hatano et al., 1991 
Human liver   Adult  +  Hatano et al., 1991 
Hep G2  Hepatocellular carcinoma cell line  -  Hatano et al., 1991 
B-Cell Lines 
Reh  Pre B-cell line  -  Zutter et al., 1990 
Nalm6   Pre B-cell line  -  Lu  et al., 1992  
Zutter  et al., 1990 
Hatano et al., 1991 
Daudi B-cell  line  -  Lu  et al., 1992 
BJAB  Burkitt lymphoma B-cell line  -  Hatano et al., 1991 
Raji  Burkitt lymphoma B-cell line  -  Lu  et al., 1992  
Zutter  et al., 1990 
Hatano et al., 1991 
Other Tumorigenic Haematopoietic Cell Lines 
K562  CML in blast crisis with embryonic 
erythroleukaemia phenotype. 
+++ Lu  et al., 1992 
Mye 4  Multiple myeloma cell line  -  Lu et al., 1992 
Mye 7  Multiple myeloma cell line  -  Lu et al., 1992 
KM HD2  Hodgkin’s lymphoma cell line  -  Lu et al., 1992   315
L428  Hodgkin’s lymphoma cell line  -  Lu et al., 1992 
U937  Monoblastic leukaemia cell line  -  Zutter et al., 1990 
HL-60 Promyelocytic  leukaemia  - Hatano  et al., 1991 
Other Cell Lines 
N2A  Neuroblastoma cell line  -  Hatano et al., 1991 
N417  Neuroblastoma cell line  +  Kennedy et al., 1991 
SK-N-SH   Neuroblastoma cell line  +  Lu et al., 1992 
H209  Small cell lung carcinoma cell line  ++++  Lu et al., 1992 
U1285  Small cell lung carcinoma cell line  +++  Kennedy et al., 1991 
D3  Embryonal stem cell line  -  Hatano et al., 1991 
FSH173WE  Normal human embryo cell line  +  Lu et al., 1992 
 
TABLE 2 EXPRESSION OF HOX11 IN HAEMATOPOIETIC TISSUES AND CELL LINES 
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TABLE A  
CLONTECH PCR-Select Subtraction Kit cDNA Synthesis Protocol 
1.    Poly A+RNA      2ug 
  cDNA synthesis primer 10uM  1ul 
   H20 to final volume     5ul 
2. Incubate at 70ºC for 2min 
3. Cool tubes on ice for 2min 
4. Add the following; 
                         5x first strand buffer       2ul 
                         dNTP mix (10mM)      1ul 
                         Sterile H20     1ul 
                         AMV reverse transcriptase(20units/ul)  1ul 
5. Gently vortex and centrifuge tubes 
6. Incubate the tubes at 42°C for 1.5hr in an air incubator 
7. Place the tubes on ice to terminate first-strand cDNA synthesis. 
8. Add the following; 
                         Sterile H20     48.4ul 
                         5x Second Strand Buffer     16.0ul 
                         dNTP mix(10mM)      1.6ul 
                         20x Second Strand Enzyme Cocktail  4.0ul 
9. Mix contents and briefly spin tubes. The final volume should be 80ul 
10. Incubate tubes at 16°C for 2hr 
11. Add 2ul (6 units) of T4 DNA polymerase. Mix contents well 
12. Incubate the tube at 16°C for 30min in a water bath 
13.Add 4ul of 20xEDTA/glygogen mix to terminate second strand synthesis 
14. Add 100ul of phenol:chloroform:isoamyl alcohol (25:24:1) to aqueous 
layer 
15. Vortex thoroughly and centrifuge the tubes at 14000rpm for 10min at 
room temperature 
16. Carefully remove the aqueous layer and place in a clean 0.5ml 
microcentrifuge tube. Discard the lower phase and interphase 
17. Add 100ul of chloroform:isoamly alcohol (24:1) to aqueous layer 
17. Repeat steps 15-16 
18. Add 40ul of 4M NH4OAc and 300ul of 95% Ethanol  
19. Vortex thoroughly and centrifuge at 14000rpm for 20min at room 
temperature 
20. Remove supernatant 
21. Wash with 500ul 80% ethanol 
22. Air dry pellet and dissolve in 50ul of H20. 
OPTIMIZATION OF THE CLONTECH PCR SELECT -cDNA SUBTRACTION KIT  
TABLE 3A Outlines the cDNA synthesis protocol from the CLONTECH PCR Select Subtraction Kit 
(Clontech Laboratories Inc., 1999)   317
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE B 
Alternative cDNA Synthesis Protocol 
1.   Poly A+ RNA        5ug 
  OligodT Primer (300ng/ul)    6ul 
  RNase free H20 to final volume    20ul 
2. Incubate at 70°C for 10min 
3. Cool tubes on ice for 5min 
4. Combine the following and then add to denatured RNA, mix by gently 
pipetting up and down; 
  5x RT Buffer    8ul 
 0.1M  DTT   2ul 
 10mM  dNTP   4ul 
  RNase free H20   2ul 
5. Add 2ul of RNase OUT(40U/ul) and gently mix 
6. Add 2ul of Thermoscript (15U/ul) and gently mix 
7. Incubate for 1hr at 50°C 
8. Terminate reaction, incubate at 85°C for 5min 
9. Add the following; 
  5X Second Strand Synthesis Buffer  40ul 
 15mM  βN A D      2 u l  
   Sterile H20     112ul 
  E.coli DNA ligase (10U/ul)    0.5ul 
  E.coli DNA polymerase I (10U/ul)  4ul 
 RNase  H  (2U/ul)   1.5ul 
10. Incubate at 15°C for 2hr and then at 22°C for 1hr 
11. Add 50ul of water 
12. Add 250ul of phenol:chloroform:isoamylalcohol (25:24:1) to aqueous 
layer 
13. Vortex thoroughly and centrifuge the tubes at 14000rpm for 10min at 
room temperature 
14.Carefully remove the aqueous layer and place in a clean 0.5ml 
microcentrifuge tube. Discard lower phase and interphase. 
15. Add 100ul of chloroform:isoamlyalcohol (24:1) to aqueous layer 
16. Repeat steps 13-14 
17. Add the following; 
 Glycogen  carrier  2ug 
  10M Ammonium acetate  65ul 
  100%  Ethanol    800ul 
18. Leave on ice for 15min 
19. Pellet cDNA by centrifuging at 14000rpm for 20min at 4°C 
20. Wash with 500ul 80% ethanol 
21. Air dry pellet and dissolve in 30ul of TE buffer 
 
TABLE 3B Outlines the alternative cDNA synthesis protocol used in conjunction with the Clontech 
PCR Select -cDNA Subtraction Kit. Underlining is used in order to indicate steps of the protocol 
that differ significantly from that outlined in TABLE 3A.   318
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SIGNAL 
LOG RATIO  GENE DESCRIPTIONS 
5.2  Mus musculus follistatin-like protein mRNA, complete cds. 
4.5 
Mus musculus CDK4 and CDK6 inhibitor protein (p16ink4a) mRNA, 
complete cds. 
3.8 
Mus musculus TNF receptor associated factor 1 (TRAF1) mRNA, complete 
cds. 
3.7  Mus musculus preprodipeptidyl peptidase I mRNA, complete cds. 
3.6 
mn98b07.r1 Stratagene mouse lung 937302 Mus musculus cDNA clone 
552085 5, mRNA sequence. 
3.5 
mu48a11.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
642620 5, mRNA sequence. 
3.5 
mu15h03.r1 Soares 2NbMT Mus musculus cDNA clone 639509 5 similar to 
SW:YKA2_YEAST P36108 HYPOTHETICAL 16.7 KD PROTEIN MRP17-
MET14 INTERGENIC REGION. ;, mRNA sequence. 
3.5 
EST01649 Mouse 7.5 dpc embryo ectoplacental cone cDNA library Mus 
musculus cDNA clone C0012F02 5, mRNA sequence. 
3.5  Mus musculus neuropilin-2(a17) mRNA, alternatively spliced, complete cds. 
3.5  Mouse mRNA for pituitary adenylate cyclase activating polypeptide. 
3.5  Mouse mRNA for beta-preprotachykinin A, complete cds. 
3.4 
mv52e05.r1 Soares mouse 3NME12 5 Mus musculus cDNA clone 658688 5, 
mRNA sequence. 
3.4 
Mus musculus sulfonylurea receptor 2A (SUR2) mRNA, alternatively spliced, 
complete cds. 
3.4  Mouse low affinity IgE receptor (Fc-epsilon-RII) mRNA, complete cds. 
3.4  Mus musculus calcium-activated potassium channel mRNA, complete cds. 
3.3 
vg40c12.r1 Soares mouse mammary gland NbMMG Mus musculus cDNA 
clone 863830 5, mRNA sequence. 
3.3 
House mouse; Musculus domesticus adult testis mRNA for truncated form of 
Sox17, complete cds. 
3.1  Mus musculus killer cell surface molecule mRNA, complete cds. 
3.1  Mus musculus lysophosphatidic acid receptor (vzg-1) mRNA, complete cds. 
3 
mz46g09.r1 Barstead mouse pooled organs MPLRB4 Mus musculus cDNA 
clone 716512 5, mRNA sequence. 
3 
vc05f11.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
765645 5, mRNA sequence. 
3  Mus musculus SOX11 (Sox11) mRNA, complete cds. 
3  Mus musculus prolactin-like protein F precursor, mRNA, complete cds. 
3  Mouse mRNA for mouse a1(XI) collagen chain. 
3  Mouse lymphocyte differentiation antigen (Ly-6.2) mRNA, complete cds. 
3 
Mus musculus nuclear matrix attachment DNA-binding protein SATB1 
mRNA, complete cds. 
2.9 
mx78f05.r1 Soares mouse NML Mus musculus cDNA clone 692481 5 similar 
to gb:X15684 Mouse mRNA for liver-type glucose transporter protein 
(MOUSE);, mRNA sequence. 
2.9 
vn05b05.r1 Knowles Solter mouse blastocyst B1 Mus musculus cDNA clone 
1006833 5, mRNA sequence. 
2.9  Mus musculus putative pheromone receptor (VR1) mRNA, complete cds. 
2.9  Mus musculus amine N-sulfotransferase (SULT-N) mRNA, complete cds. 
2.9  Mouse mRNA for B-cell surface molecule RP105, complete cds. 
2.9  Mouse c-myc gene exon 3.   319
2.9 
Mus musculus (clones p10a-[1.5n,1.7]b and pG4-14) lysyl oxidase gene, 
exon 7 and complete cds. 
2.9  Mus musculus domesticus phosducin mRNA sequence. 
2.9  Mus musculus mel (MEL91) mRNA, complete cds. 
 
TABLE 4 KNOWN GENES IN THE FIFTY MOST UP-REGULATED GENES IDENTIFIED BY 
AFFYMETRIX MICROARRAY IN THE J2E CELL LINE WITH THE EXPRESSION OF HOX11 
AND CORRESPONDING SIGNAL LOG RATIO VALUES 
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SIGNAL 
LOG RATIO  GENE DESCRIPTIONS 
5.1  Mus musculus lumican (Ldc) gene, complete cds. 
4.8  Mus musculus skeletal muscle LIM protein (FLH1) mRNA, complete cds. 
4.3  Mouse plasma-cell membrane glycoprotein PC-1 mRNA, complete cds. 
4 
mi18b09.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 463865 
5, mRNA sequence. 
3.9  Mouse mRNA for proteoglycan, complete cds. 
3.7  Mus musculus basonuclin mRNA, complete cds. 
3.5  Mus musculus p21 mRNA, complete cds. 
3.5 
Mus musculus epsilon tyrosine phosphatase (Ptpre) mRNA, transmembranal 
isoform, complete cds. 
3.4 
vb89d09.r1 Soares mouse 3NbMS Mus musculus cDNA clone 764177 5, 
mRNA sequence. 
3.4 
vn85d07.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 
1038733 5, mRNA sequence. 
3.4  Mus musculus NIH 3T3 chemokine rantes (Scya5) gene, complete cds. 
3.2  Mouse mRNA for ISBT, complete cds. 
3.1 
vq57b07.r1 Barstead mouse proximal colon MPLRB6 Mus musculus cDNA 
clone 1106389 5, mRNA sequence. 
3.1  Mus musculus hemopexin mRNA, partial cds. 
3 
mz77e03.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
719452 5 similar to gb:M90696 CATHEPSIN S PRECURSOR (HUMAN);, 
mRNA sequence. 
2.9 
mp72d09.r1 Soares 2NbMT Mus musculus cDNA clone 574769 5, mRNA 
sequence. 
2.9  Mus musculus hybrid receptor gp250 precursor, mRNA, partial cds. 
2.9 
Mouse myb proto-oncogene mRNA encoding 71 kd myb protein, complete 
cds. 
2.9 
Mus musculus suppressor of cytokine signalling-2 (SOCS-2) mRNA, 
complete cds. 
2.8 
mz97d09.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
721361 5, mRNA sequence. 
2.8 
vn65h01.r1 Barstead mouse proximal colon MPLRB6 Mus musculus cDNA 
clone 1026097 5, mRNA sequence. 
2.8 
vt25e04.r1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone 
1164126 5, mRNA sequence. 
2.7 
va32f06.r1 GuayWoodford Beier mouse kidney day 7 Mus musculus cDNA 
clone 733091 5, mRNA sequence. 
2.7 
vj69g03.r1 Knowles Solter mouse blastocyst B1 Mus musculus cDNA clone 
934324 5 similar to SW:RNBP_PIG P17560 RENIN-BINDING PROTEIN ;, 
mRNA sequence. 
2.7 
vo04a01.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone 
1040424 5, mRNA sequence. 
2.7  Mus musculus prolactin-like protein F precursor, mRNA, complete cds. 
2.7  Mouse salivary protein 2 mRNA, complete cds. 
2.7  Mus musculus laminin gamma 2 chain (B2t) mRNA, complete cds. 
2.6 
mu46a01.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
642408 5, mRNA sequence. 
2.6 
mx24h07.r1 Soares mouse NML Mus musculus cDNA clone 681181 5, 
mRNA sequence.   321
2.6  Mouse mRNA for proto-oncogene protein. 
2.6  Mus musculus ubiquitinating enzyme E2-230 kDa mRNA, partial cds. 
2.5 
Mus musculus /REF=X00686 /DEF=Mouse gene for 18S rRNA /LEN=1869 
(_5, _M, _3 represent transcript regions 5 prime, Middle, and 3 prime 
respectively) 
2.5 
vb48a04.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
752142 5, mRNA sequence. 
2.5 
vb24e02.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 
749882 5, mRNA sequence. 
2.5 
vu74f05.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone 
1197153 5, mRNA sequence. 
2.5  Mouse mRNA for pituitary adenylate cyclase activating polypeptide. 
 
TABLE 5 KNOWN GENES IN THE FIFTY MOST UP-REGULATED GENES IDENTIFIED BY 
AFFYMETRIX MICROARRAY IN THE NIH3T3 CELL LINE WITH THE EXPRESSION OF 
HOX11 AND CORRESPONDING SIGNAL LOG RATIO VALUES 
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SIGNAL 
LOG RATIO 
1             2  GENE DESCRIPTIONS 
7.7 3.6 
Cluster Incl. W26469:32f4 Homo sapiens cDNA /gb=W26469 /gi=1307375 
/ug=Hs.136639 /len=754 
6.4 5.1 
Cluster Incl. X02160:Human mRNA for insulin receptor precursor 
/cds=(48,4160) /gb=X02160 /gi=33972 /ug=Hs.89695 /len=5180 
5.6  4.5  Homo sapiens mRNA for orphan nuclear hormone receptor 
5.2  2.7  p50-NF-kappa B homolog [human, peripheral blood T cells, mRNA, 3113 nt] 
5.2 3.5 
Cluster Incl. X89399:Homo sapiens mRNA for Ins(1,3,4,5)P4-binding protein 
/cds=(46,2550) /gb=X89399 /gi=2653401 /ug=Hs.199026 /len=2837 
5 2.9 
Cluster Incl. D50924:Human mRNA for KIAA0134 gene, complete cds 
/cds=(286,2016) /gb=D50924 /gi=1469190 /ug=Hs.151706 /len=4345 
5 4 
Cluster Incl. U10301:Human glutamate receptor flip isoform (GluR3-flip) 
mRNA, complete cds /cds=(53,2737) /gb=U10301 /gi=507826 
/ug=Hs.100014 /len=3056 
4.8 4.1 
Cluster Incl. AI239869:qh33a12.x1 Homo sapiens cDNA, 3 end 
/clone=IMAGE-1846462 /clone_end=3   /gb=AI239869 /gi=3835266 
/ug=Hs.172838 /len=421   
4.7 2.5 
Cluster Incl. X63575:H.sapiens mRNA for plasma membrane calcium 
ATPase /cds=(70,3801) /gb=X63575 /gi=2193883 /ug=Hs.995 /len=4511 
4.6 2.8 
Cluster Incl. AF010235:Homo sapiens mRNA from chromosome 5q31-33 
region /cds=UNKNOWN /gb=AF010235 /gi=2707622 /ug=Hs.18593 
/len=1184 
4.6 1.5 
Cluster Incl. M62839:Human apolipoprotein H mRNA, complete cds 
/cds=UNKNOWN /gb=M62839 /gi=178856 /ug=Hs.1252 /len=1185 
4.3 1.9 
Cluster Incl. AL050137:Homo sapiens mRNA; cDNA DKFZp586L151 (from 
clone DKFZp586L151) /cds=(0,1300) /gb=AL050137 /gi=4884149 
/ug=Hs.43658 /len=1810 
4.3 3.7 
Cluster Incl. AF070547:Homo sapiens clone 24820 mRNA sequence 
/cds=UNKNOWN /gb=AF070547 /gi=3387909 /ug=Hs.146312 /len=2322 
4.3 1.9 
Cluster Incl. U55184:Human G protein Golf alpha gene /cds=(3197,4342) 
/gb=U55184 /gi=4097328 /ug=Hs.154145 /len=10539 
4.2 3.9 
Cluster Incl. W26805:13a12 Homo sapiens cDNA /gb=W26805 /gi=1305889 
/ug=Hs.169441 /len=629 
4.1 4 
Cluster Incl. AB001328:Homo sapiens mRNA for pH-sensing regulatory 
factor of peptide transporter, complete cds /cds=(66,692) /gb=AB001328 
/gi=2506042 /ug=Hs.207825 /len=1704 
4.1 3.3 
Cluster Incl. J04739:Human bactericidal permeability increasing protein 
(BPI) mRNA, complete cds /cds=(30,1493) /gb=J04739 /gi=179528 
/ug=Hs.89535 /len=1813 
4.1 2.1 
Cluster Incl. W27428:32e6 Homo sapiens cDNA /gb=W27428 /gi=1307367 
/ug=Hs.99816 /len=764 
4.1 6.5 
Cluster Incl. D78579:Homo sapiens mRNA for neuron derived orphan 
receptor, complete cds /cds=(731,2611) /gb=D78579 /gi=1651190 
/ug=Hs.80561 /len=3802 
4 2.8 
Cluster Incl. M68840:Human monoamine oxidase A (MAOA) mRNA, 
complete cds /cds=(73,1656) /gb=M68840 /gi=187352 /ug=Hs.183109 
/len=1949 
3.9 1.6 
Cluster Incl. Y18264:Homo sapiens SALL1 gene, exon 1 and joined CDS 
/cds=(240,4214) /gb=Y18264 /gi=4688922 /ug=Hs.123094 /len=4908  
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3.8 1.5 
Cluster Incl. Z98744:histone H2A /cds=(7,399) /gb=Z98744 /gi=3080457 
/ug=Hs.131954 /len=499 
3.8 3.3 
Cluster Incl. M22430:Human RASF-A PLA2 mRNA, complete cds 
/cds=(135,569) /gb=M22430 /gi=190888 /ug=Hs.76422 /len=835 
3.8 2.1 
Cluster Incl. M89957:Human immunoglobulin superfamily member B cell 
receptor complex cell surface glycoprotein (IGB) mRNA, complete cds 
/cds=(94,783) /gb=M89957 /gi=179311 /ug=Hs.89575 /len=1270 
3.8 3.6 
Cluster Incl. AF072099:Homo sapiens immunoglobulin-like transcript 3 
protein variant 1 gene, complete cds /cds=(0,1346) /gb=AF072099 
/gi=3776463 /ug=Hs.67846 /len=1705 
3.8 3.7 
Cluster Incl. U89995:Human DNA binding protein FKHL15 (FKHL15) mRNA, 
complete cds /cds=(688,1818) /gb=U89995 /gi=2078532 /ug=Hs.159234 
/len=3497 
3.7 1.5 
Cluster Incl. L76465:Homo sapiens NAD+-dependent 15 
hydroxyprostaglandin dehydrogenase (PGDH) mRNA, complete cds 
/cds=(17,817) /gb=L76465 /gi=1203983 /ug=Hs.77348 /len=2518 
3.7 3.4  Human  erythroid-specific transcription factor EKLF mRNA, complete cds. 
3.7 2.7 
Cluster Incl. M37815:Human T-cell membrane glycoprotein CD28 mRNA 
/cds=(222,884) /gb=M37815 /gi=180090 /ug=Hs.1987 /len=1638 
3.7 3.8 
Cluster Incl. AL049176:Human DNA sequence from clone 141H5 on 
chromosome Xq22.1-23. Contains parts of a novel Chordin LIKE protein with 
von Willebrand factor type C domains. Contains ESTs, STSs and GSSs 
/cds=(0,767) /gb=AL049176 /gi=4808226 /ug=Hs.82223 /len=3143 
3.6 2.8 
Cluster Incl. U05589:Human ribosomal protein S1 homolog mRNA, partial 
cds /cds=(0,1220) /gb=U05589 /gi=497001 /ug=Hs.371 /len=1478 
3.5 3 
Cluster Incl. AJ245434:Homo sapiens mRNA for G3a protein (G3a gene, 
located in the class III region of the major histocompatibility complex) 
/cds=(49,582) /gb=AJ245434 /gi=5650614 /ug=Hs.84509 /len=738 
3.4  2.8  Human tumor antigen (L6) mRNA, complete cds 
3.4 2.8 
Cluster Incl. AB002338:Human mRNA for KIAA0340 gene, partial cds 
/cds=(0,3163) /gb=AB002338 /gi=2224620 /ug=Hs.199301 /len=6395 
3.3  3.1  Human receptor tyrosine kinase (HEK) mRNA, complete cds 
3.3 3.1 
Cluster Incl. AI378632:tc72g11.x1 Homo sapiens cDNA, 3 end 
/clone=IMAGE-2070212 /clone_end=3   /gb=AI378632 /gi=4188485 
/ug=Hs.239503 /len=476   
3.2 1.4 
Cluster Incl. U79242:Human clone 23560 mRNA sequence 
/cds=UNKNOWN /gb=U79242 /gi=1710189 /ug=Hs.79981 /len=1614 
3.2 2.6 
Cluster Incl. U68488:Human 5-hydroxytryptamine7 receptor isoform d 
mRNA, complete cds /cds=(27,1466) /gb=U68488 /gi=1857144 
/ug=Hs.73739 /len=1518 
3.1 3.3 
Cluster Incl. D89479:Homo sapiens mRNA for ST1B2, complete cds 
/cds=(24,914) /gb=D89479 /gi=2826145 /ug=Hs.129742 /len=1031 
3.1 1.5 
Cluster Incl. M36200:Human synaptobrevin 1 (SYB1) gene /cds=(0,356) 
/gb=M36200 /gi=338624 /ug=Hs.20021 /len=357 
3.1 2.1 
Cluster Incl. AB018292:Homo sapiens mRNA for KIAA0749 protein, partial 
cds /cds=(0,2037) /gb=AB018292 /gi=3882218 /ug=Hs.120228 /len=3628 
3.1 2.3 
Cluster Incl. W26324:28h9 Homo sapiens cDNA /gb=W26324 /gi=1307086 
/ug=Hs.187958 /len=808 
3 3.2 
Cluster Incl. AF040990:Homo sapiens roundabout 1 (robo1) mRNA, 
complete cds /cds=(0,4955) /gb=AF040990 /gi=2804783 /ug=Hs.230104 
/len=4956 
3 2.8 
Cluster Incl. AA165410:zo83h09.s1 Homo sapiens cDNA, 3 end 
/clone=IMAGE-593537 /clone_end=3   /gb=AA165410 /gi=1741469 
/ug=Hs.193606 /len=614    
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2.9 2 
Cluster Incl. AI817618:wk39f01.x1 Homo sapiens cDNA, 3 end 
/clone=IMAGE-2417785 /clone_end=3   /gb=AI817618 /gi=5436697 
/ug=Hs.77558 /len=734   
2.9  2.6  Human cytochrome P4502C9 (CYP2C9) mRNA, clone 25 
2.9 2.8 
Cluster Incl. AA487755:ab13f01.r1 Homo sapiens cDNA, 5 end 
/clone=IMAGE-840697 /clone_end=5   /gb=AA487755 /gi=2215186 
/ug=Hs.8762 /len=596   
2.9 2.6 
Cluster Incl. U59111:Human dermatan sulfate proteoglycan 3 (DSPG3) 
mRNA, complete cds /cds=(46,1014) /gb=U59111 /gi=1794208 
/ug=Hs.169993 /len=1487 
2.8 2.4 
Cluster Incl. J04760:Human slow-twitch skeletal troponin I (TNN1) mRNA, 
complete cds /cds=(76,639) /gb=J04760 /gi=339964 /ug=Hs.84673 /len=816 
2.8  2.8  HUMGNRHR Homo sapiens GnRH receptor mRNA; complete cds. 
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Appendix 7 
 
 
SIGNAL 
LOG RATIO 
1             2  GENE DESCRIPTIONS 
5.7 2.5 
Cluster Incl. U78516:Homo sapiens cAMP-regulated guanine nucleotide 
exchange factor II (cAMP-GEFII) mRNA, complete cds /cds=(108,3143) 
/gb=U78516 /gi=4115908 /ug=Hs.91971 /len=4268 
5 3.8 
Cluster Incl. U29700:Human anti-mullerian hormone type II receptor 
precursor gene, complete cds /cds=(78,1799) /gb=U29700 /gi=1136441 
/ug=Hs.123014 /len=1855 
4.8 2.8 
Cluster Incl. AL049270:Homo sapiens mRNA; cDNA DKFZp564G223 (from 
clone DKFZp564G223) /cds=UNKNOWN /gb=AL049270 /gi=4500019 
/ug=Hs.148907 /len=1701 
4.8 2.2 
Cluster Incl. M89796:Human high affinity IgE receptor beta chain gene, 
complete cds /cds=(102,836) /gb=M89796 /gi=337417 /ug=Hs.30 /len=3729 
4.7 3.6 
Cluster Incl. L12760:Human phosphoenolpyruvate carboxykinase (PCK1) 
gene, complete cds with repeats /cds=(8,1876) /gb=L12760 /gi=307332 
/ug=Hs.1872 /len=2372 
4.7  5.7  HSGCSFG Human gene for granulocyte colony-stimulating factor (G-CSF) 
4.6 2.6 
Cluster Incl. D17570:Human mRNA for zona-pellucida-binding protein 
(sp38), complete cds /cds=(36,1091) /gb=D17570 /gi=498161 /ug=Hs.99875 
/len=1177 
4.4 3.5 
Cluster Incl. X93086:H.sapiens mRNA for biliverdin IX alpha reductase 
/cds=(60,950) /gb=X93086 /gi=1246748 /ug=Hs.81029 /len=1053 
4.1 2.9 
Cluster Incl. W26469:32f4 Homo sapiens cDNA /gb=W26469 /gi=1307375 
/ug=Hs.136639 /len=754 
3.9 3.6 
Cluster Incl. L05144:Homo sapiens (clone lamda-hPEC-3) 
phosphoenolpyruvate carboxykinase (PCK1) mRNA, complete cds 
/cds=(121,1989) /gb=L05144 /gi=189944 /ug=Hs.1872 /len=2657 
3.8 2.7 
Cluster Incl. N95229:zb53g09.s1 Homo sapiens cDNA, 3 end 
/clone=IMAGE-307360 /clone_end=3   /gb=N95229 /gi=1267510 
/ug=Hs.25816 /len=521   
3.8 2.1 
Cluster Incl. U85943:Homo sapiens mRNA-associated protein mrnp41 
mRNA, complete cds /cds=(280,1386) /gb=U85943 /gi=2231591 
/ug=Hs.196209 /len=1705 
3.6 2.4 
Cluster Incl. U10301:Human glutamate receptor flip isoform (GluR3-flip) 
mRNA, complete cds /cds=(53,2737) /gb=U10301 /gi=507826 
/ug=Hs.100014 /len=3056 
3.4 2.9 
Cluster Incl. L76465:Homo sapiens NAD+-dependent 15 
hydroxyprostaglandin dehydrogenase (PGDH) mRNA, complete cds 
/cds=(17,817) /gb=L76465 /gi=1203983 /ug=Hs.77348 /len=2518 
3.3  2.9  Human mRNA for FGF-9, complete cds 
3.2 3 
Cluster Incl. U66619:Human SWI/SNF complex 60 KDa subunit (BAF60c) 
mRNA, complete cds /cds=(180,1589) /gb=U66619 /gi=1549246 
/ug=Hs.77069 /len=1724 
2.9 2.4 
Cluster Incl. AF072099:Homo sapiens immunoglobulin-like transcript 3 
protein variant 1 gene, complete cds /cds=(0,1346) /gb=AF072099 
/gi=3776463 /ug=Hs.67846 /len=1705 
2.8 2.4 
Cluster Incl. M12267:Human ornithine aminotransferase mRNA, complete 
cds /cds=(54,1373) /gb=M12267 /gi=189328 /ug=Hs.75485 /len=2013 
2.8 3.5 
Cluster Incl. D83777:Human mRNA for KIAA0193 gene, complete cds 
/cds=(352,1392) /gb=D83777 /gi=1228036 /ug=Hs.75137 /len=5076  
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2.8 2.2 
Cluster Incl. W27619:35c7 Homo sapiens cDNA /gb=W27619 /gi=1307567 
/ug=Hs.25816 /len=674 
2.8 2.1 
Cluster Incl. M14333:Homo sapiens c-syn protooncogene mRNA, complete 
cds /cds=(579,2192) /gb=M14333 /gi=181171 /ug=Hs.169370 /len=2647 
2.7 2.4 
Cluster Incl. AF053356:Homo sapiens chromosome 7q22 sequence 
/cds=(27,2369) /gb=AF053356 /gi=3135305 /ug=Hs.63758 /len=2513 
2.7 4 
Cluster Incl. AF070584:Homo sapiens clone 24462 mRNA sequence 
/cds=UNKNOWN /gb=AF070584 /gi=3387957 /ug=Hs.199296 /len=1737 
2.6 3.1 
Cluster Incl. AF051321:Homo sapiens Sam68-like phosphotyrosine protein 
alpha (SALP) mRNA, complete cds /cds=(394,1434) /gb=AF051321 
/gi=4091773 /ug=Hs.13565 /len=1963 
2.6 2.8 
Cluster Incl. W27541:32c12 Homo sapiens cDNA /gb=W27541 /gi=1307345 
/ug=Hs.3903 /len=982 
2.6  1.8  Human SWI/SNF complex 60 KDa subunit (BAF60c) mRNA, complete cds 
2.6 2.7 
Cluster Incl. Z98744:histone H2A /cds=(7,399) /gb=Z98744 /gi=3080457 
/ug=Hs.131954 /len=499 
2.6 2 
Cluster Incl. M35252:Human CO-029 /cds=(137,850) /gb=M35252 
/gi=180925 /ug=Hs.84072 /len=1083 
2.6 2.4 
Cluster Incl. AB029037:Homo sapiens mRNA for KIAA1114 protein, 
complete cds /cds=(183,4346) /gb=AB029037 /gi=5689564 /ug=Hs.239492 
/len=4750 
2.5  2.2  Human mRNA for estrogen responsive finger protein, complete cds 
2.5  2.2  Mucin 1, Epithelial, Alt. Splice 9 
2.4 2 
Cluster Incl. AB023184:Homo sapiens mRNA for KIAA0967 protein, 
complete cds /cds=(44,4780) /gb=AB023184 /gi=4589577 /ug=Hs.163990 
/len=4916 
2.4  1.8  Homo sapiens mRNA for cathepsin O 
2.4 3.2 
Cluster Incl. AL050276:Homo sapiens mRNA; cDNA DKFZp566F123 (from 
clone DKFZp566F123) /cds=(488,2494) /gb=AL050276 /gi=4886504 
/ug=Hs.159456 /len=2809 
2.3 2.9 
Cluster Incl. AF060877:Homo sapiens Gz-selective GTPase-activating 
protein (ZGAP1) mRNA, complete cds /cds=(68,721) /gb=AF060877 
/gi=3335164 /ug=Hs.99236 /len=1565 
2.2 3.5 
Cluster Incl. D14838:Human mRNA for FGF-9, complete cds /cds=(178,804) 
/gb=D14838 /gi=391718 /ug=Hs.111 /len=1420 
2.2 2 
Cluster Incl. AL031228:dJ1033B10.12 (collagen, type XI, alpha 2 
(COL11A2)) /cds=(226,5436) /gb=AL031228 /gi=3646023 /ug=Hs.121509 
/len=6423 
2.2 2.1 
Cluster Incl. U05861:Human hepatic dihydrodiol dehydrogenase gene 
/cds=(26,997) /gb=U05861 /gi=487134 /ug=Hs.201967 /len=1222 
2.2 1.8 
Cluster Incl. L76927:Human galactokinase (GALK1) gene, complete cds 
/cds=(63,1241) /gb=L76927 /gi=1929894 /ug=Hs.92357 /len=1361 
2.2 1.5 
Cluster Incl. AL050137:Homo sapiens mRNA; cDNA DKFZp586L151 (from 
clone DKFZp586L151) /cds=(0,1300) /gb=AL050137 /gi=4884149 
/ug=Hs.43658 /len=1810 
2.2 3.6 
Cluster Incl. W26407:29b8 Homo sapiens cDNA /gb=W26407 /gi=1307106 
/ug=Hs.233806 /len=885 
2.2  2.2  Human erythropoietin receptor mRNA, complete cds 
2.1  1.7  Human bone morphogenetic protein 2A (BMP-2A) mRNA 
2 2.3 
Cluster Incl. AL031846:dJ742C19.5 (novel Chromobox protein) 
/cds=(89,844) /gb=AL031846 /gi=4164368 /ug=Hs.7442 /len=3964 
2 2.3 
Cluster Incl. X89066:H.sapiens mRNA for TRPC1 protein /cds=(137,2416) 
/gb=X89066 /gi=1370118 /ug=Hs.94413 /len=4067 
1.9  2  Human FHIT mRNA; complete cds.  
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1.9 1.6 
Cluster Incl. AB028967:Homo sapiens mRNA for KIAA1044 protein, 
complete cds /cds=(965,2857) /gb=AB028967 /gi=5689424 /ug=Hs.202687 
/len=5333 
1.7 2.9 
Cluster Incl. U49260:Human mevalonate pyrophosphate decarboxylase 
(MPD) mRNA, complete cds /cds=(7,1209) /gb=U49260 /gi=1235681 
/ug=Hs.3828 /len=1795 
1.7 2.7 
Cluster Incl. D10495:Homo sapiens mRNA for protein kinase C delta-type, 
complete cds /cds=(9,1889) /gb=D10495 /gi=520586 /ug=Hs.155342 
/len=2163 
1.7 2.5 
Cluster Incl. W27549:32d11 Homo sapiens cDNA /gb=W27549 /gi=1307353 
/ug=Hs.235634 /len=912 
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